WO2005075471A2 - Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors - Google Patents

Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors Download PDF

Info

Publication number
WO2005075471A2
WO2005075471A2 PCT/SE2005/000140 SE2005000140W WO2005075471A2 WO 2005075471 A2 WO2005075471 A2 WO 2005075471A2 SE 2005000140 W SE2005000140 W SE 2005000140W WO 2005075471 A2 WO2005075471 A2 WO 2005075471A2
Authority
WO
WIPO (PCT)
Prior art keywords
thiazol
dihydro
oxo
ethyl
ylamino
Prior art date
Application number
PCT/SE2005/000140
Other languages
French (fr)
Other versions
WO2005075471A3 (en
Inventor
Lars Tedenborg
Tjeerd Barf
Sofia Nordin
Jerk VALLGÅRDA
Meredith Williams
Guido Kurz
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0400227A external-priority patent/SE0400227D0/en
Priority claimed from SE0401324A external-priority patent/SE0401324D0/en
Priority claimed from SE0402509A external-priority patent/SE0402509D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of WO2005075471A2 publication Critical patent/WO2005075471A2/en
Publication of WO2005075471A3 publication Critical patent/WO2005075471A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11- ⁇ - hydroxysteroid dehydrogenase type 1 enzyme (ll ⁇ HSDl).
  • glucocorticoids have a central role in diabetes.
  • the removal of the pituitary gland or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and Leukins, F.D.W.
  • FR 2,384,498 discloses compounds having a high hypoglycemic effect. Therefore, treatment of hyperglycemia with these compounds may lead to hypoglycemia.
  • Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetes, and omental fat appears to be of central importance.
  • Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g., increased blood pressure, decreased levels of HDL and increased levels of NLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000).
  • Inhibition of the 1 l ⁇ HSDl in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes.
  • glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin. Endocrinol. Metab. 13: 576-581).
  • HPA hypothalamo-pituitary-adrenal
  • the balance between the cell-mediated response and humoral responses is modulated by glucocorticoids.
  • a high glucocorticoid activity such as at a state of stress, is associated with a humoral response.
  • inhibition of the enzyme is associated with a humoral response.
  • I l ⁇ HSDl has been suggested as a means of shifting the response towards a cell-based reaction.
  • the immune reaction is normaly biased towards a humoral response when in fact the appropriate response would be cell based.
  • Temporal inhibition of 1 l ⁇ HSDl local or systemic, might be used to push the immune system into the appropriate response (Mason, D. (1991) Immunology Today 12: 57-60; Rook et al., supra).
  • An analogous use of 1 l ⁇ HSDl inhibition, in this case temporal, would be to booster the immune response in association with immunization to ensure that a cell based response would be obtained, when desired.
  • I I ⁇ HSD enzymes determines the susceptibility to glaucoma (Stokes, J. et al. (2000) Invest. Ophthalmol. 41: 1629-1638). Further, inhibition of 1 l ⁇ HSDl was recently presented as a novel approach to lower the intraocular pressure (Walker E. A. et al, poster P3-698 at the Endocrine society meeting June 12-15, 1999, San Diego). Ingestion of carbenoxolone, a non-specific inhibitor of 11 ⁇ HSD 1 , was shown to reduce the intraocular pressure by 20% in normal subjects.
  • 1 l ⁇ HSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess.
  • Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., Cheng, S.L. and Kim, G.S. (1999) J. Endocrinol. 162: 371- 379).
  • the negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 1 l ⁇ HSDl in the glucocorticoid effect (Bellows, C.G., Ciaccia, A. and Heersche, J.N.M. (1998) Bone 23: 119-125).
  • WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may, e.g., be used against cancer, inflammation and arthritis.
  • US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof.
  • US 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity.
  • tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4- c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465.
  • WO 98/16520 discloses compounds inhibiting matrix metalloproteinases (MMPs) and TNF- ⁇ converting enzyme (TACE).
  • MMPs matrix metalloproteinases
  • TACE TNF- ⁇ converting enzyme
  • EP 0 749 964 Al and US 5,962,490 disclose compounds having an endothelin receptor antagonist activity.
  • WO 00/02851 discloses compounds associated with a disturbed cGMP balance.
  • US 5,783,697 discloses thiophene derivatives as inhibitors of PGE2 and LTB4.
  • EP 0 558 258, EP 0 569 193, and EP 1 069 114 disclose isoxazole derivatives as endothelin agonists and antagonists.
  • Cortisol performs a broad range of metabolic functions and other functions.
  • the multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called "Cushing's syndrome".
  • Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also have impaired wound healing and brittle skin (Ganong, W.F. Review of Medical Physiology. Eighteenth edition ed. Stamford, Connecticut: Appleton & Lange; 1997).
  • Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (Anstead, G.M. Steroids, retinoids, and wound healing.
  • EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound. The authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, conelates with large, non-healing wounds (Hutchinson, T.C., Swanike,r H.P. Wound diagnosis by quantitating cortisol in wound fluids. European patent application No.
  • Cortisone thus functions as a large precursor pool for active glucocorticoids (Hammami, M.M, Siiteri, P.K. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin f ⁇ broblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991;73(2):326-34).
  • 1 l ⁇ HSD2 is expressed in kidney, salivary glands, placenta, ileum, distal colon and epithelia of respiratory tract, where it is co-localized with MR (Hirasawa, G., Sasano, H., Takahashi, K., Fukushima, K., Suzuki, T., Hiwatashi, ⁇ ., et al. Colocalization of 11 beta- hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia.
  • 1 l ⁇ -HSDl is NADP dependent (Mercer WR, Krozowski ZS. Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology 1992;130(l):540-3). Like GR, 1 l ⁇ -HSDl is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (Monder C, White PC.
  • glucocorticoid receptor antagonist RU486 Mercado, A.M., Quan, N., Padgett, D.A., Sheridan, J.F., Marucha, P.T. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study.
  • Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inhibit wound contracture and delay epithelialization (Anstead et al., supra). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF- ⁇ , EGF, KGF and PDGF (Beer, H.D., Fassler, R, Werner, S.
  • Glucocorticoid-regulated gene expression during cutaneous wound repair Nitam Horm 2000;59:217-39; Hamon, G.A., Hunt, T.K., Spencer, E.M.
  • Epidermal growth factor (EGF) prevents methylprednisolone- induced inhibition of wound healing.
  • glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (Oishi, Y., Fu, Z.W., Ohnuki, Y., Kato, H., ⁇ oguchi, T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002;147(5):859-68).
  • WO 01/90090 discloses thiazole compounds, which compounds inhibit the human 1 l ⁇ -HSDl, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders.
  • Other 1 l ⁇ -HSDl inhibitors are disclosed in, e.g., WO 01/90091; WO 01/90092; WO 01/90093; WO 01/90094; WO 03/043999; WO 03/044000; WO 03/044009; Swedish patent application No. SE 0301504- 7, filed on May 21, 2003; and Swedish patent application Nos.
  • the compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (1 l- ⁇ -HSD , and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, hypertension, and wound healing.
  • One object of the present invention is a compound of the general formula (I)
  • R and R are each independently selected from hydrogen; -s-alkyl; C 3 - 10 -cycloalkyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl; C 2 . 8 -alkenyl; C 3 .
  • X is CH 2 ;
  • Y is CH 2 , CO or a single bond;
  • R is hydrogen; C ⁇ - 8 -alkyl; C 3 - ⁇ o-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl, halo-C ⁇ - 8 -alkyl, Q-s-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci-
  • R 3 is NR 4 R 5 , wherein R 4 and R 5 are each independently selected from hydrogen; C ⁇ - 8 -alkyl; Oj- t o-cycloalkyl optionally independently substituted by one or more of Cj.g-alkyl; C 3 - ⁇ o-cycloalkyl-C ⁇ - 8 -alkyl; C 3 - ⁇ 0 -cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkyl, - 8 -alkoxy, halo-Cj- 8 - alkoxy, arylcarbonyl, and carboxy; aryl-C ⁇ - 8 -alkyl optionally independently substituted by one or more of C-s-alkyl and halogen; Cj- 8 -acyl optionally independently substituted by one or more of aryloxy; ary
  • R is selected from C ⁇ - 8 -alkyl and aryl; CONR 7 R 8 , wherein R 7 and R 8 are each independently selected from hydrogen and C ⁇ - 8 -alkyl; or wherein R 3 is OCONR 9 R 10 , wherein R 9 and R 10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C 3 - ⁇ o-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-C ⁇ - 8 -alkyl, and -s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R 3 is OR 13 , wherein R 13 is selected from hydrogen; aryl optionally independently independently
  • R 4 and R 5 are each independently selected from C - ⁇ 0 -cycloalkyl optionally substituted by one or more of Q-s-alkyl; cyclopropylmethyl; C 3 .
  • R 4 and R 5 is hydrogen and the other of R 4 and R 5 is selected from C 3 - ⁇ 0 -cycloalkyl optionally substituted by one or more of C ⁇ - 8 -alkyl; cyclopropylmethyl; C 3 .
  • R 3 is C 3 - ! o-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl, halo-C ⁇ - 8 -alkyl, C ⁇ - 8 -alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d-s-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R 3 is NR 4 R 5 , wherein R 4 and R 5 are each independently selected from hydrogen; d-s-alkyl; C 3 - ⁇ o-cycloalkyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl; C 3 - ⁇ o-cycloalkyl-C ⁇ - 8 -alkyl; C 3 .
  • R 6 is selected from d- 8 -alkyl and aryl; CONR 7 R 8 , wherein R 7 and R 8 are each independently selected from hydrogen and d- 8 -alkyl; or wherein R 3 is OCONR 9 R 10 , wherein R 9 and R 10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; 1 1 10 1 1 10 or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C 3 .
  • R 10 10 -cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-C ⁇ - 8 -alkyl, and Ci-s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R 3 is OR 13 , wherein R 13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, d-s-alkyl, d-s-alkoxy, d- 8 -alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkoxy, mono-, or di-Ci-s-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkyl, halo-d- 8 -alkyl, C ⁇ - 8 -alkoxy, and
  • the provisos above do not apply and instead: when either R 1 or R 2 is optionally substituted aryl, then neither R 4 nor R 5 is optionally substituted aryl; neither R 1 nor R 2 is methyl, ethyl, allyl, benzyl, acetyl, phenyl and do not form together with the nitrogen atom bonded thereto piperidine; when either R 1 or R 2 is optionally substituted aryl, then neither R 4 nor R 5 is C ⁇ - 8 -alkyl, benzyl, cyclohexylmethyl; the following compounds are excluded:
  • R 1 and R 2 are each independently selected from hydrogen; Ci-s-alkyl; C 3 - ⁇ o-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C 3 - ⁇ o-cycloalkyl-d- 8 - alkyl; C - ⁇ 0 -cycloalkenyl; C 3 - ⁇ o-cycloalkenyl-C ⁇ - 8 -alkyl; heterocyclyl optionally independently substituted by one or more of d-s-alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkyl, halo-C ⁇ - 8 -alkyl, Ci-s-alkoxy, and heterocyclyl; indanyl; aryl-d-s-alkyl optionally independently substituted by one or more of halogen and C ⁇ - 8 -alkyl; aryl-C 3 - ⁇ o-
  • R 10 10 -cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cj-s-alkyl, and C ⁇ - 8 -alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R 3 is OR 13 , wherein R 13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, d- 8 -alkyl, Ci-s-alkoxy, C ⁇ - 8 -alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-d-s-alkyl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkoxy, mono-, or di-d- 8 - alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, d-s-alkyl, halo-Ci-s-alkyl, C ⁇ - 8 -alkoxy, and nitro
  • R 1 and R 2 are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.
  • R 3 is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- morpholinyl; N-phthalimidyl; piperidin-1-yl; 4-methylpiperidin-l-yl; 1 -(1,2,3, 4- tetrahydroquinolinyl); 2-( 1 ,2,3 ,4-tetrahydroisoquinolinyl); 8-methyl- 1 -( 1 ,2,3 ,4- tetrahydroquinolinyl); l-[7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolinyl; 3,4- dihydroisoquinolin-2(lH)-yl; 6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl;
  • R 9 and R 10 are each independently selected from 2-chloro ⁇ henyl; 4- bromo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; NHCONR ⁇ R 12 , wherein R 11 and R 12 are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fiuorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2- (trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl;
  • R 13 is selected from hydrogen; phenyl; 2-chlorophenyl; 4-chloro-3- methylphenyl; 2-methoxyphenyl; 4-carbomethoxy-2-chlorophenyl; 3-(4- morpholinyl)phenyl; 4-phenoxyphenyl; 2-chlorobenzyl; 2-methylbenzyl; 2- methoxybenzyl; 3-(dimethylamino)benzyl; benzoyl; 2-chlorobenzoyl; 2,4-dichlorobenzoyl; 3,4-dichlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 3,4-difluorobenzoyl; 2- chloro-6-fluorobenzoyl; 2,4,6-trichlorobenzoyl; 2,3,4-trifluorobenzoyl; 3-methylbenzoyl; 4-methylbenzoyl; 4-tert-butylbenzoyl; 3-
  • Prefened compounds are Examples 1-10, 17-47, 50-55, 57, 58, 60-69, 71-96, 99-108, 110-
  • Another object of the present invention is a process for the preparation of a compound according to any one of claims 1 to 4, comprising at least one of the following steps: a) reaction of an isothiocyanate with ammonia to give a thiourea, b) reaction of an amine with ethoxycarbonylisothiocyanate to give a thiourea, c) reaction of a thiourea with maleic anhydride to give a thiazolone carboxy lie acid, d) reaction of a thiazolone carboxylic acid with 2-chloro-l-methylpyridinium iodide in the presence of an amine to give a thiazolone amide, e) reaction of a thiourea with 2-bromo- ⁇ -butyrolactone to give a thiazolone alcohol, f) reaction of a thiazolone alcohol with an acid chloride or an isocyanate in the presence
  • Another object of the present invention is a compound of the general formula (I)
  • R 1 and R 2 are each independently selected from hydrogen; Ci-s-alkyl; C 3 -io-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C 2 - 8 -alkenyl; C 3 - 10 - cycloalkyl-Ci- 8 -alkyl; C . ⁇ 0 -cycloalkenyl; C 3 . ⁇ o-cycloalkenyl-Ci- 8 -alkyl; C ⁇ _ 8 -acyl; heterocyclyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-C ⁇ _ 8 -alkyl, d- 8 -alkoxy, and heterocyclyl; indanyl; aryl-C ⁇ _ 8 -alkyl optionally independently substituted by one or more
  • X is CH 2 ;
  • Y is CH 2 , CO or a single bond
  • R 3 is hydrogen; C ⁇ - 8 -alkyl; C 3 -i 0 -cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl, halo-d- 8 -alkyl, d- 8 -alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d- s-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R 3 is NR 4 R 5 , wherein R and R 5 are each independently selected from hydrogen; Ci-s-alkyl; C - ⁇ o-cycloalkyl optionally independently substituted by one or more of d- 8 -alkyl; C 3 - ⁇ o-cycloalkyl-C ⁇ - 8 -alkyl; C 3 -i 0 -cycloalkylcarbonyl; aryl
  • R 3 is OCONR 9 R 10 , wherein R 9 and R 10 are each independently selected from aryl optionally independently substituted by one or more of ⁇ j 1 1 10 1 1 halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C 3 - ⁇ o-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-C ⁇ - 8 -alkyl, and Ci-s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R is OR , wherein R 13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, C ⁇ - 8 -alkyl, C ⁇ - 8 -alkoxy, d- 8 -alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-C ⁇ - 8 -alkyl optionally independently independently
  • R 1 and R 2 are each independently selected from hydrogen; C ⁇ - 8 -alkyl; C - ⁇ 0 -cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C 3 - 10 -cycloalkyl-d-s- alkyl; C 3 - 10 -cycloalkenyl; C 3 - ⁇ 0 -cycloalkenyl-C ⁇ - 8 -alkyl; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, d- 8 -alkyl, halo-C ⁇ - 8 -alkyl, d- 8 -alkoxy, and heterocyclyl; indanyl; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen and C ⁇ - 8 -alkyl;
  • Y is CH 2 , CO or a single bond
  • R 3 is hydrogen; C ⁇ - 8 -alkyl; C 3 - ⁇ 0 -cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl, halo-Ci-s-alkyl, C ⁇ - 8 -alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d- s-alkyl; aryl optionally independently substituted by one or more of halogen or hydroxy; or wherein R 3 is NR 4 R 5 , wherein R 4 and R 5 are each independently selected from hydrogen; C ⁇ - 8 -alkyl; C 3 - ⁇ 0 -cycloalkyl optionally independently substituted by one or more of C ⁇ - 8 -alkyl; C 3 - 10 -cycloalkyl-C ⁇ - 8 -alkyl; C 3 - 10 -cycloalkylcarbonyl; aryl optionally independently substituted by
  • arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-C ⁇ - 8 -alkyl, Ci-s-alkoxy, and nitro.
  • R 1 and R 2 are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]he ⁇ t-3-yl; (lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl; bicyclo[2.2.1]hept-5-en-2-yl
  • R 3 is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- mo ⁇ holinyl; N-phthalimidyl; piperidin-1-yl; 4-methylpiperidin-l-yl; 1-(1,2,3,4- tetrahydroquinolinyl); 2-( 1 ,2,3 ,4-tetrahydroisoquinolinyl); 8-methyl- 1 -( 1 ,2,3 ,4- tetrahydroquinolinyl); l-[7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolinyl; 3,4- dihydroisoquinolin-2( lH)-yl; 6,7-dimethoxy-3 ,4-dihydroisoquinolin-2( 1 H)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl
  • R 9 and R 10 are each independently selected from 2-chlorophenyl; 4- bromo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; NHCONR 1 l R 12 , wherein R 1 ' and R 12 are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2- (trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl; OR 13 , wherein R 13 is selected from hydrogen; phenyl; 2-chloroph
  • Prefened compounds are Examples 1-388.
  • the compound (I) of any of claims 6 to 9 may advantageously be used in the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • Another object of the present invention is a pharmaceutical formulation comprising a compound of any of claims 6 to 9 as active ingredient, in combination with a pharmaceutically acceptable diluent or canier, especially for use in the prophylaxis or treatment of a 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
  • the pharmaceutical formulation can include a second active ingredient.
  • the second active ingredient can be an inhibitor of 11- ⁇ -hydroxysteroid dehydrogenase type 1 or it can have some other activity.
  • Another object of the present invention is a method for the prophylaxis or treatment of a 11- ⁇ -hydroxy steroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation comprising administering the compound of any of claims 6 to 9 to an individual.
  • Another object of the present invention is a method for inhibiting a 11- ⁇ - hydroxysteroid dehydrogenase type 1 enzyme comprising administering the compound of any of claims 6 to 9 to an individual.
  • Another object of the present invention is the use of a compound of any of claims 6 to 9 for the manufacture of a medicament for use in the prophylaxis or treatment of a 11- ⁇ - hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno- modulation.
  • 11- ⁇ -hydroxy steroid dehydrogenase type 1 enzyme-mediated disorders include: diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
  • the compound of any of claims 6 to 9 may be used for the treatment or prophylaxis of a disorder involving delayed or impaired wound healing.
  • the disorder involving delayed or impaired wound healing is diabetes. It is also prefened that the disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
  • the compound of any of claims 6 to 9 may be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers. It is prefened that the immuno-modulation is selected from tuberculosis, lepra, and psoriasis. Also within the scope of this invention is a method for making a compound of formula (I) with the proviso.
  • the method includes taking any intermediate compound delineated herein, reacting it with one or more reagents to form a compound of formula (I) with the proviso including any processes specifically delineated herein.
  • the compounds according to the present invention may be used in several indications which involve 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme.
  • the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis, E.
  • aryl in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph), naphthyl, and indanyl (i.e., 2,3-dihydroindenyl), which optionally may be substituted by Cj-e-alkyl.
  • substituted aryl groups are benzyl, and 2-methylphenyl.
  • heteroaryl means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system.
  • heteroaryl rings examples include pynole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline (i e 2,3-dihydroindole), isoindoline (i e 1,3- dihydroisoindole), benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3- benzoxadiazole, benzopyrazole; benzothiazole, 2,1,3-benzothiazo
  • heterocyclic and “heterocyclyl” in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the reminder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the conesponding partially saturated or fully saturated heterocyclic rings.
  • heteroatoms e.g., oxygen, sulfur, or nitrogen
  • Exemplary saturated heterocyclic rings are azetidine, pynolidine, piperidine, piperazine, mo ⁇ holine, thiomo ⁇ holine, 1,4- oxazepane, azepane, phthalimide, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, hexahydroazepine, 3,4-dihydro-2(l ⁇ )isoquinoline, 2,3- dihydro-lH-indole, l,3-dihydro-2H-isoindole, azocane, l-oxa-4-azaspiro[4.5]dec-4-ene, decahydroisoquinoline, and 1,4-diazepane.
  • C ⁇ - 8 -alkyl in the compound of formula (I) according to the present application may be a straight or branched alkyl group containing 1-8 carbon atoms.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, n-heptyl, and n-octyl.
  • Ci-s-alkoxy in the compound of formula (I) according to the present application may be a straight or branched alkoxy group containing 1-8 carbon atoms.
  • alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert- butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, n-heptyloxy, and n-octyloxy.
  • C ⁇ - 6 -alkoxy all subgroups thereof are contemplated such as C ⁇ - - alkoxy, d- 6 -alkoxy, Ci-s-alkoxy, C ⁇ - 4 -alkoxy, C 2 . 8 -alkoxy, C 2 - 7 -alkoxy, C 2 .
  • Ci-s-acyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 1-8 carbon atoms.
  • Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, n-hexanoyl, n- heptanoyl, and n-octanoyl.
  • C ⁇ - 8 -acyl For parts of the range "C ⁇ - 8 -acyl" all subgroups thereof are contemplated such as Cj- 7 -acyl, C ⁇ - 6 -acyl, C ⁇ - 5 -acyl, C ⁇ - 4 -acyl, C 2 - 8 -acyl, C . -acyl, C . 6 - acyl, C 2 - 5 -acyl, C . -acyl, C 4 - 6 -acyl, etc.
  • C 2 - 8 -alkenyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 2-8 carbon atoms.
  • alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1- pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, and 1-octenyl.
  • C 2 . 8 -alkenyl all subgroups thereof are contemplated such as C 2 . 7 -alkenyl, C 2 . 6 - alkenyl, C 2 - 5 -alkenyl, C 2 - 4 -alkenyl, C 3 .
  • C 3 - ⁇ o-cycloalkyl is either of C 3 . 10 -monocycloalkyl, d- t o-bicycloalkyl, and C 3 - 10 - tricycloalkyl.
  • C - ⁇ o-monocycloalkyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted monocyclic alkyl group containing totally 3-10 carbon atoms.
  • Exemplary monocycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl.
  • C 3 - ⁇ 0 -monocycloalkyl all subgroups thereof are contemplated such as C 3 . 9 -monocycloalkyl, C 3 . 8 -monocycloalkyl, C 3 . -monocycloalkyl, C 3 . 6 -monocycloalkyl, C .
  • C 3 - ⁇ 0 -bicycloalkyl in the compound of fonnula (I) according to the present application may be an optionally alkyl substituted bicyclic alkyl group containing totally 3- 10 carbon atoms.
  • bicycloalkyl groups include bicyclo[2.2.1]hept-2-yl, (lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, and (lS,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl.
  • C 3 - ⁇ o-bicycloalkyl all subgroups thereof are contemplated such as C 3 . 9 -bicycloalkyl, C . 8 -bicycloalkyl, C 3 . -bicycloalkyl, C - 6 -bicycloalkyl, C 3 .
  • C 3 -i 0 -tricycloalkyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted tricyclic alkyl group containing totally 3-10 carbon atoms.
  • Exemplary tricycloalkyl groups include 1-adamantyl, noradamantyl, and tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-yl.
  • C 3 - ⁇ o-tricycloalkyl For parts of the range "C 3 - ⁇ o-tricycloalkyl" all subgroups thereof are contemplated such as C 3 . 9 -tricycloalkyl, C 3 . 8 -tricycloalkyl, C . 7 - tricycloalkyl, C 3 - 6 -tricycloalkyl, C 3 - 5 -tricycloalkyl, C 4 - ⁇ 0 -tricycloalkyl, C 5 - ⁇ 0 -tricycloalkyl, Q-io-tricycloalkyl, C 7 - ⁇ 0 -tricycloalkyl, C 8 . 9 -tricycloalkyl, etc.
  • C 3 - ⁇ o-cycloalkenyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted cyclic, bicyclic or tricyclic alkenyl group containing totally 3-10 carbon atoms.
  • exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, and bicyclo[2.2. l]hept-5-en-2-yl. For parts of the range "C 3 .
  • t o-cycloalkenyl all subgroups thereof are contemplated such as C 3 - 9 -cycloalkenyl, C - 8 - cycloalkenyl, C - 7 -cycloalkenyl, C 3 . 6 -cycloalkenyl, C 3 . 5 -cycloalkenyl, C 4 - 10 -cycloalkenyl, C 5 - ⁇ o-cycloalkenyl, C 6 - ⁇ o-cycloalkenyl, C 7 - ⁇ 0 -cycloalkenyl, C 8 . 9 -cycloalkenyl, etc.
  • halogen in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • sulfanyl in the present description means a thio group. With the expression “mono- or di-substituted” is meant in the present description that the functionalities in question may be substituted with independently d- 8 -acyl, C - 8 - alkenyl, C ⁇ - 8 -(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g.
  • C 3 - ⁇ o-cycloalkyl-Cj. 8 -alkyl means a
  • halo-C ⁇ - 8 -alkyl means a C ⁇ - 8 -alkyl group that is substituted by a halogen atom.
  • DCM dichloromethane
  • DEAD means diethyl azocarboxylate
  • DMF means dimethylfonnamide
  • EDCI means l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • Ether means diethyl ether
  • HOBt means 1-hydroxybenzotriazole
  • HPLC means high performance liquid chromatography
  • MS means mass spectroscopy
  • DPPA means diphenylphosphoryl azide
  • SM starting material
  • TEA triethylamine
  • THF means tetrahydrofuran. Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the pu ⁇ oses detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11- ⁇ -HSDl inhibition, 11- ⁇ -HSDl -mediated disease).
  • prodrug forms in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity.
  • Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.
  • Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein.
  • compositions according to the present invention contain a pharmaceutically acceptable canier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient.
  • the therapeutic composition is not immunogenic when administered to a human patient for therapeutic pu ⁇ oses, unless that pu ⁇ ose is to induce an immune response.
  • the preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non- aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • Adjuvants may also be present in the composition. Phannaceutically acceptable caniers are well known in the art.
  • liquid earners are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions.
  • a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline.
  • aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose,
  • the phannaceutical composition according to one of the prefened embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or fe ic hydroxides, and such organic bases as isopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine and the like.
  • the preparations according to the prefened embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously. Other routes are known to those of ordinary skill in the art.
  • compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pynolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, calcium hydrogen phosphate, sodium starch glycolate, sorbitol or glycine; tabletting lubricant e.g.
  • Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose (optionally microcrystalline), glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g.
  • non-aqueous vehicles which may include edible oils, e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p- hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • An effective amount refers to an amount of a compound which confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
  • a pharmaceutical composition according to the present invention may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition.
  • a weight percent is a ratio by weight of total composition.
  • 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition.
  • a suitable daily oral dose for a mammal, preferably a human being may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
  • the compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or canier.
  • the compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods.
  • the compounds of the present invention in labelled fonn, e.g. isotopically labelled, may be used as a diagnostic agent.
  • This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein.
  • the compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in- vitro was studied using the following reagents and methods.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • Synthetic chemistry transformations and protecting group methodologies protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, NCH Publishers (1989); T.W. Greene and P.G.M.
  • 18- ⁇ - glycynhetinic acid was obtained from Sigma. The serial dilutions of the compounds were performed on a Tecan Genesis RSP 150. Compounds to be tested were dissolved in DMSO (1 mM) and diluted in 50 mM Tris-HCl, pH 7.2 containing 1 mM EDTA. The multiplication of plates was done on a WallacQuadra. The amount of the product [ 3 H]-cortisol, bound to the beads was determined in a Packard, Top Count microplate liquid scintillation counter.
  • the 11- ⁇ -HSD ⁇ enzyme assay was canied out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 ⁇ L and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 ⁇ M), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 ⁇ M). Reactions were initiated by the addition of human 11- ⁇ -HSDj, either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL). Following mixing, the plates were shaken for 30 to 45 minutes at room temperature. The reactions were tenninated with 10 ⁇ L 1 mM GA stop solution.
  • Monoclonal mouse antibody was then added (10 ⁇ L of 4 ⁇ M) followed by 100 ⁇ L of SPA beads (suspended according to the manufacturers instructions). Appropriate controls were set up by omitting the 11- ⁇ -HSD ⁇ to obtain the non-specific binding (NSB) value.
  • the plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting. The amount of [ 3 H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter. The calculation of the Ki values for the inhibitors was performed by use of Activity Base.
  • the IC 50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance.
  • the Ki values of the compounds of the present invention for the 11- ⁇ -HSDl enzyme lie typically between about 10 nM and about 10 ⁇ M. Illustrative Ki values for some Examples according to the present invention are given below.
  • the 2-amino-carboxylic acid (1.0 eq.) was suspended in 2.0 M H 2 SO 4 (4 eq.), KBr (8 eq.) was added and the mixture was cooled in an ice-bath. NaNO 2 (1.3 eq.) dissolved in water was added slowly. The reaction mixture was stined for 4 h at ice-bath, before allowed to reach room temperature. The reaction mixture was extracted with EtOAc. The organic phase was dried over MgSO 4 before concentrated in vacuum. This gave the crude product which was used in the next step without further purification (J. Org. Chem. 2002, 67 (11), 3595-3600; Xinhua Qian; Bin Zheng; Brian Burke; Manohar T. Saindane and David R. Kronenthal).
  • Analytical HPLC were performed on Agilent 1100 system equipped with System A: ACE 3 (C8, 50x3.0mm) or System B: YMC ODS-AQ, (33x3.0 mm) using the eluent system: water/0.1%TFA and CH 3 C ⁇ , lmL/min, with a gradient time of 3 min.
  • System A ACE 3 (C8, 50x3.0mm) or System B: YMC ODS-AQ, (33x3.0 mm) using the eluent system: water/0.1%TFA and CH 3 C ⁇ , lmL/min, with a gradient time of 3 min.
  • Preparative HPLC was performed on a Gilson system equipped with System A: ACE 5 C8 column (50x20mm) gradient time 5 min, system B: YMC ODS-AQ (150x30mm) gradient time 8.5 min or system C: YMC ODS-AQ (50x20mm) gradient time 5 min using the eluent system: water/0.1%TFA and CH CN.
  • Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh). The compounds were automatically named using ACD6.0.
  • Method A or B was used depending if the isothiacyanate or of the conesponing amine was used.
  • the amines or isothiacyanate was purchased from either Maybridge pic or from Sigma- Aldrich co.
  • the carboxylic acid 1.0 eq. and 2-chloro-l-methylpyridinium iodide (1.2 eq.) were mixed in DCM for 10 minutes before the amine (1.0 eq.) was added followed by Et N (1.5 eq.).
  • the reaction mixture was stkred at RT for 16 h, full conversion of the SM.
  • the reaction mixture was poured on a Hydromatrix column (pretreated with 1 M HCl) and the crude product was eluted with DCM. The obtained crude product was purified by reverse phase.
  • Method F The alcohol (1.0 eq.) and the appropriate acid chloride or isocyanate (1.0 eq.) were dissolved in DCM and triethylamine (3.0 eq.). The reaction mixture was stined over night at RT. The solvent was removed under reduced pressure and the product was purified using preparative HPLC.
  • the carboxylic acid (1.0 eq.14 mmol) was dissolved in dry acetonitrile, Et 3 N (1.0 eq,) and DPPA (1.0 eq.) were added.
  • the reaction mixture was stined at 50 °C for 2 hours.
  • the reaction mixture was cooled to rt, and IM HCl (6 ml) was added.
  • the reaction mixture was heated to reflux for 5 hours.
  • the acetonitrile was evaporated and the remaining aqueous solution was saturated with solid NaC0 , before the aqueous phase was extracted with DCM.
  • the organic phase was evaporated and the obtained crude product was dissolved in DCM and excess of the benzoyl chloride was added.
  • the reaction mixture was stined at RT for 2 hours. Water was added and the phases were separated. The organic phase was evaporated and the crude product was purified by preparative HPLC.
  • Example 3 N- ⁇ 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl ⁇ - 2 ,4-dimethoxybenzamide Prepared according to method K 0.0055 g, 7 % yield.
  • Example 10 (BVT.59331) N- ⁇ 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl ⁇ - 2 ,4-dichlorobenzamide Prepared according to method K 0.0106 g, 12 % yield.
  • Example 13 N- ⁇ 2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl ⁇ -2,6- dimethoxybenzamide Prepared according to method K 5 mg, 8%o yield.
  • Example 40 N- ⁇ 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl ⁇ isoxazole-5-carboxamide Prepared according to method K 0.0105 g, yield 13 %.
  • Example 63 (BVT.61824B 5-(2-anilinoethyl)-2-(cycloheptylamino)- 1 ,3 -thiazol-4(5H)-one Prepared according to method ⁇ 0.0144 g, 34 % yield of white crystals.
  • the obtained crude product was purified by preparative reverse phase (30-60) as gradient.
  • Example 80 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N- (3 -methylphenyl)acetamide Prepared according to method D 34.15 mg, yield 45%.
  • Example 102 (BVT47439) N-(2-benzoyl ⁇ henyl)-2-[2-(Bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3- thiazol-5 -y 1] acetamide Prepared according to method M 256 mg, 57% yield, as a white powder. Mp 191-192 °C.
  • Example 122 (BVT.59215D 2-(2- ⁇ [3,5-Bis(trifluoromethyl)phenyl]amino ⁇ -4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N- methyl-N-phenylacetamide trifluoroacetate Prepared according to method D 16.8 mg, 11 % yield.
  • Example 126 (BVT.59263) N-methyl-2- ⁇ 4-oxo-2-[(2-phenylethyl)amino]-4,5-dihydro-l,3-thiazol-5-yl ⁇ -N- phenylacetamide Prepared according to method D 6.1 mg, 4 % yield.
  • Example 129 (BVT.59344) 2- ⁇ 2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl ⁇ -N- phenylacetamide Prepared according to method D 252.7 mg, 64% yield as a white solid.
  • Example 132 (BVT.59370) 5-[2-(3,4-Dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2- ⁇ [3,5-bis(trifluoromethyl)phenyl]- amino ⁇ - 1 ,3-thiazol-4(577)-one Prepared according to method D 9 mg, 9 % yield. MS (ESI+) m/z 502 (M+H) + .
  • Example 139 (BVT.59581) 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2,6-dimethylphenyl)amino]-l,3- thiazol-4(5H)-one
  • Example 140 (BVT.59582) 2- ⁇ 2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl ⁇ -N-methyl-N- phenylacetamide Prepared according to method D 5.2 mg, 6% yield.
  • Example 156 (BVT.61854) 5-(2-azepan- 1 -yl-2-oxoethyl)-2-[(l , 1 ,3 ,3-tetramethylbutyl)amino]- 1 ,3-thiazol-4(5H)-one
  • Example 161 (BVT.61993) 5-(2-Aze ⁇ an-l-yl-2-oxoethyl)- 2-(tricyclo[3.3.1.0 ⁇ 3,7 ⁇ ]non-3-ylamino)-l,3-thiazol-4(577)- one

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to compounds with the formula (I), wherein R1, R2, R3, X, and Y are as defined herein, and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme.

Description

NEW COMPOUNDS
RELATED APPLICATIONS
This application claims priority to Swedish application number 0400227-5, filed on February 4, 2004, Swedish application number 0401324-9, filed on May 24, 2004, Swedish application number 0402509-4, filed on October 15, 2004, and U.S. provisional application 60/555,808, filed on March 24, 2004, the contents of which is incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-β- hydroxysteroid dehydrogenase type 1 enzyme (llβHSDl).
BACKGROUND
1. Glucorticoids, diabetes and hepatic glucose production
It has been known for more than half a century that glucocorticoids have a central role in diabetes. For example, the removal of the pituitary gland or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and Leukins, F.D.W.
(1936) J. Exp. Med. 63: 465-490; Houssay, B.A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver. The role of 1 lβHSDl as an important regulator of local glucocorticoid effect and thus of hepatic glucose production is well substantiated (see, e.g., Jamieson et al. (2000) J. Endocrinol. 165: 685-692). Hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific 1 lβHSDl inhibitor carbenoxolone (Walker, B.R. et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats. These studies showed that the mRNA levels and activities of two key enzymes in hepatic glucose production were reduced, namely: the rate-limiting enzyme in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6- phosphatase (G6Pase), the enzyme catalyzing the last common step of gluconeogenesis and glycogenolysis. Finally, blood glucose levels and hepatic glucose production are reduced in mice in which the 1 lβHSDl gene is knocked-out. Data from this model also confirm that inhibition of 1 lβHSDl will not cause hypoglycemia, as predicted since the basal levels of PEPCK and G6Pase are regulated independently of glucocorticoids (Kotelevtsev, Y. et al., (1997) Proc. Natl. Acad. Sci. USA 94: 14924-14929). Arzneim.-Forsch./Drug Res; 44 (II), No. 7, 821-826, 1994, discloses the hypoglycemic compounds 4-(3-methyl-5-oxo-2-pyrazolin-l-yl)benzoic acid and 1- (mesitylen-2-sulfonyl)-lH-l,2,4-triazole. The structures of these compounds differ considerably from the structure of the compounds of the present invention, in that the latter are thiophenes having an (hetero)arylsulfonamido substituent. FR 2,384,498 discloses compounds having a high hypoglycemic effect. Therefore, treatment of hyperglycemia with these compounds may lead to hypoglycemia.
2. Possible reduction of obesity and obesity related cardiovascular risk factors Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetes, and omental fat appears to be of central importance. Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g., increased blood pressure, decreased levels of HDL and increased levels of NLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000). Inhibition of the 1 lβHSDl in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e., reduced central obesity (Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: 1210-1213). Inhibition of 1 lβHSDl in mature adipocytes is expected to attenuate secretion of the plasminogen activator inhibitor 1 (PAI-1) - an independent cardiovascular risk factor (Halleux, CM. et al. (1999) J. Clin. Endocrinol. Metab. 84: 4097-4105). Furthermore, there is a clear conelation between glucocorticoid "activity" and cardiovascular risk factor suggesting that a reduction of the glucocorticoid effects would be beneficial (Walker, B.R. et al. (1998) Hypertension 31 : 891-895; Fraser, R. et al. (1999) Hypertension 33: 1364- 1368). Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 1 lβHSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C et al. (1998) Science, 280: 1378- 1383).
3. Possible beneficial effect on the pancreas
Inhibition of 1 lβHSDl in isolated murine pancreatic β-cells improves glucose- stimulated insulin secretion (Davani, B. et al. (2000) J. Biol. Chem. 2000 Nov 10; 275(45): 34841-4). Glucocorticoids were previously known to reduce pancreatic insulin release in vivo (Billaudel, B. and B.C.J. Sutter (1979) Horm. Metab. Res. 11: 555-560). Thus, inhibition of 1 lβHSDl is predicted to yield other beneficial effects for diabetes treatment, besides the effects on liver and fat.
4. Possible beneficial effects on cognition and dementia Stress and glucocorticoids influence cognitive function (de Quervain, D.J.-F., B.
Roozendaal, and J.L. McGaugh (1998) Nature 394: 787-790). The enzyme 1 lβHSDl controls the level of glucocorticoid action in the brain and thus contributes to neurotoxicity (Rajan, V., C.R.W. Edwards, and J.R. Seckl, J. (1996) Neuroscience 16: 65-70; Seckl, J.R., Front. (2000) Neuroendocrinol. 18: 49-99). Unpublished results indicate significant memory improvement in rats treated with a non-specific 1 lβHSDl inhibitor (J. Seckl, personal communication). Based the above and on the known effects of glucocorticoids in the brain, it may also be suggested that inhibiting 1 lβHSDl in the brain may result in reduced anxiety (Tronche, F. et al. (1999) Nature Genetics 23: 99-103). Thus, taken together, the hypothesis is that inhibition of 1 lβHSDl in the human brain would prevent reactivation of cortisone into cortisol and protect against deleterious glucocorticoid- mediated effects on neuronal survival and other aspects of neuronal function, including cognitive impairment, depression, and increased appetite. WO 98/27081 and WO 99/02502 disclose 5HT6 receptor antagonists for the treatment of CNS disorders.
5. Possible use of immuno-modulation using 11 βHSD 1 inhibitors
The general perception is that glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin. Endocrinol. Metab. 13: 576-581). The balance between the cell-mediated response and humoral responses is modulated by glucocorticoids. A high glucocorticoid activity, such as at a state of stress, is associated with a humoral response. Thus, inhibition of the enzyme
I lβHSDl has been suggested as a means of shifting the response towards a cell-based reaction. In certain disease states, including tuberculosis, lepra and psoriasis the immune reaction is normaly biased towards a humoral response when in fact the appropriate response would be cell based. Temporal inhibition of 1 lβHSDl, local or systemic, might be used to push the immune system into the appropriate response (Mason, D. (1991) Immunology Today 12: 57-60; Rook et al., supra). An analogous use of 1 lβHSDl inhibition, in this case temporal, would be to booster the immune response in association with immunization to ensure that a cell based response would be obtained, when desired.
6. Reduction of intraocular pressure Recent data suggest that the levels of the glucocorticoid target receptors and the
I I βHSD enzymes determines the susceptibility to glaucoma (Stokes, J. et al. (2000) Invest. Ophthalmol. 41: 1629-1638). Further, inhibition of 1 lβHSDl was recently presented as a novel approach to lower the intraocular pressure (Walker E. A. et al, poster P3-698 at the Endocrine society meeting June 12-15, 1999, San Diego). Ingestion of carbenoxolone, a non-specific inhibitor of 11 βHSD 1 , was shown to reduce the intraocular pressure by 20% in normal subjects. In the eye, expression of 1 lβHSDl is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris. In contrast, the distant isoenzyme 1 lβHSD2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage. Thus, 1 lβHSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
7. Reduced osteoporosis
Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess. Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., Cheng, S.L. and Kim, G.S. (1999) J. Endocrinol. 162: 371- 379). The negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 1 lβHSDl in the glucocorticoid effect (Bellows, C.G., Ciaccia, A. and Heersche, J.N.M. (1998) Bone 23: 119-125). Other data suggest a role of 1 lβHSDl in providing sufficiently high levels of active glucocorticoid in osteoclasts, and thus in augmenting bone resorption (Cooper, M.S. et al. (2000) Bone 27: 375-381). Taken together, these different data suggest that inhibition of 1 lβHSDl may have beneficial effects against osteoporosis by more than one mechanism working in parallel.
8. Reduction of hypertension
Bile acids inhibit 1 lβ-hydroxy steroid dehydrogenase type 2. This results in a shift in the overall body balance in favour of cortisol over cortisone, as shown by studying the ratio of the urinary metabolites (Quattropani C, Nogt B., Odermatt A., Dick B., Frey B.M., Frey F.J. (2001) J Clin Invest. Νov; 108(9): 1299-305. "Reduced activity of llbeta- hydroxysteroid dehydrogenase in patients with cholestasis".). Reducing the activity of 1 lbHSDl in the liver by a selective inhibitor is predicted to reverse this imbalance, and acutely counter the symptoms such as hypertension, while awaiting surgical treatment removing the biliary obstruction. WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may, e.g., be used against cancer, inflammation and arthritis. US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof. Further, US 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity. Additionally, tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4- c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465. CODEN: FAXXA3; FR 94123 19690704 CAN 72:100685 AN 1970:100685 CAPLUS and 4,5,6,7- Tetrahydrothiazolo[5,4-c]pyridines. Neth. Appl. (1967), 39 pp. CODEN: NAXXAN NL 6610324 19670124 CAN 68:49593, AN 1968: 49593 CAPLUS. WO 98/16520 discloses compounds inhibiting matrix metalloproteinases (MMPs) and TNF-α converting enzyme (TACE). EP 0 749 964 Al and US 5,962,490 disclose compounds having an endothelin receptor antagonist activity. WO 00/02851 discloses compounds associated with a disturbed cGMP balance. US 5,783,697 discloses thiophene derivatives as inhibitors of PGE2 and LTB4. EP 0 558 258, EP 0 569 193, and EP 1 069 114 disclose isoxazole derivatives as endothelin agonists and antagonists.
9. Wound healing
Cortisol performs a broad range of metabolic functions and other functions. The multitude of glucocorticoid action is exemplified in patients with prolonged increase in plasma glucocorticoids, so called "Cushing's syndrome". Patients with Cushing's syndrome have prolonged increase in plasma glucocorticoids and exhibit impaired glucose tolerance, type 2 diabetes, central obesity, and osteoporosis. These patients also have impaired wound healing and brittle skin (Ganong, W.F. Review of Medical Physiology. Eighteenth edition ed. Stamford, Connecticut: Appleton & Lange; 1997). Glucocorticoids have been shown to increase risk of infection and delay healing of open wounds (Anstead, G.M. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11(6):277-85). Patients treated with glucocorticoids have 2-5-fold increased risk of complications when undergoing surgery (Diethelm, A.G. Surgical management of complications of steroid therapy. Aim Surg 1977; 185(3):251-63). The European patent application No. EP 0902288 discloses a method for diagnosing the status of wound healing in a patient, comprising detecting cortisol levels in said wound. The authors suggest that elevated levels of cortisol in wound fluid, relative to normal plasma levels in healthy individuals, conelates with large, non-healing wounds (Hutchinson, T.C., Swanike,r H.P. Wound diagnosis by quantitating cortisol in wound fluids. European patent application No. EP 0 902 288, published 17.03.1999). In humans, the 11 βHSD catalyzes the conversion of cortisol to cortisone, and vice versa. The parallel function of 11 βHSD in rodents is the interconversion of corticosterone and 11-dehydrocorticosterone (Frey F.J., Escher, G., Frey, B.M. Pharmacology of 11 beta- hydroxysteroid dehydrogenase. Steroids 1994;59(2):74-9). The ratio of total cortisone to cortisol in human plasma is 0.2 in adults. However, the concentration of free cortisol and cortisone are almost equal, since most cortisol, but very little cortisone is protein bound. Cortisone thus functions as a large precursor pool for active glucocorticoids (Hammami, M.M, Siiteri, P.K. Regulation of 11 beta-hydroxysteroid dehydrogenase activity in human skin fϊbroblasts: enzymatic modulation of glucocorticoid action. J Clin Endocrinol Metab 1991;73(2):326-34). Two isoenzymes of 11 βHSD, 11 βHSD 1 and l lβHSD2, have been characterized, and differ from each other in function and tissue distribution (Albiston, A.L., Obeyesekere, N.R., Smith, R.E., Krozowski, Z.S., Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994; 105(2):R11-7). Mineralocorticoid receptors (MR) have similar affinity for cortisol and aldosterone, the active mineralocorticoid and circulating levels of glucocorticoids are substantially higher than levels of mineralocorticoids. Thus, for selectivity of mineralocorticoids in mineralocorticoid-target tissues, an additional mechanism must operate. This paradox led to the finding of the physiological role of 1 lβHSD2 in kidneys and other mineralocorticoid tissues. 1 lβHSD2 catalyses the inactivation of cortisol to cortisone, and thereby protects MR from circulating glucocorticoids and confers specificity of aldosterone for MR (Funder, J.W., Pearce, P.T., Smith, R., Smith, A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988;242(4878):583-5). 1 lβHSD2 is expressed in kidney, salivary glands, placenta, ileum, distal colon and epithelia of respiratory tract, where it is co-localized with MR (Hirasawa, G., Sasano, H., Takahashi, K., Fukushima, K., Suzuki, T., Hiwatashi, Ν., et al. Colocalization of 11 beta- hydroxysteroid dehydrogenase type II and mineralocorticoid receptor in human epithelia. J Clin Endocrinol Metab 1997;82(11):3859-63; Krozowski, Z., MaGuire, J.A., Stein-Oakley, A.Ν., Dowling, J., Smith, R.E., Andrews, R,K. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J Clin Endocrinol Metab 1995;80(7):2203-9). In vitro 11 β-HSDl has the capacity to act both as oxidase and reductase, but in vivo it mainly functions as a reductase, i.e. converting cortisone to cortisol and thereby locally increase glucocorticoid action. In contrast to 11 β-HSD2 which uses NAD as co- factor, 1 lβ-HSDl is NADP dependent (Mercer WR, Krozowski ZS. Localization of an 11 beta hydroxysteroid dehydrogenase activity to the distal nephron. Evidence for the existence of two species of dehydrogenase in the rat kidney. Endocrinology 1992;130(l):540-3). Like GR, 1 lβ-HSDl is expressed in numerous tissues like liver, adipose tissue, adrenal cortex, gonads, lung, pituitary, brain, eye etc (Monder C, White PC. 11 beta-hydroxysteroid dehydrogenase. Nitam Horm 1993;47:187-271; Stewart PM, Krozowski ZS. 11 beta-Hydroxysteroid dehydrogenase. Nitam Horm 1999;57:249-324; Stokes J, Noble J, Brett L, Phillips C, Seckl JR, O'Brien C, et al. Distribution of glucocorticoid and mineralocorticoid receptors and 1 lbeta-hydroxysteroid dehydrogenases in human and rat ocular tissues. Invest Ophthalmol Vis Sci 2000;41(7):1629-38). The function of 1 lβ-HSDl is to fine-tune local glucocorticoid action. It acts to amplify glucocorticoid action in certain cells to maintain basal metabolic function during for example the diurnal nadir of glucocorticoid secretion. 1 lβ-HSD activity has been shown in the skin of humans and rodents, in human fibroblasts and in rat skin pouch tissue (Hammami et al., supra; Cooper MS, Moore J, Filer A, Buckley CD, Hewison M, Stewart PM. 1 lbeta-hydroxysteroid dehydrogenase in human fibroblasts: expression and regulation depends on tissue of origin. ENDO 2003 Abstracts 2003; Teelucksingh S, Mackie AD, Burt D, Mclntyre MA, Brett L, Edwards CR. Potentiation of hydrocortisone activity in skin by glycynhetinic acid. Lancet 1990;335(8697): 1060-3; Slight SH, Chilakamani VK, Nasr S, Dhalla AK, Ramires FJ, Sun Y, et al. Inhibition of tissue repair by spironolactone: role of mineralocorticoids in fibrous tissue formation. Mol Cell Biochem 1998;189(1- 2):47-54). Wound healing consists of serial events including inflammation, fibroblast proliferation, secretion of ground substances, collagen production, angiogenesis, wound contraction and epithelialization. It can be divided in three phases; inflammatory, proliferative and remodeling phase (reviewed in Anstead et al., supra). In surgical patients, treatment with glucocorticoids increases risk of wound infection and delay healing of open wounds. It has been shown in animal models that restraint stress slows down cutaneous wound healing and increases susceptibility to bacterial infection during wound healing. These effects were reversed by treatment with the glucocorticoid receptor antagonist RU486 (Mercado, A.M., Quan, N., Padgett, D.A., Sheridan, J.F., Marucha, P.T. Restraint stress alters the expression of interleukin-1 and keratinocyte growth factor at the wound site: an in situ hybridization study. J Neuroimmunol 2002;129(l-2):74-83; Rojas, I.G., Padgett, D.A., Sheridan, J.F., Marucha, P.T. Stress-induced susceptibility to bacterial infection during cutaneous wound healing. Brain Behav Immun 2002;16(l):74-84). Glucocorticoids produce these effects by suppressing inflammation, decrease wound strength, inhibit wound contracture and delay epithelialization (Anstead et al., supra). Glucocorticoids influence wound healing by interfering with production or action of cytokines and growth factors like IGF, TGF-β, EGF, KGF and PDGF (Beer, H.D., Fassler, R, Werner, S. Glucocorticoid-regulated gene expression during cutaneous wound repair. Nitam Horm 2000;59:217-39; Hamon, G.A., Hunt, T.K., Spencer, E.M. In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds. Growth Regul 1993;3(l):53-6; Laato, M., Heino, J., Kahari, N.M., Νiinikoski, J., Gerdin, B. Epidermal growth factor (EGF) prevents methylprednisolone- induced inhibition of wound healing. J Surg Res 1989;47(4):354-9; Pierce, G.F., Mustoe, T.A., Lingelbach, J., Masakowski, N.R., Gramates, P., Deuel, T.F. Transforming growth factor beta reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor. Proc Νatl Acad Sci U S A 1989;86(7):2229-33). It has also been shown that glucocorticoids decrease collagen synthesis in rat and mouse skin in vivo and in rat and human fibroblasts (Oishi, Y., Fu, Z.W., Ohnuki, Y., Kato, H., Νoguchi, T. Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment: effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 2002;147(5):859-68). WO 01/90090 discloses thiazole compounds, which compounds inhibit the human 1 lβ-HSDl, and may be useful for treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders and immune disorders. Other 1 lβ-HSDl inhibitors are disclosed in, e.g., WO 01/90091; WO 01/90092; WO 01/90093; WO 01/90094; WO 03/043999; WO 03/044000; WO 03/044009; Swedish patent application No. SE 0301504- 7, filed on May 21, 2003; and Swedish patent application Nos. SE 0301882-7, 0301883-5, 0301884-3, 0301885-0, 0301886-8, 0301887-6, 0301888-4, and 0301889-2, all filed on June 25, 2003. SUMMARY OF THE INVENTION
The compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (1 l-β-HSD , and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, hypertension, and wound healing. One object of the present invention is a compound of the general formula (I)
Figure imgf000011_0001
wherein
R and R are each independently selected from hydrogen; -s-alkyl; C3-10-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C2.8-alkenyl; C3.10- cycloalkyl-C-s-alkyl; C3-ι0-cycloalkenyl; Cs-io-cycloalkenyl- -s-alkyl; -s-acyl; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl; heterocyclyl-Cι-8-alkyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-Cι-8-alkyl, Q-s-alkoxy, and heterocyclyl; indanyl; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3-ιo- cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl- -s-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl;
X is CH2; Y is CH2, CO or a single bond;
R is hydrogen; Cι-8-alkyl; C3-ιo-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Cι-8-alkyl, Q-s-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci-
8-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; Cι-8-alkyl; Oj-to-cycloalkyl optionally independently substituted by one or more of Cj.g-alkyl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3-ι0-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, -8-alkoxy, halo-Cj-8- alkoxy, arylcarbonyl, and carboxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of C-s-alkyl and halogen; Cj-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo-Ci-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, -s-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl;
C -ι0-cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR , wherein R is selected from Cι-8-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and Cι-8-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C3-ιo-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cι-8-alkyl, and -s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Q-s-alkoxy, Cι-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen, Ci-s- alkoxy, mono-, or di-Cι-8-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo- -s-alkyl, Cι-8-alkoxy, and nitro; or pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof; with the provisos that: 1 • R and R are each independently selected from hydrogen; 2-butyl; isobutyl; tert- butyl; 2-methylbutyl; 1,1,3,3-tetramethylbutyl; cyclopropyl; cyclopentyl; cycloheptyl; cyclooctyl; C3-ι0-bicycloalkyl; C3-ιo-tricycloalkyl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl; (1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1. ljhept- 3-yl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3_ι0-cycloalkenyl; C3-ι0-cycloalkenyl-Cι-8-alkyl; heterocyclyl substituted by one or more of .s-alkyl; heterocyclyl-Cι-8-alkyl; 1- naphthyl; phenyl substituted by one or more of halogen, d-s-alkyl, halo-Cι-8-alkyl, d-8-alkoxy, and heterocyclyl; indanyl; 4-chlorobenzyl; 4-methylbenzyl; (1R)-1- phenylethyl; (lS)-l-phenylethyl; 2-phenylethyl; (2R)-2-ρhenylproρyl; (2S)-2- phenylpropyl; aryl-C3-ι0-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl substituted by one or more of aryloxy; heterocyclyl-Ci- 8-alkyl; or form together with the nitrogen atom bonded thereto azepan-1-yl;
• when either R1 or R2 is 1 -naphthyl; phenyl substituted by one or more of halogen, Ci-s-alkyl, halo-Cι-8-alkyl, Cj-8-alkoxy, and heterocyclyl, then R4 and R5 are each independently selected from C -ι0-cycloalkyl optionally substituted by one or more of Q-s-alkyl; cyclopropylmethyl; C3.10-cycloalkylcarbonyl; 2-phenylethyl; 2- chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; d-8-acyl optionally independently substituted by one or more of aryloxy; aryl-d-8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo- Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, C].8-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl; C3-ι0- cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; or either of R4 and R5 is hydrogen and the other of R4 and R5 is selected from C3-ι0-cycloalkyl optionally substituted by one or more of Cι-8-alkyl; cyclopropylmethyl; C3.10- cycloalkylcarbonyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2- methylbenzyl; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, d-8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, Q-s-alkyl and aryl; heteroaryl-d-8- alkylcarbonyl; C3-]o-cycloalkylcarbonyl;
• when both R1 and R2 are hydrogen, then R3 is C3-!o-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Cι-8-alkyl, Cι-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d-s-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; d-s-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3.10-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, Cι-8- alkoxy, halo-Cι-8-alkoxy, arylcarbonyl, and carboxy; aryl-d-s-alkyl optionally independently substituted by one or more of Cι-8-alkyl and halogen; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-d-8-acyl optionally independently substituted by one or more of halogen, d-8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, d-8-alkyl and aryl; heteroaryl-d-8-alkylcarbonyl; C3-!o- cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR6, wherein R6 is selected from d-8-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and d-8-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; 1 1 10 1 1 10 or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C3.10-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cι-8-alkyl, and Ci-s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, d-s-alkyl, d-s-alkoxy, d-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, mono-, or di-Ci-s-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-d-8-alkyl, Cι-8-alkoxy, and nitro.
In prefened embodiments of the present invention, the provisos above do not apply and instead: when either R1 or R2 is optionally substituted aryl, then neither R4 nor R5 is optionally substituted aryl; neither R1 nor R2 is methyl, ethyl, allyl, benzyl, acetyl, phenyl and do not form together with the nitrogen atom bonded thereto piperidine; when either R1 or R2 is optionally substituted aryl, then neither R4 nor R5 is Cι-8-alkyl, benzyl, cyclohexylmethyl; the following compounds are excluded:
2-(cyclohexylamino)-N-(2,4-dimethoxyphenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
N-cyclohexyl-2-(cyclohexylamino)-4,5-dihydro-4-oxo-5-thiazoleacetamide; 2-(cyclohexylamino)-N-(3,4-dimethylphenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-N-(2,6-dimethylphenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
N-(4-chloro-2,5-dimethoxyphenyl)-2-(cyclohexylamino)-4,5-dihydro-4-oxo-5- thiazoleacetamide; 2-(cyclohexylamino)-N-(2,5-dichlorophenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-N-(2,5-dimethylphenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-4,5-dihydro-N-(4-methylphenyl)-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-4,5-dihydro-N-(3-methylphenyl)-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-4,5-dihydro-N-(2-methylphenyl)-4-oxo-5-thiazoleacetamide; 2-(cyclohexylamino)-N-(2,4-dimethylphenyl)-4,5-dihydro-4-oxo-5-thiazoleacetamide;
2-(cyclohexylamino)-4,5-dihydro-4-oxo-N-phenyl-5-thiazoleacetamide;
4- [ [4, 5 -dihydro-2-(4-morpholinyl)-4-oxo-5 -thiazolyl] acetyljmorpholine;
4,5-dihydro-2-[(4-methylphenyl)amino]-4-oxo-5-thiazolecarboxamide;
2-amino-4,5-dihydro-4-oxo-5-ethylthiazole; and 2-amino-4,5-dihydro-4-oxo-5-methylthiazole.
It is prefened that:
R1 and R2 are each independently selected from hydrogen; Ci-s-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3-ιo-cycloalkyl-d-8- alkyl; C -ι0-cycloalkenyl; C3-ιo-cycloalkenyl-Cι-8-alkyl; heterocyclyl optionally independently substituted by one or more of d-s-alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-Cι-8-alkyl, Ci-s-alkoxy, and heterocyclyl; indanyl; aryl-d-s-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3-ιo-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Ci-s-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2; Y is CH , CO or a single bond; R3 is hydrogen; Cι-8-alkyl; C3-ι0-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Ci-s-alkyl, Cι-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d- s-alkyl; aryl optionally independently substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; d-8-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3-ιo-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, d-8-alkyl, d-s-alkoxy, halo-d-8- alkoxy, arylcarbonyl, and carboxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of Cι-8-alkyl and halogen; d-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, Cι-8-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl; C _10- cycloalkylcarbonyl; heteroaryl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl substituted by one or more of halogen, nitro, and aryloxy; o 1 1 10 1 1 10 or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C .10-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cj-s-alkyl, and Cι-8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, d-8-alkyl, Ci-s-alkoxy, Cι-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-d-s-alkyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, mono-, or di-d-8- alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, d-s-alkyl, halo-Ci-s-alkyl, Cι-8-alkoxy, and nitro.
It is even more prefened that:
R1 and R2 are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0~3,7~]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl; (lS,2S,3S,5R)-2,6,6-trimethylbϊcyclo[3.1. l]hept-3-yl; bicyclo[2.2.1]hept-5-en-2-yl; (lR)-l-cyclohexylethyl; (lS)-l-cyclohexylethyl; 2-(l- cyclohexenyl)ethyl; 4-(2,2,6,6-tetramethyl)piperidyl; 2-(4-moφholinyl)ethyl; 1 -naphthyl; 2-fluorophenyl; 3-chloro-2-methylphenyl; mesityl; 3,5-di(trifluoromethyl)phenyl; 2,6- dimethylphenyl, 4-(4-morpholinyl)phenyl; 2-methylphenyl; 2-isopropylphenyl; 2- methoxyphenyl; 2-indanyl; 4-chlorobenzyl; 4-methylbenzyl; (lR)-l-phenylethyl; (1S)-1- phenylethyl; 2-phenylethyl; (2R)-2-phenylpropyl; (2S)-2-phenylpropyl; l-(4- chlorophenyl)cyclobutyl; 6-phenoxy-3-pyridyl; 2-(4-morpholinyl)ethyl; orR1 and R2 form together with the nitrogen atom bonded thereto azepan-1-yl;
R3 is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- morpholinyl; N-phthalimidyl; piperidin-1-yl; 4-methylpiperidin-l-yl; 1 -(1,2,3, 4- tetrahydroquinolinyl); 2-( 1 ,2,3 ,4-tetrahydroisoquinolinyl); 8-methyl- 1 -( 1 ,2,3 ,4- tetrahydroquinolinyl); l-[7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolinyl; 3,4- dihydroisoquinolin-2(lH)-yl; 6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl; azocan-1-yl; l-oxa-4-azaspiro[4.5]dec-4-yl; 2- decahydroisoquinolinyl; 1,4-diazepan-l-ium; l,3-dihydro-2H-isoindol-2-yl; 2,3-dihydro- lH-indol-1-yl; pynolidin-1-yl; 3-pyridinyl; 3-indolyl; l,3-benzoxazol-2-yl; 1,3- benzothiazol-2-yl; lH-benzimidazol-2-yl; 4-hydroxy-4-phenylpiperidin-l-yl; 5-(2- chlorophenyl)-l,3,4-oxadiazol-2-yl; 4-chlorophenyl; 4-hydroxyphenyl; 3,4- dihydroxyphenyl; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; methyl; ethyl; n-propyl; isopropyl; n-butyl; cyclohexyl; cycloheptyl; (lR,2R,4S)-bicyclo[2.2. l]hept-2-yl; 4-methylcyclohexyl; cyclopropylmethyl; cyclohexylmethyl; cyclohexylcarbonyl; 1-adamantylcarbonyl; phenyl; 1 -naphthyl; 4- bromophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 4-fluorophenyl; 2,6- difluorophenyl; 3-chloro-2-methylphenyl; 2-methylphenyl; 3-methylphenyl; 4- methylphenyl; 4-methoxyphenyl; 4-(trifluoromethoxy)phenyl; 2-benzoylphenyl; 3- carboxyphenyl; benzyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; 2,2-dimethylpropionamido; phenoxyacetyl; 2-chlorobenzoyl; 2-fluorobenzoyl; 4- chlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 2-chloro-6-fluorobenzoyl; 2,4- dichlorobenzoyl; 2,4,6-trichlorobenzoyl; 2-methoxybenzoyl; 4-methoxybenzoyl; 2-bromo- 5-methoxybenzoyl; 2,4-dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 4- (trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2,5- di(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; 4-cyanobenzoyl; 2- chloro-6-fluorophenylacetyl; 2-chlorophenylsulfonyl; 2,6-difluorophenylsulfonyl; 2- chloro-3-pyridylcarbonyl; 2-furylcarbonyl; 2-thienylcarbonyl; 5-isoxazolylcarbonyl; 5- methyl-3-phenylisoxazol-4-ylcarbonyl; 2-thienylmethylcarbonyl; cyclopropylcarbonyl; cyclohexylcarbonyl; isopentanoyl; indazol-6-yl;
OCONR9R10, wherein R9 and R10 are each independently selected from 2-chloroρhenyl; 4- bromo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; NHCONRπR12, wherein R11 and R12 are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fiuorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2- (trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl;
OR13, wherein R13 is selected from hydrogen; phenyl; 2-chlorophenyl; 4-chloro-3- methylphenyl; 2-methoxyphenyl; 4-carbomethoxy-2-chlorophenyl; 3-(4- morpholinyl)phenyl; 4-phenoxyphenyl; 2-chlorobenzyl; 2-methylbenzyl; 2- methoxybenzyl; 3-(dimethylamino)benzyl; benzoyl; 2-chlorobenzoyl; 2,4-dichlorobenzoyl; 3,4-dichlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 3,4-difluorobenzoyl; 2- chloro-6-fluorobenzoyl; 2,4,6-trichlorobenzoyl; 2,3,4-trifluorobenzoyl; 3-methylbenzoyl; 4-methylbenzoyl; 4-tert-butylbenzoyl; 3-methoxybenzoyl; 4-n-butoxybenzoyl; 2,4- dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 2-bromo-5-methoxybenzoyl; 3- (trifluoromethyl)benzoyl; 2,5-di(trifluoromethyl)benzoyl; 3,5-di(trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; and 4-chloro-3- nitrobenzoyl.
Prefened compounds are Examples 1-10, 17-47, 50-55, 57, 58, 60-69, 71-96, 99-108, 110-
121, 123-128, 131, 132, 134, 136-139, 141-146, 150-153, 155, 156, 161-163, 167-171, 173, 174, 176-184, 187-189, 191-193, 195-284, 286-288, 290-342, 344-346, 348-365, 368,
370-378, 381, and 383-388. Another object of the present invention is a process for the preparation of a compound according to any one of claims 1 to 4, comprising at least one of the following steps: a) reaction of an isothiocyanate with ammonia to give a thiourea, b) reaction of an amine with ethoxycarbonylisothiocyanate to give a thiourea, c) reaction of a thiourea with maleic anhydride to give a thiazolone carboxy lie acid, d) reaction of a thiazolone carboxylic acid with 2-chloro-l-methylpyridinium iodide in the presence of an amine to give a thiazolone amide, e) reaction of a thiourea with 2-bromo-γ-butyrolactone to give a thiazolone alcohol, f) reaction of a thiazolone alcohol with an acid chloride or an isocyanate in the presence of a base to give a thiazolone ester, g) reaction of a thiazolone alcohol with triphenylphosphine and then with a benzyl alcohol in the presence of dietyl azodicarboxylate to give a thiazolone ether, h) reaction of a thiourea with an N-substituted 3-bromo-l-phenylpynolidin-2-one to give a thiazolone amine, i) reaction of a thiazolone alcohol with triphenylphosphine dibromide to give a thiazolone bromide, j) reaction of a thiazolone bromide with an N-substituted aniline to give a thiazolone amine, k) reaction of a thiourea with 3-(4-chlorobenzoyl)acrylic acid to give a thiazolone,
1) reaction of a thiourea with 3-bromopynolidin-2-one to give a thiazolone amine, m) reaction of a thiazolone amine with a benzoyl chloride or a sulfonyl chloride to give a thiazolone amide or a thiazolone sulfonamide, respectively, n) hydrolysis of a thiazolone amide with hydrazine to give a thiazolone amine, o) esterification of a thiazolone carboxylic acid with a phenol in the presence of a base and a coupling agent to give a thiazolone phenol ester, p) reaction of a thiourea with a lH-pynole-2,5-dione to give a thiazolone amide, q) reaction of a thiazolone carboxylic acid with diphenylphosphoryl azide and then Λvith a benzoyl chloride to give a thiazolone amide, r) amidification of a thiazolone carboxylic acid with an amine in the presence of a base and a coupling agent to give a thiazolone amide, s) reaction of an N-C3-ι0-cycloalkylthiourea with a carboxylic acid to give a thiazolone, t) reaction of an N-C3-ιo-cycloalkylthiourea with a bromo substituted carboxylic ester to give a thiazolone, u) reaction of a thiazolone carboxylic acid with 2-chlorobenzohydrazide in the presence of
POCl3 to give a thiazolone containing a triazole group, v) reaction of a thiazolone carboxylic acid with an aromatic amine to give a thiazoline containing a benzimidazole, benzoxazole or a benzothiazole group, and w) alkylation of a thiazolone amine. Another object of the present invention is a compound of the general formula (I)
Figure imgf000019_0001
wherein
R1 and R2 are each independently selected from hydrogen; Ci-s-alkyl; C3-io-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C2-8-alkenyl; C3-10- cycloalkyl-Ci-8-alkyl; C .ι0-cycloalkenyl; C3.ιo-cycloalkenyl-Ci-8-alkyl; Cι_8-acyl; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι_8-alkyl, d-8-alkoxy, and heterocyclyl; indanyl; aryl-Cι_8-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3-10- cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Cι-8-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl;
X is CH2;
Y is CH2, CO or a single bond; R3 is hydrogen; Cι-8-alkyl; C3-i0-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl, halo-d-8-alkyl, d-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d- s-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R and R5 are each independently selected from hydrogen; Ci-s-alkyl; C -ιo-cycloalkyl optionally independently substituted by one or more of d-8-alkyl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3-i0-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, d-s-alkyl, Ci-s-alkoxy, halo-d-s- alkoxy, arylcarbonyl, and carboxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of d-s-all yl and halogen; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Ci-s-acyl optionally independently substituted by one or more of halogen, d-8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl and aryl; heteroaryl-Ci-s-alkylcarbonyl; f f
C3-ιo-cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR , wherein R is selected from Cι-8-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and C].8-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of ■j 1 1 10 1 1 halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C3-ιo-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cι-8-alkyl, and Ci-s-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R is OR , wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι-8-alkoxy, d-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen, Cι-8- alkoxy, mono-, or di-Cι-8-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-d-8-alkyl, Cι-8-alkoxy, and nitro; or pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof; for use in therapy. Also featured are methods for treating a patient comprising administering a compound of formula (I) of any of claims 6 to 9.
It is prefened that: R1 and R2 are each independently selected from hydrogen; Cι-8-alkyl; C -ι0-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3-10-cycloalkyl-d-s- alkyl; C3-10-cycloalkenyl; C3-ι0-cycloalkenyl-Cι-8-alkyl; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl; heterocyclyl-Ci-s-alkyl; aryl optionally independently substituted by one or more of halogen, d-8-alkyl, halo-Cι-8-alkyl, d-8-alkoxy, and heterocyclyl; indanyl; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3.10-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Ci-s-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2;
Y is CH2, CO or a single bond;
R3 is hydrogen; Cι-8-alkyl; C3-ι0-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Ci-s-alkyl, Cι-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-d- s-alkyl; aryl optionally independently substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; Cι-8-alkyl; C3-ι0-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C3-10-cycloalkyl-Cι-8-alkyl; C3-10-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, d-8-alkyl, Cι-8-alkoxy, halo-d-8- alkoxy, arylcarbonyl, and carboxy; aryl-Cι_s-alkyl optionally independently substituted by one or more of Cι-8-alkyl and halogen; d-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Ci-s-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, d_8-alkyl and aryl; heteroaryl-d-8-alkylcarbonyl; C3-10- cycloalkylcarbonyl; heteroaryl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C -ι0-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-C].8-alkyl, and d_8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cj-s-alkyl, Ci-s-alkoxy, C].8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Cι.8-alkyl optionally independently substituted by one or more of halogen, d-8-alkoxy, mono-, or di-d-8- alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι-8-alkyl, Ci-s-alkoxy, and nitro.
It is even more prefened that: R1 and R2 are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0~3,7~]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]heρt-3-yl; (lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl; bicyclo[2.2.1]hept-5-en-2-yl; (lR)-l-cyclohexylethyl; (lS)-l-cyclohexylethyl; 2-(l- cyclohexenyl)ethyl; 4-(2,2,6,6-tetramethyl)piperidyl; 2-(4-morpholinyl)ethyl; 1 -naphthyl; 2-fluorophenyl; 3-chloro-2-methylphenyl; mesityl; 3,5-di(trifluoromethyl)phenyl; 2,6- dimethylphenyl, 4-(4-moφholinyl)phenyl; 2-methylphenyl; 2-isopropylphenyl; 2- methoxyphenyl; 2-indanyl; 4-chlorobenzyl; 4-methylbenzyl; (lR)-l-phenylethyl; (1S)-1- phenylethyl; 2-phenylethyl; (2R)-2-phenylpropyl; (2S)-2-phenylpropyl; l-(4- chlorophenyl)cyclobutyl; 6-phenoxy-3-pyridyl; 2-(4-moφholinyl)ethyl; or R1 and R2 form together with the nitrogen atom bonded thereto azepan-1-yl;
R3 is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- moφholinyl; N-phthalimidyl; piperidin-1-yl; 4-methylpiperidin-l-yl; 1-(1,2,3,4- tetrahydroquinolinyl); 2-( 1 ,2,3 ,4-tetrahydroisoquinolinyl); 8-methyl- 1 -( 1 ,2,3 ,4- tetrahydroquinolinyl); l-[7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolinyl; 3,4- dihydroisoquinolin-2( lH)-yl; 6,7-dimethoxy-3 ,4-dihydroisoquinolin-2( 1 H)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl; azocan-1-yl; l-oxa-4-azaspko[4.5]dec-4-yl; 2- decahydroisoquinolinyl; 1,4-diazepan-l-ium; l,3-dihydro-2H-isoindol-2-yl; 2,3-dihydro- lH-indol-1-yl; pynolidin-1-yl; 3-pyridinyl; 3-indolyl; l,3-benzoxazol-2-yl; 1,3- benzothiazol-2-yl; lH-benzimidazol-2-yl; 4-hydroxy-4-phenylpiperidin-l-yl; 5-(2- chlorophenyl)-l,3,4-oxadiazol-2-yl; 4-chlorophenyl; 4-hydroxyphenyl; 3,4- dihydroxyphenyl; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; methyl; ethyl; n-propyl; isopropyl; n-butyl; cyclohexyl; cycloheptyl; (lR,2R,4S)-bicyclo[2.2. l]hept-2-yl; 4-methylcyclohexyl; cyclopropylmethyl; cyclohexylmethyl; cyclohexylcarbonyl; 1-adamantylcarbonyl; phenyl; 1 -naphthyl; 4- bromophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 4-fluorophenyl; 2,6- difluorophenyl; 3-chloro-2-methylphenyl; 2-methylphenyl; 3-methylphenyl; 4- methylphenyl; 4-methoxyphenyl; 4-(trifluoromethoxy)phenyl; 2-benzoylphenyl; 3- carboxyphenyl; benzyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; 2,2-dimethylpropionamido; phenoxyacetyl; 2-chlorobenzoyl; 2-fluorobenzoyl; 4- chlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 2-chloro-6-fluorobenzoyl; 2,4- dichlorobenzoyl; 2,4,6-trichlorobenzoyl; 2-methoxybenzoyl; 4-methoxybenzoyl; 2-bromo- 5-methoxybenzoyl; 2,4-dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 4- (trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2,5- di(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; 4-cyanobenzoyl; 2- chloro-6-fluorophenylacetyl; 2-chlorophenylsulfonyl; 2,6-difluorophenylsulfonyl; 2- chloro-3-pyridylcarbonyl; 2-furylcarbonyl; 2-thienylcarbonyl; 5-isoxazolylcarbonyl; 5- methyl-3 -phenylisoxazol-4-ylcarbonyl; 2-thienylmethylcarbonyl; cyclopropylcarbonyl; cyclohexylcarbonyl; isopentanoyl; indazol-6-yl;
OCONR9R10, wherein R9 and R10 are each independently selected from 2-chlorophenyl; 4- bromo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; NHCONR1 lR12, wherein R1 ' and R12 are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2- (trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl; OR13, wherein R13 is selected from hydrogen; phenyl; 2-chlorophenyl; 4-chloro-3- methylphenyl; 2-methoxyphenyl; 4-carbomethoxy-2-chlorophenyl; 3-(4- moφholinyl)phenyl; 4-phenoxyphenyl; 2-chlorobenzyl; 2-methylbenzyl; 2- methoxybenzyl; 3-(dimethylamino)benzyl; benzoyl; 2-chlorobenzoyl; 2,4-dichlorobenzoyl; 3,4-dichlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 3,4-difluorobenzoyl; 2- chloro-6-fluorobenzoyl; 2,4,6-trichlorobenzoyl; 2,3,4-trifluorobenzoyl; 3-methylbenzoyl; 4-methylbenzoyl; 4-tert-butylbenzoyl; 3-methoxybenzoyl; 4-n-butoxybenzoyl; 2,4- dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 2-bromo-5-methoxybenzoyl; 3- (trifluoromethyl)benzoyl; 2,5-di(trifluoromethyl)benzoyl; 3,5-di(trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; and 4-chloro-3- nitrobenzoyl. Prefened compounds are Examples 1-388. The compound (I) of any of claims 6 to 9 may advantageously be used in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation. Another object of the present invention is a pharmaceutical formulation comprising a compound of any of claims 6 to 9 as active ingredient, in combination with a pharmaceutically acceptable diluent or canier, especially for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation. The pharmaceutical formulation can include a second active ingredient. The second active ingredient can be an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1 or it can have some other activity. Another object of the present invention is a method for the prophylaxis or treatment of a 11-β-hydroxy steroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation comprising administering the compound of any of claims 6 to 9 to an individual. Another object of the present invention is a method for inhibiting a 11-β- hydroxysteroid dehydrogenase type 1 enzyme comprising administering the compound of any of claims 6 to 9 to an individual. Another object of the present invention is the use of a compound of any of claims 6 to 9 for the manufacture of a medicament for use in the prophylaxis or treatment of a 11-β- hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno- modulation. Examples of 11-β-hydroxy steroid dehydrogenase type 1 enzyme-mediated disorders include: diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases. The compound of any of claims 6 to 9 may be used for the treatment or prophylaxis of a disorder involving delayed or impaired wound healing. It is prefened that the disorder involving delayed or impaired wound healing is diabetes. It is also prefened that the disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids. The compound of any of claims 6 to 9 may be used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers. It is prefened that the immuno-modulation is selected from tuberculosis, lepra, and psoriasis. Also within the scope of this invention is a method for making a compound of formula (I) with the proviso. The method includes taking any intermediate compound delineated herein, reacting it with one or more reagents to form a compound of formula (I) with the proviso including any processes specifically delineated herein. Other features and advantages of the invention will be apparent from the detailed description and claims.
DETAILED DESCRIPTION OF THE INVENTION
The compounds according to the present invention may be used in several indications which involve 11-β-hydroxysteroid dehydrogenase type 1 enzyme. Thus, the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis, E. 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical Endocrinology and Metabolism, 81, 3441-3447) and may also be used disorders in the immune system (see Franchimont et al, "Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes", The journal of Immunology 2000, Feb 15, vol 164 (4), pages 1768-74) and also in the above listed indications. The various terms used, separately and in combinations, in the above definition of the compounds having the formula (I) will be explained. The term "aryl" in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph), naphthyl, and indanyl (i.e., 2,3-dihydroindenyl), which optionally may be substituted by Cj-e-alkyl. Examples of substituted aryl groups are benzyl, and 2-methylphenyl. The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system. Examples of such heteroaryl rings are pynole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline (i e 2,3-dihydroindole), isoindoline (i e 1,3- dihydroisoindole), benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3- benzoxadiazole, benzopyrazole; benzothiazole, 2,1,3-benzothiazole, 2,1,3- benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4- tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5-naphthyridine, 1,8- naphthyridine, acridine, fenazine and xanthene. The term "heterocyclic" and "heterocyclyl" in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the reminder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the conesponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pynolidine, piperidine, piperazine, moφholine, thiomoφholine, 1,4- oxazepane, azepane, phthalimide, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, hexahydroazepine, 3,4-dihydro-2(lΗ)isoquinoline, 2,3- dihydro-lH-indole, l,3-dihydro-2H-isoindole, azocane, l-oxa-4-azaspiro[4.5]dec-4-ene, decahydroisoquinoline, and 1,4-diazepane. Cι-8-alkyl in the compound of formula (I) according to the present application may be a straight or branched alkyl group containing 1-8 carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, n-heptyl, and n-octyl. For parts of the range "d-s-alkyl" all subgroups thereof are contemplated such as d-7-alkyl, d-6-alkyl, d-5-alkyl, C1.4-alkyl, C2.8-alkyl, C2. 7-alkyl, C2.6-alkyl, C2-5-alkyl, C -7-alkyl, C4.6-alkyl, etc. Ci-s-alkoxy in the compound of formula (I) according to the present application may be a straight or branched alkoxy group containing 1-8 carbon atoms. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert- butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, n-heptyloxy, and n-octyloxy. For parts of the range "Cι-6-alkoxy" all subgroups thereof are contemplated such as Cι- - alkoxy, d-6-alkoxy, Ci-s-alkoxy, Cι-4-alkoxy, C2.8-alkoxy, C2-7-alkoxy, C2.6-alkoxy, C2-5- alkoxy, C3. -alkoxy, C4.6-alkoxy, etc. Ci-s-acyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 1-8 carbon atoms. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, n-hexanoyl, n- heptanoyl, and n-octanoyl. For parts of the range "Cι-8-acyl" all subgroups thereof are contemplated such as Cj-7-acyl, Cι-6-acyl, Cι-5-acyl, Cι-4-acyl, C2-8-acyl, C . -acyl, C .6- acyl, C2-5-acyl, C . -acyl, C4-6-acyl, etc. C2-8-alkenyl in the compound of formula (I) according to the present application may be a straight or branched acyl group containing 2-8 carbon atoms. Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1- pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, 1-heptenyl, and 1-octenyl. For parts of the range "C2.8-alkenyl" all subgroups thereof are contemplated such as C2.7-alkenyl, C2.6- alkenyl, C2-5-alkenyl, C2-4-alkenyl, C3.8-alkenyl, C -7-alkenyl, C3-6-alkenyl, C3-5-alkenyl, C4-7-alkenyl, C5.6-alkenyl, etc. C3-ιo-cycloalkyl is either of C3.10-monocycloalkyl, d-to-bicycloalkyl, and C3-10- tricycloalkyl. C -ιo-monocycloalkyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted monocyclic alkyl group containing totally 3-10 carbon atoms. Exemplary monocycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. For parts of the range "C3-ι0-monocycloalkyl" all subgroups thereof are contemplated such as C3.9-monocycloalkyl, C3.8-monocycloalkyl, C3. -monocycloalkyl, C3.6-monocycloalkyl, C .5-monocycloalkyl, C4-ι0-monocycloalkyl, C5-ι0-monocycloalkyl, C6-10-monocycloalkyl, C7-ιo-monocycloalkyl, C8.9-monocycloalkyl, etc. C3-ι0-bicycloalkyl in the compound of fonnula (I) according to the present application may be an optionally alkyl substituted bicyclic alkyl group containing totally 3- 10 carbon atoms. Exemplary bicycloalkyl groups include bicyclo[2.2.1]hept-2-yl, (lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl, and (lS,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl. For parts of the range "C3-ιo-bicycloalkyl" all subgroups thereof are contemplated such as C3.9-bicycloalkyl, C .8-bicycloalkyl, C3. -bicycloalkyl, C - 6-bicycloalkyl, C3.5-bicycloalkyl, C4-ι0-bicycloalkyl, C5-ιo-bicycloalkyl, Cβ-io-bicycloalkyl, C7-10-bicycloalkyl, C8.9-bicycloalkyl, etc. C3-i0-tricycloalkyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted tricyclic alkyl group containing totally 3-10 carbon atoms. Exemplary tricycloalkyl groups include 1-adamantyl, noradamantyl, and tricyclo[3.3.1.0~3,7~]non-3-yl. For parts of the range "C3-ιo-tricycloalkyl" all subgroups thereof are contemplated such as C3.9-tricycloalkyl, C3.8-tricycloalkyl, C .7- tricycloalkyl, C3-6-tricycloalkyl, C3-5-tricycloalkyl, C4-ι0-tricycloalkyl, C5-ι0-tricycloalkyl, Q-io-tricycloalkyl, C7-ι0-tricycloalkyl, C8.9-tricycloalkyl, etc. C3-ιo-cycloalkenyl in the compound of formula (I) according to the present application may be an optionally alkyl substituted cyclic, bicyclic or tricyclic alkenyl group containing totally 3-10 carbon atoms. Exemplary cycloalkenyl groups include cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl, cyclodecenyl, and bicyclo[2.2. l]hept-5-en-2-yl. For parts of the range "C3. to-cycloalkenyl" all subgroups thereof are contemplated such as C3-9-cycloalkenyl, C -8- cycloalkenyl, C -7-cycloalkenyl, C3.6-cycloalkenyl, C3.5-cycloalkenyl, C4-10-cycloalkenyl, C5-ιo-cycloalkenyl, C6-ιo-cycloalkenyl, C7-ι0-cycloalkenyl, C8.9-cycloalkenyl, etc. The term "halogen" in the present description is intended to include fluorine, chlorine, bromine and iodine. The term "sulfanyl" in the present description means a thio group. With the expression "mono- or di-substituted" is meant in the present description that the functionalities in question may be substituted with independently d-8-acyl, C -8- alkenyl, Cι-8-(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g. azetidine, pynolidine, piperidine, piperazine, moφholine and thiomoφholine, which heterocyclic rings optionally may be substituted with d-s-alkyl. With the expression "optionally mono- or disubstituted" is meant in the present description that the functionalities in question may also be substituted with independently hydrogen. When two of the above-mentioned terms are used together, it is intended that the latter group is substituted by the former. For example, C3-ιo-cycloalkyl-Cj.8-alkyl means a
Cι.8-alkyl group that is substituted by a C3-!o-cycloalkyl group. Likewise, a halo-Cι-8-alkyl means a Cι-8-alkyl group that is substituted by a halogen atom. As used herein:
DCM means dichloromethane,
DEAD means diethyl azocarboxylate,
DMF means dimethylfonnamide,
EDCI means l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, Ether means diethyl ether,
EtOAc means ethylacetate,
HOBt means 1-hydroxybenzotriazole,
HPLC means high performance liquid chromatography,
LC means liquid chromatography, MeCN means acetonitrile,
MS means mass spectroscopy,
DPPA means diphenylphosphoryl azide,
RT means room temperature,
SM means starting material, TEA means triethylamine, and
THF means tetrahydrofuran. Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the puφoses detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 11-β-HSDl inhibition, 11-β-HSDl -mediated disease). The term "prodrug forms" in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13-
15). "Pharmaceutically acceptable" means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use. "Pharmaceutically acceptable salts" mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein. Pharmaceutical compositions according to the present invention contain a pharmaceutically acceptable canier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient. In a prefened embodiment, the therapeutic composition is not immunogenic when administered to a human patient for therapeutic puφoses, unless that puφose is to induce an immune response. The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non- aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified. The active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient. Adjuvants may also be present in the composition. Phannaceutically acceptable caniers are well known in the art. Exemplary of liquid earners are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions. The phannaceutical composition according to one of the prefened embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above. Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or fe ic hydroxides, and such organic bases as isopropylamine, trimethylamine, 2- ethylamino ethanol, histidine, procaine and the like. The preparations according to the prefened embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously. Other routes are known to those of ordinary skill in the art. The orally administrable compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pynolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, calcium hydrogen phosphate, sodium starch glycolate, sorbitol or glycine; tabletting lubricant e.g. magnesium stearate, talc, polyethylene glycol or silicon dioxide (optionally colloidal); disintegrants e.g. potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose (optionally microcrystalline), glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g. lecithin, sorbitan monooleate or acacia, non-aqueous vehicles (which may include edible oils), e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p- hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents. "An effective amount" refers to an amount of a compound which confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). A pharmaceutical composition according to the present invention, may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition. A weight percent is a ratio by weight of total composition. Thus, for example, 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition. A suitable daily oral dose for a mammal, preferably a human being, may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate. The compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or canier. The compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods. The compounds of the present invention in labelled fonn, e.g. isotopically labelled, may be used as a diagnostic agent. This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein. The compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in- vitro was studied using the following reagents and methods. The chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, NCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser andFieser 's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof. All publications mentioned herein are hereby incoφorated by reference. By the expression "comprising" means "including but not limited to." Thus, other non-mentioned substances, additives or earners may be present. The invention will now be described in reference to the following Examples. These Examples are not to be regarded as limiting the scope of the present invention, but shall only serve in an illustrative manner. EXAMPLES
EXPERIMENTAL METHODS Scintillation Proximity Assay [1, 2(n) - H]-cortisone was purchased from Amersham Pharmacia Biotech. Anti- cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech. NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma. The human 11-β-hydroxysteroid dehydrogenase type-1 enzyme (11-β-HSDi) was expressed in Pichiapastoris. 18-β- glycynhetinic acid (GA) was obtained from Sigma. The serial dilutions of the compounds were performed on a Tecan Genesis RSP 150. Compounds to be tested were dissolved in DMSO (1 mM) and diluted in 50 mM Tris-HCl, pH 7.2 containing 1 mM EDTA. The multiplication of plates was done on a WallacQuadra. The amount of the product [3H]-cortisol, bound to the beads was determined in a Packard, Top Count microplate liquid scintillation counter. The 11-β-HSDι enzyme assay was canied out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 μL and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 μM), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 μM). Reactions were initiated by the addition of human 11-β-HSDj, either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL). Following mixing, the plates were shaken for 30 to 45 minutes at room temperature. The reactions were tenninated with 10 μL 1 mM GA stop solution.
Monoclonal mouse antibody was then added (10 μL of 4 μM) followed by 100 μL of SPA beads (suspended according to the manufacturers instructions). Appropriate controls were set up by omitting the 11-β-HSDι to obtain the non-specific binding (NSB) value. The plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting. The amount of [3H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter. The calculation of the Ki values for the inhibitors was performed by use of Activity Base. The K; value is calculated from IC50 and the Km value is calculated using the Cheng Prushoff equation (with reversible inhibition that follows the Michaelis-Menten equation): Ki = IC50(l+[S]/Km) [Cheng, Y.C; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108]. The IC50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance. The Ki values of the compounds of the present invention for the 11-β-HSDl enzyme lie typically between about 10 nM and about 10 μM. Illustrative Ki values for some Examples according to the present invention are given below.
Example Ki (nM)
109 709 125 384 261 559 General Reaction schemes
Figure imgf000035_0001
Figure imgf000035_0002
All commercial starting materials are used without any purification. If the appropriate α-bromo carboxylic acid or ester not is commercially availiable, the substances has been prepared in accordance to this method:
The 2-amino-carboxylic acid (1.0 eq.) was suspended in 2.0 M H2SO4 (4 eq.), KBr (8 eq.) was added and the mixture was cooled in an ice-bath. NaNO2 (1.3 eq.) dissolved in water was added slowly. The reaction mixture was stined for 4 h at ice-bath, before allowed to reach room temperature. The reaction mixture was extracted with EtOAc. The organic phase was dried over MgSO4 before concentrated in vacuum. This gave the crude product which was used in the next step without further purification (J. Org. Chem. 2002, 67 (11), 3595-3600; Xinhua Qian; Bin Zheng; Brian Burke; Manohar T. Saindane and David R. Kronenthal).
COMPOUND PREPARATION
General Comments: 1H nuclear magnetic resonance (NMR) and 13C NMR were recorded on a Bruker
PMR 500 spectrometer at 500.1 MHz and 125.1 MHz, respectively or on a JEOL eclipse 270 spectrometer at 270.0 MHz and 67.5 MHz, respectively. All spectra were recorded using residual solvent or tetramethylsilane (TMS) as internal standard. IR spectra were recorded on a Perkin-Elmer Spectrum 1000 FT-IR spectrometer. Electrospray mass spectrometiy (MS) was obtained using an Agilent MSD mass spectrometer. Accurate mass measurements were performed on a Micromass LCT dual probe. Elemental analyses were performed on a Nario El instrument or sent to Mikro Kemi in Uppsala. Analytical HPLC were performed on Agilent 1100 system equipped with System A: ACE 3 (C8, 50x3.0mm) or System B: YMC ODS-AQ, (33x3.0 mm) using the eluent system: water/0.1%TFA and CH3CΝ, lmL/min, with a gradient time of 3 min.
Preparative HPLC was performed on a Gilson system equipped with System A: ACE 5 C8 column (50x20mm) gradient time 5 min, system B: YMC ODS-AQ (150x30mm) gradient time 8.5 min or system C: YMC ODS-AQ (50x20mm) gradient time 5 min using the eluent system: water/0.1%TFA and CH CN. Preparative flash chromatography was performed on Merck silica gel 60 (230-400 mesh). The compounds were automatically named using ACD6.0. General methods
Method A or B was used depending if the isothiacyanate or of the conesponing amine was used. The amines or isothiacyanate was purchased from either Maybridge pic or from Sigma- Aldrich co.
Method A
1.0 eq. of the appropriate isothiocyanate was stined in 2 M ammonia in ethanol (5 eq.) for 18 h at RT. Evaporation in vacuo afforded the crude product, which crystallized upon addition of DCM. The crystals were collected on a filter and air-dried to afford the thiourea.
Method B
1.0 eq. of the amine and ethoxycarbonylisothiocyanate (l.Oeq) were mixed in a test tube. A violently exothermic reaction resulted in a white paste. This was taken up in 5M KOH solution and stined at 70°C for 2 hours at which point LC analysis indicated full hydrolysis of the intermediate. The mixture was cooled, diluted with water and extracted 3 times with chloroform. Subsequent preparative LC yielded the desired thiourea as a colourless oil.
Method C 1.0 eq. of the appropriate thiourea and maleic anhydride (1.0 eq.) were heated to reflux in acetone for 5 h, yielding a white emulsion. Evaporation in vacuo afforded a white solid. The product was triturated with DCM, collected on a filter and air-dried giving the product as a white powder.
Method D
The carboxylic acid 1.0 eq. and 2-chloro-l-methylpyridinium iodide (1.2 eq.) were mixed in DCM for 10 minutes before the amine (1.0 eq.) was added followed by Et N (1.5 eq.). The reaction mixture was stkred at RT for 16 h, full conversion of the SM. The reaction mixture was poured on a Hydromatrix column (pretreated with 1 M HCl) and the crude product was eluted with DCM. The obtained crude product was purified by reverse phase.
Method E
1.0 eq. of the thiourea and 2-bromo-γ-butyrolactone (1.0 eq.) were heated to reflux in acetone for 3 h. Evaporation in vacuo gave a colorless oil which was taken up in saturated NaHCO3 and extracted with DCM. The combined organic layers were dried over Na2SO4, filtered and evaporated in vacuo leaving a white solid.
Method F The alcohol (1.0 eq.) and the appropriate acid chloride or isocyanate (1.0 eq.) were dissolved in DCM and triethylamine (3.0 eq.). The reaction mixture was stined over night at RT. The solvent was removed under reduced pressure and the product was purified using preparative HPLC.
Method G
1.0 eq. of the alcohol and triphenylphosphine (1.2 eq.) were dissolved in THF. The reaction mixture was stined at RT for 10 min. before the appropriate benzyl alcohol (1.2 eq.) and DEAD (1.2 eq.) were added. The reaction mixture was stined at RT over night. The solvent was removed under reduced pressure and the crude was dissolved in DCM and washed with brine. The organic layer was dried (MgSO4) and the solvent was removed under reduced pressure. Purification using preparative afforded the product.
Method H
The appropriate N-substituted 3-bromo-l-phenylpynolidin-2-one (1.0 eq.) and thiourea (1.0 eq.) in acetone was heated to reflux for 3h. NaHCO3 (sat. solution) was added and extracted with DCM. The organic phase was dried (Na2SO4) and concentrated in vacuum to give the product as a solid.
Method I 1.0 eq. of the alcohol and triphenylphosphine dibromide (2.5 eq.) was dissolved in DCM and stined at RT for 16 h. The reaction mixture was washed with water and dried (MgSO4) the solvent was evaporated and the obtained solid crude product was purified by flash chromatography using MeCN as eluent.
1.0 eq. of the obtained bromide and 10 eq. of the appropriate N-substituted aniline were dissolved in DMSO and stined at 60 °C for 16 h. The reaction mixture was mixed with water and the aqueous phase was extracted twice with ether. The combined organic phases were dried (MgSO4) and the solvent was evaporated. The obtained crude product was purified by preparative HPLC. Method J
1.0 eq. of the thiourea and 3-(4-chlorobenzoyl)acrylic acid (1.0 eq.) in water were heated to reflux for 18 h. The precipitate was collected on a filter after cooling and recrystallized from ethanol, yielding the product as white crystals.
Method K
1.0 eq. of 3-bromopynolidin-2-one (J. Med. Chem. 1987, 30, 1995-1998. H. Ikuta, H.
Shirota, S. Kobayashi, Y. Yamagashi, K. Yamada, I. Yamatsu, K. Katayama) and 1.0 eq. of the appropriate thiourea was dissolved in acetone and heated to reflux for 8h. The rection mixture cooled to RT and NaHCO3 (sat. solution) was added and the aqueous phase was extracted with DCM. The organic phase was separated and concentrated in vacuum to give the crude product. The obtained crude product was dissolved in pyridine and a few drops of DMF was added followed by the appropriate benzoyl chloride (3.0 eq.) and the reaction mixture was shaken at RT. (2.0 eq.) of the benzoyl chloride was added after lh and the reaction mixture was shaken at RT over night. 10% HCl was added and extracted with DCM. The organic phase was concentrated in vaccum. Purification was performed using preparative HPLC.
Method L
1.0 eq. of the carboxylic acid, HOBt (1.0 eq.) and EDCI (1.0 eq.) were suspended in DCM. Triethylamine (2 eq) was added and the resulting suspension was stined for 30 min at ambient temperature. Then 3.0 eq. of the phenol of choice was added, and stining continued for 3 h. The reaction mixture was eluted over a column containing hydromatrix (5 x 1 cm) treated with 2M HCl and thoroughly washed with DCM. Evaporation in vacuo afforded the crude product.
Method M
1.0 eq. of the appropriate 1 -phenyl- lH-pynole-2,5-dione in absolute ethanol was treated with the thiourea (1.05 eq.) and stirred for 18 h at 50 °C The clear solution was reduced to dryness on a rotavapor and the resulting white foam was recrystallised from acetonitrile. Method T
The carboxylic acid (1.0 eq.14 mmol) was dissolved in dry acetonitrile, Et3N (1.0 eq,) and DPPA (1.0 eq.) were added. The reaction mixture was stined at 50 °C for 2 hours. The reaction mixture was cooled to rt, and IM HCl (6 ml) was added. The reaction mixture was heated to reflux for 5 hours. The acetonitrile was evaporated and the remaining aqueous solution was saturated with solid NaC0 , before the aqueous phase was extracted with DCM. The organic phase was evaporated and the obtained crude product was dissolved in DCM and excess of the benzoyl chloride was added. The reaction mixture was stined at RT for 2 hours. Water was added and the phases were separated. The organic phase was evaporated and the crude product was purified by preparative HPLC.
Examples
Compounds of type 1
Example 1 (BVT.59212)
N- {2-[2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2- chloro-6-fluorobenzamide
Prepared according to method K 17.9 mg, 44% yield of orange oil.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.64-1.86 (m, 4 H) 2.07-2.25 (m, 1 H) 2.4-2.622 (m, 1 H) 3.04 (s, 2 H) 3.37 (dd, J=6.93, 3.22 Hz, 1 H) 3.43-3.61 (m, 1 H) 3.89- 4.05 (m, 1 H) 4.38-4.49 (m, 1 H) 6.02-6.10 (m, 1 H) 6.28 (dd, J=5.44, 2.97 Hz, 1 H) 6.57 (s, 1 H) 7.04 (t, J=8.54 Hz, 1 H) 7.18-7.26 (m, 1 H) 7.27-7.38 (m, 1 H). MS (ESI+) for Cι9Hι9ClFΝ3O2S m/z 408 (M+H)+.
Example 2 (BNT.59213)
N- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl}- 2,6-dimethoxybenzamide Prepared according to method K 28.6 mg, 70% of orange oil.
!H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.54-1.89 (m, 3 H) 2.02-2.21 (m, 1 H) 2.44-2.60 (m, 1 H) 3.03 (d, J=6.93 Hz, 2 H) 3.33-3.45 (m, 2 H) 3.78-3.82 (m, 6 H) 3.91 (s, 1 H) 4.01-4.20 (m, 1 H) 4.54-4.63 (m, 1 H) 6.03-6.10 (m, 1 H) 6.25-6.31 (m, 1 H) 6.52- 6.60 (m, 3 H) 7.28-7.37 (m, 1 H). MS (ESI+) for C21H25N3O4S m/z 416 (M+H)+.
Example 3 (BNT.59436) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- 2 ,4-dimethoxybenzamide Prepared according to method K 0.0055 g, 7 % yield.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.65-1.80 (m, 4 H) 2.00 (s, 2 H) 2.12- 2.26 (m, 1 H) 2.45-2.55 (m, 1 H) 2.98-3.03 (m, 2 H) 3.35-3.37 (m, 1 H) 3.49-3.66 (m, 1 H) 3.85(s, 3 H) 3.96(s, 3H) 4.27-4.33 (m, 1 H) 6.04-6.08 (m,l H) 6.26-6.29 (m, 1 H) 6.48- 6.49 (m, 1 H) 6.55-6.60 (m, 1 H) 8.00-8.11 (m, 2 H). MS (ESI+) for C21H25Ν3O4S m/z 416 (M+H)+.
Example 4 (BVT.59387)
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-
2,6-difluorobenzamide
Prepared according to method K
0.0099 g, 13 % yield. 1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.67-1.78 (m, 4 H) 2.12-2.26 (m, 1 H)
2.46-2.55 (m, 1 H) 3.01-3.05 (m, 2 H) 3.35-3.39 (m, 1 H) 3.51-3.64 (m, 1 H) 3.86-3.96 (m,
1 H) 4.31-4.38 (m, 1 H) 6.05-6.08 (m, 1 H) 6.27-6.30 (m, 1 H) 6.45 (s, 1 H) 6.96 (t, J=8.66
Hz, 2 H) 7.37-7.45 (m, 1 H). MS (ESI+) for C19H19F2Ν3O2S m/z 392 (M+H)+.
Example 5 (BVT.56664)
2-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- lH-isoindole-l,3(2H)-dione
Prepared according to method K
Crude 2-bromo-4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid (0.204 g, 0.654 mmol) and N-bicyclo[2.2. l]hept-5-en-2-ylthiourea (0.112 g, 0.666 mmol) were dissolved in aceton (15 ml) and heated to reflux for 8h. The reaction mixture was allowed to cool to room temperature. ΝaΗCO (sat. solution) was added and extracted with DCM. The organic phase was concentrated in vacuum to give the crude product (0.269 g) of which 10 mg was purified using preparative LC-MS (System C, 20-80% MeCN). This afforded 6.73 mg of pure product.
Only small part of the crude was purified, the rest used in next step.
6.73 mg of pure product.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.65- 1.84 (m, 4 H) 2.16-2.37 (m, 1 H)
2.57-2.73 (m, 1 H) 2.99-3.11 (m, 2 H) 3.37 (t, J=4.58 Hz, 1 H) 3.73-3.88 (m, 1 H) 3.96-
4.12 (m, 1 H) 4.20 (dd, J=10.27, 3.59 Hz, 1 H) 6.03-6.10 (m, 1 H) 6.29 (dd, J=5.69, 2.97
Hz, 1 H) 7.73-7.81 (m, 2 H) 7.81-7.91 (m, 2 H). MS (ESI+) for C20Hι9N3O3S m/z 382
(M+H)+.
Example 6 (BNT.59209)
N- {2-[2-(bicyclo[2.2. l]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -
2,5 -difluorobenzamide
Prepared according to method K 5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-l,3-thiazol-4(5H)-one (0.025 g, 0.101 mmol) was dissolved in a few drops of DMF and Pyridine (2ml). 2,5- difluorobenzoyl chloride (0.053 g,0.302 mmol) was added and the reaction mixture was shaken in room temperature. Additional 2,5-difluorobenzoyl chloride (0.036 g, 0.202 mmol) was added after lh and the reaction mixture was shaken in room temperature over night. 10% ΗC1 was added and extraction with DCM performed. The organic phase was concentrated in vaccum. Purification using preparative LC-MS (System C, 30-80% MeCΝ) gave 0.022 g (56%) of product as yellow oil.
1H ΝMR (270 MHz, METHANOL-D4) δ ppm 1.43-1.79 (m, 4 H) 2.07-2.22 (m, 1 H) 2.37- 2.52 (m, 1 H) 2.86-3.02 (m, 2 H) 3.48-3.69 (m, 2 H) 3.78 (dd, J=7.79, 2.85 Hz, 1 H) 4.35- 4.46 (m, 1 H) 6.05-6.12 (m, 1 H) 6.20-6.30 (m, 1 H) 7.18-7.35 (m, 2 H) 7.42-7.51 (m, 1 H). HPLC 98%, RT= 1.91 min (System A, 10-97% MeCN over 3 min). 99%, Rτ= 1.65 min (System B, 10-97% MeCN over 3 min). MS (ESI+) for C19H19F2N3O2S m/z 392 (M+H)+.
Example 7 (BVT.59210) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- chlorobenzamide Prepared according to method K 14.1 mg, 36% yield, orange oil. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.61-1.85 (m, 4 H) 2.10-2.28 (m, 1 H) 2.43-2.60 (m, 1 H) 2.99-3.08 (m, 2 H) 3.38 (dd, J=6.93, 3.46 Hz, 1 H) 3.49-3.65 (m, 1 H) 3.86-4.01 (m, 1 H) 4.35-4.46 (m, 1 H) 6.06 (dd, J=5.44, 2.97 Hz, 1 H) 6.29 (dd, J=5.69, 2.97 Hz, 1 H) 6.75 (t, J=5.07 Hz, 1 H) 7.29-7.44 (m, 4 H) 7.57-7.63 (m, 1 H). MS (ESI+) for C19H20C1N3O2S m/z 390 (M+H)+.
Example 8 (BVT.59211)
N- {2-[2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2- bromo-5-methoxybenzamide Prepared according to method K
23.7 mg, 52% yield, yellow oil.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.67 (s, 2 H) 1.71-1.85 (m, 2 H) 2.07-
2.25 (m, 1 H) 2.45-2.62 (m, 1 H) 3.03 (d, J=8.41 Hz, 2 H) 3.38 (dd, J=7.18, 3.46 Hz, 1 H)
3.43-3.60 (m, 1 H) 3.79 (s, 3 H) 3.84-4.00 (m, 1 H) 4.42-4.52 (m, 1 H) 6.06 (dd, J=5.20, 3.22 Hz, 1 H) 6.28 (dd, J-5.57, 2.85 Hz, 1 H) 6.61 (s, 1 H) 6.84 (dd, J=8.78, 2.60 Hz, 1 H)
7.03 (d, J=2.97 Hz, 1 H) 7.45 (d, J=8.91 Hz, 1 H). MS (ESI+) for C20H22BrN3O3S m/z 466
(M+H)+.
Example 9 (BVT.59330) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- fluoro-4-(trifluoromethyl)benzamide
Prepared according to method K
0.0100 g, 11 % yield.
IH ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.34-71.70 (m, 4 H) 1.95-2.10 (m, 1 H) 2.32-2.42 (m, 1 H) 2.79-2.80 (m, 2 H) 3.46-3.55 (m, 2 H) 3.70-3.74 (m, 1 H) 4.23-4.30 (m,
1 H) 5.95-6.00(m, 1 H) 6.10-6.13 (m, 1 H) 7.47-7.52 (m, 2 H) 7.76-7.82 (m, 1 H). MS
(ESI+) for C20H19F4N3O2S m/z 442 (M+H)+.
Example 10 (BVT.59331) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- 2 ,4-dichlorobenzamide Prepared according to method K 0.0106 g, 12 % yield. IH NMR (270 MHz, METHANOL-D4) δ ppm 1.36-1.71 (m, 4 H) 1.96-2.05 (m, 1 H) 2.21-2.39 (m, 1 H) 2.80-2.83 (m, 2 H) 3.31-3.55 (m, 2 H) 3.68-3.72 (m, 1 H) 4.27-4.32 (m, 1 H) 5.96-6.02 (m, 1 H) 6.10-6.14 (m,l H) 7.29-7.44 (m, 3 H). MS (ESI+) for C19H19CI2N3 O2S m/z 424 (M+H)+.
Example 1 KB VT067002)
2-chloro-N-{2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}benzamide
Method K
5-(2-aminoethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one (36mg, 0.15 mmol) was suspended in 5% ΝaOH (aq.) (5 mL) and 2-chloro-benzoyl chloride (38 μL, 0.3 mmol) was added. The reaction mixture was stined overnight. EtOAc (5 mL) was added and the reaction mixture was stined for 10 min. The organic layer was collected and the solvent was removed under reduced pressure. Purification using preparative HPLC (20-70% MeCΝ over 10 min followed by 100% MeCΝ for 5 min) afforded the product in 19% yield, 11 mg.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.15-1.48 (m, 5 H) 1.57-1.89 (m, 3 H) 1.92- 2.21 (m, 3 H) 2.37-2.54 (m, 1 H) 3.39-3.52 (m, 1 H) 3.51-3.68 (m, 1 H) 3.73-3.88 (m, 1 H) 4.43 (dd, J=9.77, 4.08 Hz, 1 H) 7.30-7.48 (m, 4 H). HPLC 93% Rτ=1.88 (System A. 10- 97% MeCN over 3 min), 96% Rτ=1.70 (System B. 10-97% MeCN over 3 min). MS m/z: (M+H) 381.
Example 12 (BVT067003)
N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,6- difluorobenzamide Prepared according to method K
18 mg, 31% yield.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.17-1.55 (m, 5 H) 1.57-1.88 (m, 3 H) 1.90-
2.20 (m, 3 H) 2.38-2.53 (m, 1 H) 3.38-3.55 (m, 1 H) 3.57-3.76 (m, 1 H) 3.77-3.91 (m, 1 H)
4.39 (dd, J=10.02, 4.08 Hz, 1 H) 6.98-7.10 (m, 1 H) 7.40-7.54(m, 1 H). MS (ESI+) for C1SH21F2N3O2S m/z 382 (M+H)+.
Example 13 (BVT067004) N-{2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- dimethoxybenzamide Prepared according to method K 5 mg, 8%o yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.12-1.48 (m, 5 H) 1.58-2.07 (m, 6 H) 2.35- 2.53 (m, 1 H) 3.35-3.44 (m, IH) 3.60-3.78 (m, 1 H) 3.72-3.84 (m, IH) 3.79 (s, 6 H) 4.50 (dd, J=10.89, 3.71 Hz, 1 H) 6.64-6.70 (m, 2 H) 7.28-7.34 (m, 1 H). MS (ESI+) for C20H27N3O4S m/z 406 (M+H)+.
Example 14 (BVT067005)
2-bromo-N-{2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5- methoxybenzamide
Prepared according to method K
12 mg, 17% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.15-1.46 (m, 5 H) 1.58-1.88 (m, 3 H) 1.91-
2.14 (m, 3 H) 2.38-2.53 (m, 1 H) 3.42-3.66 (m, 2 H) 3.81 (s, 3 H) 3.78-3.91 (m, 1 H) 4.41-
4.49 (m, 1 H) 6.90-6.94 (m, 1 H) 7.00-7.03 (m, 1 H) 7.47-7.53 (m, 1 H). MS (ESI+) for
C19H24BrN3O3S m/z 456 (M+H)+.
Example 15 (BVT067006)
2-chloro-N-{2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-6- fluorobenzamide
Prepared according to method K
21 mg, 35% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.17-1.47 (m, 5 H) 1.68-1.71 (m, 1 H) 1.71-
1.88 (m, 1 H) 1.92-2.07 (m, 3 H) 2.39-2.53 (m, 1 H) 3.33-3.47 (m, 1 H) 3.55-3.72 (m, 1 H)
3.78-3.90 (m, 1 H) 4.39 (dd, J=10.27, 4.08 Hz, 1 H) 7.14-7.20 (m, 1 H) 7.31 (d, J=8.16 Hz,
1 H) 7.40-7.49 (m, 1 H). MS (ESI+) for C18H2ιClFN3O2S m/z 399 (M+H)+.
Example 16 (BVT067007)
2,4-dichloro-N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } benzamide
Prepared according to method K 19 mg, 31% yield.
1HNMR (270 MHz, METHANOL-D4) δ ppm 1.15-1.44 (m, 5 H) 1.57-1.66 (m, 1 H) 1.67-
1.87 (m, 2 H) 1.93-2.08 (m, 3 H) 2.39-2.52 (m, 1 H) 3.40-3.49 (m, 1 H) 3.50-3.64 (m, 1 H)
3.83-3.94 (m, 1 H) 4.30 (dd, J=9.77, 4.08 Hz, 1 H) 7.36 (dd, J=8.16, 1.98 Hz, 1 H) 7.45 (d, J=8.64 Hz 1 H) 7.49 (d, J=1.73 Hz, 1 H). MS (ESI+) for C18H2iCl2N3θ2S m/z 415 (M+H)+
Example 17 (BVT067008
2-chloro-N- {2-[4-oxo-2-(tricyclo[3.3.1.0-3 ,7~]non-3-ylamino)-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } b enzamide Prepared according to method K l l mg, 18% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.50-1.69 (m, 4 H) 1.94-2.57 (m, 11 H)
3.42-3.63 (m, 2 H) 4.30 (dd, J=9.65, 3.96 Hz, 1 H) 7.31-7.49 (m, 4 H). MS (ESI+) for
C21H24ClN3O2S m/z 419 (M+H)+.
Example 18 (BVT067009)
2,6-difluoro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro-l,3- thiazol-5 -y 1] ethyl } benzamide
Prepared according to method K 9 mg, 14% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.52-1.73 (m, 4 H) 1.86-2.24 (m, 7 H) 2.20-
2.34 (m, 2 H) 2.35-2.57 (m, 2 H) 3.28-3.50 (m, 1 H) 3.52-3.69 (m, 1 H) 4.25 (dd, J=10.02,
3.84 Hz, 1 H) 6.97-7.09 (m, 2 H) 7.40-7.52 (m, 1 H). MS (ESI+) for C21H23F2N3O2S m/z
420 (M+H)+.
Example 19 (BVT067013)
2-chloro-6-fluoro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro-l,3- thiazol-5 -yl] ethyl } benzamide
Prepared according to method K l l mg, 17% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.52-1.73 (m, 4 H) 1.85-2.57 (m, 11 H)
3.34-3.46 (m, 1 H) 3.52-3.72 (m, 1 H) 4.30 (dd, J=10.14, 3.96 Hz, 1 H) 7.11-7.20 (m, 1 H) 7.29 (d, J=7.92 Hz, 1 H) 7.4137-7.46 (m, 1 H). MS (ESI+) for C2ιH23ClFN3O2S m/z 437 (M+H)+.
Example 20 (BNT067018) 2,4-dichloro-N- {2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro- 1 ,3 - thiazol-5-yl]ethyl } benzamide Prepared according to method K 9 mg, 13% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.48-1.68 (m, 4 H) 1.96-2.16 (m, 7 H) 2.21- 2.30 (m, 2 H) 2.34-2.55 (m, 2 H) 3.42-3.52 (m, 1 H) 3.50-3.66 (m, 1 H) 4.24 (dd, J=9.53, 4.08 Hz, 1 H) 7.33 (dd, J=8.16, 1.98 Hz, 1 H) 7.45 (d, J=1.98 Hz, 1 H). MS (ESI+) for C2ιH23Cl2N3O2S m/z 453 (M+H)+.
Example 21 (BNT067022) 2-chloro-N-(2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl } ethyl)benzamide
Prepared according to method K
9 mg, 15% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 0.89-1.10 (m, 2 H) 1.10-1.37 (m, 4 H) 1.55- 1.82 (m, 6 H) 1.94-2.09 (m, 1 H) 2.40-2.53 (m, 1 H) 3.18 (d, J=6.68 Hz, 1 H) 3.42-3.67
(m, 2 H) 4.34-3.42 (m, 1 H) 7.35-50 (m, 4 H). MS (ESI+) for C19H24ClN3O2S m/z 395
(M+H)+.
Example 22 (BNT067025) 2-bromo-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} ethyl)-5- methoxybenzamide
Prepared according to method K
2 mg, 3% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 0.89-1.38 (m, 6 H) 1.55-1.83 (m, 6 H) 1.97- 2.12 (m, 1 H) 2.40-2.54 (m, 1 H) 3.20 (d, J=6.68 Hz, 1 H) 3.40-3.67 (m, 2 H) 3.81 (s, 3 H)
4.44 (dd, J=9.65, 4.21 Hz, 1 H) 6.88-6.95 (m, 1 H) 7.01 (d, J=2.97 Hz, 1 H) 7.46-7.52 (m,
1 H). MS (ESI+) for C20H26BrN3O3S m/z 470 (M+H)+. Example 23 (BNT067027)
2,4-dichloro-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} ethyl)benzamide
Prepared according to method K
8 mg, 12% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 0.86-1.35 (m, J=69.77 Hz, 6 H) 1.53-1.84
(m, 6 H) 1.96-2.08 (m, 1 H) 2.35-2.52 (m, 1 H) 3.14 (d, J=6.68 Hz, 1 H) 3.38-3.65 (m, 2
H) 4.26-4.37 (m, 1 H) 7.32-7.48 (m, 3 H). MS (ESI+) for C19H23Cl2N3O2S m/z 429
(M+H)+.
Example 24 (BNT067030)
2-chloro-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}benzamide Prepared according to method K
2 mg, 3% yield. 'H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.40-1.84 (m, 10 H) 1.92-2.11 (m, 3 H)
2.37-2.51 (m, 1 H) 3.34-3.65 (m, 2 H) 3.98-4.13 (m, 1 H) 4.32-4.43 (m, 1 H) 7.31-7.52 (m, 4 H). MS (ESI+) for C19H24ClN3O2S m/z 395 (M+H)+.
Example 25 (BVT06703n N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzamide
Prepared according to method K
13 mg, 22% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.45-1.81 (m, 10 H) 1.94-2.16 (m, 3 H) 2.38-2.52 (m, 1 H) 3.37-3.53 (m, 1 H) 3.52-3.73 (m, 1 H) 3.99-4.12 (m, 1 H) 4.35 (dd,
J=10.02, 4.08 Hz, 1 H) 6.98-7.09 (m, 2 H) 7.41-7.54 (m, 1 H). MS (ESI+) for
Cι9H23F2N3O2S m/z 396 (M+H)+.
Example 26 (BVT067032^) N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- dimethoxybenzamide Prepared according to method K
3 mg, 5% yield. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.42-2.15 (m, 13 H) 2.38-2.57 (m, 1 H) 3.52-3.83 (m, 2 H) 3.81 (s, 6 H) 3.98-4.14 (m, 1 H) 4.47-4.54 (m, 1 H) 6.64-6.72 (m, 2 H) 7.27-7.38 (m, 1 H). MS (ESI+) for C2ιH29N3O4S m/z 420 (M+H)+.
Example 27 (BNTQ67033)
2-bromo-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5- methoxybenzamide Prepared according to method K 15 mg, 21% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.44-1.83 (m, 10 H) 1.90-2.14 (m, 3 H) 2.38-2.52 (m, 1 H) 3.40-3.66 (m, 2 H) 3.81 (s, 3 H) 4.01-4.13 (m, 1 H) 4.41 (dd, J=9.53, 4.08 Hz, 1 H) 6.90-6.95 (m, 1 H) 6.99-7.02 (m, 1 H) 7.47-7.53 (m, 1 H). MS (ESI+) for C20H26BrN3O3S m/z 470 (M+H)+.
Example 28 (BNT062688)
2-chloro-Ν- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -6- fluorobenzamide
Prepared according to method K
21 mg, 34% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.44-1.77 (m, 10 H) 1.86-2.06 (m, 3 H)
2.37-2.51 (m, 1 H) 3.34-3.47 (m, 1 H) 3.49-3.71 (m, 1 H) 4.01-4.13 (m, 1 H) 4.33 (dd,
J=10.14, 3.96 Hz, 1 H) 7.10-7.18 (m, 1 H) 7.29 (d, J=8.16 Hz, 1 H) 7.37-7.47 (m, 1 H).
MS (ESI+) for C19H23ClFN3O2S m/z 412 (M+H)+.
Example 29 (BNT067359)
2,4-dichloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } benzamide
Prepared according to method K
14 mg, 20% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.44-1.84 (m, 10 H) 1.93-2.17 (m, 3 H)
2.37-54 (m, 1 H) 3.42-3.67 (m, 2 H) 3.97-4.12 (m, 1 H) 4.38 (dd, J=9.53, 4.08 Hz, 1 H)
7.37-7.56 (m, 3 H). MS (ESI+) for C19H23Cl2N3O2S m/z 428 (M+H)+. Example 30 (BNT67360)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- difluorobenzamide Prepared according to method K 11 mg, 16% yield.
1H ΝMR (270 MHz, METHANOL-D4) δ ppm 1.44-1.82 (m, 10 H) 1.93-2.22 (m, 3 H) 2.38-2.53 (m, 1 H) 3.46-3.69 (m, 2 H) 3.98-4.11 (m, 1 H) 4.35 (dd, J=9.28, 4.08 Hz, 1 H) 7.17-7.35 (m, 2 H) 7.42-7.50 (m, 1 H). MS (ESI+) for C19H23F2N3O2S m/z 396 (M+H)+.
Example 31 (BNT067361)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- bis(trifluoromethyl)benzamide
Prepared according to method K
14 mg, 18% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.43-1.82 (m, 10 H) 1.93-2.16 (m, 3 H)
2.34-2.50 (m, 1 H) 3.42-3.66 (m, 2 H) 4.00-4.15 (m, 1 H) 4.35 (dd, J=9.15, 4.21 Hz, 1 H)
7.90-8.04 (m, 3 H). MS (ESI+) for C21H23F6N3O2S m/z 496 (M+H)+.
Example 32 (BVT067362) N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-fluoro-5-
(trifluoromethyl)benzamide
Prepared according to method K
10 mg, 13% yield.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.41-1.84 (m, 10 H) 1.90-2.18 (m, 3 H) 2.37-2.53 (m, 1 H) 3.47-3.69 (m, 2 H) 3.99-4.10 (m, 1 H) 4.34 (dd, J=9.28, 4.08 Hz, 1 H)
7.42 (t, J=9.40 Hz, 1 H) 7.81-7.91 (m, 1 H) 8.05 (dd, J=6.31, 2.35 Hz, 1 H). MS (ESI+) for
C2oH23F4N3O2S m/z 446 (M+H)+.
Example 33 (BNT067363) 2-chloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } nicotinamide Prepared according to method K 0.2 mg, 0.3% yield. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.48-1.81 (m, 10 H) 1.92-2.13 (m, 3 H) 2.40-2.52 (m, 1 H) 4.01-4.12 (m, 1 H) 4.38 (dd, J=9.40, 4.21 Hz, 1 H) 7.45 (dd, J=7.67, 4.95 Hz, 1 H) 7.94 (dd, J=7.55, 1.86 Hz, 1 H) 8.44 (dd, J=4.95, 1.98 Hz, 1 H). MS (ESI+) FOR C18H23ClN4O M/Z m z: (M+H) 395.
Example 34 (BNT067365
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2-furamide Prepared according to method K 7 mg, 12% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.43-1.80 (m, 10 H) 1.92-2.19 (m, 3 H) 2.37-2.53 (m, 1 H) 3.44-3.67 (m, 2 H) 3.94-4.06 (m, 1 H) 4.34 (dd, J=9.40, 3.96 Hz, 1 H) 6.54-6.61 (m, 1 H) 7.07-7.13 (m, 1 H) 7.64-7.68 (m,l H). MS (ESI+) for Cι8H23ClN4O2S m/z 350 (M+H)+.
Example 35 (BNT067366)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}thiophene-2- carboxamide
Prepared according to method K l l mg, 19% yield. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.42-1.79 (m, 10 H) 1.92-2.21 (m, 3 H)
2.38-2.49 (m, 1 H) 3.46-3.67 (m, 2 H) 3.94-4.05 (m, 1 H) 4.35 (dd, J=9.03, 4.08 Hz, 1 H)
7.07-7.14 (m, 1 H) 7.61-7.70 (m, 2 H). MS (ESI+) for Cι7H23N3O2S2 m/z 366 (M+H)+.
Example 36 (BNT067367) N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-(2- thienyl)acetamide
Prepared according to method K
12 mg, 20% yield.
'H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.43-1.81 (m, 10 H) 1.84-2.09 (m, 3 H) 2.26-2.43 (m, 1 H) 3.23-3.50 (m, 2 H) 3.71 (d, J 3.51 Hz, 2 H) 3.99-4.10 (m, 1 H) 4.24
(dd, J=9.65, 4.21 Hz, 1 H) 6.88-6.96 (m, 2 H) 7.23-7.28 (m, 1 H). MS (ESI+) for
Cι8H25N3O2S2 m/z 381 (M+H)+. Example 37 (BNT067368)
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl}cyclopropanecarboxamide Prepared according to method K 2 mg, 4% yield.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 0.69-0.89 (m, 4 H) 1.44-1.81 (m, 11 H) 1.87-2.09 (m, 3 H) 2.28-2.42 (m, 1 H) 3.23-3.49 (m, 2 H) 3.98-4.09 (m, 1 H) 4.27 (dd, J=9.90, 3.96 Hz, 1 H). MS (ESI+) for Cι6H25N3O2S m/z 381 (M+H)+.
Example 38 (BVT067369)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-3- methylbutanamide
Prepared according to method K
3 mg, 5% yield. Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 0.88-1.01 (m, 6 H) 1.44-1.81 (m, 10 H)
1.87-2.12 (m, 6 H) 2.26-2.43 (m, 1 H) 3.20-3.48 (m, 2 H) 3.96-4.08 (m, 1 H) 4.28 (dd,
J=9.77, 4.08 Hz, 1 H). MS (ESI+) for Cι7H29N3O2S m/z 340 (M+H)+.
Example 39 (BVT.63235) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } cyclohexanecarboxamide
Prepared according to method K
0.0079 g, yield 37 %).
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.12-1.49 (m, 5 H) 1.62-1.88 (m, 9 H) 1.94-2.16 (m, 2 H) 2.30-2.47 (m, 1 H) 3.01 (d, J=11.13 Hz, 2 H) 3.22-3.49 (m, 1 H) 3.58-
3.75 (m, 1 H) 4.18 (dd, J=10.27, 4.08 Hz, 1 H) 5.95 (s, 1 H) 6.05 (dd, J=5.44, 3.22 Hz, 1
H) 6.27 (dd, J=5.69, 3.22 Hz, 1 H). MS (ESI+) for Cι9H27N3O2S m/z 362 (M+H)+.
Example 40 (BVT.63237) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}isoxazole-5-carboxamide Prepared according to method K 0.0105 g, yield 13 %. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.39-1.79 (m, 4 H) 2.01-2.20 (m, 1 H) 2.38- 2.53 (m, 1 H) 2.84-2.99 (m, 2 H) 3.47-3.66 (m, 2 H) 3.80 (dd, J=7.67, 2.72 Hz, 1 H) 4.29- 4.39 (m, 1 H) 6.07 (dd, J=5.57, 3.34 Hz, 1 H) 6.21 (dd, J=5.57, 2.85 Hz, 1 H) 6.94 (s, 1 H) 8.10 (t, J=7.05 Hz, 1 H) 8.51 (s, 1 H) 8.87 (d, J=5.44 Hz, 1 H). MS (ESI+) for Cι6Hι8N4O3S m/z 347 (M+H)+.
Example 41 (BVT.66767)
N- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -
2,4,6-trichlorobenzamide Prepared according to method K
0.0043 g, yield 9 %.
1H NMR (270 MHz, METHANOL-D4) δ ppm 1.43-1.63 (m, 3 H) 1.68-1.81 (m, 1 H) 1.89-
2.08 (m, 1 H) 2.39-2.56 (m, 1 H) 2.87-2.98 (m, 2 H) 3.36-3.52 (m, 1 H) 3.54-3.71 (m, 1 H)
3.83 (dd, J-7.92, 2.97 Hz, 1 H) 4.37-4.47 (m, 1 H) 6.05-6.13 (m, 1 H) 6.19-6.25 (m, 1 H) 7.55 (s, 2 H). MS (ESI+) for d9H18Cl3N3O2S m/z 460 (M+H)+.
Example 42 (BVT066958)
N-[(2-azepan-l-yl-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)methyl]-2-fluorobenzamide Method T The carboxylic acid (1.0 eq.14 mmol) was dissolved in dry acetonitrile, Et3N (1.0 eq,) and DPPA (1.0 eq.) were added. The reaction mixture was stined at 50 °C for 2 hours. The reaction mixture was cooled to rt, and IM HCl (6 ml) was added. The reaction mixture was heated to reflux for 5 hours. The acetonitrile was evaporated in vacuo and the remaining aqueous solution was saturated with solid NaCO3, and the aqueous phase was extracted with DCM. The organic phase was evaporated in vacuo and the received intermediate amine was dissolved in DCM (3ml) and 2-fluorobenzoyl chloride (50 μl) was added. The reaction mixture was stined for 2 hours and the product was purified by prep-HPLC (15- 60% MeCN/H2O) to yield 3.2 mg (7%). 1H NMR (400 MHz, CDC13) δ ppm 1.55 (s, 4 H) 1.74-1.88 (m, 4 H) 3.53 (t, J=6.0 Hz, 2 H) 3.78-3.93 (m, 2 H) 3.96-4.07 (m, 1 H) 4.08-4.21 (m, 1 H) 4.44 (t, J=5.4 Hz, 1 H) 5.45 (s, 1 H) 7.11 (dd, J=l 1.6, 8.4 Hz, 1 H) 7.38-7,52 (m, 2 H) 8.01 (t, J=7.7 Hz, 1 H). MS (ES+) for d7H20FN3O2S m/z 350 (M+H)+. HPLC 95% Rτ=2.65 min (System A. 10-97% MeCN over 3 min), 95% Rτ=1.15 min (System B. 2-95% MeCN over 2 min). Compounds of type 2
Example 43 (BNT.51528) 2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5- {2-[methyl(phenyl)amino]ethyl} - 1 ,3-thiazol-
4(5H)-one
Method I
2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-5-(2-bromoethyl)-l,3-thiazol-4(5H)-one (0.03 g,
0.1 mmol) and Ν-methyl aniline (0.11 g, 1 mmol) was dissolved in DMSO (2 mL) and stined at 60 °C for 16 h. The reaction mixture was mixed with water and the aqueous phase was extracted with ether twice. The combined organic phases were dried (MgSO4) and the solvent was evaporated. The obtained crude product was purified by preparative reverse phase (10-90) to give 8.38 mg of the desired product. Yield 25%, 89% pure.
1H ΝMR (270 MHz, METHAΝOL-D) δ ppm 1.58-1.42 (m, 3H) 1.72-1.67 (m, IH) 2.29- 2.18 (m, 2H) 2.95-2.85 (m, 2H) 3.11 (s, 3H) 3.38-3.35 (m, IH) 3.76-3.62 (m, 2H) 4.44-
4.37 (m, IH) 6.10-6.04 (m, IH) 6.29-6.20 (m, IH) 7.26-7.14 (m, 3H) 7.45-7.40 (m, 2H).
MS (ESI+) for Cι9H23Ν3OS m/z 342 (M+H)+.
Example 44 (BNT.51579) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)ethyl]-l,3-thiazol-
4(5H)-one
Prepared according to method I
0.0225 g, yield 80%.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.71-1.42 (m, 4H) 2.65-2.37 (m, 2H) 3.10- 2.83 (m, 5H) 3.60-3.38 (m, 4H) 4.45-4.51 (m, IH) 6.03-5.94 (m, IH) 6.21-6.16 (m, IH)
6.74-6.69 (m, 2H) 7.05-6.97 (m, 2H). MS (ESI+) for C20 H23 N3 O S m/z 354 (M+H)+.
Example 45 (BVT051580)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)ethyl]-l,3- thiazol-4(5H)-one
Prepared according to method I 0.013 g, yield 30%. Η NMR (270 MHz, METHANOL-D4) δ ppm 1.71-1.47 (m, 4H) 2.01-1.93 (m, 2H) 2.41-
2.23 (m, 2H) 2.80-2.65 (m, 2H) 2.96-2.87 (m, 2H) 3.19-3.13 (m, IH) 3.41-3.28 (m, 3H)
3.63-3.52 (m, 2H) 6.09-6.02 (m, IH) 6.23-6.21 (m, IH) 6.70.6.61 (m, IH) 6.83-6.80 (m,
IH) 7.04-6.93 (m, 2H). MS (ESI+) for C21 H25 N3 O S m/z 368 (M+H)+.
Example 46 (BNT.51583)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)ethyl]-l,3- thiazol-4(5H)-one
Prepared according to method I 0.029 g, yield 70%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.61-1.45 (m, 4H) 1.77-1.70 (m, 2H) 2.58-
2.35 (m, 2H) 3.00-2.89 (m, 2H) 3.57-3.39 (m, 2H) 3.78-3.69 (m, 2H) 3.86-3.83 (m, IH) 4-
50-4.45 (m, IH) 6.10-6.07 (m, IH) 6.24-6.21 (m, IH) 7.45-7.30 (m, 4H). MS (ESI+) for
C20H23N3OS m/z 354 (M+H)+.
Example 47 (BNT.51590)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-piperidin-l-ylethyl)-l,3-thiazol-4(5H)-one
Prepared according to method I
0.0085 g, yield 23%. Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.61-1.43 (m, 4H) 1.98-1.67 (m, 6H) 2.48-
2.26 (m, 2H) 2.97-2.88 (m, 4H) 3.15-3.10 (m, IH) 3.39-3.37 (m, IH) 3.60-3.50 (m, 2H)
3.86-3.83 (m, IH) 4.49-4.43 (m, IH) 6.09-6.07 (m, IH) 6.23-6.21 (m, IH). MS (ESI+) for
C17H25N3OS m/z 320 (M+H)+.
Example 48 (BVT.61777B)
5 -(2- Anilinoethyl)-2- [(2-methylphenyl)amino]- 1 ,3 -thiazol-4(5H)-one hydrobromide
Prepared according to method Η
363 mg as a white solid, 99% yield.
Η NMR (400 MHz, DMSO-D6) δ ppm 2.13-2.26 (m, 1 H) 2.26 (s, 3 H) 2.76 (m, 1 H) 3.97 (m, 2 H) 5.10 (t, J= 8.6 Hz, 1 H) 7.22 (t, J= 7.4 Hz, 1 H) 7.31-7.45 (m, 6 H) 7.66 (d,
J= 7.8 Hz, 1 H) 9.08 (s br, 1 H) 9.89 (s br, 1 H). MS (ESI+) for Cι8H19N3 OS HBr m/z 326
(M+H)+. Example 49 (BVT.61778B)
5-(2-Anilinoethyl)-2-[(2-methoxyphenyl)amino]-l,3-thiazol-4(5H)-one hydrobromide Prepared according to method Η 345 mg as a white solid, 99 % yield. Η NMR (400 MHz, DMSO-D6) δ ppm 2.20 (m, 1 H) 2.76 (m, 1 H) 3.85 (s, 3 H) 3.97 (m, 2 H) 5.05 (t, J= 8.8 Hz, 1 H) 7.07 (dt, J= 8.2 Hz, J= 1.2 Hz, 1 H) 7.21-7.25 (m, 2 H) 7.33 (dd, J= 7.8 Hz, J= 1.6 Hz, 1 H) 7.40-7.47 (m, 3 H) 7.66 (m, 2 H) 9.16 (s br, 1 H) 9.87 (s br, 1 H) 11.42 (s br, 1 H). MS (ESI+) for C18H19N3O2S HBr m/z 342 (M+H)+.
Example 50 (BVT.61779B)
5-(2-Anilinoethyl)-2- {[(lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1. l]hept-3-yl]amino}-l,3- thiazol-4(5H)-one hydrobromide
Method Η;
N-[(lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]thiourea (120 mg, 0.565 mmol) and 3-bromo-l-phenylpynolidin-2-one (136 mg, 0.566 mmol) in acetone (3 mL) were heated at 60 °C for 6 h. The solvent was removed to yield the give the product as a white solid (250 mg, 98 % yield).
1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.01 (s, 3 H) 1.04-1.10 (m, 4 H) 1.19 (s, 3 H) 1.64
(m, 1 H) 1.78 (m, 1 H) 1.93 (m, 1 H) 2.06-2.17 (m, 2 H) 2.29-2.37 (m, 1 H) 2.61 (m, 1 H) 2.66-2.80 (m, 1 H) 3.90-4.00 (m, 2 H) 4.01-4.11 (m, 1 H) 4.99 (m, 1 H) 7.19-7.24 (m, 1
H) 7.38-7.45 (m, 2 H) 7.63-7.68 (m, 2 H) 9.43 (s br, 1 H) 9.59 (s br, 1 H) 10.07 (t, J= 8.9
Hz, 1 H). MS (ESI+) for C2ιH29Ν3OS m/z 372 (M+H)+.
Example 51 (BVT.61780B) 5-(2-Anilinoethyl)-2-{[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}-l,3- thiazol-4(5H)-one hydrobromide
Prepared according to method Η
255 mg as a white solid, 100 % yield.
Η NMR (400 MHz, DMSO-D6) δ ppm 1.01 (s, 3 H) 1.04-1.10 (m, 4 H) 1.19 (s, 3 H) 1.64 (m, 1 H) 1.78 (m, 1 H) 1.93 (m, 1 H) 2.06-2.18 (m, 2 H) 2.29-2.38 (m, 1 H) 2.61 (m, 1 H)
2.66-2.80 (m, 1 H) 3.90-4.00 (m, 2 H) 4.01-4.11 (m, 1 H) 4.98 (q, J= 8.5 Hz, 1 H) 7.17-
7.25 (m, 1 H) 7.38-7.45 (m, 2 H) 7.63-7.68 (m, 2 H) 9.42 (s br, 1 H) 9.59 (s br, 1 H) 10.07
(t, J= 9.0 Hz, 1 H). MS (ESI+) for C2ιH29N3OS HBr m/z 372 (M+H)+. Example 52 (BVT.61791B)
5-(2-Anilinoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-4(5H)-one Prepared according to method Η 110 mg as a white solid, 71 % yield.
Η NMR (400 MHz, DMSO-D6) δ ppm 1.44-1.59 (m, 4 H) 1.71 (m, 2 H) 1.87 (m, 2 H) 2.10 (m, 1 H) 2.32 (m, 2 H) 2.51 (m, 1 H) 2.63 (m, 1 H) 2.69 (m, 1 H) 3.92-4.02 (m, 2 H) 4.99 (t, J= 8.8 Hz, 1 H) 7.23 (m, 1 H) 7.43 (m, 2 H) 7.64 (m, 2 H) 8.32 (s br, 1 H) 9.80 (s br, 1 H) 10.43 (s, 1 H). MS (ESI+) for C20H25N3OS HBr m/z 356 (M+H)+.
Example 53 (BVT.59495^)
5-(2-anilinoethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-4(5H)-one Prepared according to method H 0.736 g, yield 99% of white crystals. 1H NMR (270 MHz, DMSO-D6) δ ppm 0.99-1.19 (m, 3 H) 1.30-1.54 (m, 4 H) 1.66 (dd, J=11.51, 9.03 Hz, 1 H) 1.73-1.90 (m, 1 H) 2.13-2.38 (m, 3 H) 3.01-3.15 (m, 2 H) 3.73 (d, J=4.21 Hz, 1 H) 4.17-4.32 (m, 1 H) 6.52 (t, J=7.67 Hz, 3 H) 7.05 (t, J=7.79 Hz, 2 H) 9.10 (d, J=6.68 Hz, 1 H). MS (ESI+) for Cι8H23N3OS m/z 330 (M+H)+.
Example 54 (BVT.59587
5-(2-anilinoethyl)-2-[(2-cyclohex-l-en-l-ylethyl)amino]-l,3-thiazol-4(5H)-one
Prepared according to method H
28.9 mg, 16% yield.
IH NMR (400 MHz, METHANOL-D4) δ ppm 1.56 (m, 2 H) 1.65 (m, 2 H) 1.99 (m, J-4.15 Hz, 4 H) 2.16 (m, 1 H) 2.31 (t, J=6.84 Hz, 2 H) 2.79 (m, 1 H) 3.48 (m, 2 H) 4.04
(m, 2 H) 4.71 (m, 1 H) 5.54 (s, 1 H) 7.26 (t, J=7.45 Hz, 1 H) 7.42 (t, J=7.93 Hz, 2 H) 7.63
(d, J=8.30 Hz, 2 H). MS (ES+) for C)9H25N3OS m/z 344 (M+H)+.
Example 55 (BVT.61703B 5-(2-anilinoethyl)-2-[(l,l,3,3-tetramethylbutyl)amino]-l,3-thiazol-4(5H)-one hydrobromide
Prepared according to method H 31.6 mg, yield 28%. IH NMR (400 MHz, DMSO-D6) δ ppm 0.98 (s, 9 H) 1.43 (s, 3 H) 1.45 (s, 3 H) 1.69 (d, J=15.38 Hz, 1 H) 1.86 (m, 1 H) 2.12 (m, 1 H) 2.69 (m, 1 H) 3.97 (m, 2 H) 4.91 (t, J=8.91 Hz, 1 H) 7.24 (t, J=7.32 Hz, 1 H) 7.44 (t, J=7.81 Hz, 2 H) 7.64 (d, J=7.81 Hz, 2 H) 8.62 (s, 1 H) 9.86 (s, 1 H). MS (ES+) for C19H29N3OS HBr m/z 348 (M+H)+.
Example 56 (BVT.61802)
5-(2-anilinoethyl)-2-(2,3-dihydro-lH-inden-2-ylamino)-l,3-thiazol-4(5H)-one Prepared according to method H 115mg, 63% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 2.03 (m, 1 H) 2.66 (m, 1 H) 2.94 (dd, J-16.11, 5.37 Hz, 2 H) 3.35 (m, 2 H) 3.90 (m, 2 H) 4.50 (m, 1 H) 4.88 (t, J=8.67 Hz, 1 H) 7.18 (m, 5 H) 7.38 (t, J=7.93 Hz, 2 H) 7.59 (d, J=7.81 Hz, 2 H) 9.39 (s, 1 H) 9.68 (s, 1 H) 10.28 (d, JN5.84 Hz, 1 H). MS (ESI+) for C20H21N3OS m/z 352 (M+H)+.
Example 57 (BVT.61804B)
5-(2-anilinoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one
Prepared according to method H
85 mg, 44% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.85-1.77 (m, 11 H) 2.12 (m, 1 H) 2.71 (m, 1 H) 3.19 (d, J=7.08 Hz, 2 H) 3.95 (m, 2 H) 4.90 (t, J=8.79 Hz, 1 H) 7.23 (t, J=7.45 Hz, 1 H)
7.43 (m, 2 H) 7.65 (d, J=8.79 Hz, 2 H). MS (ESI+) for d8H25N3OS m/z 332 (M+H)+.
Example 58 (BVT.61805C)
5-(2-anilinoethyl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-l,3-thiazol-4(5H)-one Prepared according to method H 30mg, 17% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.4-2.0 (m, 17 H) 2.12 (m, 1 H) 2.71 (m, 1 H) 3.96 (m, 2 H) 5.07 (t, J=8.67 Hz, 1 H) 7.22 (t, J=7.32 Hz, 1 H) 7.43 (t, J=7.81 Hz, 2 H) 7.64 (d, J=8.06 Hz, 2 H). MS (ESI+) for C20H30N4OS m/z 375 (M+H)+.
Example 59 (BVT.61983B)
5-(2-anilinoethyl)-2-(cyclohexylamino)- 1 ,3-thiazol-4(5H)-one hydrobromide
Prepared according to method H 120mg, 30% yield.
Η NMR (400 MHz, DMSO-D6) δ ppm 1.0-2.0 (m, 10 H) 2.11 (m, 1 H) 2.70 (m, 1 H) 3.66 (s, 1 H) 3.96 (m, 2 H) 4.92 (t, J=8.67 Hz, 1 H) 7.23 (t, J=7.32 Hz, 1 H) 7.43 (t, J=7.81 Hz, 2 H) 7.64 (d, J=8.30 Hz, 2 H) 9.31 (s, 1 H) 9.58 (s, 1 H) 9.92 (d, J=7.81 Hz, 1 H). MS (ESI+) for Cι7H23N3OS m/z 318 (M+H)+.
Example 60 (BVT.61995C)
5-(2-anilinoethyl)-2- { [( 1R)- 1 -phenylethyl] amino} - 1 ,3-thiazol-4(5H)-one hydrochloride
Prepared according to method H 0.057 g 43% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.52 (d, J=6.10 Hz, 3 H) 2.11 (m, 1 H) 2.69 (m, 1
H) 3.94 (m, J=7.32, 3.66 Hz, 2 H) 5.10 (m, 1 H) 5.23 (m, 1 H) 7.22 (t, J=7.32 Hz, 1 H)
7.31 (m, 1 H) 7.39 (m, 2 H) 7.44 (t, J=8.06 Hz, 4 H) 7.64 (d, J=7.08 Hz, 2 H). MS (ES+) for Cι9H2,N3OS HCl m/z 340 (M+H)+.
Example 61 (BVT.61996C)
5-(2-anilinoethyl)-2- {[(1 S)- 1 -phenylethyl] amino} - 1 ,3-thiazol-4(5H)-one hydrochloride
Prepared according to method H
0.0512 g, 36% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 1.52 (d, J=6.35 Hz, 3 H) 2.10 (m, 1 H) 2.70 (m, 1
H) 3.94 (m, 2 H) 5.07 (m, 1 H) 5.21 (m, 1 H) 7.22 (t, J=7.20 Hz, 1 H) 7.32 (m, 1 H) 7.41
(m, 6 H) 7.64 (d, J=7.57 Hz, 2 H). MS (ES+) for Cι9H21N3OS HCl m/z 340 (M+H)+.
Example 62 (BVT.61997C) 5-(2-anilinoethyl)-2-{[(2R)-2-phenylpropyl]amino}-l,3-thiazol-4(5H)-one hydrochloride
Prepared according to method H
0.0465 g, 22%yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.25 (dd, J-6.84, 1.46 Hz, 3 H) 2.04 (m, 1 H) 2.61
(m, 1 H) 3.09 (m, 1 H) 3.56 (m, 2 H) 3.91 (m, 2 H) 4.84 (td, J=8.55, 2.44 Hz, 1 H) 7.23 (m, 2 H) 7.32 (m, 4 H) 7.42 (t, J-7.93 Hz, 2 H) 7.63 (d, J=8.30 Hz, 2 H). MS (ES+) for
C2oH23N3OS HCl m/z 354 (M+H)+.
Example 63 (BVT.61824B 5-(2-anilinoethyl)-2-(cycloheptylamino)- 1 ,3 -thiazol-4(5H)-one Prepared according to method Η 0.0144 g, 34 % yield of white crystals.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.31-1.69 (m, 12 H) 1.81-2.04 (m, 3 H) 3.09-3.46 (m, 1 H) 3.95 (s, 2 H) 7.11 (d, J=7.18 Hz, 3 H) 7.32 (d, J=7.42 Hz, 2 H) 9.62 (s, 1 H). MS (ESI+) for C18H25N3OS m/z 332 (M+H)+.
Example 64 (BVT.59446)
5-(2-anilinoethyl)-2-[(4-methylbenzyl)amino]-l,3-thiazol-4(5H)-one Prepared according to method H
17,52 mg, yield 6,2%.
1H NMR (400 MHz, METHANOL-D4) δ ppm 2.15 (m, 1 H) 2.33 (m, 3 H) 2.78 (m, 1 H)
4.03 (m, 2 H) 4.54 (m, 2 H) 4.76 (m, 1 H) 7.25 (m, 5 H) 7.41 (m, 2 H) 7.60 (m, 2 H). MS
(ESI+) for Cι9H21N3OS m/z 340 (M+H)+.
Example 65 (BVT.62617B)
5-(2-anilinoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one hydrobromide
Prepared according to method H
0.0795 g, yield 85 %, as white crystals. 1H NMR (270 MHz, DMSO-D6) δ ppm 1.40-1.89 (m, 15 H) 1.99-2.22 (m, 2 H) 2.69 (d,
J=7.42 Hz, 1 H) 3.77-4.01 (m, 2 H) 4.88 (t, J=8.78 Hz, 1 H) 7.23 (t, J=7.30 Hz, 1 H) 7.43
(t, J=7.92 Hz, 2 H) 7.64 (d, J=7.92 Hz, 2 H) 9.95 (d, J=8.16 Hz, 1 H). MS (ESI+) for
C19H27N3OS m/z 346 (M+H)+.
Example 66 (BVT062639B^)
5-(2-anilinoethyl)-2-{[(lR)-l-cyclohexylethyl]amino}-l,3-thiazol-4(5H)-one
Prepared according to method H
32.4 mg, yield 14% as a white solid.
1H NMR (400 MHz, DMSO- ) δ ppm 0.96 (m, 2 H) 1.14 (d, J=6.6 Hz, 3 H) 1.14 (m, 3 H) 1.44 (m, 1 H) 1.61 (d, J=10.5 Hz, 1 H) 1.71 (d, J=10.5 Hz, 4 H) 2.12 (m, 1 H) 2.70 (m, 1
H) 3.51 (m, 1 H) 3.68 (d, J=5.6 Hz, 1 H) 3.95 (m, 2 H) 4.89 (td, J=8.7, 4.4 Hz, 1 H) 7.23
(t, J=7.5 Hz, 1 H) 7.43 (t, J=7.9 Hz, 2 H) 7.64 (d, J=8.1 Hz, 2 H) 9.86 (d, J=8.8 Hz, 1 H).
MS (ES+) for Cι9H27N3OS m/z 346 (M+H)+. Example 67 (BVT062640B)
5-(2-anilinoethyl)-2- { [( 1 S)- 1 -cyclohexylethyl]amino } - 1 ,3 -thiazol-4(5H)-one Prepared according to method H 87.0 mg, yield 33% as a white solid.
1H NMR (400 MHz, DMSO- 6) δ ppm 0.98 (m, 2 H) 1.14 (d, J=6.4 Hz, 3 H) 1.15 (m, 3 H) 1.45 (m, 1 H) 1.61 (d, J=9.8 Hz, 1 H) 1.71 (d, J=10.0 Hz, 4 H) 2.12 (m, 1 H) 2.70 (m, 1 H) 3.35 (m, 1 H) 3.73 (s, 1 H) 3.94 (m, 2 H) 4.94 (m, 1 H) 7.22 (t, J=7.3 Hz, 1 H) 7.43 (t, J=7.9 Hz, 2 H) 7.64 (d, J=7.8 Hz, 2 H) 9.87 (d, J-8.6 Hz, 1 H). MS (ES+) for Cι9H27N3OS m/z 346 (M+H)+.
Example 68 (BVT063212B)
5-(2-anilinoethyl)-2-azepan- 1 -yl- 1 ,3-thiazol-4(5H)-one
Prepared according to method A followed by method H. 83.4 mg, yield 5% over two steps.
1H NMR (400 MHz, OMSO-d6) δ ppm 1.54 (m, 4 H) 1.74 (m, 4 H) 2.18 (m, 1 H) 2.73 (m,
1 H) 3.40 (s, 1 H) 3.68 (m, 2 H) 3.79 (m, 2 H) 3.97 (m, 2 H) 4.97 (m, 1 H) 7.23 (t, J=7.5
Hz, 1 H) 7.43 (t, J=7.9 Hz, 2 H) 7.65 (d, J-8.1 Hz, 2 H). MS (ES+) for C17H23N3OS m/z
318 (M+H)+.
Example 69 (BVT063213B)
5-(2-anilinoethyl)-2-{[(2S)-2-phenylpropyl]amino}-l,3-thiazol-4(5H)-one
Prepared according to method A followed by method H.
61.0 mg, yield 83%. Η NMR (400 MHz, DMSO-d6) δ ppm 1.25 (dd, J=6.8, 2.0 Hz, 3 H) 2.06 (m, 1 H) 2.60
(m, 1 H) 3.07 (m, 1 H) 3.53 (m, 2 H) 3.92 (m, 2 H) 4.73 (t, J=8.8 Hz, 1 H) 7.23 (m, 2 H)
7.31 (m, 4 H) 7.43 (t, J=7.8 Hz, 2 H) 7.63 (d, J=8.3 Hz, 2 H). MS (ES+) for C20H23N3OS m/z 354 (M+H)+.
Example 70 (BVT.63334B)
2-Anilino-5-(2-anilinoethyl)- 1 ,3-thiazol-4(5H)-one hydrobromide Prepared according to method Η. 84 mg, yield 55% as a white solid. IH NMR (400 MHz, METHANOL-D4) δ ppm 2.23 (m, 1 H) 2.85 (m, 1 H) 4.08 (m, 2 H) 4.93 (t, J=8.55 Hz, 1 H) 7.27 (t, J=7.45 Hz, 1 H) 7.44 (m, 5 H) 7.55 (m, 2 H) 7.65 (d, J=7.81 Hz, 2 H). MS (ES) for C17H]7N3OS m/z 312 (M+H)+.
Example 71 (BVT.66791T)
2-[(cyclohexylmethyl)amino]-5-{2-[(4-fluorophenyl)amino]ethyl}-l,3-thiazol-4(5H)-one trifluoroacetate
Prepared according to method H.
9,8 mg, yield 3%. IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.07 (m, 5 H) 1.64 (m, 6 H) 2.12 (m, 1
H) 2.81 (m, 1 H) 3.20 (m, 2 H) 3.96 (m, 2 H) 4.45 (m, 1 H) 7.09 (m, 2 H) 7.50 (m, 2 H) )
MS (ES) for CιsH24FN3OS m/z 350 (M+H)+.
Compounds of type 3
Example 72 (BVT.51282)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-
1 ,3-thiazol-4(5H)-one
Method D [2-(Bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetic acid
(0.10 g, 0.375 mmol) and 2-chloro-l-methylpyridinium iodide (0.115 g, 0.451 mmol) was mixed in DCM (3 mL) for 10 minutes before 1,2,3,4-tetrahydroquinoline (0.05 g, 0.375 mmol) was added followed by Et3N (0.057 g, 0.563 mmol). The reaction mixture was stined for 16 h, full conversion of the SM. The reaction mixture was poured on a Hydromatrix column (pretreated with water) and the crude product was eluted with DCM.
The obtained crude product was purified by preparative reverse phase (30-60) as gradient.
This gave 0.090 g of the title compound, 98 % pure, yield 63%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.57-1.40 (m, 4H) 1.95-1.78 (m, 2H) 2.73-2.68
(m, 2H) 2.97-2.80 (m, 3H) 3.61-3.41 (m, 2H) 3.83-3.68 (m, 2H) 4.34-4.26 (m, IH) 6.12- 6.06 (m, IH) 6.25-6.20 (m, IH) 7.24-7.10 (m, 4H) 9.30 (br.d, 7.43 Hz, IH, N-H). MS
(ESI+) for C2ιH23N3O2S m/z 382 (M+H)+.
Example 73 (BVT.47556) 2-[2-(Bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(3- chloro-2-methylphenyl)acetamide Prepared according to method D
83 mg, 28% yield as a white solid. Mp 201-202 °C. 1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.41-1.62 (m, 4H) 2.21 (s, 3H) 2.67-2.86 (m, 3H) 3.20-3.27 (m, IH, obscured by HDO peak) 3.75-3.76 (m, IH) 4.34-4.40 (m, IH) 6.08 (dd, Jl=5.52, J2=3.01 Hz, IH) 6.21 (dd, Ji=5.52, J2=2.76 Hz, IH) 7.18 (t, J=7.91 Hz, IH) 7.27-7.33 (m, 2H) 9.37 (br s, ΝH) 9.76 (br s, ΝH). MS (EI+) for Cι9H2oClΝ3O2S m/z 390.0 (M+H)+.
Example 74 (BVT.49940)
N-Benzyl-2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetamide
Prepared according to method D
30 mg of white crystals: Mp 206-207 °C. !H NMR (400 MHz, DMSO-D6) δ ppm 1.41- 1.59 (m, 4H) 2.45-2.53 (m, IH) 2.79-2.86 (m, 2H) 3.04-3.11 (m, IH) 3.73-3.77 (m, IH)
4.22-4.34 (m, 3H) 6.07-6.10 (m, IH) 6.19-6.24 (m, IH) 7.21-7.26 (m, 3H) 7.29-7.33 (m,
2H) 8.53-8.57 (m, NH) 9.26 (d, J=7.03 Hz, NH). MS (EI+) for Cι9H2ιN3O2S m/z 377.2
(M+H)+.
Example 75 (BVT.51283)
N-benzyl-2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide
Prepared according to method D
0.091 g, yield 57%. Η NMR (270 MHz, DMSO-D6) δ ppm 1.64-1.42 (m, 4H) 2.46-2.25 (m, IH) 3.00-2.75
(m, 3H) 3.80-3.65 (m, IH) 4.34-4.26 (m, IH) 4.90-4.85 (m, 2H) 6.08-6.04 (m, IH) 6.26-
6.20 (m, IH) 7.41-7.18 (m, 10H) 9.26 (d, J= 6.93 Hz, IH; N-H). MS (ESI+) for
C25H25N3O2S m/z 432 (M+H)+.
Example 76 (BVT.51284)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- methoxyphenyl)-N-methylacetamide
Prepared according to method D 0.095 g, yield 66%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.56-1.40 (m, 4H) 2.30-2.23 (m, IH) 2.92-2.74 (m, 4H) 3.13 (s, 3H) 3.78 (s, 3H) 4.26-4.17 (m,lH) 6.08-6.04 (m, IH) 6.26-6.18 (m, IH) 7.01-6.98 (m, 2H) 7.32-7.26 (m, 2H) 9.32 (br.d, J= 6.83 Hz, 1 H., N-H). MS (ESI+) for C20H23N3O3S m/z 386 (M+H)+.
Example 77 (BVT.51285)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-
N-phenylacetamide Prepared according to method D
0.11 g, yield 83%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.58-1.39 (m, 4H) 2.44-2.25 (m, IH) 2.97-2.75
(m, 4H) 3.17 (s, 3H) 4.274.17 (m, IH) 6.08-6.06 (m, IH) 6.26-6.19 (m, IH) 749-7.30 (m,
5H) 9.34 (br.d, J= 7.17 Hz, IH, N-H). MS (ESI+) for C19H2ιN3O2S m/z 356 (M+H)+.
Example 78 (BVT.51286)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one
Prepared according to method D 0.08 g, yield 6%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.62-143 (m, 4H) 2.88-2.75 (m, 3H) 3.31-3.29
(m, 2H) 4.35-4.28 (m, IH) 4.65 (s, 2H) 4.84 (s, 2H) 6.12-6.10 (m, IH) 6.24-6.22 (m, IH)
7.37-7.27 (m, 4H) 9.35 (br.d, J= 9.63 Hz, IH, N-H). MS (ESI+) for C20H21N3O2S m/z 368
(M+H)+.
Example 79 (BVT.51296)
2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one
Prepared according to method D 0.007 g, yield 5%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.63-142 (m, 4H) 2.92-2.82 (m, 3H) 3.17-3.11
(m, 3H) 3.80-3.70 (m, IH) 4.12-4.03 (m, 2H) 4.39-4.30 ( , IH) 6.12-6.10 (m, IH) 6.24- 6.21 (m, IH) 7.03-6.98 (m, IH) 7.19-7.16 (m, IH) 7.26-7.23 (m, IH) 8.03 (d, J= 7.92 Hz, IH) 9.34 (br.d, J- 7.17 Hz, 1HH, N-H). MS (ESI+) for C20H2ιN3O2S m/z 368 (M+H)+.
Example 80 (BVT056660) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N- (3 -methylphenyl)acetamide Prepared according to method D 34.15 mg, yield 45%.
1H NMR (270 MHz, DMSO-D6) δ ppm 0.97-1.02 (m, 3H) 140-1.59 (m, 4H) 2.20-2.32 (m, 5H) 2.75-2.87 (m, 3H) 3.20-3.30 (m, IH) 3.60-3.72 (m, 2H) 4.17-4.23 (m, IH, 6.06- 6.10 (m, IH) 6.19-6.26 (m, IH) 7.10-7.24 (m, 3H) 7.33-7.43 (m, IH) 9.26-9.29 (m, IH, N- H). MS (ESI+) for C2ιH25N3O2S m/z 384 (M+H)+.
Example 81 (BVT056661) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one
Prepared according to method D
9.08 mg, yield 12%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.39-1.64 (m, 4H) 2.75-2.93 (m, 5H) 3.30-340 (m, IH) 3.59-3.78 (m, 4H) 4.23-4.33 (m, IH) 4.58-4.69 (m, IH) 6.05-6.17 (m, IH) 6.19-
6.27 (m, IH) 4.06 (br.s, 4H) 9.30-9.32 (m, IH, N-H). MS (ESI+) for C21H23N3O2S m/z 382
(M+H)+.
Example 82 (BVT056662) 2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-
N- [4-(trifluoromethoxy)phenyl] acetamide
Prepared according to method D
16.26 mg, yield 19%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.37-1.62 (m, 4H) 2.75-2.96 (m, 4H) 3.13-3.23 (m, 4H) 3.66-3.79 (m, IH) 4.17-4.28 (m, IH) 6.03-6.12 (m, IH) 6.17-6.26 (m, IH) 7.37-
7.59 (m, 4H) 9.27-9.30 (m, IH, N-H). MS (ESI+) for C20H20F3N3O3S m/z 440 (M+H)+
Example 83 (BVT056663) 2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-ethyl-N- [4-(trifluoromethoxy)phenyl]acetamide Prepared according to method D 10.19 mg, yield 11%. 1H NMR (270 MHz, DMSO-D6) δ ppm 0.97-1.08 (m, 3H) 1.34-1.64 (m, 4H) 2.21-245 (m, 2H) 2.77-2.94 (m, 3H) 3.62-3.77 (m, 3H) 4.18-4.28 (m, IH) 6.06-6.13 (m, IH) 6.19- 6.26 (m, IH) 745-7.55 (m, 4H) 9.26-9.29 (m, IH, N-H). MS (ESI+) for C21H22F3N3O3S m/z 454 (M+H)+.
Example 84 (BVT056666)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-oxo-2-[7-(trifluoromethyl)-3,4- dihydroquinolin- 1 (2H)-yl] ethyl} - 1 ,3-thiazol-4(5H)-one
Prepared according to method D
11.5 mg, yield 13%. ]H NMR (270 MHz, DMSO-D6) δ ppm 0.97-1.05 (m, 3H) 1.37-1.61 (m, 5H) 2.21-242
(m, IH) 2.75-2.92 (m, 3H) 340-3.50 (m, IH) 3.59-3.77 (m, 3H) 4.16-4.26 (m, IH) 6.05-
6.15 (m, IH) 6.19-6.26 (m, IH) 743-7.5 (m, 3H) 9.26-9.29 (m, IH, N-H).
MS (ESI+) for C22H22F3N3O2S m/z 450 (M+H)+.
Example 85 (BVT056668)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-
N-(2-methylphenyl)acetamide
Prepared according to method D
10.99 mg, yield 15%. 1H NMR (270 MHz, DMSO-D6) δ ppm 1.38-1.62 (m, 4H) 1.95-2.37 (m, 4H) 2.52 (s, 3H)
2.76-2.91 (m, 2H) 3.08 (s, 3H) 4.16-4.31 (m, IH) 6.04-6.12 (m, IH) 6.19-6.28 (m, IH)
7.23-742 (m, 4H) 9.36-9.38 (m, IH, N-H). MS (ESI+) for C20H23N3O2S m/z 370 (M+H)+.
Example 86 (BVT056669) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N- phenylacetamide Prepared according to method D 23.29 mg, yield 32%. 1H NMR (270 MHz, DMSO-D6) δ ppm 0.98-1.03 (m, 3H) 1.37-1.59 (m, 4H) 2.19-2.34
(m, IH) 2.72-2.89 (m, 3H) 3.60-3.70 (m,3H) 4.17-4.27 (m, IH) 6.04-6.12 (m, IH) 6.19-
6.26 (m, IH) 7.32-7.52 (m, 5H) 9.34-9.37 (m, IH, N-H). MS (ESI+) for C20H23N3O2S m/z
370 (M+H)+.
Example 87 (BVT056670)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydiO-l,3-thiazol-5-yl]-N-methyl-
N-(4-methylphenyl)acetamide
Prepared according to method D 21.33 mg, yield 29%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.37-1.62 (m, 4H) 2.22-240 (m, 2H) 2.33 (s, 3H)
2.75-2.93 (m, 3H) 3.14 (s, 3H) 3.20-3.35 (m, IH) 4.17-4.27 (m, IH) 6.06-6.13 8m, IH)
6.19-6.27 (m, IH) 7.16-7.31 (m, 4H) 9.32-9.35 (m, IH, N-H). MS (ESI+) for C20H23N3O2S m/z 370 (M+H)+.
Example 88 (BVT056671)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- bromophenyl)-N-methylacetamide
Prepared according to method D 17.54 mg, yield 20%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.38-1.59 (m, 4H) 2.22-2.57 (m, 3H) 2.74-2.97
(m, 4H) 3.16 (s, 3H) 4.15-4.27 (m, IH) 6.06-6.12 (m, IH) 6.19-6.26 (m, IH) 7.29-741 (m,
IH) 7.60-7.73 (m, IH) 9.32-9.34 (m, IH, N-H). MS (ESI+) for C19H20BrN3O2S m/z 434
(M+H)+.
Example 89 (BVT056672)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- chlorophenyl)-N-methylacetamide
Prepared according to method D 15.8 mg, yield 21%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.38-1.68 (m, 4H) 2.27-2.54 (m, 2H) 2.76-2.99
(m, 3H) 3.16 (s, 3H) 4.14-4.30 (m, IH) 6.06-6.13 (m, IH) 6.19-6.24 (m, IH) 7.36-7.58 (m,
4H) 9.33-9.35 (m, IH, N-H). MS (ESI+) for C19H20C1N3O2S m/z 390 (M+H)+. Example 90 (BVT056673)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- fluorophenyl)-N-methylacetamide Prepared according to method D 19.62 mg, yield 25%.
1H NMR (270 MHz, DMSO-D6) δ ppm 1.38-1.63 (m, 4H) 2.66-240 (m, IH) 2.74-2.97 (m, 3H) 3.15 (s, 3H) 3.62-3.73 (m, IH) 4.16-4.28 (m, IH) 6.03-6.11 (m, IH) 6.19-6.26 (m, IH) 7.22-7.33 (m, 2H) 7.39-7.51 (m, 2H) 9.33-9.36 (m, IH, N-H). MS (ESI+) for Cι9H20FN3O2S m/z 374 (M+H)+.
Example 91 (BVT056674)
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(3- chlorophenyl)-N-methylacetamide Prepared according to method D
19.62 mg, yield 25%.
1H NMR (270 MHz, DMSO-D6) δ ppm 140-1.62 (m, 4H) 2.38-2.55 (m, IH) 2.76-2.97
(m, 3H) 3.18 (s, 3H) 3.70-3.60 (m, IH) 4.20-4.30 (m, IH) 6.05-6.13 (m, IH) 6.19-6.26 (m,
IH) 7.32-7.63 (m, 4H) 9.34-9.37 (m, IH, N-H). MS (ESI+) for C19H20C1N3O2S m/z 390 (M+H)+.
Example 92 (BVT056675)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N-
(2-methylphenyl)acetamide Prepared according to method D
3545 mg, yield 47%.
1H NMR (270 MHz, DMSO-D6) δ ppm 0.99-1.07 (m, 3H) 1.38-1.59 (m, 4H) 1.92-2.34
(m, 4H) 2.76-2.87 (m, 4H) 3.08-3.24 (m, IH) 3.66-3.71 (m, IH) 4.22-4.31 (m, IH) 6.06-
6.12 (m, IH) 6.20-646 (m, IH) 7.15-746 (m, 4H) 9.35-9.37 (m, IH, N-H). MS (ESI+) for C21H25N3O2S m/z 384 (M+H)+.
Example 93 (BVT.59056^) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(8-methyl-3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one Prepared according to method D 0.00709 g, yield 36%. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.56-1.78 (m, 4H) 2.18-3.05 (m, 6H) 2.30 (s, 3H) 3.29-340 (m, IH) 4.28-4.54 (m, IH) 4.72-4.82 (m, IH) 6.02-6.09 (m, IH) 6.20- 6.28 (m, IH) 6.97-7.19 (m, 3H). MS (ESI+) for C22H25N3O2S m/z 396 (M+H)+.
Example 94 (BVT.59097) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-4(5H)- one
Prepared according to method D
31,16 mg, yield 25%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.77-143 (m, 10H) 2.81-2.70 (m IH) 3.03-2.97 (m 2H) 3.65-3.33 (m, 6H) 443-4.39 (m IH) 6.05-6.00 (m, IH) 6.27-6.24 (m
IH). MS (ESI+) for Cι7H23N3O2S m/z 334 (M+H)+.
Example 95 (BVT.59098)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- isopropyl-N-phenylacetamide
Prepared according to method D
1.9 mg, yield 1.3%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.31-1.24 (m, 6H) 2.05-1.61 (m, 5H)
3.05-2.98 (m, 3H) 341-3.33 (m, IH) 3.66-3.54 (m, IH) 4.55-446 (m, IH) 6.09-6.02 (m, IH) 6.28-6.24 (m, IH) 7.00-6.94 (m, 2H) 7.26-7.14 (m, 2H) 7.73-7.68 (m, IH). MS (ESI+) for C2ιH25N3O2S m/z 384 (M+H)+.
Example 96 (BVT.59099)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2,6- difluorophenyl)acetamide
Prepared according to method D 1 mg, yield 0.7%. Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.13-1.04 (m, 3H) 1.88-1.65 (m, 2H) 3.04-2.95 (m, 3H) 341-3.32 (m, IH) 4.37-4.30 (m, IH) 5.01-4.88 (m, IH) 6.07-6.04 (m, IH) 6.31-6.23 (m, IH) 7.26-7.04 (m, 3H) 749-740 (m, 2H). MS (ESI+) for Cι8H17F2N3O2S m/z 378 (M+H)+.
Example 97 (BVT.39225)
N-(2-Chlorophenyl)-2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetamide
Method M
A solution of 1 -(2-chlorophenyl)- lH-pynole-2,5-dione (100 mg, 0.48 mmol) in absolute ethanol (3 mL) was treated with l-cyclohexyl-2 -thiourea (80 mg, 0.50 mmol) and stined for 18 h at 50 °C. The clear solution was reduced to dryness on a rotavapor and the resulting white foam was recrystallised from acetonitrile giving 148 mg (84%) of white crystals: Mp 183 °C 1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.11-1.33 (m, 5H) 1.54-1.57 (m, IH) 1.68-1.71 (m, 2H) 1.84-1.87 (m, 2H) 2.73 (dd, Ji=16.31, J2=11.29 Hz, IH) 3.27- 3.29 (m, IH, obscured by HDO peak) 3.75-3.81 (m, IH) 4.35 (dd, Ji=l 1.29, J2=3.51 Hz, IH) 7.17-7.21 (m, IH) 7.30-7.34 (m, IH) 7.49 (d, J=8.03 Hz, IH) 7.65 (d, J=8.53 Hz, IH) 9.15 (d, J=7.53 Hz, ΝH) 9.75 (s, ΝH). MS (ESI+) for Cι7H2oClΝ3O2S m/z 366 (M+H)+.
Example 98 (BVT.39226) N-(2-Chlorophenyl)-2-(4-oxo-2-piperidin-l-yl-4,5-dihydro-l,3-thiazol-5-yl)acetamide
Prepared according to method M
156 mg, 93% yield of white crystals.
Mp 177 °C. 1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.53-1.65 (m, 6H) 2.76 (dd, Ji=16.82,
J?=l 1.29 Hz, IH) 3.30-3.34 (m, IH, obscured by HDO peak) 344-347 (m, 2H) 3.73-3.86 (m, 2H) 4.43 (dd, J7=l 1.17, J2=3.39 Hz, IH) 7.19 (t, J=7.15 Hz, IH) 7.30-7.34 (m, IH)
7.49 (dd, Ji=8.03, J2=1.25 Hz, IH) 7.67 (d, J=7.78 Hz, IH) 9.77 (s, ΝH). MS (EI+) for
C16Hι8ClΝ3O2S m/z 352.2 (M+H)+.
Example 99 (BVT47436 2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide Prepared according to method M 306 mg, 90% yield, as white crystals. Mp 216-217 °C. 1H NMR (400 MHz, DMSO-D6) δ ppm 141-1.60 (m, 4H) 2.64-2.73 (m, IH) 2.80-2.86 (m, 2H) 3.22-3.28 (m, IH) 3.72-3.79 (m, IH) 4.34-440 (m, IH) 6.09 (dd, J7=5.65, J2=3.14 Hz, IH) 6.21 (dd, J/=5.52, J2=2.76 Hz, IH) 7.03 (t, J-7.40 Hz, IH) 7.29 (t, J=7.91 Hz, 2H) 7.54-7.57 (m, 2H) 9.29 (d, J=5.27 Hz, NH) 10.10 (br s, NH); MS (EI+) for CιsH19N3O2S m/z 342.0 (M+H)+.
Example 100 (BVT47437)
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-lH- indazol-6-ylacetamide Prepared according to method M
110 mg, 29% yiled as off-white crystals.
Mp 222-223 °C. 1H ΝMR (400 MHz, DMSO-D6) δ ppm 142-1.60 (m, 4H) 2.65-2.74 (m,
IH) 2.81-2.86 (m, 2H) 3.25-3.30 (m, IH) 3.75-3.78 (m, IH) 4.34-442 (m, IH) 6.09 (dd,
J/=5.65, J2=3.14 Hz, IH) 6.21 (dd, J7=5.52, J2=2.76 Hz, IH) 7.36-740 (m, IH) 7.46- 7.48 (m, IH) 8.00 (s, IH) 8.09 (d, J=1.00 Hz, IH) 9.29 (dd, J7=6.90, J2=2.13 Hz, ΝH)
10.11 (br s, ΝH) 12.97 (br s, ΝH). MS (EI+) for Cι9H19Ν5O2S m/z 382.2 (M+H)+.
Example 101 (BVT47438)
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- fluorophenyl)acetamide
Prepared according to method M
297 mg yield 83%, as of white crystals.
Mp 215 °C 1H ΝMR (400 MHz, DMSO-D6) δ ppm 141-1.60 (m, 4H) 2.64-2.72 (m, IH)
2.80-2.86 (m, 2H) 3.21-3.27 (m, IH) 3.72-3.78 (m, IH) 4.34-440 (m, IH) 6.08 (dd, Jl=5.52, J2=3.01 Hz, IH) 6.20 (dd, J7=5.65, J2=2.89 Hz, IH) 7.13 (t, J=841 Hz, 2H)
7.54-7.59 (m, 2H) 9.28 (m, ΝH) 10.17 (br s, ΝH). MS (EI+) for Cι8H18FΝ3O2S m/z 360.2
(M+H)+.
Example 102 (BVT47439) N-(2-benzoylρhenyl)-2-[2-(Bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3- thiazol-5 -y 1] acetamide Prepared according to method M 256 mg, 57% yield, as a white powder. Mp 191-192 °C. 1H NMR (400 MHz, DMSO-D6) δ ppm 1.38-1.59 (m, 4H) 2.27-2.37 (m, IH) 2.77-2.92 (m, 3H) 3.70-3.74 (m, IH) 4.02-4.09 (m, IH) 6.07 (dd, Ji=5.65, J2=3.14 Hz, IH) 6.20 (dd, Ji=5.65, J2=2.89 Hz, IH) 7.27-7.32 (m, IH) 7.39-742 (m, IH) 7.45- 7.50 (m, 3H) 7.55-7.65 (m, 4H) 9.26 (d, J=7.03 Hz, NH) 10.18 (br s, NH). MS (EI+) for C25H23N3O3S m/z 446.2 (M+H)+.
Example 103 (BVT47489)
3-({[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- y 1] acetyl } amino)benzoic acid Prepared according to method M
290 mg, 75% yield.
Mp 242 °C. 1H NMR (400 MHz, DMSO-D6) δ ppm 141-1.59 (m, 4H) 2.66-2.75 (m, IH)
2.80-2.86 (m, 2H) 3.23-3.29 (m, IH, obscured by HDO) 3.74-3.77 (m, IH) 4.33-440 (m,
IH) 6.08 (dd, J7=5.40, J2=3.14 Hz, IH) 6.20 (dd, Ji=5.52, J =2.76 Hz, IH) 7.41 (t, J=7.78 Hz, IH) 7.61 (d, J-7.53 Hz, IH) 7.74 (d, J=7.28 Hz, IH) 8.21 (s, IH) 9.29 (dd,
J7-6.90, J2=1.88 Hz, NH) 10.29 (s, NH) 12.90 (br s, OH); MS (ΕΫ) for Cι9H19N3O4S m/z
386.0 (M+H)+.
Example 104 (BVT.47502 2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide
Prepared according to method M
92 mg, 31% yield, as white crystals.
Mp 187-188 °C; 1H ΝMR (400 MHz, DMSO-D6) δ ppm 0.97-1.02 (m, 3H) 1.39-1.60 (m, 4H) 2.33-241 (m, IH) 2.79-2.86 (m, 2H) 2.96 (dd, J/=15.81, J2=3.26 Hz, IH) 3.02-3.09
(m, 2H) 3.71-3.77 (m, IH) 4.20-4.27 (m, IH) 6.08 (dd, J7=540, J2=3.39 Hz, IH) 6.20 (dd,
Jl=5.77, J2=2.76 Hz, IH) 7.98-8.02 (m, ΝH) 9.23 (d, J=5.02 Hz, ΝH). MS (EI+) m/z 294.2
(M+H)+.
Example 105 (BVT47491)
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methylacetamide
Prepared according to method M 170 mg, 61% yield, as a white powder.
Mp 205 °C. 1H NMR (400 MHz, DMSO-D6) δ ppm 141-1.57 (m, 4H) 2.34-242 (m, IH) 2.56-2.59 (m, 3H) 2.79-2.86 (m, 2H) 2.95-3.00 (m, IH) 3.72-3.75 (m, IH) 4.22-4.27 (m, IH) 6.08 (dd, J7=540, J2=3.14 Hz, IH) 6.20 (dd, J7=5.90, J2=2.89 Hz, IH) 7.94-7.98 (m, NH) 9.24 (d, J=6.53 Hz, NH). MS (EI+) for C13H17N3O2S m/z 280.2 (M+H)+.
Example 106 (BVT.50132)
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-
4(577)-one Prepared according to method M
41 mg, 16% yield. Crystallisation from ethanol gave 30 mg of white crystals.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.38-1.59 (m, 4H) 2.60-2.86 (m, 3H) 3.20-3.25
(m, IH) 3.39-343 (m, 4H) 3.51-3.56 (m, 4H) 3.72-3.75 (m, IH) 4.19-4.25 (m, IH) 6.07-
6.09 (m, IH) 6.19-6.23 (m, IH) 9.23 (d, J=7.03 Hz, NH). MS (EI+) for Cι6H2ιN3O3S m z 336.2 (M+H)+.
Example 107 (BVT.50369)
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2- chlorophenyl)-N-methylacetamide Prepared according to method M
45 mg, 20% yield.
Mp 149-150 °C 1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.38-1.60 (m, 4H) 2.67-2.86 (m,
3H) 2.62-2.68 (m, 0.5H) 2.75-2.92 (m, 2.5H) 3.09 (s, 3H) 3.20-3.27 (m, IH) 3.66-3.72 (m,
IH) 4.18-4.28 (m, IH) 6.03-6.10 (m, IH) 6.17-6.23 (m, IH) 745-7.70 (m, 4H) 9.26 (d, J=7.03 Hz, 0.8ΝH) 9.89 (br s, 0.2NH). MS (EI+) for Cι9H2oClN3O2S m z 390.0 (M+H)+.
Example 108 (BVT.56860)
2-(Bicyclo[2.2.1]hept-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one Prepared according to method D 0.0360 g, yield 25%. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.19 (m, 3 H) 1.56 (m, 3 H) 1.77 (m, 2 H) 2.38 (m, 2 H) 2.83 (m, 3 H) 3.32 (t, J=544 Hz, 1 H) 3.70 (m, 3 H) 4.41 (d, J=l 1.63 Hz, 1 H) 4.57 (s, 1 H) 4.72 (s, 1 H) 7.13 (m, 4 H). MS (EI+) for C2ιH25N3O2S m/z 384 (M+H)+.
Example 109 (BVT.59085)
2-{2-[(3-chloro-2-methylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide Prepared according to method D 82.3 mg, 32% yield 1H NMR (400 MHz, METHANOL-D4) δ ppm 2.17 (s, 3 H) 2.57 (dd, J=17.09, 9.77 Hz, 1 H) 2.92 (dd, J=17.21, 3.05 Hz, 1 H) 3.16 (s, 3 H) 4.33 (dd, J=9.52, 3.17 Hz, 1 H) 6.83 (d, J=7.57 Hz, 1 H) 7.09 (t, J=7.81 Hz, 1 H) 7.16 (m, 1 H) 7.22 (d, J=7.57 Hz, 2 H) 7.35 (m, 1 H) 742 (t, J-7.20 Hz, 2 H). MS (ES+) for Cι9H18ClN3O2S m/z 388 (M+H)+.
Example 110 (BVT.59088)
2-[(3 -chloro-2-methylphenyl)amino]-5- [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1,3- thiazol-4(5H)-one
Prepared according to method D
50 mg, 18% yield. 1H NMR (400 MHz, METHANOL-D4) δ ppm 1.94 (m, 2 H) 2.20 (s, 3 H) 2.69 (s, 2 H)
3.09 (m, 1 H) 3.43 (s, 1 H) 3.67 (m, 1 H) 3.77 (s, 1 H) 4.45 (d, J=6.35 Hz, 1 H) 6.86 (d,
J=7.81 Hz, 1 H) 7.15 (m, 6 H). MS (ES+) for C2ιH20ClN3O2S m/z 414 (M+H)+.
Example 111 (BVT.59107) 2-[2-(l-Adamantylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide
Prepared according to method D
0.012 g, yield 9%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.68 (m, J=12.12 Hz, 6 H) 2.10 (m, 10 H) 2.53 (dd, .7=17.69, 12.25 Hz, 1 H) 3.16 (dd, J=17.57, 3.22 Hz, 1 H) 3.30 (s, 3 H) 4.33 (dd,
J=12.12, 3.22 Hz, 1 H) 7.15 (m, 2 H) 7.43 (m, 3 H). MS (EI+) for C22H27N3O2S m/z 398
(M+H)+. Example 112 (BVT.59117)
2-[2-( 1 -adamantylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(2,6- difluorophenyl)acetamide Prepared according to method D 0.02O0g, yield 15%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.70 (s, 5 H) 2.16 (m, 10 H) 3.31 (m, J=17.07 Hz, 1 H) 3.62 (m, 1 H) 448 (m, 1 H) 6.95 (m, J=7.92, 7.92 Hz, 2 H) 7.24 (m, J=7.92 Hz, 1 H). MS (EI+) for C21H23F2N3O2S m/z 420 (M+H)+.
Example 113 (BVT.59124C)
2-[2-(tert-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N-phenylacetamide
Prepared according to method D
150 mg, 53% yield.
Η NMR (400 MHz, DMSO-D6) δ ppm 1.32 (s, 9 H) 2.26 (m, 1 H) 2.89 (m, 1 H) 3.16 (s, 3 H) 4.11 (m, 1 H) 7.41 (m, 5 H) 8.96 (s, 1 H). MS (ESI+) for d6H2ιN3O2S m/z 320
(M+H)+.
Example 114 (BVT.59134)
2-[2-(cyclopropylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide
Prepared according to method D
58 mg, 39% yield.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 0.64-1.00 (m, 4 H) 2.51 (dd, J=17.57,
11.88 Hz, 1 H) 2.66-2.73 (m, 1 H) 3.12 (dd, J=17.57, 3.46 Hz, 1 H) 3.29 (s, 3 H) 4.32 (dd, J=11.88, 3.22 Hz, 1 H) 7.14-7.20 (m, 2 H) 7.33-748 (m, 3H). MS (ESI+) for d5Hι7N3O2S m/z 304 (M+H)+.
Example 115 (BVT.59135)
2-(cyclopentylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol- 4(5H)-one
Prepared according to method D 72 mg, 46% yield. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 145-1.75 (m, 2 H) 1.70-2.00 (m, 4H) 1.94-2.17 (m, 2 H) 2.64-2.81 (m, 1 H) 2.78-2.93 (m, 2 H) 3.53-3.72 (m, 2 H) 3.70-3.94 (m, 2H) 4.34-4.43 (m, 1 H) 4.57 (br.s, 1 H) 4.71 (s, 1 H) 7.07-7.27 (m, 4 H). MS (ESI+) for Cι9H23N3O2S m/z 358 (M+H)+.
Example 116 (BVT.59136)
2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide Prepared according to method D 80 mg 56% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.42-1.64 (m, 2 H) 1.65-1.90 (m, 4 H) 1.88-2.10 (m, 2 H) 240 (dd, J=11.88, 17.55 Hz, 1 H) 3.12 (dd, J=3.24, 17.55 Hz, 1 H)
3.26 (s, 3 H) 3.67-3.78 (m, 1 H) 4.28 (dd, J=12.00, 3.09 Hz, 1 H) 7.12-7.18 (m, 2 H) 7.30- 7.44 (m, 3 H). MS (ESI+) for C17H21N3O2S m/z 332 (M+H)+.
Example 117 (BVT.59137)
5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-2-(isobutylamino)-l,3-thiazol-4(5H)- one
Prepared according to method D 54mg 34% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.84-1.04 (m, 6 H) 1.98-2.18 (m, 1 H)
2.62-2.94 (m, 3 H) 3.14 (d, J=6.93 Hz, 2 H) 3.50-3.68 (m, 2 H) 3.63-3.94 (m, IH) 4.32-
4.44 (m, 1 H) 4.57 (br. s, 1 H) 4.65-4.73 (m, 1 H) 7.05-7.27 (m, 4 H). MS (ESI+) for
Cι8H23N3O2S m/z 346 (M+H)+.
Example 118 (BVT.59138)
2-[2-(isobutylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N-phenylacetamide
Prepared according to method D
63 mg 43% yield. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.98 (d, J=6.68 Hz, 5 H) 1.94-2.12 (m, 1
H) 2.54 (dd, J=\7.57, 11.88 Hz, 1 H) 3.09 (d, J=3.22 Hz, 1 H) 3.17 (d, J=7.18 Hz, 2 H)
3.27 (s, 3 H) 4.35 (dd, J=11.88, 346 Hz, 1 H) 7.12-7.19 (m, 2 H) 7.33-748 (m, 3 H). MS (ESI+) for C16H2,N3O2S m/z 320 (M+H)+. Example 119 (BVT.59139
2-(l -adamantylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)- one
Prepared according to method D
0.0130 g, yield 10%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.68 (m, 5 H) 2.11 (m, 9 H) 2.80 (m, 3 H)
3.65 (m, 2 H) 3.87 (m, J=5.69 Hz, 1 H) 4.42 (d, J=12.12 Hz, 1 H) 4.58 (m, 1 H) 4.72 (d,
J=6.19 Hz, 1 H) 7.11 (m, 4 H). MS (EI+) for C24H29N3O2S m/z 424 (M+H)+.
Example 120 (BVT.5914O)
2-(cyclopropylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol- 4(5H)-one
Prepared according to method D 53 mg, 33% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.93 (d, J=7.83 Hz, 4 H) 2.66-2.94 (m, 4 H) 3.50-368 (m, 2 H) 3.70-3.96 (m, 1 H) 4.38-4.45 (m, 1 H) 4.57-4.62 (m, 1 H) 4.74 (s, 1 H) 7.07-7.26 (m, 4 H). MS (EI+) for C17H19N3O2S m/z 330 (M+H)+.
Example 121 (BVT.59147T)
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-(mesitylamino)-l,3-thiazol-4(5H)-one
Prepared according to method D
55 mg, 40% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.87 (m, 2 H) 2.08 (s, 6 H) 2.23 (s, 3 H) 2.68 (m, 2 H) 2.96 (dd, J-16.85, 9.64 Hz, 1 H) 3.35 (d, J=1648 Hz, 1 H) 3.59 (m, 1 H) 3.74 (m, 1 H)
4.35 (d, J=842 Hz, 1 H) 6.89 (s, 2 H) 7.10 (td, J=7.26, 0.85 Hz, 1 H) 7.16 (m, 2 H) 7.45
(d, J=6.10 Hz, 1 H). MS (ESI+) for C23H25N3O2S m/z 408 (M+H)+.
Example 122 (BVT.59215D 2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N- methyl-N-phenylacetamide trifluoroacetate Prepared according to method D 16.8 mg, 11 % yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 2.60 (dd, J= 17.3 Hz, J= 10.6 Hz, 1 H) 3.04 (dd, J= 17.3 Hz, J= 3.2 Hz, 1 H) 3.25 (s, 3 H) 442 (dd, J= 10.6 Hz, J= 3.2 Hz, 1 H) 7.17 (m, 2 H) 7.38 (m, 1 H) 7.43 (m, 1 H) 7.49 (s, 2 H) 7.65 (s 1 H). MS (ESI+) for C20H15F6N3O2S C2HF3O2 m/z 476 (M+H)+.
Example 123 (BVT.59260)
N-(2-chlorophenyl)-2- {2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} acetamide
Prepared according to method D 12.3 mg, 4 % yield.
1H NMR (400 MHz, METHANOL-D4) δ ppm 0.94 (m, 6 H) 1.21 (m, 1 H) 1.46 (m, 1 H) 1.71 (m, 1 H) 2.93 (dd, J=16.60, 10.50 Hz, 1 H) 3.13 (m, 1 H) 3.44 (m, 2 H) 4.57 (dd, J=10.50, 3.42 Hz, 1 H) 7.17 (t, J=7.57 Hz, 1 H) 7.29 (t, J=7.69 Hz, 1 H) 7.43 (d, J=8.06 Hz, 1 H) 7.73 (d, J=6.84 Hz, 1 H). MS (ESI+) for Cι6H2oClN3O2S m/z 354 (M+H)+.
Example 124 (BVT.59261)
N-methyl-2- {2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- phenylacetamide
Prepared according to method D 29.5 mg, 11 % yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.91 (t, J=7.32 Hz, 3 H) 0.96 (dd, J=6.71, 1.34 Hz, 3 H) 1.22 (m, 1 H) 1.43 (m, 1 H) 1.83 (m, 1 H) 2.50 (dd, J=17.58, 11.96 Hz, 1 H) 3.12 (m, 2 H) 3.25 (t, J=4.88 Hz, 1 H) 3.28 (s, 3 H) 4.34 (dd, J=11.96, 3.17 Hz, 1 H) 7.16 (d, J=7.32 Hz, 2 H) 7.40 (m, 3 H). MS (ESI+) for Cι7H23N3O2S m/z 334 (M+H)+.
Example 125 (BVT.59262)
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-methylbutyl)amino]-l,3-thiazol-
4(5H)-one
Prepared according to method D 19.3 mg, yield 6 %.
Η NMR (400 MHz, METHANOL-D4) δ ppm 0.92 (m, 6 H) 1.18 (m, 1 H) 144 (m, 1 H) 1.68 (m, 1 H) 1.97 (m, 2 H) 2.73 (m, J=5.62 Hz, 2 H) 2.99 (m, J=14.04, 10.38 Hz, 1 H) 3.12 (m, 1 H) 3.40 (m, 1 H) 3.51 (dd, J=11.60, 3.78 Hz, 1 H) 3.71 (m, 1 H) 3.79 (d, J=5.62 Hz, 1 H) 4.50 (dd, J= 0.50, 3.17 Hz, 1 H) 7.19 (s, 4 H). MS (ESI+) for C19H25N3O2S m/z 360 (M+H)+.
Example 126 (BVT.59263) N-methyl-2-{4-oxo-2-[(2-phenylethyl)amino]-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide Prepared according to method D 6.1 mg, 4 % yield.
Η NMR (400 MHz, CHLOROFORM-D) δ ppm 243 (dd, J=1746, 11.84 Hz, 1 H) 3.02 (t, J-745 Hz, 2 H) 3.08 (dd, J=1746, 3.O5 Hz, 1 H) 3.57 (t, J=745 Hz, 2 H) 4.30 (dd,
J=11.72, 2.93 Hz, 1 H) 7.18 (m, 5 H) 7.30 (t, J=7.20 Hz, 2 H) 7.41 (m, 3 H). MS (ESI+) for C20H2ιN3O2S m/z 368 (M+H)+.
Example 127 (BVT.59264) 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-phenylethyl)amino]-l,3-thiazol-
4(5H)-one
Prepared according to method D
2.7 mg, 2 % yield.
1H NMR (400 MHz, METHANOL-D4) δ ppm 1.97 (m, 2 H) 2.75 (m, J=5.62 Hz, 2 H) 2.91 (t, J=7.08 Hz, 2 H) 2.97 (m, 2 H) 3.60 (m, 1 H) 3.72 (t, J=647 Hz, 2 H) 3.77 (m, 1 H)
4.50 (m, 1 H) 7.23 (m, 9 H). MS (ESI+-) for C22H23N3O2S m/z 394 (M+H)+.
Example 128 (BVT.59300T)
2-(2- {[3 ,5-Bis(trifluoromethyl)phenyl] amino} -4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl)-N-(2- chloro-6-fluorobenzyl)acetamide trifluoroacetate
Prepared according to method D
21.5 mg, 19 % yield.
1H ΝMR (400 MHz, DMSO-D6) δ ppm 2.70 (m, 1 H) 2.97 (m, 1 H) 4.42 (m, 1 H) 4.48
(m, 2 H) 7.14-742 (m, 3 H) 7.55 (s, 2 H) 7.81 (s, 1 H) 8.38 (s, 1 H). MS (ESI+) for C20Hι3ClF7Ν3O2S C2HF3O2 m/z 528 (M+H)+.
Example 129 (BVT.59344) 2-{2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide Prepared according to method D 252.7 mg, 64% yield as a white solid. 1H NMR (400 MHz, DMSO-D6) δ ppm 2.05 (s, 3 H) 2.09 (s, 3 H) 2.86 (dd, J=16.36, 9.28 Hz, 1 H) 3.16 (dd, J=16.36, 342 Hz, 1 H) 4.45 (dd, J=8.91, 3.30 Hz, 1 H) 6.94 (m, 1 H) 7.02 (m, 3 H) 7.26 (t, J=7.81 Hz, 2 H) 7.50 (d, J=7.81 Hz, 2 H) 10.05 (s, 1 H) 11.62 (s, 1 H). MS (ESI+) for C19H19N3O2S m/z 354 (M+H)+.
Example 130 (BVT.59345)
N-methyl-2- {2-[(4-moφholin-4-ylphenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- phenylacetamide
Prepared according to method D
29.9 mg, 23% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 3.10 (m, 4 H) 3.15 (s, 3 H) 3.17 (s, 2 H) 3.71 (m, 4
H) 4.25 (d, J=10.74 Hz, 1 H) 6.94 (m, 3 H) 7.36 (d, J=7.32 Hz, 3 H) 7.45 (d, J=6.84 Hz, 2
H) 7.56 (d, J=8.55 Hz, 1 H). MS (ESI+) for C22H24N4O3S m/z 425 (M+H)+.
Example 131 (BVT.59346) 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(4-moφholin-4-ylphenyl)amino]-l,3- thiazol-4(5H)-one
Prepared according to method D
17. 5 mg, 13% yield.
1H NMR (400 MHz, METHANOL-D4) δ ppm 1.97 (m, 2 H) 2.75 (m, 2 H) 3.08 (d, J=25.39 Hz, 1 H) 3.34 (s, 3 H) 3.52 (m, 1 H) 3.75 (m, 3 H) 3.92 (d, J=2.20 Hz, 4 H) 4.51
(m, 1 H) 7.23 (m, 7 H) 7.62 (d, .7=8.06 Hz, 1 H). MS (ESI+) for C24H26N4O3S m/z 451
(M+H)+.
Example 132 (BVT.59370) 5-[2-(3,4-Dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-{[3,5-bis(trifluoromethyl)phenyl]- amino} - 1 ,3-thiazol-4(577)-one Prepared according to method D 9 mg, 9 % yield. MS (ESI+) m/z 502 (M+H)+.
Example 133 (BVT.59371)
N-Benzyl-2-(2-{[3,5-bis(trifluoromethyl)phenyl]a-ιnino}-4-oxo-4,5-dihydro-l,3-thiazol-5- yl)acetamide
Prepared according to method D
20.5 mg, 25 % yield.
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.82 (dd, J= 16.4 Hz, J= 9.9 Hz, 1 H) 3.16 (dd, J= 16.4 Hz, J= 3.3 Hz, 1 H) 441 (t, J= 6.2 Hz, 2 H) 4.50 (dd, J= 9.9 Hz, J= 3.5 Hz, 1 H) 5.91 (m, 1 H) 7.20-7.33 (m, 5 H) 7.48 (s, 2 H) 7.65 (s, 1 H). MS (ESI+) m/z 476 (M+H)+. MS (ESI+) for C20Hι5F6Ν3O2S m/z 476 (M+H)+.
Example 134 (BVT.59372) 2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N-(2- phenylethyl)acetamide Prepared according to method D
24.6 mg, 29 % yield.
Η ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.67-2.80 (m, 3 H) 3.07 (m, 1 H) 3.50 (m, 2 H) 4.45 (m, 1 H) 5.63 (m, 1 H) 7.12-7.28 (m, 5 H) 7.47 (s, 2 H) 7.63 (s, 1 H). MS (ESI+) for C2ιH,7F6Ν3O2S m/z 490 (M+H)+.
Example 135 (BVT.59373)
2-{2-[(2-Fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide
Prepared according to method D
10.9 mg, 8 % yield.
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.51 (dd, J= 17.2 Hz, J= 11.7 Hz, 1 H)
3.06 (m, 1 H) 3.22 (s, 3 H) 4.38 (m, 1 H) 7.06-7.15 (m, 6 H) 7.33-744 (m, 3 H). MS (ESI+) for Cι8Hι6FΝ3O2S m/z 358 (M+H)+.
Example 136 (BVT.59374) 5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]-l,3-thiazol- 4(5H)-one
Prepared according to method D 5 mg, 5 %). MS (ESI+) for C20Hι8FN3O2S m/z 384 (M+H)+.
Example 137 (BVT.59375)
N-(2-Chloro-6-fluorobenzyl)-2-{2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-
5 -yl} acetamide Prepared according to method D
15.6 mg, 15 % yield.
1H ΝMR (400 MHz, DMSO-D6) δ ppm 2.63 (dd, J= 16.5 Hz, J= 10.4 Hz, 1 H) 2.96 (dd,
J= 16.5 Hz, J= 3.5 Hz, 1 H) 4.34 (d, J= 4.7 Hz, 2 H) 445 (dd, J= 10.3 Hz, J= 3.5 Hz, 1
H) 6.99 (m, 1 H) 7.12-7.25 (m, 4 H) 7.30-7.40 (m, 2 H) 8.38 (t, J= 4.9 Hz, 1 H). MS (ESI+) for C18H14ClF2Ν3O2S m/z 410 (M+H)+.
Example 138 (BVT.59578)
2-{2-[(2-Fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-(4- methylcyclohexyl)acetamide Prepared according to method D
2.7 mg, 2 % yield, as off-white powder.
MS (ESI+) for Cι8H22FΝ3O2S m/z 364 (M+H)+.
Example 139 (BVT.59581) 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2,6-dimethylphenyl)amino]-l,3- thiazol-4(5H)-one
Prepared according to method D
17 mg, 18% yield.
Η NMR (400 MHz, METHANOL-D4) δ ppm 1.98 (m, 2 H) 2.21 (s, 6 H) 2.72 (m, 2 H) 3.05 (s, 1 H) 3.72 (m, 3 H) 444 (d, J=9.03 Hz, 1 H) 7.16 (m, 7 H). MS (ESI+) for
C22H23N3O2S m/z 394 (M+H)+.
Example 140 (BVT.59582) 2-{2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide Prepared according to method D 5.2 mg, 6% yield. 1H ΝMR (400 MHz, METHAΝOL-D4) δ ppm 2.21 (s, 6 H) 2.55 (dd, J=l 7.21, 9.89 Hz, 1 H) 2.98 (dd, J=17.09, 3.17 Hz, 1 H) 3.20 (s, 3 H) 4.35 (dd, J=9.77, 3.42 Hz, 1 H) 7.13 (s, 3 H) 7.27 (d, J=7.57 Hz, 1 H) 7.32 (d, J=7.57 Hz, 1 H) 7.41 (d, J=7.08 Hz, 1 H) 7.47 (t, J=745 Hz, 1 H). MS (ESI+) for C20H2ιN3O2S m/z 368 (M+H)+.
Example 141 (BVT.59583)
N-(2-chloro-6-fluorobenzyl)-2- {2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro- 1 ,3- thiazol-5-yl} acetamide
Prepared according to method D
8.7 mg, 9% yield Η ΝMR (400 MHz, METHAΝOL-D4) δ ppm 2.22 (s, 6 H) 2.69 (dd, J=16.11, 9.52 Hz, 1
H) 3.06 (dd, J=16.11, 3.91 Hz, 1 H) 4.42 (dd, J=9.52, 3.91 Hz, 1 H) 4.48 (s, 2 H) 7.10 (m,
4 H) 7.24 (d, J-7.81 Hz, 1 H) 7.30 (m, 1 H). MS (ESI+) for C20Hι9ClFN3O2S m/z 420
(M+H)+.
Example 142 (BVT.61669)
5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-[(2-methylphenyl)amino]-l,3-thiazol-
4(5H)-one
Prepared according to method D
12.2 mg, 13 % yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.93 (m, 2 H) 2.22 (s, 3 H) 2.68 (m, 2 H)
2.89 (dd, J= 17.0 Hz, J= 11.2 Hz, 1 H) 3.52 (m, 1 H) 3.69 (m, 1 H) 3.76 (m, 1 H) 442
(dd, J= 11.2 Hz, J= 2.9 Hz, 1 H) 7.05-7.21 (m, 8 H). MS (ESI+) for C21H2ιN3O2S m/z
380 (M+H)+.
Example 143 (BVT.61670)
5-(2-Azepan-l-yl-2-oxoethyl)-2-[(2-methylphenyl)amino]-l,3-thiazol-4(577)-one Prepared according to method D 21.9 mg, 24 % yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.52 (m, 4 H) 1.67 (m, 4 H) 2.24 (s, 3 H) 2.68 (dd, J= 17.0 Hz, J= 11.7 Hz, 1 H) 3.28-344 (m, 4 H) 3.51-3.57 (m, 1 H) 4.37 (dd, J = 11.7 Hz, J= 3.0 Hz, 1 H) 7.08-7.20 (m, 4 H). MS (ESI+) for C18H23N3O2S m/z 346 (M+H)+.
Example 144 (BVT.61671)
N-(2-Chloro-6-fluorobenzyl)-2- {2-[(2-methylphenyl)amino]-4-oxo-4,5-dihydro- 1,3- thiazol-5-yl} acetamide
Prepared according to method D 47.7 mg, 48 % yield.
Η ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.28 (s, 3 H) 2.74 (dd, J= 16.6 Hz, J= 11.4 Hz, 1 H) 3.24 (dd, J= 16.6 Hz, J= 3.4 Hz, 1 H) 4.36 (dd, J= 1 1.4 Hz, J= 3.4 Hz, 1 H) 4.50 (dd, J= 14.3 Hz, J= 5.4 Hz, 1 H) 4.62 (dd, J= 14.3 Hz, J= 5.8 Hz, 1 H) 642 (t, J = 5.5 Hz, 1 H) 6.97 (m, 1 H) 7.15-7.29 (m, 6 H). MS (ESI+) for d9H17ClFΝ3O2S m/z 406 (M+H)+.
Example 145 (BVT.61672)
5-(2-Azepan- 1 -yl-2-oxoethyl)-2-[(2-isopropylphenyl)amino]- 1 ,3-thiazol-4(57 )-one
Prepared according to method D 15.0 mg, 17 % yield.
Η NMR (400 MHz, CHLOROFORM-D) δ ppm 1.09 (d, J= 6.8 Hz, 3 H) 1.13 (d, J= 6.8 Hz, 3 H) 147-1.57 (m, 4 H) 1.61-1.72 (m, 4 H) 2.70 (dd, J= 17.0 Hz, J= 11.7 Hz, 1 H) 3.05 (sept, J= 6.9 Hz, 1 H) 3.29-344 (m, 4 H) 3.50-3.56 (m, 1 H) 4.39 (dd, J= 11.6 Hz, J = 2.9 Hz, 1 H) 7.01 (dd, J= 7.7 Hz, J= 1.4 Hz, 1 H) 7.12 (dt, J= 7.6 Hz, J= 1.6 Hz, 1 H) 7.18 (dt, J= 7.6 Hz, J= 1.5 Hz, 1 H) 7.26 (m, 1 H). MS (ESI+) for C20H27N3O2S m/z 374 (M+H)+.
Example 146 (BVT.6168n
N-benzyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}acetamide Prepared according to method D 100 mg, 24% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 0.8-1.8 (m, 11 H) 3.07 (m, 4 H) 4.29 (m, 3 H) 7.15-7.45 (m, 5 H) 8.52 (m, 1 H) 9.15 (s, 1 H). MS (ESI+) for C19H25N3O2S m/z 360 (M+H)+.
Example 147 (BVT.61682C)
2-(cyclohexylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one
Prepared according to method D 65 mg, 45% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 1.07-1.99 (m, 12 H) 2.71 (t, J=6.65 Hz, 2 H) 2.96 (dd, J=16.85, 10.62 Hz, 1 H) 341 (dd, J=16.91, 3.36 Hz, 1 H) 3.65 (m, 1 H) 3.75 (m, 1 H) 3.83 (s, 1 H) 4.38 (dd, J=10.62, 3.30 Hz, 1 H) 7.15 (m, 3 H) 7.48 (m, 1 H) 9.72 (s, 1 H). MS (ESI+) for C20H25N3O2S m/z 372 (M+H)+.
Example 148 (BVT.61683C)
2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N-phenylacetamide
Prepared according to method D
70 mg, 52% yield.
1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.04-1.94 (m, 10 H) 2.50 (m, 1 H) 2.99 (m, 1 H) 3.20 (s, 3 H) 3.80 (s, 1 H) 4.33 (m, 1 H) 7.28-742 (m, 3 H) 742-7.53 (m, 2 H) 9.80 (s, 1
H). MS (ESI+) for Cι8H23Ν3O2S m/z 346 (M+H)+.
Example 149 (BVT.61684T
2-[2-(mesitylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N-phenylacetamide Prepared according to method D 57mg, 44% yield.
Η ΝMR (400 MHz, DMSO-D6) δ ppm 2.06 (s, 6 H) 2.23 (s, 3 H) 2.42 (m, 1 H) 2.88 (m, 1 H) 3.11 (s, 3 H) 4.29 (m, 1 H) 6.90 (s, 2 H) 7.30-7.50 (m, 5 H). MS (ESI+) for C21H23Ν3O2S m/z 382 (M+H)+.
Example 150 (BVT.61705)
N-methyl-2-{4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide Prepared according to method D 6.8 mg, 10% yield.
Η NMR (400 MHz, CHLOROFORM-D) δ ppm 2.53 (dd, J=17.33, 11.23 Hz, 1 H) 3.05 (dd, J=17.33, 2.93 Hz, 1 H) 3.24 (s, 3 H) 3.89 (s, 1 H) 4.37 (dd, J=l l.l l, 3.05 Hz, 1 H) 6.88 (d, J=8.55 Hz, 1 H) 7.14 (t, J=8.30 Hz, 4 H) 7.20 (t, J=745 Hz, 1 H) 7.39 (m, 5 H) 7.48 (dd, J=8.55, 2.69 Hz, 1 H) 7.99 (d, J-244 Hz, 1 H). MS (ES+) for C23H20N4O3S m/z 433 (M+H)+.
Example 151 (BVT.61707) N-(2-chloiO-6-fluorobenzyl)-2- {4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5-dihydro- 1,3- thiazol-5-yl} acetamide Prepared according to method D
7.3 mg, 8 % yield
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.68 (dd, J=15.99, 10.86 Hz, 1 H) 3.1 5 (d, J=1440 Hz, 1 H) 4.40 (d, J=7.81 Hz, 1 H) 4.59 (m, 2 H) 5.95 (s, 1 H) 6.88 (d, J=8.55 Hz, 1 H) 6.97 (t, J=8.55 Hz, 1 H) 7.11 (d, J=8.06 Hz, 2 H) 7.18 (m, 3 H) 7.38 (t, J=7.81 Hz, 2 H) 7.46 (d, J=7.81 Hz, 1 H) 7.97 (s, 1 H). MS (ES+) for C23H18ClFΝ4O3S m/z 485 (M+H)+.
Example 152 (BVT.61792)
2-[(2-cyclohex-l-en-l-ylethyl)amino]-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one
Prepared according to method D
10.2 mg, 19% yield. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.53 (m, 2 H) 1.61 (m, 2 H) 1.99 (m, 6 H)
2.34 (t, J=7.08 Hz, 2 H) 2.77 (m, 2 H) 2.98 (dd, J= 7.21, 11.84 Hz, 1 H) 345 (t, J=7.2
Hz, 2 H) 3.58 (d, J=15.87 Hz, 1 H) 3.67 (m, 2 H) 3.98 (s, 1 H) 4.43 (m, 1 H) 5.50 (s, 1 H)
7.04 (s, 1 H) 7.19 (s, 3 H). MS (ES+) for C22H27N3O2Sm/z 398 (M+H)+.
Example 153 (BVT.61793)
N-(4-fluorophenyl)-2- {4-oxo-2-[( 1 , 1 ,3 ,3 -tetramethylbutyl)amino]-4,5-dihydro- 1 ,3 -thiaz:ol-
5 -yl} acetamide
Prepared according to method D 8.6 mg, 10% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.97 (s, 6 H) 1.01 (s, 3 H) 1.51 (d, .7=1.95 Hz, 6 H) 1.86 (m, 2 H) 2.79 (dd, J=16.24, 10.13 Hz, 1 H) 3.46 (dd, J=16.36, 4.15 Hz, 1 H) 447 (dd, J=10.13, 4.27 Hz, 1 H) 6.03 (s, 1 H) 6.95 (t, J=8.55 Hz, 2 H) 7.49 (m, 1 H) 7.55 (dd, J=8.79, 4.88 Hz, 1 H) 8.52 (s, 1 H). MS (ES+) for Cι9H26FN3O2S m/z 380(M+H)+.
Example 154 (BVT.61803)
5-(2-azepan-l-yl-2-oxoethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one Prepared according to method D 60 mg, yield 56%.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.0-2.0 (m, 19 H) 2.73 (m, 1 H) 3.33 (m, 5 H) 4.24 (m, 1 H) 9.25 (d, J=7.32 Hz, 1 H). MS (ESI+) for C17H27N3O2S m/z 338 (M+H)+.
Example 155 (BVT.61807) 5-[2-(3,4-dilιydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(l , 1 ,3 ,3-tetramethylbutyl)amino]- 1 ,3- thiazol-4(5H)-one
Prepared according to method D
15.3 mg, 16% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.00 (s, 9 H) 1.57 (s, 3 H) 1.58 (s, 3 H) 1.82 (m, 2 H) 2.02 (m, 2 H) 2.77 (m, 2 H) 2.98 (dd, J=17.21, 11.84 Hz, 1 H) 3.68 (m, 3 H)
4.03 (s, 1 H) 441 (m, 1 H) 7.11 (m, J=54.69 Hz, 4 H). MS (ES+) for C22H31N3O2S m/z 402
(M+H)+.
Example 156 (BVT.61854) 5-(2-azepan- 1 -yl-2-oxoethyl)-2-[(l , 1 ,3 ,3-tetramethylbutyl)amino]- 1 ,3-thiazol-4(5H)-one
Prepared according to method D
7.0 mg, 8%) yield.
Η NMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (s, 6 H) 1.00 (s, 3 H) 1.52 (s, 6 H)
1.55 (m, 4 H) 1.73 (m, 4 H) 1.87 (m, 2 H) 2.64 (m, J=12.02, 12.02, 4.76 Hz, 1 H) 3.41 (m, 3 H) 3.51 (dd, J=17.09, 2.93 Hz, 1 H) 3.61 (m, 1 H) 4.40 (dt, J=12.15, 3.57 Hz, 1 H) 5.63
(s, 1 H); MS (ES+) for Cι9H33N3O2S m/z 368 (M+H)+.
Example 157 (BVT.61984) 2-(cyclohexylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol- 4(5H)-one
Prepared according to method D 60 mg, 41% yield. 1H NMR (400 MHz, DMSO-D6) δ ppm 1.23 (m, 5 H) 1.58 (m, 1 H) 1.72 (m, 2 H) 1.90 (m, 2 H) 2.82 (dd, J=17.03, 11.29 Hz, 3 H) 3.34 (dd, J=16.97, 3.17 Hz, 1 H) 3.66 (m, 2 H) 3.82 (m, 1 H) 4.29 (dd, J=l 1.29, 3.11 Hz, 1 H) 4.62 (s, 2 H) 7.18 (m, 4 H) 8.97 (d, J=6.71 Hz, 1 H). MS (ESI+) for C20H25N3O2S m/z 372 (M+H)+.
Example 158 (BVT.61985)
N-benzyl-2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methylacetamide
Prepared according to method D
52 mg, 37% yield.
1H ΝMR (400 MHz, DMSO-D6) δ ppm 1.18 (m, 1 H) 1.30 (m, 4 H) 1.58 (m, 1 H) 1.72 (m, 2 H) 1.90 (m, 2 H) 2.79 (dd, J=16.54, 11.90 Hz, 1 H) 2.86 (s, 1 H) 2.92 (s, 2 H) 3.29 (t,
J=16.17 Hz, 1 H) 3.82 (m, 1 H) 4.29 (dd, J=l 1.29, 2.99 Hz, 1 H) 4.55 (m, 2 H) 7.28 (m, 5
H) 8.95 (d, J=5.98 Hz, 1 H). MS (ESI+) for Cι9H25Ν3O2S m/z 360 (M+H)+.
Example 159 (BVT.61990) 2-(cyclohexylamino)-5-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one
Prepared according to method D
13 mg, 8% yield.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.2-2.1 (m, 10 H) 2.85 (m, 3 H) 3.33 (m, 1 H) 3.65 (m, 2 H) 3.7-3.9 (m, 7 H) 445 (m, 1 H) 4.52 (d, J=8.55 Hz, 1 H) 4.67 (s, 1 H)
6.62 (m, 2 H) 8.75 (s, 1 H). MS (ESI+) for C22H29N3O4S m/z 432 (M+H)+.
Example 160 (BVT.61991)
5-[2-(4-benzylpiperidin- 1 -yl)-2-oxoethyl]-2-(cyclohexylamino)- 1 ,3-thiazol-4(5H)-one Prepared according to method D 43mg, 27% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 1.25 (m, 8 H) 1.59 (m, 3 H) 1.78 (m, 6 H) 2.53 (m, 1 H) 2.67 (m, 1 H) 2.95 (m, 1 H) 3.21 (m, 1 H) 3.82 (m, 2 H) 4.23 (dd, J=11.23, 2.81 Hz, 1 H) 4.25 (m, 1 H) 7.18 (m, 3 H) 7.28 (m, 2 H) 8.93 (m, 1 H). MS (ESI+) for C23H3ιN3O2S m/z 414 (M+H)+.
Example 161 (BVT.61993) 5-(2-Azeρan-l-yl-2-oxoethyl)- 2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-4(577)- one
Prepared according to method D 35 mg, 27% yield.
1H NMR (400 MHz, DMSO-D6) δ ppm 143-1.66 (m, 12 H) 1.90-2.11 (m, 6 H) 2.23-2.27 (m, 2 H) 246 (t, J= 6.7 Hz, 1 H) 2.67 (dd, J= 17.0 Hz, J= 11.7 Hz, 1 H) 3.19 (dd, J= 17.1 Hz, J= 3.1 Hz, 1 H) 3.33-3.52 (m, 4 H) 4.17 (dd, J= 11.7 Hz, J= 3.1 Hz, 1 H) 9.23 (s, 1 H). MS (ESI+) for C20H29N3O2S m/z 376 (M+H)+.
Example 162 (BVT.59293) 2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(2,6- difluorophenyl)acetamide
Prepared according to method D
30 mg in 20% yield.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.57-1.94 (m, 6 H) 2.02-2.18 (m, 2 H) 3.17-3.35 (m, 1 H) 3.58-3.70 (m, 1 H) 3.78-3.88 (m, 1 H) 444-4.53 (m, 1 H) 6.95 (t,
J=8.16 Hz, 1 H) 8.52 (s, 1 H). MS m/z (M+H) 354.
MS (ESI+) for Cι6H17F2N3O2S m/z 376 (M+H)+.
Example 163 (BVT.14204) 2- {2-[(4-chlorobenzyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- 1 -naphthylacetamide
Prepared according to method M
260 mg, yield 50 %, as a white solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.89 (dd, J=16.36, 10.99 Hz, 1 H) 3.46 (dd,
J=16.36, 3.66 Hz, 1 H) 4.50 (dd, J=l l.l l, 3.54 Hz, 1 H) 445/4.65 (s/m, 2H, taut.) 7.35 (m, 2 H) 743 (m, 2 H) 7.49 (m, 1 H) 7.55 (m, 2 H) 7.68 (d, J=7.32 Hz, 1 H) 7.77 (d, J=8.30
Hz, 1 H) 7.94 (m, 1 H) 8.09 (m, 1 H) 9.70 (br s, NH) 10.11 (s, NH). 13C NMR (100 MHz,
DMSO-D6) δ ppm 46.84, 51.28, 121.45, 122.58, 125.22, 125.37, 125.69, 125.89, 127.48, 127.95, 128.33 (2) 129.11, 129.32 (2) 133.05, 133.52, 136.44, 169.19, 180.11, 188.04. MS (frag, EI+) for C22H18C1N302S m/z 423 (M+H)+.
Example 164 (BVT.14212) N-l-naphthyl-2-[2-(l-naplithylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetamide Prepared according to method M 240 mg, yield 56 %, as a white solid
1H ΝMR (400 MHz, DMSO-D6) δ ppm 3.09 (dd, J=16.60, 9.52 Hz, 1 H) 3.42 (dd, J=16.60, 3.66 Hz, 1 H) 4.60 (dd, J=940, 3.78 Hz, 1 H) 7.06 (d, J=7.08 Hz, 1 H) 7.49 (m, 6 H) 7.61 (d, J=7.32 Hz, 1 H) 7.69 (d, J=8.06 Hz, 1 H) 7.75 (d, J=8.06 Hz, 1 H) 7.93 (m, 3 H) 8.04 (d, J=8.06 Hz, 1 H) 10.08/10.17 (s/s, ΝH, taut.) 11.24/12.03 (s/s, ΝH). 13C ΝMR (100 MHz, DMSO-D6) δ ppm 3844, 4549, 115.72, 121.41, 122.52, 122.93, 124.11, 125.22, 125.33, 125.55, 125.64, 125.74, 125.86, 126.21, 127.00, 127.40, 127.72, 127.92, 132.90, 13348, 133.73, 16840. MS (frag, EI+) for C25H19Ν3O2S m/z 425 (M+H)+.
Example 165 (BVT.59416)
2-(2-anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N-methyl-N-phenylacetamide Prepared according to method D 42.1 mg, yield 31%. !H ΝMR (400 MHz, DMSO-D6) δ ppm 2.89 (m, 2 H) 3.13 (m, 3 H) 4.32 (d, J=10.01 Hz, 1 H) 6.98 (d, J=7.08 Hz, 1 H) 7.14 (t, J=7.32 Hz, 1 H) 7.36 (m, 5 H) 7.46 (d, J=7.08 Hz, 2 H) 7.65 (d, J=6.84 Hz, 1 H). MS (frag, EI+) for CιsH17Ν3O2S m/z 340 (M+H)+.
Example 166 (BVT.59417) 2-(2-anilino-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl)-N-(2-chlorophenyl)acetamide
Prepared according to method D
7.5 mg, yield 5%.
1H NMR (400 MHz, DMSO-D6) δ ppm 2.88 (m, 2 H) 4.48 (d, J=8.79 Hz, 1 H) 6.99 (m, 1
H) 7.17 (m, 2 H) 7.36 (m, 3 H) 7.48 (m, 1 H) 7.66 (m, 2 H) 9.76 (d, J=16.60 Hz, 1 H). MS (ESI+) for Cι7H14ClN3O2S m/z 360 (M+H)+.
Example 167 (BVT.59418) 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-moφholin-4-ylethyl)amino]-l,3- thiazol-4(5H)-one Prepared according to method D 7.7 mg, yield 6%, as a yellow oil. 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.99 (m, 2 H) 2.12 (m, 1 H) 2.75 (m, 2 H)
2.96 (m, 2 H) 3.39 (m, 2 H) 346 (m, 1 H) 3.74 (m, 4 H) 3.98 (m, 6 H) 446 (dd, J=10.25, 3.17 Hz, 1 H) 7.14 (m, 4 H). MS (frag, EI+) for C20H26N4O3S m/z 403 (M+H)+.
Example 168 (BVT.59110T) 2-[2-(sec-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N-phenylacetamide trifluoroacetate
Prepared according to method D
209 mg, yield 60%.
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.92 (m, 3 H) 1.32 (m, 3 H) 1.68 (m, 2 H) 2.58 (m, 1 H) 3.08 (m, 1 H) 3.24 (m, 3 H) 3.41 (m, 1 H) 4.36 (dd, J=14.65, 3.42 Hz, 1 H)
7.15 (m, 2 H) 7.38 (m, 3 H). MS (ESI+) for Cι6H2ιΝ3O2S C2HF3O2 m/z 320 (M+H)+.
Example 169 (BVT.59132T)
2-(sec-butylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)- one trifluoroacetate
Prepared according to method D
104,7mg, yield 52%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 0.97 (m, 3 H) 1.36 (m, 3 H) 1.73 (m, 2 H)
1.97 (m, 2 H) 2.77 (m, 2 H) 3.01 (m, 1 H) 3.43 (m, 1 H) 3.63 (m, 2 H) 4.00 (m, 1 H) 443 (m, 1 H) 7.11 (m, 4 H). MS (ESI+) for C18H23N3O2S C2HF3O2 m/z 346 (M+H)+.
Example 170 (BVT.59133D
2-[2-(sec-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2-chlorophenyl)acetamide trifluoroacetate Prepared according to method D 62,3 mg, yield 30%.
Η ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.96 (m, 3 H) 1.37 (m, 3 H) 1.73 (m, 2 H) 3.13 (m, 1 H) 344 (m, 1 H) 3.59 (dd, J=20.26, 3.17 Hz, 1 H) 4.52 (m, 1 H) 4.91 (m, 1 H) 7.09 (t, J=7.32 Hz, 1 H) 7.25 (t, J=8.79, 6.84 Hz, 1 H) 7.37 (d, J=8.06 Hz, 1 H) 8.05 (d, J=8.06 Hz, 1 H) 8.27 (m, 1 H). MS (ESI+) for C15H18ClN3O2S C2HF3O2 m/z 340 (M+H)+.
Example 171 (BVT.59265T) 2- {2-[(cyclopropylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-methyl-N- phenylacetamide trifluoroacetate Prepared according to method D 15 mg, yield 10%.
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.52 (m, 4 H) 1.16 (m, 1 H) 2.66 (m, 1 H) 3.08 (m, 1 H) 3.26 (m, 3 H) 3.29 (m, 1 H) 3.80 (m, 1 H) 4.41 (m, 1 H) 7.18 (m, 2 H) 7.43 (m, 3 H). MS (ESI+) for d6Hι9Ν3O2S C2HF3O2 m/z 318 (M+H)+.
Example 172 (BVT.59352)
N-methyl-2-[2-( 1 -naphthylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-phenylacetamide Prepared according to method D
14 mg, yield 12%.
1H ΝMR (400 MHz, METHAΝOL-D4) δ ppm 2.52 (m, 1 H) 2.89 (m, 1 H) 3.10 (m, 3 H)
4.29 (dd, J=9.77, 3.66 Hz, 1 H) 7.14 (m, 3 H) 7.38 (m, 6 H) 7.67 (m, 1 H) 7.84 (m, 2 H).
MS (ESI+) for C22H,9N3O2S m/z 390 (M+H)+.
Example 173 (BVT.59386)
2- {2-[(4-methylbenzyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-phenylacetamide
Prepared according to method D
246 mg, yield 47%. 1H ΝMR (400 MHz, DMSO-D6) δ ppm 2.27 (m, 3 H) 2.69 (m, 1 H) 3.26 (m, 1 H) 440
(m, 1 H) 7.03 (m, 1 H) 7.17 (m, 4 H) 7.29 (m, 2 H) 7.55 (m, 2 H). MS (ESI+) for
C19Hι9Ν3O2S m/z 390 (M+H)+.
Example 174 (BVT.59385) 2-{2-[(4-chlorobenzyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-phenylacetamide Prepared according to method D 163mg, yield 29%. 1H NMR (400 MHz, DMSO-D6) δ ppm 2.70 (m, 1 H) 3.26 (m, 1 H) 4.42 (m, 1 H) 7.03 (m, 1 H) 7.31 (m, 4 H) 7.42 (m, 2 H) 7.54 (m, 2 H). MS (ESI+) for C18H16ClN3O2S m/z 374 (M+H)+.
Example 175 (BVT.59415)
2-Anilino-5-[2-(3,4-dihydroquinolin-l(277)-yl)-2-oxoethyl]-l,3-thiazol-4(577)-one Prepared according to method D 37.1 mg, yield 26%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.95 (m, 2 H) 2.69 (m, 2 H) 2.92 (m, 1 H) 3.55 (m, 1 H) 3.70 (m, 1 H) 3.81 (m, 1 H) 444 (d, J=9.03 Hz, 1 H) 7.14 (m, 4 H) 7.23 (d, J=7.32 Hz, 1 H) 7.29 (d, J=7.57 Hz, 2 H) 7.37 (m, Hz, 2 H). MS (ESI+) for C20H19N3O2S m/z 366 (M+H)+.
Example 176 (BVT.63192) 5-[2-(3,4-Dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3-thiazol-4(577)-one
Prepared according to method D
30 mg, yield 32 % as a white solid.
1H NMR (400 MHz, DMSO- 6) δ ppm 146-1.57 (m, 4 H) 1.90-2.10 (m, 6 H) 2.23-2.26 (m, 2 H) 245-249 (m, 1 H) 2.74-2.86 (m, 3 H) 3.29-3.34 (m, 1 H) 3.56-3.74 (m, 2 H)
4.17-4.27 (m, 1 H) 4.54-4.66 (m, 2 H) 7.17 (m, 4 H) 9.27 (s, 1 H). MS (ESI+) for
C23H27N3O2S m/z 410 (M+H)+.
Example 177 (BVT.63199) 2-(cycloheptylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one
Prepared according to method D
0.007g, yield 5% as an off-white powder.
IH NMR (400 MHz, DMSO-D6) δ ppm 1.50 (m, 12 H) 1.88 (m, J=6.10 Hz, 2 H) 2.87 (m, 2 H) 3.33 (m, 1 H) 3.63 (m, J=5.92 Hz, 1 H) 3.97 (m, 1 H) 4.28 (m, 1 H) 4.60 (m, 2 H)
7.17 (m, J=3.91 Hz, 4 H) 9.29 (s, 1 H). MS (ESI) for C21H27N3O2S m/z 386 (M+H)+.
Example 178 (BVT.63210 5-(2-azepan-l-yl-2-oxoethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one Prepared according to method D 0.007g, yield 5% as a yellow solid.
IH NMR (400 MHz, DMSO-D6) δ ppm 1.53 (m, 18 H) 1.89 (m, 2 H) 2.73 (none, J=17.09, 11.35 Hz, 1 H) 3.21 (dd, J=17.21, 3.17 Hz, 1 H) 3.40 (m, 4 H) 3.97 (m, 1 H) 4.23 (dd, J=11.60, 3.17 Hz, 1 H) 9.19 (d, J=6.96 Hz, 1 H). MS (ESI ) for C18H29N3O2S m/z 352 (M+H)+.
Example 179 (BVT.63220) 5-(2-azepan- 1 -yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]- 1 ,3-thiazol-4(5H)-one
Prepared according to method D.
8.8 mg, yield 13%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.37 (m, 19 H) 2.77 (m, 1 H) 3.21 (d,
J=6.59 Hz, 2 H) 3.47 (m, 5 H) 4.42 (dd, J=12.21, 3.42 Hz, 1 H). MS (ES) for C18H29N3O2S
Figure imgf000094_0001
Example 180 (BVT063223)
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide Prepared according to method D.
0.04 g, yield 20% as an off-white solid.
IH ΝMR (400 MHz, DMSO-D6) δ ppm 1.51 (m, 10 H) 1.85 (m, 2 H) 2.38 (dd, J=1746,
10.74 Hz, 1 H) 2.90 (m, J=1642, 1.89 Hz, 1 H) 3.17 (s, 3 H) 3.96 (m, 1 H) 4.25 (dd,
J=10.99, 2.56 Hz, 1 H) 7.38 (m, 1 H) 7.36 (d, J=6.96 Hz, 2 H) 747 (m, 2 H) 9.55 (d, J=6.96 Hz, 1 H). MS (ES) for Cι9H25Ν3O2S m/z 360 (M+H)+.
Example 181 (BVT.63320)
5-[2-(4-Methylpiperidin-l-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3- thiazol-4(577)-one Prepared according to method D. 44 mg, yield 41 % as white solid.
Η NMR (400 MHz, DMSO- 6) δ ppm 1.82-1.09 (m, 5 H) 146-1.65 (m, 7 H) 1.90-2.11 (m, 6 H) 2.23-2.27 (m, 2 H) 2.46 (t, J= 6.2 Hz, 1 H) 2.53-2.58 (m, 1 H) 2.63-2.72 (m, 1 H) 2.88-2.98 (m, 1 H) 3.18 (ddd, J= 17.0 Hz, J= 5.6 Hz, J= 3.2 Hz, 1 H) 3.70-3.76 (m, 1 H) 4.11-4.22 (m, 1 H) 4.25-4.33 (m, 1 H) 9.23 (d, J= 2.8 Hz, 1 H). MS (ESI+) for
C20H29N3O2S m/z 376 (M+H)+.
Example 182 (BVT.63321)
5-[2-(l,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)- 1 ,3-thiazol-4(577)-one Prepared according to method D. 65 mg, yield 57%. 1H NMR (400 MHz, DMSO- 6) δ ppm 146-1.58 (m, 4 Η) 1.91-2.11 (m, 6 H) 248 (m, 1 H) 2.75 (dd, J= 17.1 Hz, J= 11.7 Hz, 1 H) 3.30 (dd, J= 17.1 Hz, J= 3.1 Hz, 1 H) 4.23 (dd, J= 11.7 Hz, J= 3.1 Hz, 1 H) 4.63 (s, 2 H) 4.82 (s, 2 H) 7.26-7.36 (m, 4 H) 9.27 (s, 1 H). MS (ESI+) C 2H25N3O2S m/z 396 (M+H)+.
Example 183 (BVT.63322)
2-[(cyclohexylmethyl)amino]-5-(2-oxo-2-pynolidin-l-ylethyl)-l,3-thiazol-4(5H)-one
Prepared according to method D
13,3 mg, yield 14%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.12 (m, 5 H) 1.69 (m, 5 H) 1.97 (m, 5 H) 3.22 (m, 2 H) 343 (m, 6 H) 443 (dd, J=l 1.96, 342 Hz, 1 H) MS (ES) for C16H25N3O2S m/z 324 (M+H)+.
Example 184 (BVT.63323)
2-[(cyclohexylmethyl)amino]-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one
Prepared according to method D
13,3mg, yield 19%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.12 (m, 6 H) 1.72 (m, 5 H) 2.90 (m, 2
H) 3.23 (m, 2 H) 3.75 (m, 4 H) 4.52 (m, 2 H) 4.73 (m, 1 H) 7.17 (m, 4 H) MS (ES) for C2 ιH27N3O2S m/z 386 (M+H)+.
Example 185 (BVT.63329) 2-[2-(Dicyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-benzylacetamide Prepared according method M. 30.8 mg, yield 29%.
IH NMR (400 MHz, DMSO-D6) δ ppm 1.16 (m, 3 H) 1.32 (m, 5 H) 1.47 (d, J=10.25 Hz, 2 H) 1.58 (t, J=9.22 Hz, 2 H) 1.70 (m, 6 H) 1.80 (d, J=1245 Hz, 2 H) 2.44 (dd, J=16.24, 11.72 Hz, 1 H) 3.10 (dd, J=16.17, 348 Hz, 1 H) 3.50 (m, 2 H) 4.23 (dd, J=11.60, 3.42 Hz, 1 H) 4.28 (d, J=5.86 Hz, 2 H) 7.24 (m, 1 H) 7.25 (m, 2 H) 7.32 (m, 2 H) 8.54 (t, J=5.86 Hz, 1 H). 13C NMR (101 MHz, DMSO-D6) δ ppm 244, 24.8, 25.1, 25.4, 29.1, 29.3, 29.7, 38.9, 42.2, 49.8, 62.9, 126.7, 127.1, 128.1, 139.0, 169.5, 178.3, 187.5. MS (ES) for C24H33N3O2S m/z 428 (M+H)+.
Example 186 (BVT.63331)
2-(2-Anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N-phenylacetamide Prepared according method M. 36.0 mg, yield 12%. IH ΝMR (400 MHz, DMSO-D6) δ ppm 3.23 (m, 2 H) 4.48 (d, J=8.55 Hz, 1 H) 7.03 (m, 2 H) 7.15 (m, 1 H) 7.32 (m, 4 H) 7.53 (dd, J=17.82, 7.57 Hz, 2 H) 7.70 (d, J=6.84 Hz, 1 H) 10.11 (d, J=12.21 Hz, 1 H). MS (ES) for d7Hι5Ν3O2S m/z 326 (M+H)+.
Example 187 (BVT063335) 2-azepan- 1 -yl-5-(2-azepan- 1 -yl-2-oxoethyl)- 1 ,3 -thiazol-4(5H)-one
Prepared according method D.
11 mg, yield 34%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.58 (m, 8 H) 1.71 (d, J=2.9 Hz, 4 H)
1.82 (dd, J=9.0, 4.9 Hz, 4 H) 2.65 (dd, J=17.1, 12.2 Hz, 1 H) 3.48 (m, 7 H) 3.86 (m, 2 H) 4.45 (dd, J=12.1, 3.1 Hz, 1 H). MS (ES+) for Cι7H27N3O2S m/z 338 (M+H)+.
Example 188 (BVT063336)
2-azepan- 1 -yl-5-[2-(3,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)-one Prepared according method D. 60.4 mg, yield 42%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.60 (s, 4 H) 1.82 (dd, J=13.6, 5.0 Hz, 4 H) 1.98 (m, 2 H) 2.72 (s, 2 H) 2.88 (dd, J=17.0, 11.8 Hz, 1 H) 3.55 (m, 4 H) 3.71 (m, 1 H) 3.85 (m, 2 H) 449 (d, J=10.0 Hz, 1 H) 7.16 (m, 4 H). MS (ES+) for C20H25N3O2S m/z 372 (M+H)+.
Example 189 (BVT063337) 2-azepan-l-yl-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one Prepared according method D. 61.2 mg, yield 42%.
1H NMR (400 MHz, CDC13) δ ppm 1.59 (s, 4 H) 1.81 (s, 4 H) 2.73 (m, 1 H) 2.88 (m, 2 H) 3.53 (t, J=5.7 Hz, 2 H) 3.63 (m, 2 H) 3.75 (m, 1 H) 3.88 (m, 2 H) 4.46 (m, 1 H) 4.58 (d, J=4.9 Hz, 1 H) 4.72 (s, 1 H) 7.07 (m, 1 H) 7.14 (m, 1 H) 7.19 (m, 2 H). MS (ES+) for C20H25N3O2S m/z 372 (M+H)+.
Example 190 (BVT063339)
5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-2-piperidin-l-yl-l,3-thiazol-4(5H)-one Prepared according method D.
44.9 mg, yield 32%.
]H NMR (400 MHz, CDC13) δ ppm 1.70 (s, 6 H) 2.74 (m, 1 H) 2.88 (m, 2 H) 3.47 (s, 2 H)
3.62 (m, 2 H) 3.74 (m, 1 H) 3.88 (m, 2 H) 4.49 (m, 1 H) 4.58 (d, J=64 Hz, 1 H) 4.72 (s, 1
H) 7.14 (m, 4 H). MS (ES+) for C,9H23N3O2S m/z 358 (M+H)+.
Example 191 (BVT063341)
2-(cycloheptylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one
Prepared according method D.
0.0 lg, yield 8.7% as a coloured solid. IH NMR (400 MHz, DMSO-D6) δ ppm 1.35 - 1.70 (m, 10 H) 1.80 - 1.97 (m, 2 H) 2.88
(dd, J=17.58, 1147 Hz, 1 H) 3.13 (t, J=842 Hz, 2 H) 3.38 (dd, J=17.58, 3.05 Hz, 1 H)
3.94 - 4.04 (m, 1 H) 4.04 - 4.13 (m, 2 H) 4.31 (dd, J=11.54, 2.99 Hz, 1 H) 7.00 (td, J=745,
0.85 Hz, 1 H) 7.15 (t, J=7.69 Hz, 1 H) 7.24 (dd, J=745, 0.49 Hz, 1 H) 8.03 (d, J=8.18 Hz,
1 H) 9.14 (d, J=7.69 Hz, 1 H). MS (ES) for C2oH25N3O2S m/z 372 (M+H)+.
Example 192 (BVT063342)
2-(cycloheptylamino)-5-(2-oxo-2-pynolidin-l-ylethyl)-l,3-thiazol-4(5H)-one Prepared according method D. 0.03g, yield 25% as an off-white solid.
IH NMR (400 MHz, DMSO-D6) δ ppm 1.34 - 1.70 (m, 10 H) 1.71 - 1.81 (m, 2 H) 1.80 - 1.93 (m, 4 H) 2.62 (dd, J=17.09, 11.72 Hz, 1 H) 3.16 (dd, J=17.21, 3.17 Hz, 1 H) 3.23 - 3.32 (m, 2 H) 3.33 - 3.40 (m, 2 H) 3.92 - 4.02 (m, 1 H) 4.20 (dd, J=11.72, 3.17 Hz, 1 H) 9.16 (d, J=7.57 Hz, 1 H). MS (ES) for C16H25N3O2S m/z 324 (M+H)+.
Example 193 (BVT063343)
2-(cycloheptylamino)-5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one Prepared according method D. 0.86 g, yield 66% as an off-white solid.
IH NMR (400 MHz, DMSO-D6) δ ppm 0.89 (d, J=6.10, 1.83 Hz, 3 H) 0.93 - 1.12 (m, 2 H) 1.34 - 1.70 (m, 13 H) 1.79 - 1.96 (m, 2 H) 2.51 - 2.62 (m, 1 H) 2.67 - 2.78 (m, 1 H) 2.87 - 3.01 (m, 1 H) 3.17 - 3.27 (m, 1 H) 3.73 (d, J=13.31 Hz, 1 H) 3.91 - 4.03 (m, 1 H) 4.20 (ddd, J=l 1.44, 7.54, 2.87 Hz, 1 H) 4.25 - 4.35 (m, 1 H) 9.18 (d, J=6.96 Hz, 1 H). MS (ES) for C18H29N3O2S m/z 352 (M+H)+.
Example 194 (BVT.66775)
2-[2-(Dicyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-phenylacetamide
Prepared according method M. 23.1 mg, yield 23%.
IH ΝMR (400 MHz, DMSO-D6) δ ppm 1.12 (m, H) 1.30 (m, 5 H) 146 (m, 2 H) 1.57 (m,
2 H) 1.72 (m, 9 H) 2.63 (dd, J=1648, 11.60 Hz, 2 H) 3.27 (m, 1 H) 3.47 (m, 1 H) 4.29 (dd,
J=l 1.47, 3.17 Hz, 1 H) 7.04 (t, J=7.32 Hz, 1 H) 7.29 (t, J=7.93 Hz, 2 H) 7.55 (d, J=7.81
Hz, 2 H) 10.10 (s, 1 H). MS (ES) for C23H31Ν3O2S m/z 414 (M+H)+.
Example 195 (BVT.63344)
N-cyclohexyl-2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} acetamide
Prepared according method D. 9,4 mg, yield 14%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 1.16 (m, 10 H) 1.69 (m, 10 H) 1.89 (m, 1
H) 2.79 (m, 1 H) 3.26 (m, 2 H) 3.72 (m, 2 H) 442 (dd, J=l 1.47, 342 Hz, 1 H) 6.03 (m, 1
H) 7.04 (m, 1 H) MS (ES) for C18H29Ν3O2S m/z 352 (M+H)+. Example 196 (BVT.66802)
N-Cyclohexyl-N-ethyl-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro-l,3- thiazol-5-yl]acetamide
Prepared according method D.
24 mg, yield 22% as a white solid.
1H ΝMR (400 MHz, DMSO-^6) δ ppm 0.98-1.14 (m, 4 H) 1.17-1.75 (m, 14 H) 1.90-2.11
(m, 6 H) 2.23-2.28 (m, 2 H) 2.46 (t, J= 6.6 Hz, 1 H) 2.63-2.76 (m, 1 H) 3.16-3.29 (m, 3
H) 4.13-4.25 (m, 1 H) 9.21 (s, 1 H). MS (ESI+) for C22H33Ν3O2S m/z 404 (M+H)+.
Example 197 (BVT.66803)
N-(Cyclopropylmethyl)-N-propylacetamide-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)-4,5-dihydro- 1 ,3-thiazol-5-yl]acetamide Prepared according method D. 46 mg, yield 43% as a white solid.
Η ΝMR (400 MHz, OMSO-d6) δ ppm 0.17-0.24 (m, 2 H) 0.38-043 (m, 1 H) 046-0.50 (m, 1 H) 0.79 and 0.84 (t, J= 7.4 Hz and t, J= 7.4 Hz, 3 H) 0.88-0.98 (m, 1 H) 144-1.57 (m, 6 H) 1.90-2.11 (m, 6 H), 2.23-2.27 (m, 2 H), 246 (t, J= 6.7 Hz, 1 H), 2.71 (dd, J=
17.0 Hz, J= 11.7 Hz, 1 H) 3.07-3.30 (m, 5 H) 4.14-4.25 (m, 1 H) 9.21 (s, 1 H). MS (ESI+) for C2ιH3ιΝ3O2S m/z 390 (M+H)+.
Example 198 (BVT.66804)
5-(2-Azocan-l-yl-2-oxoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-4(577)- one Prepared according method D. 60 mg, yield 57% as a white solid.
1H NMR (400 MHz, DMSO-d6) δ ppm 1.39-1.66 (m, 14 H) 1.90-2.11 (m, 6 H) 2.23-2.28 (m, 2 H) 2.46 (t, J= 6.7 Hz, 1 H) 2.68 (dd, J= 17.1 Hz, J= 11.7 Hz, 1 H) 3.20 (dd, J=
17.1 Hz, J= 3.1 Hz, 1 H) 3.34-3.37 (m, 4 H) 4.18 (dd, J= 11.7 Hz, J= 3.1 Hz, 1 H) 9.22 (s, 1 H). MS (ESI+) for C2,H3 ιN3O2S m/z 390 (M+H)+.
Example 199 (BVT.66805) 5-[2-(l-Oxa-4-azaspko[4.5]dec-4-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3 -thiazol-4(577)-one Prepared according method D. 13 mg, yield 12% as an off-white solid. 1H NMR (400 MHz, CDC13) δ ppm 1.19-1.30 (m, 1 H) 147-1.67 (m, 11 H) 2.00-2.21 (m, 6 H) 2.27-240 (m, 4 H) 2.76 (t, J= 6.7 Hz, 1 H) 2.85 (dd, J= 17.3 Hz, J= 12.1 Hz, 1 H) 341 (dd, J= 17.3 Hz, J= 3.3 Hz, 1 H) 3.50-3.62 (m, 2 H) 3.96-4.06 (m, 2 H) 4.39 (dd, J = 12.1 Hz, J= 3.2 Hz, 1 H). MS (ESI+) for C22H3IN3O3S m/z 418 (M+H)+.
Example 200 (BVT066950)
2-{[(lR)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one
Prepared according method D.
65.0 mg yield 46%. 1H NMR (400 MHz, DMSO-tf6) δ ppm 0.89-1.05 (m, 2 H) 1.10 (dd, J=6.8, 4.3 Hz, 3 H)
1.12-1.29 (m, 2 H) 1.34-149 (m, 1 H) 1.58-1.77 (m, 6 H) 1.90 (m, 2 H) 2.71 (t, J=6.7 Hz,
2 H) 2.78-2.88 (m, 1 H) 3.07-3.18 (m, 0.3 H) 3.34-343 (m, 1 H) 3.61-3.79 (m, 2 H) 3.84-
3.93 (m, 0.7 H) 4.27 (dt, J=l 1.1, 34 Hz, 1 H) 7.07-7.13 (m, 1 H) 7.13-7.22 (m, 2 H) 745-
7.52 (m, 1 H). MS (ES+) for C22H29N3O2S m/z 400 (M+H)+.
Example 201 (BVT066951)
2-{[(lR)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one
Prepared according method D. 79.8 mg yield 57%.
1H NMR (400 MHz, DMSO-d6) δ ppm 0.92-1.05 (m, 2 H) 1.11 (dd, J=6.7, 3.8 Hz, 3 H)
1.13-1.29 (m, 2 H) 1.35-1.51 (m, 1 H) 1.58-1.75 (m, 6 H) 2.70-2.95 (m, 3 H) 3.11-3.20 (m,
0.3 H) 3.30-340 (m, 1 H) 3.61-3.73 (m, 2 H) 3.92 (ddd, J=13.5, 6.7, 5.7 Hz, 0.7 H) 4.26
(dt, J=l 1.4, 3.2 Hz, 1 H) 4.62 (s, 2 H) 7.15-7.21 (m, 4 H). MS (ES+) for C22H29N3O2S m/z 400 (M+H)+.
Example 202 (BVT066952)
5-(2-azepan- 1 -yl-2-oxoethyl)-2- {[(1R)- 1 -cyclohexylethyl] amino} - 1 ,3-thiazol-4(5H)-one Prepared according method D. 73.8 mg, yield 58%.
Η NMR (400 MHz, OMSO-d6) δ ppm 0.91-1.05 (m, 2 H) 1.11 (dd, J=6.7, 2.5 Hz, 3 H) 1.13-1.28 (m, 2 H) 1.36-146 (m, 1 H) 147-1.76 (m, 14 H) 2.58-2.70 (m, 1 H) 3.13-3.19 (m, 0.3 H) 3.24 (d, J=16.9 Hz, 1 H) 3.36-3.50 (m, 4 H) 3.88-3.97 (m, 0.7 H) 4.23 (dt, J=114, 2.8 Hz, 1 H). MS (ES+) for C,9H31N3O2S m/z 366 (M+H)+.
Example 203 (BVT066953)
2- {[(1 S)- 1 -cyclohexylethyljamino} -5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3- thiazol-4(5H)-one
Prepared according method D.
64.1 mg, yield 46%.
Η NMR (400 MHz, DMSO-d6) δ ppm 0.82-1.01 (m, 5 H) 1.02-1.31 (m, 3 H) 1.54-1.72
(m, 6 H) 1.80-1.92 (m, 2 H) 2.54-2.64 (m, 1 H) 2.64-2.74 (m, 2 H) 2.74-2.82 (m, 0.5 H) 3.19-3.39 (m, 1 H) 3.54-3.71 (m, 2 H) 3.71-3.81 (m, 0.5 H) 3.96 (ddd, J=10.8, 2.9, 2.6 Hz,
0.5 H) 4.12 (dd, J=l 1.3, 3.0 Hz, 0.5 H) 7.04-7.22 (m, 3 H) 740 (s, 1 H). MS (ES+) for
C22H29N3O2S m/z 400 (M+H)+.
Example 204 (BVT066954) 2- { [( 1 S)- 1 -cyclohexylethyl] amino} -5-[2-(3,4-dihydroisoquinolin-2( lH)-yl)-2-oxoethyl]-
1 ,3-thiazol-4(5H)-one
Prepared according method D.
38.8 mg, yield 28%.
1H NMR (400 MHz, DMSO- 6) δ ppm 0.89-1.01 (m, 2 H) 1.08 (dd, J=6.5, 4.9 Hz, 3 H) 1.11-1.24 (m, 2 H) 1.32-144 (m, 1 H) 1.57-1.75 (m, 6 H) 2.74-2.89 (m, 3 H) 3.09-3.17 (m,
0.3 H) 3.32 (dd, J=17.2, 2.6 Hz, 1 H) 3.57-3.77 (m, 2 H) 3.83-3.92 (m, 1 H) 4.19-4.28 (m,
1 H) 4.57-4.66 (m, 2 H) 7.14-7.22 (m, 4 H). MS (ES+) for C22H29N3O2S m/z 400 (M+H)+.
Example 205 (BVT066956) 5-(2-azepan- 1 -yl-2-oxoethyl)-2- {[( 1 S)- 1 -cyclohexylethyl]amino} - 1 ,3-thiazol-4(5H)-one Prepared according method D. 70.7 mg, yield 55%. 1H NMR (400 MHz, OMSO-d6) δ ppm 0.85-1.01 (m, 2 H) 1.08 (dd, J=6.7, 3.7 Hz, 3 H)
1.10-1.26 (m, 2 H) 1.32-142 (m, 1 H) 143-1.53 (m, 4 H) 1.54-1.74 (m, 10 H) 2.60-2.73
(m, 1 H) 3.05-3.13 (m, 0.3 H) 3.16-3.23 (m, 1 H) 3.31-3.50 (m, 4 H) 3.80-3.94 (m, 1 H)
4.11-4.25 (m, 1 H). MS (ES+) for Cι9H31N3O2S m/z 366 (M+H)+.
Example 206 (BVT.67010)
2-[(cyclohexylmethyl)amino]-5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one
Prepared according method D. 23mg, yield 35%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (m, 3 H) 1.20 (m, 6 H) 1.70 (m, 10
H) 2.66 (m, J=10.2, 2.62 Hz, 1 H) 2.79 (m, 1 H) 3.06 (m, 1 H) 3.24 (m, 2 H) 3.54 (m, 1 H)
3.70 (m, J=13.5, 1.65 Hz, 1 H) 4.44 (m, 2 H) 941 (m, 1 H) MS (ES) for C18H29N3O2S m/z
352 (M+H)+.
Example 207 (BVT.67011)
N-cyclohexyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- ethylacetamide
Prepared according method D. 14 mg, yield 20%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 1.01 (m, 2 H) 1.20 (m, 10 H) 1.78 (m, 12
H) 2.81 (m, 1 H) 3.24 (m, 4 H) 3.56 (m, 1 H) 4.21 (m, 1 H) 446 (m, 1 H) MS (ES) for
C20H33Ν3O2S m/z 380 (M+H)+.
Example 208 (BVT.67012)
2-[(cyclohexylmethyl)amino]-5-[2-(l-oxa-4-azaspiro[4.5]dec-4-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one
Prepared according method D.
8,8 mg, yield 12%. IH NMR (400 MHz, DMSO-D6) δ ppm 0.92 (m, 3 H) 1.17 (m, 5 H) 146 (m, 12 H) 2.27
(m, 1 H) 249 (m, 1 H) 2.66 (m, 1 H) 3.03 (m, 1 H) 3.12 (m, 1 H) 3.23 (m, 1 H) 3.38 (m, 1
H) 3.57 (m, 1 H) 3.89 (m, 1 H) 4.28 (m, 1 H) 9.26 (m, 1 H) MS (ES) for C20H31N3O3S m/z
394 (M+H)+ Example 209 (BVT.67015)
5-(2-azocan-l-yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one Prepared according method D. 43,5 mg, yield 64%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (m, 2 H) 1.21 (m, 3 H) 1.66 (m, 16 H) 2.81 (dd, J=17.0, 12.1 Hz, 1 H) 2.91 (dd, J=17.0, 10.4 Hz, 1 H) 3.23 (m, 2 H) 3.54 (dd, J=16.97, 34 Hz, 1 H) 444 (dd, J=12.1, 3.42 Hz, 1 H) 4.54 (dd, J=10.5, 3.05 Hz, 1 H). MS (ES) for C19H31N3O2S m/z 366 (M+H)+.
Example 210 (BVT.67016)
2-[(cyclohexylmethyl)amino]-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one
Prepared according method D. 25,25 mg, yield 37%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.02 (m, 2 H) 1.23 (m, 3 H) 1.73 (m, 6
H) 2.89 (dd, J=17.2, 12.0 Hz, 1 H) 3.25 (d, J=6.6 Hz, 2 H) 3.58 (dd, J=17.3, 3.2 Hz, 1 H)
4.52 (dd, J=12.0, 3.3 Hz, 1 H) 4.82 (m, 4 H) 7.31 (m, 4 H) 13.30 (m, 1 H). MS (ES) for
C20H25N3O2S m/z 372 (M+H)+.
Example 211 (BNT067017)
N-(3-chloro-2-methylbenzyl)-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3- thiazol-5-yl} acetamide
Prepared according method D. 23,6 mg, yield 31%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 1.01 (m, 2 H) 1.25 (s, 4 H) 1.75 (m,
J=10.50 Hz, 5 H) 2.34 (s, 3 H) 2.94 (dd, J=l 1.72 Hz, 1 H) 3.24 (d, J=6.59 Hz, 2 H) 3.33
(dd, J=342, 1.71 Hz, 1 H) 4.45 (m, J=3.66 Hz, 3 H) 6.74 (t, J=6.10, 5.13 Hz, 1 H) 7.10 (m,
1 H) 7.30 (dd, J=6.84, 2.44 Hz, 1 H). MS (ES) for C20H26C1Ν3O2S m/z 408 (M+H)+.
Example 212 (BVT067019)
N-(cyclohexylmethyl)-2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} acetamide Prepared according method D. 1,83 mg, yield 3%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.95 (m, 4 H) 1.21 (m, 6 H) 1.72 (m, 12 H) 2.85 (m, 1 H) 3.10 (m, 2 H) 3.23 (m, J=6.59 Hz, 2 H) 3.29 (dd, J=1343, 3.42 Hz, 1 H) 4.38 (dd, J=8.55, 3.42 Hz, 1 H). MS (ES) for C19H31N3O2S m/z 366 (M+H)+.
Example 213 (BNT067020)
2-[(cyclohexylmethyl)amino]-5-[2-(octahydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one Prepared according method D.
27,6 mg, yield 38%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (m, 4 H) 1.28 (m, 8 H) 1.68 (m, 10
H) 1.89 (m, 1 H) 2.58 (m, 1 H) 2.75 (m, 1 H) 3.08 (m, 1 H) 3.21 (m, 2 H) 3.50 (m, 2 H)
3.72 (m, 1 H) 4.41 (m, 1 H) MS (ES) for C21H33Ν3O2S m/z 392 (M+H)+.
Example 214 (BVT067021)
N-[(lR,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5- dihydro- 1 ,3-thiazol-5-yl} acetamide
Prepared according method D. 23,2 mg, yield 35%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.14 (m, 10 H) 1.48 (m, 2 H) 1.74 (m, 7
H) 2.20 (m, 1 H) 2.29 (m, 1 H) 2.75 (m, 1 H) 3.23 (d, J=5.62 Hz, 2 H) 3.27 (m, 1 H) 3.67
(m, 1 H) 4.40 (m, 1 H) MS for Cι9H29N3O2S m/z 364 (M+H)+.
Example 215 (BNT067035T)
4- { [2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]acetyl} - 1 ,4-diazepan- 1 -ium trifluoroacetate
Prepared according method D.
0.06 g, yield 47% as clear crystals. MS (ES) for C17H29Ν4O2S m/z 353 (M+H)+.
Example 216 (BNT067036) 2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(cyclopropylmethyl)-N- propylacetamide Prepared according method D. 0.88 g, yield 60% as an off-white solid. IH ΝMR (400 MHz, DMSO-D6) δ ppm 0.15 - 0.29 (m, 2 H) 0.36 - 0.45 (m, 1 H) 0.44 - 0.54 (m, 1 H) 0.83 (t, J=745 Hz, 3 H) 0.88 - 1.02 (m, 1 H) 1.31 - 1.73 (m, 12 H) 1.79 - 1.99 (m, 2 H) 2.78 (dd, J=17.09, 11.47 Hz, 1 H) 3.04 - 3.34 (m, 5 H) 3.91 - 4.04 (m, 1 H) 4.21 - 4.30 (m, 1 H) 9.29 (d, J=745 Hz, 1 H). MS (ES) for Cι9H3ιΝ3O2S m/z 366 (M+H)+.
Example 217 (BVT067037)
2-(cycloheptylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one
Prepared according method D.
0.70 g, yield 51% as an off-white solid. IH NMR (400 MHz, DMSO-D6) δ ppm 1.27 - 1.70 (m, 10 H) 1.74 - 2.01 (m, 2 H) 3.18 -
3.40 (m, 2 H) 3.97 (s, 1 H) 4.18 - 4.39 (m, 1 H) 4.63 (s, 2 H) 4.82 (s, 2 H) 7.22 - 7.40 (m, 4
H) 9.10 - 9.22 (m, 1 H). MS (ES) for C20H25N3O2S m/z 372 (M+H)+.
Example 218 (BNT067038) 5-(2-azocan- 1 -yl-2-oxoethyl)-2-(cycloheptylamino)- 1 ,3-thiazol-4(5H)-one
Prepared according method D.
0.98 g, yield 100% as an off-white solid.
IH ΝMR (400 MHz, DMSO-D6) δ ppm 1.28 - 2.00 (m, 22 H) 3.10 - 3.26 (m, 2 H) 3.27 -
342 (m, 4 H) 3.84-4.02 (m, 1 H) 4.13- 4.30 (m, 1 H) 9.06-9.28 (m, 1 H). MS (ES) for C19H31Ν3O2S m/z 366 (M+H)+.
Example 219 (BNT067055)
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-cyclohexyl-N- ethylacetamide Prepared according method D.
0.64 g, yield 45% as an off-white solid. MS (ES) for C20H33Ν3O2S m/z 380 (M+H)+. Example 220 (BNT.67371)
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide
Prepared according method D.
32 mg, yield 48%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.98 (m, 2 H) 1.21 (m, 3 H) 1.72 (m, 6
H) 2.57 (m, 1 H) 3.14 (dd, J=17.58, 3.42 Hz, 1 H) 3.22 (dd, J=6.59, 1.71 Hz, 2 H) 3.29 (m,
3 H) 4.36 (dd, J=l 1.72, 3.17 Hz, 1 H) 7.17 (m, 2 H) 7.43 (m, 3 H). MS (ES) for
Cι9H25Ν3O2S m/z 360 (M+H)+.
Example 221 (BNT.67372)
2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-(4- methoxyphenyl)-N-methylacetamide
Prepared according method D. 20 mg, yield 28%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (m, 2 H) 1.22 (m, 3 H) 1.73 (m, 6
H) 2.53 (m, 1 H) 3.15 (dd, J=17.58, 342 Hz, 1 H) 3.21 (dd, J=6.59, 0.98 Hz, 2 H) 3.26 (m,
3 H) 3.83 (m, 3 H) 4.34 (dd, J=l 1.96, 342 Hz, 1 H) 6.93 (m, 2 H) 7.08 (m, 2 H). MS (ES) for C20H27Ν3O3S m/z 390 (M+H)+.
Example 222 (BVT.67373)
2- {2- [(cyclohexylmethyl)amino] -4-oxo-4, 5 -dihydro- 1 ,3 -thiazol-5 -yl } -N-ethyl-N- phenylacetamide
Prepared according method D. 38 mg, yield 55%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.99 (m, 2 H) 1.13 (t, J=7.08 Hz, 3 H)
1.25 (m, 3 H) 1.72 (m, 6 H) 2.50 (m, 1 H) 3.09 (dd, J=17.58, 3.42 Hz, 1 H) 3.21 (dd,
J=6.35, 1.22 Hz, 2 H) 3.76 (m, 2 H) 4.35 (dd, J=l 1.96, 342 Hz, 1 H) 7.14 (m, 2 H) 7.44
(m, 3 H). MS (ES) for C20H27Ν3O2S m/z 374 (M+H)+.
Example 223 (BVT.67374)
N-butyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide Prepared according method D. 38 mg, yield 52%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.89 (t, J=7.32 Hz, 3 H) 0.97 (m, 2 H) 1.19 (m, 3 H) 1.30 (m, 2 H) 1.49 (m, 2 H) 1.71 (m, 6 H) 246 (m, 1 H) 3.09 (dd, J=17.58, 3.17 Hz, 1 H) 3.19 (d, J=6.35 Hz, 2 H) 3.69 (m, 2 H) 4.33 (dd, J=11.96, 3.42 Hz, 1 H) 7.13 (m, 2 H) 7.42 (m, 3 H). MS (ES) for C22H31N3O2S m/z 402 (M+H)+.
Example 224 (BVT067392) N-butyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-phenylacetamide Prepared according method D.
0.69 g, yield 47% as an off white solid.
IH ΝMR (400 MHz, DMSO-D6) δ ppm 0.83 (t, 3 H) 1.16 - 1.68 (m, 12 H) 1.71 - 1.98 (m, 2 H) 2.70 - 2.96 (m, 1 H) 3.51 - 3.77 (m, 2 H) 3.81 - 4.01 (m, 1 H) 4.08 - 4.30 (m, 1 H) 7.39 (d, J=48.34 Hz, 5 H) 8.96 - 9.28 (m, 1 H). MS (ES) for C22H31Ν3O2S m/z 402 (M+H)+.
Example 225 (BVT067394)
N-benzyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-phenylacetamide Prepared according method D. 0.60 g, yield 37% as an off-white solid.
IH ΝMR (400 MHz, DMSO-D6) δ ppm 1.22 - 1.68 (m, J=6.84 Hz, 10 H) 1.66 - 1.99 (m, 2 H) 2.81 - 3.07 (m, 1 H) 3.82 - 4.05 (m, 1 H) 4.17 - 4.36 (m, 1 H) 4.73 - 4.99 (m, 2 H) 6.84 - 7.51 (m, 10 H) 8.89 - 9.31 (m, 1 H). MS (ES) for C25H29Ν3O2S m/z 436 (M+H)+.
Example 226 (BVT067453)
5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-2-[(2,2,3,3-tetramethylcyclopropyl)- amino]- 1 ,3-thiazol-4(5H)-one
Prepared according method D.
2.4 mg, yield 4%. Η NMR (400 MHz, CHLOROFORM-D) δ ppm 1.11 (d, J=2.0 Hz, 6 H), 1.18 (d, J=10.5
Hz, 6 H), 2.13 (s, 1 H), 2.83 (dd, J=17.1, 12.0 Hz, 1 H), 3.56 (dd, J=17.2, 3.1 Hz, 1 H),
4.48 (dd, J=12.0, 3.2 Hz, 1 H), 4.74 - 4.88 (m, 4 H), 7.27 - 7.39 (m, 4 H); MS (ES+) m/z
372 (M+H+). MS (ES) for C20H25N3O2S m/z 372 (M+H)+. Example 227 (BVT067454)
5-(2-azepan-l-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3-thiazol- 4(5H)-one Prepared according method D. 7.2 mg, yield 14%.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.10 (s, 6 H), 1.18 (d, J=9.8 Hz, 6 H), 1.52 - 1.64 (m, 4 H), 1.67 - 1.80 (m, 4 H), 2.13 (s, 1 H), 2.77 (dd, J=17.0, 12.1 Hz, 1 H), 3.33 - 3.57 (m, 4 H), 3.57 - 3.67 (m, 1 H), 4.42 (dd, J=12.0, 3.2 Hz, 1 H). MS (ES) for C18H29N3O2S m/z 352 (M+H)+.
Compounds of type 4
Example 228 (BVT.51206) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl benzoate
Method F
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one (76mg,
0.3 mmol) and benzoyl chloride (35 μL, 0.3 mmol) were dissolved in DCM (3 mL) and triethylamine (0.13 mL, 0.9 mmol) was added. The reaction mixture was stined over night at RT. The solvent was removed under reduced pressure and the product was purified using preparative HPLC (10-90% MeCN over 10 min followed by 100% MeCN for 5 min) affording the product in 19% yield (20 mg).
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1-52-1.72 (m, 3 H) 1.89-1.99 (m, 1 H) 2.17-242 (m, 1 H) 2.65-2.80 (m, 1 H) 2.96 (d, J=14.85 Hz, 2 H) 3.27-3.37 (m, 1 H) 4.18-
4.28 (m, 1 H) 4.40-4.62 (m, 2 H) 5.95-6.05 (m, 1 H) 6.18-6.28 (m, 1 H) 7.43 (t, 2 H) 7.57
(m, 1 H) 8.03 (m, 2 H). HPLC 96% Rτ=2.15 (System A. 10-97% MeCN over 3 min) 94%
Rτ=1.98 (System B. 10-90% MeCN over 3 min). MS (ESI+) for C19H20N2O3S m/z 357
(M+H)+.
Example 229 (BVT.51207)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2-chlorobenzoate Prepared according to method F 30 mg 25% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.53-0.93 (m, 1 H) 1.15-140 (m, 2 H) 1.65-1.87 (m, 3 H) 2.23-244 (m, 1 H) 2.64-2.74 (m, 1 H) 2.85-3.06 (m, 2 H) 3.26-3.38 (m, 1 H) 4.25-440 (m, 1 H) 443-4.65 (m, 2 H) 5.95-6.07 (m, 1 H) 6.25-6.33 (m, 1 H) 7.25- 7.50 (m, 2 H) 7.77-7.95 (m, 1 H). MS (ESI+) for C19H19ClN2O3S m/z 391 (M+H)+.
Example 230 (BVT.51601G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3,4- dichlorobenzoate
Prepared according to method F
25 mg, 29% yield.
Η NMR (270 MHz, METHANOL-D4) δ ppm 1.27-1.77 (m, 4 H) 245-2.63 (m, 2 H) 2.84-
2.95 (m, 2 H) 3.70-3.80 (m, 1 H) 442-4.60 (m, 3 H) 5.90-6.10 (m, 1 H) 6.14-6.20 (m, 1 H) 7.60-7.70 (m, 1 H) 7.85-7.95 (m, 1 H) 8.04 (dd, J=4.82, 1.86 Hz, 1 H). MS (ESI+) for
Ci9Hi8Cl2N2O3S C2HCl3O2 m/z 426 (M+H)+.
Example 231 (BVT.51602G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,6- difluorobenzoate
Prepared according to method F
76 mg, 97% yield.
1H NMR (270 MHz, METHANOL-D4) δ ppm 1.34-1.53 (m, 3 H) 1.57-1.70 (m, 1 H) 2.09-
2.28 (m, 1 H) 245-2.60 (m, 1 H) 2.73-2.88 (m, 2 H) 3.63-3.72(m, 1 H) 4.30-447 (m, 3 H) 5.94-6.00 (m, 1 H) 6.07-6.13 (m, 1 H) 6.98 (t, J=8.29 Hz, 1 H) 740-7.53 (m, 1 H). MS
(ESI+) for C19Hι8F2N2O3S C2HCl3O2 m/z 393 (M+H)+.
Example 232 (BVT.51603G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,5- bis(trifluoromethyl)benzoate Prepared according to method F 19 mg, 19% yield. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.20-1.68 (m, 4 H) 2.16-2.34 (m, 1 H) 2.43-
2.60 (m, 1 H) 2.75-2.90 (m, 2 H) 3.68-3.76 (m, 1 H) 4.28-4.32(m, 1 H) 440-4.53 (m, 2 H)
5.92-6.00 (m, 1 H) 6.07-6.20 (m, 1 H) 7.92-8.00 (m, 2 H) 8.11 (d, J=6.48 Hz, 1 H). MS
(ESI+) for C2ιHι8F6N2O3S C2HCl3O2 m/z 493 (M+H)+.
Example 233 (BVT.51605G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3,4- difluorobenzoate trifluoroacetate
Prepared according to method F 27 mg, 33%o yield.
Η NMR (270 MHz, METHANOL-D4) δ ppm 1.15-1.57 (m, 4 H) 2.33-2.57 (m, 2 H) 2.68-
2.87 (m, 2 H) 3.55-3.60 (m, 1 H) 440-4.50 (m, 3 H) 5.96-6.12 (m, 2 H) 745-7.55 (m, 2 H)
7.80-7.87 (m, 1 H) 7.90-8.00 (m, 1 H) 848-8.53 (m, 1 H). MS (ESI+) for C23H22N2O3S
C2HCl3O2 m/z 407 (M+H)+.
Example 234 (BVT.51606G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3,4- difluorobenzoate
Prepared according to method F 8 mg, 10%) yield.
!H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.57-1.65 (m, 2 H) 1.67-1.82 (m, 2 H)
2.33-2.52 (m, 1 H) 2.62-2.75 (m, 1 H) 2.90-3.04) 3.28-3.36 (m, 1 H) 4.25-4.35 (m, 1 H)
444-4.60 (m, 2 H) 5.99-6.07 (m, 1 H) 6.24-6.32 (m, 1 H) 7.16-7.28 (m, 1 H) 7.75-7.93 (m,
2 H). MS (ESI+) for Cι9H18F2N2O3S C2HCl3O2 m/z 393 (M+H)+.
Example 235 (BVT.51608G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,5- difluorobenzoate
Prepared according to method F 9 mg, 1 1% yield.
Η NMR (270 MHz, METHANOL-D4) δ ppm 1.15-1.67 (m, 4 H) 2.19-2.38 (m, 1 H) 2.43-
2.55 (m, 1 H) 2.77-2.88 (m, 2 H) 3.68 (dd, J=7.67, 2.97 Hz, 1 H) 4.34-447 (m, 3 H) 5.90- 6.00 (m, 1 H) 6.07-6.13 (m, 1 H) 7.08-7.21 (m, 1 H) 7.23-7.34 (m, 1 H) 7.52-7.62 (m, 1 H). MS (ESI+) for d9H18F2N2O3S C2HCl3O2 m/z 393 (M+H)+.
Example 236 (BVT.51607G) 2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl 4- methylbenzoate Prepared according to method F 20 mg, 27% yield.
!H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.54-1.77 (m, 4 H) 2.30-247 (m, 1 H) 2.40 (s, 3 H) 2.63-2.77 (m, 1 H) 2.90-3.04 (m, 2 H) 3.25-3.33 (m, 1 H) 4.27-4.35 (m, 1 H) 4.42-4.60 (m, 2 H) 5.97-6.04 (m, 1 H) 6.23-6.28 (m, 1 H) 7.25 (d, J=7.56 Hz 2 H) 7.89 (d, J=8.10 Hz 2H). MS (ESI+) for C20H22N2O3S C2HCl3O2 m/z 371 (M+H)+.
Example 237 (BVT.51609G) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 4- chloro-3-nitrobenzoate
Prepared according to method F
18 mg, 21% yield. H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.61 (br s, 2 H) 1.70-1.78 (m, 2 H) 2.40- 2.57 (m, 1 H) 2.62-2.68 (m, 1 H) 2.97 (br s, 1 H) 3.02 (br s, 1 H) 3.28-3.38 (m, 1 H) 4.27-
4.35 (m, 1 H) 447-4.68 (m, 2 H) 6.02-6.09 (m, 1 H) 6.27-6.32 (m, 1 H) 7.67 (d, J=841 Hz
1 H) 8.12 (dd, J=841, 1.98 Hz, 1 H) 846-8.52 (m, 1 H). MS (ESI+) for C19H18ClN3O5S C2HCl3O2 m/z 436 (M+H)+.
Example 238 (BVT.51611G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3- methylbenzoate
Prepared according to method F
9 mg, 12% yield. !H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.57-1.67 (m, 2 H) 1.68-1.78 (m, 2 H)
2.25-247 (m, IH) 2.39 (s, 3 H) 2.68-2.80 (m, 1 H) 2.92-3.04 (m, 2 H) 3.26-3.335 (m, 1 H)
4.27-4.34 (m, 1 H) 442-4.62 (m, 2 H) 5.96-6.03 (m, 1 H) 6.23-6.29 (m, 1 H) 7.30-744 (m,
2 H) 7.77-7.86 (m, 2 H). ). MS (ESI+) for C20H22N2O3S C2HCl3O2 m/z 371 (M+H)+. Example 239 (BVT.51682G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3- (trifluoromethyl)benzoate Prepared according to method F 32 mg, 38% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.52-1.72 (m, 3 H) 1.94-2.08 (m, 1 H) 2.18-242 (m, 1 H) 2.65-2.84 (m, 1 H) 2.95 (d, J=13.11 Hz, 2 H) 3.27-3.37 (m, 1 H) 4.14- 4.23 (m, 1 H) 4.42-4.65 (m, 2 H) 5.94-6.03 (m, 1 H) 6.17-6.25 (m, 1 H) 7.57 (t, J=7.79 Hz, 1 H) 7.81 (d, J=7.67 Hz, 1 H) 8.22 (d, J=7.67 Hz, 1 H) 8.30 (s, 1 H). MS (ESI+) for C20Hι9F3N2O3S C2HCl3O2 m/z 425 (M+H)+.
Example 240 (BVT.51683G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,3,4- trifluorobenzoate
Prepared according to method F
21 mg, 26% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.52-1.68 (m, 3 H) 1.93-2.08 (m, 1 H)
2.16-2.36 (m, 1 H) 2.60-2.77 (m, 1 H) 2.89-3.02 (m, 2 H) 3.27-3.36 (m, 1 H) 4.16-428 (m, 1 H) 442-4.60 (m, 2 H) 5.97-6.06 (m, 1 H) 6.18-6.28 (m, 1 H) 6.96-7.08 (m, 1 H) 7.67-
7.80 (m, 1 H). MS m z: (M+H) 411.
Example 241 (BNT.51684G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2- bromo-5-methoxybenzoate
Prepared according to method F
10 mg, 11% yield.
Η ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.55-1.72 (m, 3 H) 1.85-1.97 (m, 1 H)
2.18-2.37 (m, 1 H) 2.65-2.80 (m, 1 H) 2.92-3.03 (m, 2 H) 3.27-3.36 (m, 1 H) 3.81 (s, 3 H) 4.22-4.34 (m, 1 H) 444-4.56 (m, 2 H) 5.98-6.04 (m, 1 H) 6.18-6.27 (m, 1 H) 6.89 (dd,
J=8.78, 3.09 Hz, 1 H) 7.28-7.33 (m, 1 H) 7.48-7.54 (m, 1 H). ). MS (ESI+) for
C20H2ιBrΝ2O S C2HCl3O2 m/^ 467 (M+H)+. Example 242 (BNT.51685G)
2-[2-(bicyclo[2.2.1 ]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl 2- chloro-6-fluorobenzoate Prepared according to method F 10 mg, 12% yield.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.52-1.72 (m, 3 H) 1.85-1.98 (m, 1 H) 2.08-2.27 (m, 1 H) 2.65-2.82 (m, 1 H) 2.90-3.02 (m, 2 H) 3.28-3.37 (m, 1 H) 4.17-4.28 (m, 1 H) 446-4.63 (m, 2 H) 5.96-6.07 (m, 1 H) 6.18-6.25 (m, 1 H) 7.05 (t, J=8.66 Hz, 1 H) 7.17-7.27 (m, 1 H) 7.29-7.39 (m, 1 H). MS (ESI+) for C19Hι8ClFΝ2O3S C2HCl3O2 m/z 409 (M+H)+.
Example 243 (BNT.51686G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2- fluoro-5-(trifluoromethyl)benzoate Prepared according to method F
6 mg, 7% yield.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.55-1.75 (m, 3 H) 1.85-2.04 (m, 1 H)
2.14-2.37 (m, 1 H) 2.70-2.84 (m, 1 H) 2.97 (d, J=11.38 Hz, 2 H) 3.28-3.38 (m, 1 H) 4.17-
4.29 (m, 1 H) 4.45-4.63 (m, 2 H) 5.97-6.08 (m, 1 H) 6.17-6.28 (m, 1 H) 7.20-7.35 (m, 1 H) 7.74-7.86 (m, 1 H) 8.20-8.30 (m, 1 H). ). MS (ESI+) for C20H18F4Ν2O3S C2HCl3O2 m/z
443 (M+H)+.
Example 244 (BNT.51687G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2- fluoro-4-(trifluoromethyl)benzoate
Prepared according to method F
22 mg, 25% yield.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 1.52-1.68 (m, 3 H) 1.92-2.06 (m, 1 H)
2.17-244 (m, 1 H) 2.58-2.77 (m, 1 H) 2.95 (d, J=14.10 Hz, 2 H) 3.27-3.36 (m, 1 H) 4.15- 4.27 (m, 1 H) 4.44-4.65 (m, 2 H) 5.96-6.08 (m, 1 H) 6.17-6.26 (m, 1 H) 7.35-7.52 (m, 2 H)
8.06 (t, J=7.30 Hz, 1 H). MS (ESI+) for C20H18F4Ν2O3S C2HCl3O2 m/z 443 (M+H)+.
Example 245 (BVT.56824G) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3- methoxybenzoate Prepared according to method F 23 mg, 20% yield. ]H NMR (270 MHz, METHANOL-D4) δ ppm 1.17-1.72 (m, 4 H) 2.31-2.50 (m, 3 H) 2.68- 2.77 (m, 1 H) 3.58-3.68 (m, 1 H) 3.75 (d, J=445 Hz, 3 H) 4.27-445 (m, 3 H) 5.82-5.98 (m, 1 H) 6.02-6.18 (m, 1 H) 6.98-7.08 (m, 1 H) 7.23-7.28 (m, 1 H) 742-7.52 (m, 2 H). MS (ESI+) for C20H22N2O4S C2HCl3O2 m/z 387 (M+H)+.
Example 246 (BVT.56825G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,6- dimethoxybenzo ate
Prepared according to method F
12 mg, 10% yield. Η NMR (270 MHz, METHANOL-D4) δ ppm 1.28-148 (m, 3 H) 1.50-1.62 (m, 1 H) 1.85-
2.05 (m, 1 H) 2.43-2.54 (m, 1 H) 2.67-2.84 (m, 2 H) 3.10-3.16 (m, 1 H) 3.64(s, 6 H) 4.17-
4.37 (m, 3 H) 5.87-5.96 (m, 1 H) 6.03-6.13 (m, 1 H) 6.51 (d, J=841 Hz, 2 H) 6.03-6.13
(m, 1 H) 7.18 (t, J=8.24 Hz, 1 H).). MS (ESI+) for C21H24N2O5S C2HCl3O2 m/z 417
(M+H)+.
Example 247 (BNT.56826G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,4- dimethoxybenzoate
Prepared according to method F 15 mg, 12% yield.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.27-1.64 (m, 4 H) 2.13-2.34 (m, 1 H) 2.42-
2.55 (m, 1 H) 2.72-2.86 (m, 1 H) 3.54-3.62 (m, 1 H) 3.73 (s, 6 H) 4.22-443 (m, 3 H) 5.84-
5.98 (m, 1 H) 6.05-6.18 (m, 1 H) 640-6.53 (m, 2 H) 7.65-7.76 (m, 1 H). MS (ESI+) for
C2ιH24N2O5S C2HCl3O2 m/z 417 (M+H)+.
Example 248 (BVT.56827G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 4- butoxybenzoate Prepared according to method F
6 mg, 4% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.93 (t, J=742 Hz, 3 H) 1.36-1.59 (m, 5
H) 1.60-1.79 (m, 3 H) 2.08-2.28 (m, 1 H) 2.58-2.74 (m, 1 H) 2.75-2.94 (m, 2 H) 3.22-3.30
(m, 1 H) 3.96 (t, J=643 Hz, 2 H) 4.16-4.28 (m, 1 H) 4.32-449 (m, 2 H) 5.93-6.02 (m, 1 H)
6.07-6.23 (m, 1 H) 6.85 (d, J=8.16 Hz, 2 H) 7.93 (d, J=8.16 Hz, 2 H). MS (ESI+) for
C23H28N2O4S C2HCl3O2 m/z 430 (M+H)+.
Example 249 (BVT.56857G) 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 3,5- bis(trifluoromethyl)benzoate
Prepared according to method F
30 mg, 20% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 147-1.78 (m, 3 H) 1.84-2.02 (m, 1 H) 2.20-244 (m, 1 H) 2.63-2.81 (m, 1 H) 2.83-2.98 (m, 2 H) 3.24-3.36 (m, 1 H) 4.13-4.23 (m,
1 H) 440-4.68 (m, 2 H) 5.92-6.04 (m, 1 H) 6.13-6.25 (m, 1 H) 8.06 (br.s, 1 H) 8.48 (br.s, 2
H). MS (ESI+) for C2]H18F6N2O3S C2HCl3O2 m/z 493 (M+H)+.
Example 250 (BVT.56858G) 2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl 4-tert- butylbenzoate
Prepared according to method F
7 mg, 5% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.32 (s, 9 H) 1.55-1.72 (m, 3 H) 1.86- 1.94 (m, 1 H) 2.18-2.36 (m, 1 H) 2.67-2.78 (m, 1 H) 2.88-3.00 (m, 2 H) 3.27-3.36 (m, 1 H)
4.17-4.28 (m, 1 H) 440-4.62 (m, 2 H) 5.92-6.08 (m, 1 H) 6.18-6.26 (m, 1 H) 7.44 (d,
J=8.41 Hz, 2 H) 7.95 (d, J=8.40 Hz, 2 H). MS (ESI+) for C23H28N2O3S C2HCl3O2 m/z 414
(M+H)+.
Example 251 (BVT.56890G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,4- dichlorobenzoate
Prepared according to method F 5 mg, 4% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.21-145 (m, 1 H) 1.52-1.74 (m, 2 H) 1.82-1.93 (m, 1 H) 2.17-2.37 (m, 1 H) 2.64-2.76 (m, 1 H) 2.88-3.02 (m, 2 H) 3.30-3.36 (m, 1 H) 4.20-4.30 (m, 1 H) 4.42-4.57 (m, 2 H) 5.97-6.06 (m, 1 H) 6.22-6.27 (m, 1 H) 7.25- 7.35 (m, 1 H) 7.47 (d, J=l .98 Hz, 1 H) 7.82 (dd, J=2.16, 8.37 Hz, 1 H). MS (ESI+) for Cι9H18Cl2N2O3S C2HC1302 m/z 425 (M+H)+.
Example 252 (BVT.59294G)
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl 2,4,6- trichlorobenzoate
Prepared according to method F
5 mg, 3% yield.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.17-1.37 (m, 1 H) 1.65 (s, 2 H) 1.73-
1.78 (m, 2 H) 2.23-2.36 (m, 1 H) 2.69-2.84 (m, 1 H) 2.95-3.06 (m, 2 H) 3.28-3.34 (m, 1 H) 4.31-4.38 (m, 1 H) 4.48-4.67 (m, 2 H) 6.04 (dd, J=5.57, 3.09 Hz, 1 H) 6.28 (dd, J=5.57,
2.85 Hz, 1 H) 7.33-743 (m, 2 H). MS (ESI+) for C19H17Cl3N2O3S C2HCl3O2 m/z 461
(M+H)+.
Compounds of type 4B
Example 253 (BVT051436G)
2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl (2- chlorophenyl)carbamate Method F 2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one (76 mg, 0.3 mmol) and 2-chlorophenyl isocyanate (78 μL, 0.6 mmol) were dissolved in anhydrous DCM and the reaction mixture was stined at RT over night. The solvent was removed under reduced pressure and the crude was purified using preparative HPLC (20-80%) MeCN over 10 min followed by 100% MeCN for 5 min) affording the product in 43 %> yield (54 mg).
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.60-1.84 (m, 3 H) 2.00-2.13 (m, 1 H) 2.20-240 (m, 1 H) 2.65-2.79 (m, 1 H) 3.00-3.11 (m,2 H) 3.42 (d, J=5.69 Hz, 1 H) 4.26- 4.36 (m, 1 H) 4.48 (q, J=5.40 Hz, 1 H) 4.37-4.55 (m, 1 H) 6.07-6.16 (m, 1 H) 6.30-6.34 (m, 1 H) 7.09 (t, J=7.79 Hz, 1 H) 7.34 (t, J=7.97 Hz, 1 H) 7.43 (d, J=8.16 Hz, 1 H) 8.18 (d, J=7.92 Hz, 1 H). HPLC 100% Rτ=2.18 (System A. 10-97% MeCN over 3 min) 99% Rτ=1.43 (System B. 10-90% MeCN over 3 min). MS (ESI+) for C19H20C1N3O3S 2C2HCl3O2 m/z 406 (M+H)+.
Example 254 (BVT051437G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl (4- chloro-3-nitrophenyl)carbamate Prepared according to method F 23 mg, 16% yield.
!H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.54-1.75 (m, 3 H) 1.87-2.00 (m, 1 H) 2.17-2.37 (m, 1 H) 2.58-2.70 (m, 1 H) 2.99 (br s, 2 H) 3.34 (d, J=7.67 Hz, 1 H) 4.17-4.24 (m, 1 H) 4.33-4.50 (m, 2 H) 6.02-6.09 (m, 1 H) 6.21-6.27 (m, 1 H) 7.55-7.62 (m, 1 H) 8.20 (d, J=247 Hz, 1 H) 8.52 (dd, J=9.15, 2.72 Hz, 1 H) 9.82 (d, J=3.96 Hz, 1 H). MS (ESI+) for Cι9Hι9ClN4O5S C2HCl3O2 m/z 451 (M+H)+.
Example 255 (BVT051438G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl (4- bromo-2,6-difluorophenyl)carbamate Prepared according to method F
55 mg, 40% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.53-1.74 (m, 3 H) 1.83-1.97 (m, 1 H)
2.05-2.23 (m, 1 H) 2.54-2.67 (m, 1 H) 2.92-3.O2 (m, 2 H) 3.27-3.37 (m, 1 H) 4.12-4.22 (m,
1 H) 4.25-445 (m, 2 H) 6.02-6.08 (m, 1 H) 6.21-6.28 (m, 1 H) 7.07-7.16 (m, 2H). MS (ESI+) for Cι9Hι8BrF2N3O3S C2HCl3O2 m/z 388 (M+H)+.
Example 256 (BVT051516G)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl (3- phenoxyphenyl)carbamate Prepared according to method F 15 mg, 11% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.58-1.84 (m, 4 H) 2.28-247 (m, 1 H) 2.50-2.63 (m, 1 H) 3.00-3.08 (m, 2 H) 3.28-3.37 (m, 1 H) 4.27-447 (m, 3 H) 5.98-6.07 (m, 1 H) 6.25-6.32 (m, 1 H) 6.70 (d, J=7.92 Hz, 1 H) 6.94-7.37 (m, 8 H). MS (ESI+) for C25H25N3O4S C2HCl3O2 m/z 464 (M+H)+.
Example 257 (BVT067466) N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N'-(2- fluorophenyl)urea Prepared according to method F 37 mg, yield 59%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.38-1.78 (m, 10 H) 1.91-2.18 (m, 3 H) 2.31-244 (m, 1 H) 3.36-347 (m, 2 H) 3.94-4.06 (m, 1 H) 4.37 (dd, J=940, 4.21 Hz, 1 H) 6.90-7.12 (m, 3 H) 7.90-8.02 (m, 1 H). MS (ESI+) for C19H25FN4O2S m/z 393 (M+H)+.
Example 258 (BVT067467)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N'-(4- fluorophenyl)urea
Prepared according to method F
15 mg, yield 24%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 144-1.78 (m, 10 H) 1.91-2.07 (m, 3 H)
2.38-243 (m, 1 H) 3.37 (t, J=6.68 Hz, 1 H) 3.98-4.11 (m, 1 H) 4.28 (dd, J=940, 3.96 Hz, 1 H) 6.93-7.02 (m, 2 H) 7.29-7.39 (m, 2 H). MS (ESI+) for C19H25FN4O2S m/z 393 (M+H)+.
Example 259 (BVT067468)
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N*-(2,6- difluorophenyl)urea Prepared according to method F 21 mg, yield 32%.
Η ΝMR (270 MHz, METHAΝOL-D4) δ ppm 143-1.78 (m, 10 H) 1.83-2.06 (m, 3 H) 2.28-244 (m, 1 H) 3.25-346 (m, 2 H) 4.02-4.12 (m, 1 H) 4.26 (dd, J=9.77, 4.08 Hz, 1 H) 6.92-7.04 (m, 2 H) 7.14-7.31 (m, 1 H). MS (ESI+) for C19H24F2N4O2S m/z 411 (M+H)+.
Example 260 (BVT067469)
N-{2-[2-(cycloheρtylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,4- difluorophenyl)urea Prepared according to method F 28 mg, yield 43%.
1H NMR (270 MHz, METHANOL-D4) δ ppm 142-1.76 (m, 10 H) 1.88-2.04 (m, 3 H) 2.28-243 (m, 1 H) 3.27-343 (m, 2 H) 3.98-4.10 (m, 1 H) 4.27 (dd, J=9.40, 3.96 Hz, 1 H) 6.80-6.99 (m, 2 H) 7.77-7.92 (m, 1 H). MS (ESI+) for C19H24F2N4O2S m/z 411 (M+H)+.
Example 261 (BVT067470)
N-(2-chlorophenyl)-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}urea Prepared according to method F
26 mg, yield 40%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 143-1.62 (m, 10 H) 1.94-2.12 (m, 3 H)
2.32-247 (m, 1 H) 3.36-347 (m, 2 H) 3.96-4.06 (m, 1 H) 4.36 (dd, J=9.28, 3.84 Hz, 1 H)
6.96-7.03 (m, 1 H) 7.20-7.28 (m, 1 H) 7.35-7.40 (m, 1.36 Hz, 1 H) 7.93-8.02 (m, 1 H). MS (ESI+) for Cι9H25ClN4O2S m/z 409 (M+H)+.
Example 262 (BVT067471)
N-[2-chloro-5-(trifluoromethyl)phenyl]-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-
1 ,3-thiazol-5-yl]ethyl}urea Prepared according to method F
26 mg, yield 34%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.27-1.79 (m, 10 H) 1.80-2.13 (m, 3 H)
2.15-2.57 (m, 1 H) 3.34-3.62 (m, 2 H) 3.83-4.15 (m, 1 H) 4.11-4.36 (m, 1 H) 6.99-7.30 (m,
1 H) 7.34-7.58 (m, 1 H) 8.39-8.64 (m, 1 H). MS (ESI+) for C20H24C1F3N4O2S m/z 478 (M+H)+.
Example 263 (BVT067472)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N'-[4-fluoro-2- (trifluoromethyl)phenyl]urea Prepared according to method F 37 mg, yield 50%. Η NMR (270 MHz, METHANOL-D4) δ ppm 1.37-1.78 (m, 10 H) 1.85-2.08 (m, 3 H) 2.27-247 (m, 1 H) 3.28-3.66 (m, 2 H) 3.97-4.10 (m, 1 H) 4.30 (dd, J=9.8, 3.8 Hz, 1 H) 7.25-745 (m, 2 H) 7.65-7.80 (m, 1 H). MS (ESI+) for C20H24F4N4O2S m/z 461 (M+H)+.
Example 264 (BVT067473)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N'-(2- methoxyphenyl)urea Prepared according to method F 36 mg, yield 56%. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.38-1.78 (m, 10 H) 1.92-2.12 (m, 3 H)
2.27-242 (m, 1 H) 3.30-347 (m, 2 H) 3.84 (s, 3 H) 3.95-4.09 (m, 1 H) 4.32 (dd, J=9.5, 3.8 Hz, 1 H) 6.77-7.01 (m, 3 H) 7.94 (d, J=74 Hz, 1 H). MS (ESI+) for C20H28N4O3S m/z 405 (M+H)+.
Example 265 (BVT067474)
N-(5-chloro-2-methoxyphenyl)-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1,3- thiazol-5-yl]ethyl}urea
Prepared according to method F
32 mg, yield 46%. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 141 - 1.76 (m, 10 H) 1.84-2.08 (m, 3 H)
2.28 -2.42 (m, 1 H) 3.33-3.50 (m, 2 H) 3.86 (s, 3 H) 3.92-4.1 1 (m, 1 H) 4.32 (dd, J=9.2,
4.0 Hz, 1 H) 6.89 (t, J=1.5 Hz, 2 H) 8.06-8.13 (m, 1 H). MS (ESI+) for C20H27C1N4O3S m/z 440 (M+H)+.
Example 266 (BVT067475)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-7V-(2,4- dimethoxyphenyl)urea
Prepared according to method F
23 mg, yield 33%. 1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.38-1.81 (m, 10 H) 1.86-2.08 (m, 3 H)
2.22-246 (m, 1 H) 3.27-347 (m, 2 H) 3.74 (s, 3 H) 3.82 (s, 3 H) 3.92-4.12 (m, 1 H) 4.30
(dd, J=9.5, 3.8 Hz, 1 H) 6.43 (dd, J=8.8, 2.6 Hz, 1 H) 6.53 (d, J=2.7 Hz, 1 H) 7.58-7.74
(m, 1 H). MS (ESI+) for C2ιH30N4O4S m/z 435 (M+H)+. Example 267 (BVT067476)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,6- dichloropyridin-4-yl)urea Prepared according to method F
26 mg, yield 37%.
1H ΝMR (270 MHz, DMSO-D6) δ ppm 1.25-1.96 (m, 13 H) 2.11-2.32 (m, 1 H) 3.08-3.31
(m, 2 H) 3.85-4.04 (m, 1 H) 4.14 (dd, J=9.8, 3.8 Hz, 1 H) 6.73-6.89 (m, 1 H) 744-7.59 (m,
1 H) 9.25 (d, J=74 Hz, 1 H) 948-9.64 (m, 1 H). MS (ESI+) for C18H23Cl2Ν5O2S m/z 445 (M+H)+.
Example 268 (BVT067478)
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N'-cyclohexylurea Prepared according to method F 22 mg, yield 36%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.02-2.12 (m, 23 H) 2.22-241 (m, 1 H) 3.16-3.65 (m, 3 H) 3.96-4.13 (m, 1 H) 4.26 (dd, J=9.9, 4.0 Hz, 1 H). MS (ESI+) for C19H32N4O2S m/z 381 (M+H)+.
Example 269 (BVT067480')
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N-cyclopentylurea
Prepared according to method F
32 mg, yield 55%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ ppm 1.26-2.10 (m, 21 H) 2.22-2.39 (m, 1 H) 3.15-342 (m, 2 H) 3.85-3.99 (m, 1 H) 3.99-4.12 (m, 1 H) 4.20-4.30 (m, 1 H). MS (ESI+) for Cι8H30N4O2S m/z 367 (M+H)+.
Compounds of type 5
Example 270 (BVT.51309G)
2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5- {2-[(2-chlorobenzyl)oxy]ethyl} - 1 ,3-thiazol-
4(5H)-one
Method G 2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one (50 mg, 0.20 mmol) and triphenylphosphine (64 mg, 0.24 mmol) were dissolved in THF (5 mL). The reaction mixture was stined at RT for 10 min. and 2-chloro-benzyl alcohol (34 mg, 0.24 mmol) and DEAD (37 μL, 0.24 mmol) was added. The reaction mixture was stined at RT over night. The solvent was removed under reduced pressure and the crude was dissolved in DCM (15 mL) and was washed with brine (1x5 mL). The organic layer was dried (MgSO4) and the solvent was removed under reduced pressure. Purification using preparative HPLC (10-90% MeCN over 10 min followed by 100% MeCN for 5 min) afforded the product in 68% yield (50 mg). 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.20-1.29 (m, 1 H) 1.34-140 (m, 1 H) 149-1.63 (m, 2 H) 2.05-2.18 (m, 1 H) 2.33-247 (m, 1 H) 2.58 (br s, 1 H) 2.81 (br s, 1 H) 3.13-3.22 (m, 1 H) 3.76-3.96 (m, 2 H) 4.25-4.38 (m, 1 H) 4.94-5.09 (m, 2 H) 5.99 (dd, J=5.81, 3.09 Hz, 1 H) 6.16 (dd, J=5.69, 2.97 Hz, 1 H) 7.07-7.7.19 (m, 1 H) 7.3O-7.38 (m, 1 H) 740-748 (m, 1 H) 7.65-7.75 (m, 1 H). HPLC 94% Rτ=2.71 (System A. 10-97% MeCN over 3 min) 95% Rτ=l .71 (System B. 10-90% MeCN over 3 min). MS (ESI+) for C19H21ClN2O2S C2HCl3O2 m/z 378 (M+H)+.
Example 271 (BVT.51314G)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-methylbenzyl)oxy]ethyl}-l,3-thiazol- 4(5H)-one trifluoroacetate
Prepared according to method G
26 mg, 18% yield.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.30-1.38 (m, 1 H) 147-1.62 (m, 2 H)
1.77 (d, J=8.16 Hz, 1 H) 1.95-2.11 (m, 1 H) 2.27-242 (m, 2 H) 2.66 (br s, 1 H) 2.87 (br s, 1 H) 3.14-3.22 (m, 1 H) 3.68-3.92 (m, 2 H) 4.18 (m, 1 H) 4.78-4.95 (m, 2 H) 6.00 (dd,
J=5.69, 3.22 Hz, 1 H) 6.18 (dd, J=5.69, 2.97 Hz, 1 H) 7.17-7.30 (m, 3 H) 7.37-7.44 (m, 2
H). MS (ESI+) for Cι9H22N2O2S C2HCl3O2 m/z 343 (M+H)+.
Example 272 (BVT.51315G) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-methoxybenzyl)oxy]ethyl}-l,3-thiazol- 4(5H)-one
Prepared according to method G 6mg, 4% yield. Η NMR (270 MHz, CHLOROFORM-D) δ ppm 140-1.72 (m, 4 H) 2.13-2.28 (m, 1 H) 2.35-2.50 (m, 1 H) 2.76-2.83 (m, 1 H) 2.90 (br.s, 1 H) 3.32 (dd, J=7.42, 2.72 Hz, 1 H) 3.86 (s, 3H) 3.78-3.95 (m, 2 H) 4.37 (dd, J=7.67, 5.20 Hz, 1 H) 4.94-5.13 (m, 2 H) 5.97-6.05 (m, 1 H) 6.18-6.26 (m, 1 H) 6.91 (dd, J=8.10, 5.40 Hz, 2 H) 7.25 (dd, J=8.10, 5.40Hz, 2 H). MS (ESI+) for C20H24N2O3S C2HCl3O2 m/z 373 (M+H)+.
Example 273 (BVT.51316G)
2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-5-(2- {[3-(dimethylamino)benzyl]oxy} ethyl)- 1 ,3- thiazol-4(5H)-one Prepared according to method G
30 mg, 20% yield.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.39-1.53 (m, 2 H) 1.58-1.69 (m, 2 H)
2.13-2.24 (m, 1 H) 2.33-248 (m, 1 H) 2.77 (br s, 1 H) 2.88 (br s, 1 H) 3.17 (s, 6 H) 3.28 (d,
J=6.19 Hz, 1 H) 3.70-3.95 (m, 2 H) 4.34 (td, J=5.51, 2.35 Hz, 1 H) 4.92-5.05 (m, 2 H) 5.98-6.04 (m, 1 H) 6.16-6.23 (m, 1 H) 7.32-7.54 (m, 4 H). MS (ESI+) for C21H27N3O2S
C2HCl3O2 m/z 386 (M+H)+.
Example 274 (BVT.51005)
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-4(5H)- one
Prepared according to method G
13 mg, 15 % yield, as a white solid.
MS (ESI+) for Ci8H19ClN2O2S m/z 363 (M+H)+.
Example 275 (BVT.51070)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one
Method E
3-bromodihydrofuran-2(377)-one (1.0 g, 6.1 mmol) andN-Bicyclo[2.2.1]hept-5-en-2- ylthiourea (1.02 g, 6 mmol) were mixed in acetone (60 mL) and heated to reflux for lh. The reaction mixture was poured on water and the pH was set to 7, using ΝaHCO3- solution. Extracted the aqueous phase with DCM, dried the organic phase (MgSO4) evaporated the solvent, got 1.52 g of the product, yield 99%. 1HNMR (270 MHz, CHLOROFORM-D) δ ppm 1.24-1.19 (m, IH) 1.68-1.37 (m, 2H) 2.06-1.80 (m, 2H) 244-2.37 (m, IH) 2.96-2.86 (m, 2H) 3.86-3.65 (m, 2H) 4.26-4.20 (m, IH) 6.07-6.04 (m, IH) 6.22-6.15 (m, IH) 3.36-3.32 (m, IH). MS (ESI+) for Cι2H16N2O2S m/z 253 (M+H)+.
Example 276 (BVT.51120)
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]-l,3-thiazol-4(5H)- one
Prepared according to method G white solid (3 mg)
MS (ESI+) for C24H24N2O3S m/z 421 (M+H)+.
Example 277 (BVT.51121)
Methyl 4-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethoxy}-3-chlorobenzoate Prepared according to method G as a white solid (23 mg). MS (ESI+) for C20H2ιClN2O4S m/z 421 (M+H)+.
Example 278 (BVT.51136)
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]-l,3- thiazol-4(5H)-one
Prepared according to method G as a white solid (2 mg). MS (ESI+) for Cι9H21ClN2O2S m/z 377 (M+H)+.
Compounds of type 5B
Example 279 (BVT49923) 2-Chlorophenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate Method L
[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetic acid (100 mg, 0.375 mmol) HOBt (50 mg, 0.375 mmol) and EDCI (72 mg, 0.375 mmol) were suspended in DCM (5 mL). Triethylamine (104 μL, 0.75 mmol, 2 eq) was added and the resulting suspension was stined for 30 min at ambient temperature. Then phenol (1.1 mmol, 3 eq.) was added, and stining continued for 3 h. The reaction mixture was eluted over a column containing hydromatrix (5 x 1 cm) treated with 2M HCl and thoroughly washed with DCM. Evaporation in vacuo afforded the crude product.
This gave 130 mg (46%) of the title compound as a white solid: Mp 211 °C Η NMR (400 MHz, CHLOROFORM-D) δ ppm 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (ESI+) for Cι8Hι7ClN2O3S m/z 377 (M+H)+.
Example 280 (BVT.50180)
Phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetate
Prepared according to method L 48 mg, 37% yield, as a white solid.
Η NMR (400 MHz, CHLOROFORM-D) δ ppm 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (ESI+) for C18Hι8N2O3S m/z 343 (M+H)+.
Example 281 (BVT.50205)
2-Methoxyphenyl [2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-
5 -yl] acetate
Prepared according to method L 57 mg, 41% yield, as a white solid.
Mp 175-176 °C 1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.58-1.60 (m, IH) 1.68- 1.72 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J =2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (ESI+) for C19H20N2O4S m/z 373 (M+H)+.
Example 282 (BVT.50213)
3-Moφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetate Prepared according to method L 35 mg, 22% yield.
Mp 203-204 °C 1HNMR (400 MHz, CHLOROFORM-D) δ ppm 1.58-1.60 (m, IH) 1.68- 172 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 4.44-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (ESI+) for C22H25N3O4S m/z 428 (M+H)+.
Compounds of type 6
Example 283 (BVT.51151)
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chlorophenyl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one
Method J
N-Bicyclo[2.2.1]hept-5-en-2-ylthiourea (93 mg, 0.55 mmol) and 3-(4- chlorobenzoyl)acrylic acid (116 mg, 0.55 mmol) in water (5 mL) was refluxed for 18 h. The precipitate was collected on a filter after cooling and recrystallized from ethanol, yielding 96 mg (48 %) of white crystals: Mp 244-245 °C lH ΝMR (400 MHz, DMSO-dό) δ ppm 1.41-1.61 (m, 4H) 2.81-2.86 (m, 2H) 347-3.57 (m, IH) 3.75-3.78 (m, IH) 3.91-4.00 (m, IH) 4.34-442 (m, IH) 6.04-6.11 (m, IH) 6.21 (dd, J7=5.65, J2=2.98 Hz, IH) 7.59- 7.62 (m, 2H) 7.97-8.01 (m, 2H) 9.29 (d, J=6.78 Hz, ΝH). MS (ESI+) for Cι8H]7ClΝ2O2S m/z 361 (M+H)+.
Comparative Example 1 (BVT.51047) N-Bicyclo[2.2.1]hept-5-en-2-ylthiourea Method A
5-Isothiocyanatobicyclo[2.2.1]hept-2-ene (10.5 g, 69.43 mmol) was stined in 2 M ammonia in ethanol (170 mL, 345 mmol) for 18 h. The reaction flask was evaporated until viscous oil was obtained. DCM was added and the obtained crystals were collected and dried. This gave 3.13 g of the title compound. Yield 30%, 95% pure. An additional 4.74 g was obtained by recrystallisation of the mother liquor. Totally 7.87 g, yield 68%.
1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 6.54 (br. S, IH, Ν-H) 6.22-6.20 (m, IH) 6.04-6.03 (m, IH) 5.95-5.80 (br.s, 2H, Ν-H) 3.30-3.20 (m, IH) 2.99-2.90 (m, 2H) 1.77- 1.70 (m, IH) 1.62-1.59 (m, IH) 1.53-147 (m, IH) 144-1.36 (m, IH). MS (ESI+) for C8Hι2N2S m/z 169 (M+H)+.
Synthesis of compounds of type 1
Comparative Example 2
4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid
Method K
Phtalic anhydride (7.19 g, 48.5 mmol) 4-aminobutyric acid (5.00 g, 48.5 mmol) and TEA (0.68 ml) in toluene (75 ml) were placed in a round bottom flask fitted with a Dean Stark condenser and heated to reflux for 3.5h. The reaction mixture was then left in the refrigerator over night. The crystals that formed were collected, first washed with hexane and then ΗC1 (5%) and finally with water, and then dried in a vacuum oven. This afforded the product 645 g (58%) as white crystals. Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.94-2.09 (m, 2 H) 2.41 (t, J=742 Hz, 2
H) 3.76 (t, J=6.80 Hz, 2 H) 7.67-7.76 (m, 2 H) 7.80-7.88 (m, 2 H). HPLC 97%, Rτ= 1.50 min (System A, 10-97% MeCN over 3 min). MS (ESI+) for C12HnNO4m/z 234 (M+H)+.
Comparative Example 3 2-bromo-4-(l ,3-dioxo- 1 ,3-dihydro-2H-isoindol-2-yl)butanoic acid
4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid (3.00 g, 12.9 mmol) and SOCl2 (20 ml) were heated to reflux for 2h. Br2 (2.06 g, 12.9 mmol) was added slowly during 4 h while heating was continued. The reaction was heated to reflux until all starting material was consumed, approximately 48h (followed with LC-MS). Excess SOCl2 was removed in vacuum. Crushed ice was added to the residue and it was left over night. The white solid that had formed was filtered and dried in a vacuum oven to give 4.01 g of the crude product. This material was used in the next step without further purification. !Η NMR (270 MHz, METHANOL-D4) δ ppm 2.19-2.38 (m, 1 H) 2.39-2.58 (m, 1 H) 3.83 (t, J=6.68 Hz, 2 H) 4.37 (t, J=7.18 Hz, 1 H) 7.73-7.91 (m, 4 H). HPLC 71%, Rτ= 1.12 min (System A, 30-80% MeCN over 3 min). MS (ESI+) for C12H10BrNO4 m/z 312 (M+H)+.
Example 284 5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-l,3-thiazol-4(577)-one 2- {2-[2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} - lH-isoindole-l,3(2H)-dione (3.31 g, 8.68 mmol) was dissolved in a 0.2 M solution of Hydrazine in MeOH. The reaction mixture was heated to reflux for 3 h. Solvent and excess Hydrazine was removed in vacuum and co-evaporation with EtOH was repeated several times. The residue was dissolved in a small volume of MeOH and DCM was added. The white precipitate that formed was filtered and washed with DCM. The filtrate was concentrated in vacuum to give 3.0 g of the crude product. Purification was performed using column chromatography, eluent 20%> MeOH in DCM and thereafter MeOH containing some TEA. This afforded 1.8 g of apricot coloured crystals which showed to be a 1 : 1 (according to NMR) mixture of the wanted product and 2,3 -dihydrophtalazine- 1 ,4- dione. This mixture was used in the next step without further purification. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.20 (t, J=7.30 Hz, 2 H) 1.36-1.78 (m, 4 H) 1.95-2.15 (m, 1 H) 2.23-2.38 (m, 1 H) 2.81-3.06 (m, 5 H) 3.34 (s, 1 H) 3.83 (dd, J=7.05, 2.10 Hz, 1 H) 6.08 (dd, J=544, 3.22 Hz, 1 H) 6.21 (dd, J=5.69, 2.97 Hz, 1 H) (from 2,3- dihydrophtalazine- 1,4-dione) 7.75-7.86 (m, 2 H) 8.13-8.26 (m, 2 H). HPLC 37%, Rτ= 1.58 min (System A, 5-60% MeCN over 3 min). MS (ESI+) for C12H17N3OS m/z 252 (M+H)+.
Comparative Example 4 (BVT056635) 4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid Method K
To phtalimide ( 8.6 g, 58.2 mmol) and 4-aminobutyric acid (6.0g, 58.2 mmol) was 70 mL toluene added. The reaction mixture was heated to reflux and the fonned water was removed using a Dean-Stark apparatus. The reaction mixture was cooled to 10 °C after 3 h and the precipitate was filter off. The crystals were washed with pentane (40 mL) and water (20 mL) and were then dried under reduced pressure over night to afford 11. Ig, 81 % yield.
1H NMR (270 MHz, METHANOL-D4) δ ppm 1.95 (m, 2 H) 2.35 (t, J=7.18 Hz, 2 H) 3.72 (t, J=6.68 Hz, 2 H) 7.81 (m, 4 H). HPLC 96% Rτ=1.51 (System A. 10-97% MeCN over 3 min), 98% Rτ=1.39 (System B. 10-97% MeCN over 3 min). MS (ESI+) for Cι2HnNO4 m/z 234 (M+H)+.
Comparative Example 5 (BVT063226)
2-bromo-4-(l ,3-dioxo- 1 ,3-dihydro-2H-isoindol-2-yl)butanoic acid 4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid (ll.Og, 47.2mmol) was dissolved in thionyl chloride (50 mL) and the reaction mixture was heated to reflux for 2h. Bromine (2.7 mL 51.9mmol) was added over 6h using a syring pump under reflux. The reaction mixture was refluxed overnight. The reaction mixture was then cooled to rt and the solvent was removed under reduced pressure. The crude product was used without further purifications.
1H NMR (270 MHz, METHANOL-D4) δ ppm 2.22-2.33 (m, 1 H) 241-2.56 (m, 1 H) 3.84 (t, J=6.68 Hz, 1 H) 4.37 (t, J=7.05 Hz, 1 H) 7.75-7.91 (m, 4 H). HPLC 95% Rτ=1.80 (System A. 10-97% MeCN over 3 min), 96% Rτ=1.69 (System B. 10-97% MeCN over 3 min). MS (ESI+) for C12H10BrNO4 m/z 314 (M+H)+.
Comparative Example 6 (BVT063218) 3 -bromopynolidin-2-one 2-bromo-4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid (47.2 mmol) was dissolved in 47% HBr (aq.) and the reaction mixture was heated to reflux for 12 h. The reaction mixture was then cooled to 10 °C, the precipitate was filtered off and the solvent was removed from the filtrate under reduced pressure. The crude product was dissolved in MeOH and was shaken with resin bound tosyl acid (97. Og, 146g/mmol) over night. The resin was washed several times with 2.0M NH3 in MeOH to release the product. The solvent was removed under reduced pressure to afford the product in 59% yield (4.55g) from 4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid.
1H NMR (270 MHz, METHANOL-D4) δ ppm 2.29-2.39 (m, 2 H) 2.71 (td, J=14.78, 7.55 Hz, 1 H) 3.36 (ddd, J=10.39, 7.67, 2.72 Hz, 1 H) 344-3.54 (m, 1 H) 4.44 (dd, J=7.18, 2.97 Hz, 1 H). HPLC 100% Rτ=0.66 (System A. 5-60% MeCN over 3 min), 100% Rτ=0.89 (System B. 5-60% MeCN over 3 min). MS (ESI+) for C4H6BrNO m/z 164 (M+H)+.
Example 285 (BVT063224)
5-(2-aminoethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one
N-cyclohexylthiourea (0.8g, 3.3mmol) and 3-bromopynolidin-2-one (0.54 g, 3.3mmol) were dissolved in acetone and the reaction mixture was heated to reflux over night. The reaction mixture was cooled to rt and the solvent was removed under reduced pressure. Purification using preparative HPLC (x-x% MeCΝ in H2O over 10 min followed by 100% MeCΝ for 5 min) afforded the TFA-salt of the product in 34% yield, 040g. !H NMR (270 MHz, METHANOL-D4) δ ppm 1.15-1.50 (m, 5 H) 1.60-1.73 (m, 1 H) 1.71- 1.88 (m, 2 H) 1.92-2.03 (m, 2 H) 2.12-2.26 (m, 1 H) 2.27-244 (m, 1 H) 2.93-3.08 (m, 1 H) 3.10-3.22 (m, 1 H) 3.81-3.94 (m, 1 H) 4.37-448 (m, 1 H). HPLC 100% Rτ=0.95 (System A. 10-97% MeCN over 3 min), 100% Rτ=1.17 (System B. 10-97% MeCN over 3 min). MS (ESI+) for d ιH,9N3OS m/z 242 (M+H)+.
Synthesis of compounds of type 2
Comparative Example 7 (BVT.51047) N-Bicyclo[2.2. l]hept-5-en-2-ylthiourea Method A
5-Isothiocyanatobicyclo[2.2.1]hept-2-ene (10.5 g, 69.43 mmol) was stined in 2 M ammonia in ethanol (170 mL, 345 mmol) for 18 h. The reaction flask was evaporated until viscous oil. DCM was added and the obtained crystals were collected and dried. This gave 3.13 g of the title compound. Yield 30%, 95% pure. An additional 4.74 g was obtained by recrystallisation of the mother liquor. Totally 7.87 g, yield 68%. 1H ΝMR (270 MHz, CHLOROFORM-D) δ ppm 144-1.36 (m, IH) 1.53-147 (m, IH) 1.62-1.59 (m, IH) 1.77- 1.70 (m, IH) 2.99-2.90 (m, 2H) 3.30-3.20 (m, IH) 5.95-5.80 (br.s, 2H, Ν-H) 6.04-6.03 (m, IH) 6.22-6.20 (m, IH) 6.54 (br. S, IH, Ν-H). MS (ESI+) for C8Hι2Ν2S m/z 169 (M+H)+.
Example 286 (BVT.51359
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-bromoethyl)-l,3-thiazol-4(5H)-one Method I 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one (0.5 g, 2 mmol) and triphenylphosphine dibromide (2.11 g, 5 mmol) was dissolved in DCM (200 mL) and stined at RT for 16 h. The reaction mixture was washed with water and dried (MgSO4) the solvent was evaporated and the obtained solid crude product was purified by flash chromatography using MeCN as eluent. The first fraction contained the product. Got 0.47 g of the desired product, yield 74%, 98% pure. 1H NMR (270 MHz, DMSO-D6) δ ppm 1.62-141 (m, 4H) 2.20-2.15 (m, IH) 2.61-2.56 (m, IH) 2.90-2.80 (m, 2H) 3.65-3.57 (m, 2H) 3.78-3.70 (m, IH) 4.31-4.25 (m, IH) 6.11- 6.08 (m, IH) 6.23-6.20 (m, IH) 9. 37 (br.d, J= 6.93 Hz, 1 H, N-H). MS (ESI+) for C12Hι5BrN2OS m/z 315 (M+H)+. Comparative Example 8 (BVT.59513)
N-[(lR,2R,3R,5»S)-2,6,6-Trimethylbicyclo[3.1.1]hept-3-yl]thiourea Method B To (lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-ylamine (547 μL, 3.26 mmol) was added ethyl isothiocyanatidocarbonate (385 μL, 3.26 mmol) and the mixture was stined for 5 min until which a yellow solid had been formed. After addition of 5 M ΝaOH (aq) (8 mL) the reaction was stined at 70 °C for 6 h. Water (20 mL) and ethyl acetate (25 mL) were added, and the phases were separated. The water phase was extracted with ethyl acetate (5 mL) and the combined organic phases were dried (MgSO4). After evaporation of the solvent and drying in vacuo, the product was obtained as a white solid (615 mg, 89% yield)
1H ΝMR (400 MHz, CHLOROFORM-D) δ ppm 0.89 (d, J= 10.0 Hz, 1 H) 1.00 (s br, 3 H) 1.13 (d, J= 7.2 Hz, 3 H) 1.20 (s, 3 H) 147-1.80 (m, 1 H) 1.82 (m, 1 H) 1.87-2.00 (m, 2 H) 2.39 (m, 1 H) 2.57 (s br, 1 H) 3.59 (s br, 0.5 H) 4.65 (s br, 0.5 H) 6.07, (s, 2 H) 6.61 (s br, 0.5 H) 6.86 (s br, 0.5 H). MS (ESI+) for CnH20Ν2S m/z 213 (M+H)+.
Example 287 2-(bicyclo[2.2.1]hept-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one Method E
To N-bicyclo[2.2.1]hept-2-ylthiourea (2.003 g, 11.77 mmol) acetone (7ml) and alpha- bromo-gamma-butyrolactone (974ul, 11.75 mmol) was added the reaction mixture was refluxed at 70°C for 20 h. The solvent was evaporated under reduced pressure. Saturated NaHCO3 was added and the product was extracted with DCM (3x ml). The organic phases were combined and washed with brine, dried over MgSO4. The solvent was evaporated under reduced pressure. The residue was dissolved in ethylacetate (30 ml) and the organic phase was washed with IM HCl (2+30 ml) and then with brine (30 ml). The water phase was made basic pH 10 using IM NaOH, and was then extracted with ethylacetate (3x100ml) washed with brine, dried over MgSO4. The solvent was evaporated under reduced pressure to give white crystals (1.7647 g, 59 %) of the title compound.
1H NMR (0307dd031, F12091003h): (270 MHz, CHLOROFORM-D) δ ppm 1.09-1.25 (m, 5 H) 1.77-1.79 (m, 2 H) 1.98-2.10 (m, 2 H) 2.32-248 (m, 4 H) 3.31-3.35 (m, 1 H) 3.71- 3.85 (m, 3 H) 4.19-4.25 (m, 1 H). MS (ESI+) for C12 Hl8 N2O2S m/z 255 (M+H)+. Synthesis of compounds of type 3
Comparative Example 9 (BVT.51047 N-Bicyclo[2.2. l]hept-5-en-2-ylthiourea Method A
5-Isothiocyanatobicyclo[2.2.1]hept-2-ene (10.5 g, 69.43 mmol) was stined in 2 M ammonia in ethanol (170 mL, 345 mmol) for 18 h. The reaction flask was evaporated until viscous oil. DCM was added and the obtained crystals were collected and dried. This gave 3.13 g of the title compound. Yield 30%, 95% pure. An additional 4.74 g was obtained by recrystallisation of the mother liquor. Totally 7.87 g, yield 68%. Η NMR (270 MHz, CHLOROFORM-D) δ ppm 144-1.36 (m, IH) 1.53-147 (m, IH) 1.62-1.59 (m, IH) 1.77-1.70 (m, IH) 2.99-2.90 (m, 2H) 3.30-3.20 (m, IH) 5.95-5.80 (br.s, 2H, N-H) 6.04-6.03 (m, IH) 6.22-6.20 (m, IH) 6.54 (br. S, IH, N-H). MS (ESI+) for C8Hι2N2S m/z 169 (M+H)+.
Example 288 (BVT47509)
[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetic acid
Method C N-Bicyclo[2.2.1]hept-5-en-2-ylthiourea (1.00 g, 5.94 mmol) and maleic anhydride (0.58 g,
5.94 mmol) were heated to reflux in acetone for 5 h, yielding a white emulsion.
Evaporation in vacuo afforded 1.58 g of a white solid. The product was triturated with
DCM, collected on a filter and air-dried giving 1.43 g (91%) of a white powder: Mp 232
°C. Η ΝMR (400 MHz, DMSO-D6) δ ppm 1.41-1.59 (m, 4H) 2.58-2.67 (m, IH) 2.79- 2.86 (m, 2H) 3.00-3.09 (m, IH) 3.71-3.77 (m, IH) 4.27-4.34 (m, IH) 6.08 (dd, J7=5.27,
J2=3.07 Hz, IH) 6.19-6.23 (m, IH) 9.28 (d, J=6.78 Hz, ΝH) 12.38 (br s, OH). MS (EI+) for Cι2H14Ν2O3S m/z 267.2 (M+H)+.
Fwther miscellaneous examples
Example 289 (BVT063338)
5-[2-(3,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-piperidin- 1 -yl- 1 ,3-thiazol-4(5H)-one
Prepared according to method D.
50mg, yield 35%. 1H NMR (400 MHz, CDC13) δ ppm 1.67 (s, 6 H), 1.94 (m, 2 H), 2.68 (s, 2 H), 2.83 (dd, J=17.1, 11.7 Hz, 1 H), 3.43 (s, 2 H), 3.57 (d, J=14.2 Hz, 1 H), 3.69 (m, 1 H), 3.83 (m, 3 H), 4.47 (dd, J=l 1.7, 2.4 Hz, 1 H), 7.12 (m, 4 H). MS (ES+) m/z 358 (M+H+).
Example 290 (BVT067662)
5-(2-moφholin-4-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3-thiazol- 4(5H)-one
Prepared according to method D. 5mg, yield 9%. 1H NMR (400 MHz, CDC13) δ ppm 1.10 (s, 6 H), 1.18 (d, J=8.1 Hz, 6 H), 2.13 (s, 1 H), 2.75 (dd, J=17.1, 11.7 Hz, 1 H), 3.38 - 3.76 (m, 9 H), 4.42 (dd, J=11.8, 3.1 Hz, 1 H). MS (ES+) m z 340 (M+H+).
Example 291 (BVT067664) N-[(2-{[(lS)-l-cyclohexylethyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)methyl]-2- methoxybenzamide
Prepared according to method T.
2 mg, yield 4%.
Η NMR (400 MHz, CDC13) δ ppm 0.73 - 1.20 (m, 6 H), 1.27 (dd, J=33.0, 6.6 Hz, 3 H), 1.36 - 1.82 (m, 5 H), 3.17 - 3.30 (m, 1 H), 3.97 (d, J=34 Hz, 3 H), 4.12 - 4.25 (m, 1 H),
4.27 - 4.37 (m, 1 H), 4.37 - 4.45 (m, 1 H), 6.99 (dd, J=8.2, 3.1 Hz, 1 H), 7.08 (dt, J=7.3,
3.2 Hz, 1 H), 7.43 - 7.54 (m, 1 H), 8.13 (dt, J=6.9, 1.6 Hz, 1 H). MS (ES+) m/z 390
(M+H+).
Example 292 (BVT06767)
2-(cyclooctylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)-one
Prepared according to method D.
28 mg, yield 43%.
1H NMR (400 MHz, CDC13) δ ppm 1.41 - 1.70 (m, 8 H), 1.69 - 1.83 (m, 2 H), 1.83 - 1.96 (m, 4 H), 2.76 (dd, J=17.0, 12.1 Hz, 1 H), 3.38 - 3.76 (m, 10 H), 442 (dd, J=12.1, 3.0 Hz,
1 H). MS (ES+) m/z 354 (M+H+).
Example 293 (BVT059380C) 2-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- cycloheptylacetamide hydrochloride Prepared according to method D.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.29 (m, 19 H) 2.36 (d, J=9.15 Hz, 1 H) 2.77 (m, 1 H) 3.28 (m, 1 H) 3.75 (m, 1 H) 4.00 (m, 3 H) 4.36 (m, 1 H). MS (EI+) for Cι9H29N3O2S m/z 364 (M+H)+.
Example 294 (BVT067663)
N-[(2-{[(lS)-l-cyclohexylethyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)methyl]-2- fluorobenzamide
Prepared according to method T.
7mg, yield 15%.
1H NMR (400 MHz, CDC13) δ ppm 0.81 - 1.24 (m, 6 H), 1.30 (dd, J=13.7, 6.6 Hz, 3 H),
1.46 - 1.82 (m, 5 H), 3.20 - 3.31 (m, 1 H), 3.99 - 4.28 (m, 2 H), 4.41 - 4.48 (m, 1 H), 7.14 (dd, J=l 1.8, 8.4 Hz, 1 H), 7.24 - 7.31 (m, 1 H), 7.51 (q, J=6.5 Hz, 1 H), 8.03 (td, J=7.8, 1.7
Hz, 1 H). MS (ES+) m/z 378 (M+H+).
Example 295 (BVT070752)
2-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5-dihydro-l,3-thiazol- 5-yl}ethyl)benzamide
Prepared according to method K.
13 mg, yield 16%.
Η NMR (400 MHz, CDC13) δ ppm 1.09 (d, J=4.9 Hz, 6 H), 1.16 (s, 6 H), 2.14 (s, 1 H),
2.16 - 2.28 (m, 1 H), 247 - 2.59 (m, 1 H), 3.59 - 3.70 (m, 1 H), 3.81 - 3.92 (m, 1 H), 4.29 (dd, J=9.6, 4.3 Hz, 1 H), 6.98 - 7.08 (m, 1 H), 7.14 (dd, J=12.2, 8.3 Hz, 1 H), 7.26 - 7.30
(m, 1 H), 746 - 7.54 (m, 1 H), 8.05 (dt, J=7.9, 1.8 Hz, 1 H). MS (ES+) m z 378 (M+H+).
Example 296 (BVT059139)
2-(l-adamantylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one
Prepared according to method D. 13mg, yield 10%. Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.68 (m, 5 H) 2.11 (m, 9 H) 2.80 (m, 3 H) 3.65 (m, 2 H) 3.87 (m, J=5.69 Hz, 1 H) 4.42 (d, J=12.12 Hz, 1 H) 4.58 (m, 1 H) 4.72 (d, J=6.19 Hz, 1 H) 7.11 (m, 4 H). MS (EI+) for C24H29N3O2S m/z 424 (M+H)+.
Example 297 (BVT059406C)
2-[2-(bicyclo[2.2. l]hept-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(2-chloro-6- fluorobenzyl)acetamide hydrochloride Prepared according to method D.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 1.17 (m, 2 H) 1.33 (d, J=10.14 Hz, 1 H) 1.54 (m, J=30.19 Hz, 5 H) 1.85 (m, 1 H) 2.40 (m, 2 H) 2.91 (s, 1 H) 3.40 (m, 1 H) 3.54 (m, J=14.35 Hz, 1 H) 4.36 (m, 1 H) 4.59 (m, 2 H) 6.97 (m, 1 H) 7.17 (m, 2 H) 7.76 (s, 1 H). MS (EI+) for Cι9H21ClιF1N3O2S m/z 410/412 (M+H)+.
Example 298 (BVT059509) 2-(cycloheptylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one
Prepared according to method D.
25mg, yield 16%.
MS (EI+) for C2ιH27N3O2S m/z 387 (M+H)+.
Example 299 (BVT067665)
2-(cyclooctylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)- one
Prepared according to method D. 16mg, yield 22%.
Η NMR (400 MHz, CDC13) δ ppm 1.42 - 2.11 (m, 16 H), 2.61 - 2.88 (m, 2 H), 2.99 (dd,
J=17.1, 12.0 Hz, 1 H), 3.48 - 3.74 (m, 3 H), 3.93 - 4.11 (m, 1 H), 4.33 - 4.54 (m, 1 H), 6.95
- 7.24 (m, J=60.3 Hz, 4 H). MS (ES+) m/z 400 (M+H+).
Example 300 (BVT067669)
N-cyclohexyl-2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide
Prepared according to method D. ll mg, yield 16%.
!H NMR (400 MHz, CDC13) δ ppm 1.14 (t, J=7.0 Hz, 3 H), 1.26 - 2.01 (m, 24 H), 2.80 (dd, J=16.7, 12.3 Hz, 1 H), 3.18 - 3.47 (m, 3 H), 3.47 - 3.64 (m, 2 H), 4.44 (ddd, J=11.8, 8.0, 3.2 Hz, 1 H), 8.37 (s, 1 H). MS (ES+) m/z 394 (M+H+).
Example 301 (BVT059405C)
5-(2-azepan-l-yl-2-oxoethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-4(5H)-one hydrochloride
Prepared according to method D. 13C NMR (67.5 MHz, CHLOROFORM-D) δ ppm 26.19, 26.91, 27.26, 27.40, 28.09, 28.74, 35.80, 36.13, 36.77, 38.91, 38.97, 42.50, 4640, 48.06, 60.92, 168.21, 172.01, 173.93. MS (EI+) for Cι8H27N3O2S m/z 350 (M+H)+.
Example 302 (BVT067918) N-cyclohexyl-N-ethyl-2- {4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5-dihydro-
1 ,3-thiazol-5-yl} acetamide
Prepared according to method D.
5 mg, yield 11%.
1H NMR (400 MHz, CDC13) δ ppm 1.07 (d, J=3.2 Hz, 6 H), 1.10 - 1.22 (m, 9 H), 1.23 - 1.55 (m, 4 H), 1.58 - 1.88 (m, 5 H), 2.10 (s, 1 H), 2.67 - 2.80 (m, 1 H), 3.17 - 3.28 (m, 2
H), 3.29 - 3.42 (m, 1 H), 3.45 - 3.56 (m, 1 H), 4.33 - 4.44 (m, 1 H). MS (ES+) m/z 380
(M+H ).
Example 303 (BVT073837) 2-chloro-N- { [2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]methyl} -6- fluorobenzamide
Prepared according to method T.
3 mg, yield 5%.
1H NMR (400 MHz, CDC13) δ ppm 1.45 - 1.78 (m, 11 H), 1.80 - 2.00 (m, 3 H), 3.53 - 3.64 (m, 1 H), 3.95 - 4.18 (m, 2 H), 4.32 - 4.37 (m, J=6.2, 4.5 Hz, 1 H), 4.42 (dd, J=6.0, 4.5 Hz,
1 H), 6.97 - 7.06 (m, 1 H), 7.14 - 7.23 (m, 1 H), 7.27 - 7.42 (m, 1 H). MS (ES+) m/z 412
(M+H4). Example 304 (BVT067917)
5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3- thiazol-4(5H)-one Prepared according to method D. 7 mg, yield 7%.
Η NMR (400 MHz, CDC13) δ ppm 0.96 (d, J=6.3 Hz, 3 H), 1.06 - 1.14 (m, 7 H), 1.14 - 1.25 (m, 7 H), 1.54 - 1.81 (m, 3 H), 2.13 (d, J=6.6 Hz, 1 H), 2.59 - 2.83 (m, 2 H), 3.05 (q, J=134 Hz, 1 H), 3.52 (dd, J=17.1, 2.9 Hz, 1 H), 3.69 (d, J=12.7 Hz, 1 H), 4.35 - 4.54 (m, 2 H). MS (ES+) m/z 352 (M+H+).
Example 305 (BVT073920)
2-chloro-N-{[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]methyl}-6- fluorobenzamide Prepared according to method T.
7mg, yield 7%>.
Η NMR (400 MHz, CDC13) δ ppm 1.37 - 1.81 (m, 10 H), 1.83 - 2.04 (m, 2 H), 342 - 3.55
(m, 1 H), 3.94 - 4.09 (m, 2 H), 4.28 - 445 (m, 1 H), 7.01 (dt, J=84, 1.7 Hz, 1 H), 7.18 (d,
J=8.1 Hz, 1 H), 7.26 - 7.34 (m, 1 H). MS (ES+) m/z 398 (M+H+).
Example 306 (BVT067789)
5-(2-anilinoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3-thiazol-4(5H)-one
Prepared according to method H.
16mg, yield 17%. 1H NMR (400 MHz, CDC13) δ ppm 1.02 (d, J=26.1 Hz, 6 H), 1.09 (d, J=7.8 Hz, 6 H), 2.03
(s, 1 H) 2.11 - 2.24 (m, 1 H), 2.84 (dd, J=13.7, 7.1 Hz, 1 H, 3.94 - 4.08 (m, 2 H), 4.37 (dd,
J=9.5, 6.1 Hz, 1 H), 4.80 (s, 1 H), 7.23 - 7.28 (m, 1 H), 7.36 - 7.45 (m, 2 H,) 7.54 (d, J=7.6
Hz, 2 H). MS (ES+) m/z 332 (M+H+).
Example 307 (BVT070751)
2-chloro-6-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5-dihydro- l,3-thiazol-5-yl}ethyl)benzamide
Prepared according to method K. 3mg, yield 3%.
1H NMR (400 MHz, CDC13) δ ppm 1.11 (d, J=7.3 Hz, 6 H), 1.20 (s, 6 H), 2.17 (s, 1 H), 2.18 - 2.27 (m, 1 H), 245 - 2.56 (m, 1 H), 3.49 - 3.59 (m, 1 H), 3.89 - 4.00 (m, 1 H), 4.38 (dd, J=9.8, 4.9 Hz, 1 H), 6.22 - 6.31 (m, 1 H), 7.05 (t, J=8.5 Hz, 1 H), 7.20 - 7.26 (m, 1 H), 7.28 - 7.39 (m, 1 H). MS (ES+) m/z 412 (M+H ).
Example 308 (BVT067670)
5-(2-azepan-l-yl-2-oxoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one Prepared according to method D. 23mg, yield 35%.
1H NMR (400 MHz, CDC13) ppm 1.41 - 1.67 (m, 12 H), 1.67 - 1.81 (m, J=5.1 Hz, 6 H), 1.83 - 1.96 (m, 4 H), 2.79 (dd, J=17.0, 12.1 Hz, 1 H), 3.33 - 3.66 (m, 6 H), 4.43 (dd, J=12.0, 3.2 Hz, 1 H), 10.25 - 11.05 (m, 1 H). MS (ES+) m/z 366 (M+H+).
Example 309 (BVT067954)
2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-6- fluorobenzamide
Prepared according to method K.
45 mg, yield 53%. 1H NMR (400 MHz, DMSO-d6) δ 147-1.82 (m, 15 H), 2.24-2.33 (m, 1 H), 3.27 (m, 1 H),
3.39 (m, 1 H), 4.02 (m, 1 H), 4.20 (m, 1 H), 7.26-7.31 (m, 1 H), 7.36 (m, 1 H), 744-749
(m, 1 H), 8.82 (m, 1 H), 9.19 (d, J= 7.6 Hz, 1 H).
MS (ESI+) for C20H25C1FN3O2S m/z 426 (M+H)+.
Example 310 (BVT067955
2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } benzenesulfonamide
Prepared according to method K using a sulfonyl chloride.
48 mg, yield 54%. 1H NMR (400 MHz, DMSO- ) δ 148-1.77 (m, 15 H), 2.10-2.22 (m, 1 H), 2.91 (m, 2 H),
3.98 (m, 1 H), 4.13 (m, 1 H), 7.51-7.68 (m, 3 H), 7.94-8.03 (m, 2 H), 9.14 (d, J= 7.2 Hz,
I H).
MS (ESI+) for Cι9H26ClN3O3S2 m/z 444 (M+H)+. Example 311 (BVT056890)
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl 2,4- dichlorobenzoate Prepared according to method F. 5mg, yield 4%.
1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.21-145 (m, 1 H) 1.52-1.74 (m, 2 H) 1.82-1.93 (m, 1 H) 2.17-2.37 (m, 1 H) 2.64-2.76 (m, 1 H) 2.88-3.02 (m, 2 H) 3.30-3.36 (m,
1 H) 4.20-4.30 (m, 1 H) 442-4.57 (m, 2 H) 5.97-6.06 (m, 1 H) 6.22-6.27 (m, 1 H) 7.25- 7.35 (m, 1 H) 7.47 (d, J=1.98 Hz, 1 H) 7.82 (dd, J=2.16, 8.37 Hz, 1 H).
MS m/z: (M+H) 425.
Example 312 (BVT067956)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzenesulfonamide
Prepared according to method K using a sulfonyl chloride.
54 mg, yield 60%.
1H NMR (400 MHz, DMSO- 6) δ 145-1.76 (m, 15 H), 2.15-2.25 (m, 1 H), 2.95-3.08 (m,
2 H), 3.99 (m, 1 H), 4.14 (m, 1 H), 7.28 (m, 2 H), 7.70 (m, 1 H), 8.36 (s br., 1 H), 9.16 (d, J = 74 Hz, 1 H).
MS (ESI+) for C19H25F2N3O3S2 m/z 446 (M+H)+.
Example 313 (BVT070765)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzamide
Prepared according to method K.
26mg, yield 69%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 - 1.67 (m, 8 H) 1.70 - 1.81 (m, 2 H)
1.84 - 1.96 (m, 4 H) 2.10 - 2.22 (m, 1 H) 2.43 - 2.56 (m, 1 H) 3.51 - 3.63 (m, 2 H) 3.82 - 3.94 (m, 1 H) 4.28 - 4.35 (m, 1 H) 6.89 - 6.98 (m, 2 H) 7.31 - 7.42 (m, 1 H) MS m/z 410
(M+H)+
Example 314 (BVT051005) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-4(5H)- one
Prepared according to method G. 13 mg, yield 15 %. MS (E ) m/z 363.
Example 315 (BVT070764)
2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}benzamide Prepared according to method K. 16mg, yield 44%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.47 - 1.68 (m, 8 H) 1.71 - 1.83 (m, 2 H) 1.85 - 1.97 (m, 4 H) 2.12 - 2.27 (m, 1 H) 244 - 2.58 (m, 1 H) 3.52 - 3.63 (m, 2 H) 3.80 -
3.95 (m, 1 H) 4.29 - 4.38 (m, 1 H) 6.64 - 6.74 (m, 1 H) 7.28 - 746 (m, 2 H) 7.58 - 7.66 (m, 1 H) MS m z 408 (M+H)+
Example 316 (BVT067659)
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one
Prepared according to method D.
60mg, yield 38%. IH NMR (400 MHz, DMSO-D6) δ ppm 0.89 - 1.20 (m, 2 H) 1.33 - 1.80 (m, 14 H) 2.60 -
2.76 (m, 2 H) 2.82 - 2.96 (m, 1 H) 3.10 - 3.26 (m, J=1.22 Hz, 2 H) 3.68 - 3.78 (m, 2 H)
3.96 (s, 1 H) 4.12 - 4.24 (m, 1 H) 4.24 - 4.35 (m, 1 H) 7.11 - 7.21 (m, J=7.08 Hz, 3 H) 7.22 - 7.31 (m, 2 H) 9.08 - 9.23 (m, 1 H).
M/S m/z 428 (M+H)+
Example 317 (BVT059331)
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-
2,4-dichlorobenzamide
Prepared according to method K. l lmg, yield 12 %. lH NMR (270 MHz, METHANOL-D4) δ ppm 1.36-1.71 (m, 4 H) 1.96-2.05 (m, 1 H)
2.21-2.39 (m, 1 H) 2.80-2.83 (m, 2 H) 3.31-3.55 (m, 2 H) 3.68-3.72
(m, 1 H) 4.27-4.32 (m, 1 H) 5.96-6.02 (m, 1 H) 6.10-6.14 (m,l H) 7.29-744 (m, 3 H). MS (ESI+) for Cl9 H19 Cl2 N3 O2 S m/z 424 (M+H)+.
Example 318 (BVT049923)
2-chlorophenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate
Prepared according to method L. 130 mg, yield 46%. Mp 211 °C.
1H NMR (400 MHz, CDC13) δ 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (EI+) m/z 377.2.
Example 319 (BVT059210)
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- chlorobenzamide
Prepared according to method K.
14 mg, yield 36%. 1H NMR (270 MHz, CHLOROFORM-D) δ 1.61-1.85 (m, 4 H) 2.10-2.28 (m, 1 H) 2.43-
2.60 (m, 1 H) 2.99-3.08 (m, 2 H) 3.38 (dd, J=6.93, 3.46 Hz, 1 H) 349-3.65 (m, 1 H) 3.86-
4.01 (m, 1 H) 4.35-446 (m, 1 H) 6.06 (dd, J=544, 2.97 Hz, 1 H) 6.29 (dd, J=5.69, 2.97
Hz, 1 H) 6.75 (t, J=5.07 Hz, 1 H) 7.29-744 (m, 4 H) 7.57-7.63 (m, 1 H).
MS (ESI+) for C19H20C1N3O2S m/z 390 (M+H)+
Example 320 (BVT070733)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5-methyl-3- phenylisoxazole-4-carboxamide
Prepared according to method K. 23mg, yield 57%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 - 1.69 (m, 8 H) 1.73 - 1.83 (m, 2 H)
1.87 - 2.04 (m, 5 H) 2.19 - 2.30 (m, 1 H) 2.69 - 2.74 (m, 3 H) 3.23 - 3.32 (m, 1 H) 3.52 -
3.70 (m, 2 H) 4.11 - 4.17 (m, 1 H) 7.51 - 7.60 (m, 5 H). MS m/z 455 (M+H)+.
Example 321 (BVT067922
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)- one
Prepared according to method D.
19mg, yield 30%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 12.32 - 14.24 (m, 1 H), 7.27 - 7.34 (m, 2
H), 7.19 - 7.26 (m, 1 H), 7.10 - 7.17 (m, 2 H), 448 - 4.60 (m, 1 H), 4.43 (dd, J=11.72, 3.30 Hz, 0.5 H), 4.40 (dd, J=11.72, 3.30 Hz, 0.5 H), 3.65 - 3.78 (m, 1 H), 3.54 (dd, J=16.97,
3.54 Hz, 0.5 H), 3.52 (dd, J=16.97, 3.54 Hz, 0.51 H), 3.22 (t, J=7.26 Hz, 2 H), 2.94 - 3.10
(m, 1 H), 2.77 (dd, J=12.02, 6.16 Hz, 0.5 H), 2.73 (dd, J=12.21, 6.47 Hz, 0.5 H), 2.58 (d,
J=6.96 Hz, 2 H), 2.52 - 2.67 (m, 1 H), 1.62 - 1.88 (m, 9 H), 1.08 - 1.39 (m, 5 H), 0.89 -
1.10 (m, 2 H) MS m/z 428 (M+H)+
Example 322 (BVT051121) methyl 4- {2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethoxy}-3-chlorobenzoate
Prepared according to method G. MS (EI+) m/z 421.
Example 323 (BVT050180) phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetate Prepared according to method L. 48mg, yield 37%>.
1H NMR (400 MHz, CDC13) δ 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H) 1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (EI+) m/z 343.0.
Example 324 (BVT059211)
N- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2- bromo-5-methoxybenzamide
Prepared according to method K. 23.7 mg, yield 52%.
1H NMR (270 MHz, CHLOROFORM-D) δ 1.67 (s, 2 H) 1.71-1.85 (m, 2 H) 2.07-2.25 (m, 1 H) 245-2.62 (m, 1 H) 3.03 (d, J=841 Hz, 2 H) 3.38 (dd, J=7.18, 346 Hz, 1 H) 343-3.60 (m, 1 H) 3.79 (s, 3 H) 3.84-4.00 (m, 1 H) 4.42-4.52 (m, 1 H) 6.06 (dd, J=5.20, 3.22 Hz, 1 H) 6.28 (dd, J=5.57, 2.85 Hz, 1 H) 6.61 (s, 1 H) 6.84 (dd, J=8.78, 2.60 Hz, 1 H) 7.03 (d, J=2.97 Hz, 1 H) 7.45 (d, J=8.91 Hz, 1 H). MS (ESI+) for C20H22BrN3O3S m/z 466 (M+H)+
Example 325 (BVT070734) N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- phenoxyacetamide
Prepared according to method K.
31mg, yield 83%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.49 - 1.68 (m, 8 H) 1.71 - 1.81 (m, 2 H) 1.87 - 1.94 (m, 4 H) 2.03 - 2.14 (m, 1 H) 240 - 2.50 (m, 1 H) 3.42 - 3.60 (m, 2 H) 3.67 -
3.78 (m, 1 H) 4.16 - 4.22 (m, 1 H) 448 - 4.52 (m, 2 H) 6.89 - 6.94 (m, 2 H) 7.00 - 7.06 (m,
1 H) 7.28 - 7.35 (m, 2 H) MS m z 404 (M+H)+
Example 326 (BVT067355) 2-(cycloheptylamino)-5-[2-(l-oxa-4-azaspiro[4.5]dec-4-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one
Prepared according to method D.
40mg, yield 25%.
M/S m/z 394 (M+H)+
Example 327 (BVT059330)
N-{2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- fluoro-4-(trifluoromethyl)benzamide
Prepared according to method K. lOmg, yield 11 %.
IH NMR(270 MHz, METHANOL-D4) δ ppm 1.34-71.70 (m, 4 H) 1.95-2.10 (m, 1 H)
2.32-242 (m, 1 H) 2.79-2.80 (m, 2 H) 346-3.55 (m, 2 H) 3.70-3.74 (m, 1 H) 4.23-4.30 (m, 1 H) 5.95-6.00(m, 1 H) 6.10-6.13 (m, 1 H) 747-7.52 (m, 2 H) 7.76-7.82 (m, 1 H). MS (ESI+) for C20 Hi 9 F4 N3 O2 S m/z 442 (M+H)+.
Example 328 (BVT051136) 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]-l,3-thiazol- 4(5H)-one Prepared according to method G.
2 mg, yield
MS (EI+) m/z 377.
Example 329 (BVT067353)
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N-phenylacetamide
Prepared according to method D.
70mg, yield 51%. IH NMR (400 MHz, DMSO-D6) d ppm 0.93 (t, 2 H) 1.25 - 1.64 (m, 11 H) 1.66 - 1.89 (m,
2 H) 2.12 - 2.31 (m, 1 H) 2.71 - 2.85 (m, 2 H) 3.78 - 3.95 (m, 2 H) 4.05 - 4.21 (m, 1 H)
7.20 - 7.50 (m, J=62.26 Hz, 5 H) 9.07 - 9.23 (m, 1 H).
M/S m/z 374 (M+H)+
Example 330 (BVT067656)
N-(2-chloro-6-fluorobenzyl)-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetamide
Prepared according to method K.
80mg, yield 50%. M/S m/z 412 (M+H)+
Example 331 (BVT050205)
2-methoxyphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate Prepared according to method L. 57 mg, yield 41%.
Mp 175-176 °C. 1H NMR (400 MHz, CDC13) δ 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H) 1.97- 2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m, IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31 (m, 3H) 743-746 (m, IH). MS (EI+) m/z 373.0.
Example 332 (BVT067951)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}adamantane-l- carboxamide
Prepared according to method K. 15mg, yield 4%. IH NMR (400 MHz, CHLOROFORM-D) δ ppm 144 - 1.85 (m, 22 H) 1.85 - 1.95 (m, 4 H) 2.01 - 2.15 (m, 4 H) 2.33 - 244 (m, 1 H) 3.34 - 3.44 (m, 1 H) 3.53 - 3.71 (m, 2 H) 4.17 (dd, J=10.01, 4.15 Hz, 1 H). MS m/z 432 (M+H)+.
Example 333 (BVT059374)
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]- 1 ,3-thiazol-
4(5H)-one
Prepared according to method D.
5 mg, yield 5 %. MS (ESI+) m/z 384 (M+H)+.
Example 334 (BVT059209)
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-
2,5-difluorobenzamide 5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-l,3-thiazol-4(577)-one
(0.025 g, 0.101 mmol) was dissolved in a few drops of DMF and Pyridine (2ml). 2,5- difluorobenzoyl chloride (0.053 g,0.302 mmol) was added and the reaction mixture was shaken at room temperature. Additional 2,5-difluorobenzoyl chloride (0.036 g, 0.202 mmol) was added after lh and the reaction mixture was shaken at room temperature over night.
10%) HCl was added and extraction with DCM performed. The organic phase was concentrated under vacuum. Purification was performed using preparative LC-MS. 22mg, yield 56%. 1H NMR (270 MHz, METHANOL-D4) δ 143-1.79 (m, 4 H) 2.07-2.22 (m, 1 H) 2.37-2.52
(m, 1 H) 2.86-3.02 (m, 2 H) 348-3.69 (m, 2 H) 3.78 (dd, J=7.79, 2.85 Hz, 1 H) 4.35-446
(m, 1 H) 6.05-6.12 (m, 1 H) 6.20-6.30 (m, 1 H) 7.18-7.35 (m, 2 H) 742-7.51 (m, 1 H)
MS (ESI+) for Cι9H19F2N3O2S m/z 392 (M+H)+
Example 335 (BVT074258B)
5-(2-anilinoethyl)-2- { [ 1 -(4-chlorophenyl)cyclobutyl]amino} - 1 ,3-thiazol-4(5H)-one hydrobromide
Prepared according to method H. 97 mg, yield 69%.
LH NMR (400 MHz, DMSO- 6) δ 1.89-2.17 (m, 3 H), 2.54-2.75 (m, 5 H), 3.99 (m, 2 H),
5.01 (m, 1 H), 7.23 (t, J= 7.3 Hz, 1 H), 7.39-7.53 (m, 6 H), 7.66 (d, J= 8.1 Hz, 1 H), 8.08
(s br., 1 H), 9.77 (s br, 1 H), 10.88 (s, 1 H).
MS (ESI+) for C21H22ClN3OS m/z 400 (M+H)+.
Example 336 (BVT067360)
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,5- difluorobenzamide
Prepared according to method K. l lmg, yield 16%.
1H NMR (270 MHz, METHANOL-D4) δ ppm 144-1.82 (m, 10 H) 1.93-2.22 (m, 3 H)
2.38-2.53 (m, 1 H) 346-3.69 (m, 2 H) 3.98-4.11 (m, 1 H) 4.35 (dd, J=9.28, 4.08 Hz, 1 H)
7.17-7.35 (m, 2 H) 742-7.50 (m, 1 H).
MS m/z: (M+H) 396.
Example 337 (BVT067354)
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4-methoxyphenyl)-N- methylacetamide
Prepared according to method D. 70mg, yield 47%.
IH NMR (400 MHz, DMSO-D6) d ppm 1.25 - 1.70 (m, 10 H) 1.76 - 1.92 (m, 2 H) 2.16 -
2.38 (m, 2 H) 2.79 - 2.96 (m, 1 H) 3.11 (s, 3 H) 3.77 (s, 3 H) 4.12 - 4.23 (m, 1 H) 6.92 -
7.07 (m, 2 H) 7.20 - 7.32 (m, 2 H) 9.08 - 9.21 (m, 1 H). M/S m/z 390 (M+H)+ Example 338 (BVT051120)
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]-l,3-thiazol-4(5H)- one Prepared according to method G MS (EI+) m/z 421.
Example 339 (BVT070727)
4-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}benzamide Prepared according to method K. Yield 19,5mg (52%)
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 145 - 1.68 (m, 8 H) 1.70 - 1.81 (m, 2 H) 1.85 - 1.97 (m, 4 H) 2.14 - 2.25 (m, 1 H) 2.39 - 2.50 (m, 1 H) 3.53 - 3.67 (m, 2 H) 3.74 -
3.84 (m, 1 H) 4.27 - 4.33 (m, 1 H) 7.40 (d, J=8.30 Hz, 2 H) 7.72 (d, J=8.55 Hz, 2 H) MS m z 408 (M+H)+
Example 340 BVT070731
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl} cyclohexanecarboxamide Prepared according to method K.
23mg, yield 65%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.18 - 1.32 (m, 3 H) 1.34 - 1.45 (m, 2 H)
1.50 - 1.71 (m, 9 H) 1.72 - 1.96 (m, 10 H) 2.03 - 2.19 (m, 2 H) 2.33 - 2.43 (m, 1 H) 3.33 -
343 (m, 1 H) 3.54 - 3.71 (m, 2 H) 4.21 (dd, J=10.01, 4.15 Hz, 1 H) MS m/z 380 (M+H)+
Example 341 (BVT070728)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4-
(trifluoromethyl)benzamide
Prepared according to method K. 14mg, yield 34%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.45 - 1.69 (m, 8 H) 1.70 - 1.83 (m, 2 H)
1.85 - 1.98 (m, 4 H) 2.18 - 2.29 (m, 1 H) 2.39 - 2.50 (m, 1 H) 3.53 - 3.73 (m, 2 H) 3.75 - 3.86 (m, 1 H) 4.29 - 4.36 (m, 1 H) 7.70 (d, J=8.30 Hz, 2 H) 7.90 (d, J=8.06 Hz, 2 H) MS m z 442 (M+H)+
Example 342 (BVT059370) 2-{[3,5-bis(trifluoromethyl)phenyl]amino}-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one
To a suspension of PS-Carbodiimide resin (1.10 mmol/g, 314 mg, 0.345 mmol) in 10% DMF in DCM (4 mL) was added (2-{[3,5-bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5- dihydro-l,3-thiazol-5-yl)acetic acid (100.0 mg, 0.259 mmol) and the mixture was gently shaken for 45 min. After addition of 1,2,3,4-tetrahydroquinoline (22 μL, 0.175 mmol), the mixture was shaken overnight and then filtered with the aid of methanol. The solvent was removed, and the residue was purified by preparative reverse-phase HPLC to give the title compound as an off-white solid. 9 mg, yield 9 %. MS (ESI+) m/z 502 (M+H)+.
Example 343 (BVT074103)
2-anilino-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one (2-anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)acetic acid (25 mg, 1 eq) was dissolved in DCM (1 mL) and l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC, 29 mg, 1.5 eq), 1-hydroxybenzotriazole hydrate (HOBt, 20 mg, 1.5 eq), and N- methylmoφholine (ΝMM, 44 μL, 4 eq) were added sequentially. After 10 min stining at room temperature isoindoline (13 μL, 1.1 eq) was added and the reaction mixture was stined overnight at room temperature H2O (5 mL) and DCM (5 mL) was added, the organic layer separated on a 1-PS syringe and concentrated. Purified by flashtube DCM- MeOH (14:l). 17 mg, yield 47%.
IH ΝMR (400 MHz, CHLOROFORM-D) δ ppm 2.09 - 245 (m, 2 H), 4.19 - 4.42 (m, 1 H), 4.53 - 4.77 (m, 4 H), 7.01 - 7.22 (m, 7 H), 7.30 - 7.42 (m, 2 H). MS [M+H]+ m/z = 352.
Example 344 (BVT067657
2-(cycloheptylamino)-5-[2-(4-hydroxy-4-phenylpiperidin-l-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one
Prepared according to method D. 30mg, yield 18%. M/S m/z 430 (M+H)+
Example 345 (BNT067923) 2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -Ν,Ν- diethylacetamide
Prepared according to method D.
19mg, yield 39%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 12.44 - 13.74 (m, 1 H), 445 (dd, J=12.15, 3.36 Hz, 1 H), 3.53 (dd, J=16.97, 3.42 Hz, 0.8 H), 3.38 - 346 (m, 2 H), 3.40 (dd,
J=16.72, 3.66 Hz, 0.2 H), 3.33 (q, J=7.20 Hz, 2 H), 3.25 (d, J=647 Hz, 2 H), 2.93 (dd,
J=18.07, 10.74 Hz, 0.2 H), 2.80 (dd, J=16.97, 12.09 Hz, 0.8 H), 1.64 - 1.85 (m, 7 H), 1.24
(t, J=7.20 Hz, 3 H), 1.16 (t, J=7.14 Hz, 3 H), 1.11 - 1.38 (m, 2 H), 0.92 - 1.10 (m, 2 H) MS m/z 326 (M+H)+
Example 346 (BNT070730)
Ν-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,2- dimethylpropanamide
Prepared according to method K. 23mg, yield 70%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.19 - 1.21 (m, 9 H) 1.49 - 1.68 (m, 8 H)
1.72 - 1.83 (m, 2 H) 1.85 - 1.97 (m, 4 H) 2.00 - 2.11 (m, 1 H) 2.34 - 2.44 (m, 1 H) 3.31 -
340 (m, 1 H) 3.54 - 3.73 (m, 2 H) 4.16 - 4.22 (m, 1 H).
MS m/z 354 (M+H)+
Example 347 (BVT067971)
2-anilino-5-(2-azepan- 1 -yl-2-oxoethyl)- 1 ,3-thiazol-4(5H)-one
Prepared according to method D.
22 mg, yield 33%. IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.50 - 1.61 (m, 4 H), 1.64 - 1.78 (m, 4
H), 2.78 (dd, J=17.0, 12.1 Hz, 1 H), 3.30 - 3.61 (m, 5 H), 4.44 (dd, J=l 1.8, 2.8 Hz, 1 H),
7.30 - 7.38 (m, 3 H), 7.39 - 747 (m, 2 H).
MS [M+H]+ m z = 332. Example 348 (BVT050213)
3-moφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetate
Prepared according to method L.
57 mg, yield 41%
Mp 175-176 °C.
Η NMR (400 MHz, CDC13, major tautomer given) δ 1.58-1.60 (m, IH) 1.68-1.72 (m, 2H)
1.97-2.05 (m, IH) 2.97-3.01 (m, 2H) 3.03-3.10 (m, IH) 3.34-3.38 (m, IH) 3.65-3.72 (m,
IH) 444-448 (m, IH) 6.04-6.07 (m, IH) 6.23 (dd, J7=5.52, J2=2.51 Hz, IH) 7.13-7.31
(m, 3H) 743-7.46 (m, IH).
MS (EI+) m/z 373.0.
Example 349 (BVT059442) N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4- cyanobenzamide
Prepared according to method K.
15mg, yield 19 %.
IH NMR (270 MHz, DMSO-D6) δ ppm 1.39-1.59 (m, 6 H) 1.85-1.90 (m, 1 H) 2.26-2.35 (m, 1 H) 2.78-2.85 (m, 2 H) 3.72-3.73 (m, 1 H) 4.18-4.24 (m, 1 H) 6.06-6.21 (m, 2 H) 7.97
(m, 4 H) 8.82-8.84 (m, 1 H) 9.29-9.31 (m,l H).
MS (ESI+) for m/z 381 (M+H)+.
Example 350 (BVT070726) N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -4- methoxybenzamide
Prepared according to method K.
23mg, yield 61%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.45 - 1.68 (m, 9 H) 1.70 - 1.82 (m, 2 H) 1.85 - 1.96 ( , 4 H) 2.15 - 2.24 (m, 1 H) 241 - 2.52 (m, 1 H) 3.53 - 3.66 (m, 2 H) 3.83 -
3.87 (m, 3 H) 4.29 - 4.35 (m, 1 H) 6.93 (d, J=8.79 Hz, 2 H) 7.72 (d, J=8.79 Hz, 2 H).
MS m/z 404 (M+H)+ Example 351 (BVT051309)
2-(bicyclo[2.2.1 ]heρt-5-en-2-ylamino)-5- {2-[(2-chlorobenzyl)oxy]ethyl} - 1 ,3-thiazol- 4(5H)-one
Prepared according to method G. 50 mg, yield 68%.
1H NMR (270 MHz, CHLOROFORM-D) d ppm 1.20-1.29 (m, 1 H) 1.34-140 (m, 1 H) 149-1.63 (m, 2 H) 2.05-2.18 (m, 1 H) 2.33-247 (m, 1 H) 2.58 (br s, 1 H) 2.81 (br s, 1 H) 3.13-3.22 (m, 1 H) 3.76-3.96 (m, 2 H) 4.25-4.38 (m, 1 H) 4.94-5.09 (m, 2 H) 5.99 (dd, J=5.81, 3.09 Hz, 1 H) 6.16 (dd, J=5.69, 2.97 Hz, 1 H) 7.07-7.7.19 (m, 1 H) 7.30-7.38 (m, 1 H) 740-748 (m, 1 H) 7.65-7.75 (m, 1 H). MS m/z: (M+H) 378.
Example 352 (BVT059578)
2-{2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-(4- methylcyclohexyl)acetamide
Prepared according to method D.
3 mg, yield 2 %.
MS (ESI+) m/z 364 (M+H)+.
Example 353 (BVT067464)
2-[(cyclohexylmethyl)amino]-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)-one
Prepared according to method D.
29mg, yield 58%.
IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.98 (m, 2 H) 1.23 (m, 3 H) 1.72 (m, 6 H) 2.81 (m, J=9.00, 6.00 Hz, 1 H) 3.23 (d, J=6.35 Hz, 2 H) 3.44 (m, 2 H) 3.51 (m, 1 H)
3.61 (m, 2 H) 3.71 (m, 4 H) 4.44 (dd, J=11.72, 3.17 Hz, 1 H).
MS m z 340 (M+H)+
Example 354 (BVT067463) 2-(cycloheptylamino)-5-isobutyl- 1 ,3-thiazol-4(5H)-one
(2S)-2-amino-4-methylpentanoic acid (1.0 g, 7.6 mmol) was added to a solution of KBr (2.72 g, 22.9 mmol) in H2SO4 (1.25 M, 8.6 ml) and the reaction mixture was cooled in an ice-bath containing NaCl. NaNU2 (0.53 g, 7.6 mmol) was added portion wise over 30 min and the mixture was stined for 3h while cooling was continued. The mixture was then stined at room temperature for 1.5 h. The reaction mixture was then extracted with EtOAc and the organic phase was dried (Na2SO4) and concentrated in vacuum. This afforded 0.098 g of crude product, which was used in the next step without further purification. 2-bromo-4-methylpentanoic acid (0.030 g, 0.15 mmol) from above and N- cycloheptylthiourea (0.026 g, 0.15 mmol) in acetone (3 ml) were heated with stining to 70 °C for 24 h. The reaction mixture was then concentrated in vacuum. Purification was performed using preparative LC (System A, 40-70% MeCΝ over 5 min). 32 mg, yield 77%.
1H ΝMR (270 MHz, METHAΝOL-D4) δ 0.91-1.04 (m, 6 H) 1.43-1.86 (m, 12 H) 1.92- 2.12 (m, 3 H) 3.95-4.11 (m, 1 H) 4.29-448 (m, 1 H) MS (ESI+) for Cι4H24N2OS m/z 269 (M+H)+
Example 355 (BVT070723)
(5R)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one Prepared using the same procedure as Example 354.
13mg, yield 29%.
Η NMR (270 MHz, CHLOROFORM-D) δ ppm 0.85 - 1.90 (m, 22 H) 1.93 - 2.10 (m, 2 H)
2.14 - 2.30 (m, 1 H) 3.35 - 3.57 (m, 1 H) 4.23 (dd, J=l 1.32, 3.77 Hz, 1 H)
MS (ESI+) for Cι7H28N2OS m/z 309 (M+H)+
Example 356 (BVT070735)
(5S)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one
Prepared using the same procedure as Example 354.
18mg, yield 41%. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 0.87 - 1.86 (m, 22 H) 1.89 - 2.11 (m, 2 H)
2.11 - 2.30 (m, 1 H) 3.34 - 3.60 (m, 1 H) 4.23 (dd, J=l 1.32, 3.77 Hz, 1 H) 8.81 (br.s, 1 H)
MS (ESI+) for C]7H28N2OSm/z 309 (M+H)+
Example 357 (BVT070725) 2-(cyclooctylamino)-5-(4-hydroxybenzyl)- 1 ,3-thiazol-4(5H)-one Prepared using the same procedure as Example 354. 10 mg, yield 15%. 1H NMR (270 MHz, CHLOROFORM-D) δ ppm 1.41 - 1.95 (m, 14 H) 3.07 (dd, J=14.47,
9.65 Hz, 1 H) 343 - 3.59 (m, 2 H) 4.46 (dd, J=9.65, 3.96 Hz, 1 H) 6.81 (d, J=841 Hz, 2 H)
7.08 (d, J=8.41 Hz, 2 H)
MS (ESI+) for Cι8H24N2O2S m/z 333 (M+H)+
Example 358 (BVT067796)
2-(cycloheptylamino)-5-(lH-indol-3-ylmethyl)-l,3-thiazol-4(5H)-one
Prepared using the same procedure as Example 354 from (2S)-2-amino-3-(lH-indol-3- yl)propanoic acid 8mg, yield 19%.
Η NMR (270 MHz, CHLOROFORM-D) δ 1.27 - 1.80 (m, 11 H) 1.84 - 1.99 (m, 1 H) 3.23
- 340 (m, 2 H) 3.76 (dd, J=15.09, 3.46 Hz, 1 H) 4.65 (d, J=9.15, 3.96 Hz, 1 H) 7.10 - 7.28
(m, 3 H) 740 (d, J=7.92 Hz, 1 H) 7.59 (d, J=7.92 Hz, 1 H) 8.26 (s, 1 H)
MS (ESI+) for C19H23N3OS m/z 342 (M+H)+
Example 359 (BVT067868)
2-(cycloheptylamino)-5-(4-hydroxybenzyl)- 1 ,3-thiazol-4(5H)-one
Prepared using the same procedure as Example 354 from (2S)-2-amino-3-(4- hydroxyphenyl)propanoic acid. lOmg, yield 21%.
1H NMR (270 MHz, METHANOL-D4) δ ppm 1.37 - 2.07 (m, 12 H) 2.91 - 3.11 (m, 1 H)
3.32 - 3.43 (m, 1 H) 3.86 - 4.02 (m, 1 H) 448 - 4.66 (m, 1 H) 6.60 - 6.76 (m, 2 H) 6.99 -
7.11 (m, 2 H)
MS (ESI+) for Cι7H22N2O2S ;w/z 319 (M+H)+
Example 360 (BVT063177)
2-(bicyclo[2.2.1]hept-2-ylamino)-5-(4-hydroxybenzyl)-l,3-thiazol-4(5H)-one
Prepared using the same procedure as Example 354 from 2-amino-3-(4- hydroxyphenyl)propanoic acid. 233mg, yield 27 %.
Η NMR (270 MHz, DMSO-D6) δ 1.11 (d, J=9.65 Hz, 3 H) 1.24-1.54 (m, 4 H) 1.56-1.76
(m, 1 H) 2.04-2.27 (m, 2 H) 2.61-2.84 (m, 1 H) 3.26 (dd, J=14.10, 3.96 Hz, 1 H) 3.70 (s, 1 H) 442-4.52 (obscured by HDO peak) (m, 1 H) 6.57-6.72 (m, 2 H) 6.92-7.08 (m, 2 H) 9.07 (d, J=6.19 Hz, 1 H) lH NMR (270 MHz, METHANOL-D4) 1.07-1.62 (m, 7 H) 1.67-1.88 (m, 1 H) 2.07-2.36 (m, 2 H) 2.92-3.11 (m, 1 H) 3.32-344 (partly obscured by MeOD peak) (m, 1 H) 3.64-3.76 (m, 1 H) 4.51-4.68 (m, 1 H) 6.62-6.76 (m, 2 H) 6.99-7.12 (m, 2 H). MS (ESI+) for Cι7H20N2O2S m/z 317 (M+H)+
Example 361 (BVT067403)
2-(cycloheptylamino)-5-(3,4-dihydroxybenzyl)-l,3-thiazol-4(5H)-one Prepared using the same procedure as Example 354 from (2S)-2-amino-3-(3,4- dihydroxyphenyl)propanoic acid.
2mg, yield 4%).
1H NMR (500 MHz CHLOROFORM-D) δ 143-1.57 (m, 6 H) 1.56-1.73 (m, 5 H) 1.84-
2.01 (m, 2 H) 2.87 (dd, J=14.13, 9.42 Hz, 1 H) (IH hidden in MeOD peak) 3.97-4.06 (m, 1 H) 444-4.51 (m, 1 H) 6.52-6.57 (m, 1 H) 6.64-6.68 (m, 2 H)
MS (ESI+) for C17H22N2O3S m/z 335 (M+H)+
Example 362 (BVT073749)
2-(cycloheptylamino)-5-(pyridin-3-ylmethyl)-l,3-thiazol-4(5H)-one Prepared using the same procedure as Example 354 from (2S)-2-amino-3-pyridin-3- ylpropanoic acid.
5mg, yield 52%.
IH NMR (270 MHz, CHLOROFORM-D) δ ppm 1.39 - 1.84 (m, 9 H) 1.88 - 2.06 (m, 2 H)
3.39 - 3.54 (m, 1 H) 3.64 (s, 2 H) 3.97 (s, 1 H) 4.75 (s, 1 H) 7.84 - 7.95 (m, 1 H) 8.34 (d, J=7.67 Hz, 1 H) 8.75 (d, J=5.07 Hz, 1 H) 9.10 (s, 1 H)
MS (ESI+) for Cι6H2ιN3OS m/z 304 (M+H)+
Example 363 (BVT105288B)
2-(cyclooctylamino)-5-propyl- 1 ,3-thiazol-4(5H)-one hydrobromide The thiourea (0.8 lmmol) and the alpha-bromo ester (0.81 mmol) was dissolved in acetone and heated to 60°C for 40-72 hours. The reactions was cooled and the products collected by filtration. 1H NMR (400 MHz, DMSO-D6) δ ppm 0.82 - 0.93 (m, 3 H) 1.22 - 1.32 (m, 1 H) 1.35 - 1.72 (m, 14 H) 1.73 - 1.85 (m, 2 H) 1.95 (s, 1 H) 3.99 (s, 1 H) 4.23 - 4.33 (m, 1 H) 9.74 (s, I H).
Example 364 (BVT105308B)
5-butyl-2-(cyclooctylamino)- 1 ,3-thiazol-4(5H)-one hydrobromide
Prepared using the same procedure as for Example 363.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.82 - 0.89 (m, 3 H) 1.25 - 1.33 (m, 2 H) 1.33 -
1.84 (m, 17 H) 1.93 - 2.04 (m, 1 H) 4.01 (s, 1 H) 4.22 - 4.32 (m, 1 H) 9.70 (s, 1 H).
Example 365 (BVT062674B)
2-(bicyclo[2.2. l]hept-2-ylamino)-5-ethyl- 1 ,3-thiazol-4(5H)-one hydrobromide Prepared using the same procedure as for Example 363. 105mg, yield 38%. IH NMR (400 MHz, DMSO-D6) δ ppm 0.90 (m, 3 H) 1.03-1.23 (m, 3 H) 1.35-1.56 (m, 4 H) 1.65-1.84 (m, 2 H) 1.98 (m, 1 H) 2.24 (m, 2 H) 3.75 (m, 1 H) 4.22-440 (m, 1 H) 9.84 (s, 1 H). MS (ESI+) for d2H18N2OS m/z 239 (M+H)+
Example 366 (BVT062676B) 2-(cyclohexylamino)-5-ethyl- 1 ,3-thiazol-4(5H)-one hydrobromide
Prepared using the same procedure as for Example 363.
201mg, yield 75%.
IH NMR (400 MHz, DMSO-D6) δ ppm 0.91 (m, 3 H) 1.05-2.06 (m, 12 H) 3.76 (m, 1 H)
4.36 (m, 1 H) 10.11 (s, 1 H). MS (ESI+) for CnHι8N2OS m z 227 (M+H)+
Example 367 (BVT061842)
5-ethyl-2-[(2-methylphenyl)amino]-l,3-thiazol-4(5H)-one
Prepared using the same procedure as for Example 363.
13 mg, yield 18%. 1H NMR (270 MHz, METHANOL-D4) δ ppm 1.07 - 1.18 (m, J=7.36, 7.36 Hz, 3 H) 1.98 -
2.36 (m, 2 H) 2.11 - 2.13 (m, 3 H) 4.52 - 4.75 (m, 1 H) 7.12 (dd, J=20.54, 7.67 Hz, 1 H)
7.22 - 7.46 (m, 3 H).
MS (ESI+) for C,2H14N2OS m/z 235 (M+H)+. Example 368 (BVT067912)
(5S)-2-(cycloheptylamino)-5-methyl-l,3-thiazol-4(5H)-one
Prepared using the same procedure as for Example 363.
56mg, yield 80 %.
[α]D = +04 °, c= 2.0 at 20.0 °C and in MeOH.
1H NMR (400 MHz, CHLOROFORM-D) δ ppm 1.35-1.70 (m, 12H) 1.45 (d, J= 7.3 Hz,
3H) 1.72-2.00 (m, IH) 3.90-4.03 (m, IH).
MS (ESI+) for CπH18N2OS m/z 227 (M+H)+.
Example 369 (BVT073763)
5-ethyl-2-[(2-isopropylphenyl)amino]- 1 ,3-thiazol-4(5H)-one Prepared using the same procedure as for Example 363. 26mg, yield 19%. IH NMR (270 MHz, DMSO-D6) δ ppm 0.88 (t, J=7.30 Hz, 3 H) 1.14 (d, J=6.93 Hz, 6 H) 1.63 - 2.06 (m, 2 H) 2.93 - 3.11 (m, 1 H) 4.32 (dd, J=7.36, 4.27 Hz, 1 H) 6.75 - 6.92 (m, 1 H) 7.06 - 7.21 (m, 2 H) 7.24 - 7.42 (m, 1 H). MS (ESI+) for C14Hi8N2OS m/z 263 (M+H)+.
Example 370 (BVT093650')
2-(cyclooctylamino)-5 -methyl- 1 ,3-thiazol-4(5H)-one
Prepared using the same procedure as for Example 363.
20 mg, yield
1H NMR (400 MHz, DMSO-D6) δ ppm 1.41 - 1.52 (m, 11 H) 1.57 - 1.65 (m, 4 H) 1.71 - 1.80 (m, 2 H) 4.O0 (ddd, J=8.55, 4.64, 4.39 Hz, 1 H) 4.12 (q, J=7.16 Hz, 1 H) 9.09 (brs,
0.72 H). MS(ESI) for C12H20N2OS m/z 241 (M+H).
Example 371 (BVT073636N) 2-(cyclooctylamino)-5-ethyl- 1 ,3-thiazol-4(5H)-one Prepared using the same procedure as for Example 363. 620mg, yield 6%.
IH NMR (270 MHz, METHANOL-D4) δ ppm 0.89 - 1.03 (m, 3 H) 1.43 - 1.99 (m, 15 H) 1.98 - 2.16 (m, 1 H) 4.21 - 4.32 (m, 1 H) 4.55 - 4.66 (m, 1 H). MS (ESI+) for Cι3H22N2OS m/z 255 (M+H)+.
Example 372 (BVT073633)
2-(cycloheptylamino)-5-ethyl-l,3-thiazol-4(5H)-one
Prepared using the same procedure as for Example 363. lmg, yield 6%.
IH NMR (270 MHz, METHANOL-D4) δ ppm 0.90 - 1.06 (m, 3 H) 140 - 2.17 (m, 14 H)
4.26 (dd, J=7.86, 4.02 Hz, 1 H) 4.52 - 4.68 (m, 1 H).
MS (ESI+) for Cι2H20N2OS m/z 241 (M+H)+.
Example 373 fBVT056664)
2-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- lH-isoindole- 1 ,3(2H)-dione 2-bromo-4-(l,3-dioxo-l,3-dihydro-2H-isoindol-2-yl)butanoic acid (0.204 g, 0.654 mmol) and N-bicyclo[2.2.1]hept-5-en-2-ylthiourea (0.112 g, 0.666 mmol) were dissolved in acetone (15 ml) and heated to reflux for 8h. The reaction mixture was allowed to cool to room temperature. ΝaΗCO3 (sat. solution) was added and extraction with DCM was performed. The organic phase was concentrated in vacuum to give the crude product (0.269 g) of which 10 mg was purified using preparative LC-MS (System C, 20-80% MeCN). 7mg, yield
1H NMR (270 MHz, CHLOROFORM-D) 1.65-1.84 (m, 4 H) 2.16-2.37 (m, 1 H) 2.57-2.73 (m, 1 H) 2.99-3.11 (m, 2 H) 3.37 (t, J=4.58 Hz, 1 H) 3.73-3.88 (m, 1 H) 3.96-4.12 (m, 1 H) 4.20 (dd, J=10.27, 3.59 Hz, 1 H) 6.03-6.10 (m, 1 H) 6.29 (dd, J=5.69, 2.97 Hz, 1 H) 7.73- 7.81 (m, 2 H) 7.81-7.91 (m, 2 H)
MS (ESI+) for C20Hι9N3O3S m/z 382 (M+H)+
Example 374 (BVT059579)
5- { [5-(2-chlorophenyl)- 1 ,3 ,4-oxadiazol-2-yl]methyl} -2-[(2-fluorophenyl)amino]- 1 ,3- thiazol-4(5H)-one
Prepared by modification of the method described by Kataky et al. Heterocyclic Chem.
1986, 23, 793.
To a mixture of {2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl} acetic acid (100.0 mg, 0.373 mmol) and 2-chlorobenzohydrazide (64 mg, 0.375 mmol) in a small tube with screw-cap was added POCl (0.5 mL) and the tube heated at 100 °C for 1.5 h. The product mixture was poured onto ice/water (ca 5 mL) and made basic by addition of saturated NaHCO (aq). After filtration, the solid was dissolved in a minimum amount of MeOH and purified by reverse-phase preparative HPLC to give the title compound as an off-white solid 22 mg, yield 15 %.
Η NMR (400 MHz, CDC13) δ 3.44 (dd, J= 17.0 Hz, J= 10.2 Hz, 1 H), 3.90 (dd, J= 17.0 Hz, J= 3.6 Hz, 1 H), 4.74 (dd, J= 10.2 Hz, J= 3.6 Hz, 1 H), 7.05-7.20 (m, 4 H), 7.38 (t, J = 7.6 Hz, 1 H), 7.46 (dt, J= 7.7 Hz, J= 1.7 Hz, 1 H), 7.52 (dd, J= 7.9 Hz, J= 1.2 Hz, 1 H), 7.92 (dd, J= 7.8 Hz, J= 1.6 Hz, 1 H). MS (ESI+) m/z 403 (M+H)+.
Example 375 (BVT061992)
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3-thiazol-4(5H)-one Preparation according to the procedure described for Example 374 starting from [4-oxo-2-
(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro-l,3-thiazol-5-yl]acetic acid.
22 mg, yield 15%.
1H NMR (400 MHz, DMSO- ) δ 145-1.56 (m, 4 H), 1.88-2.08 (m, 6 H), 2.21-2.25 (m, 2
H), 2.42 (t, J= 6.7 Hz, 1 H), 3.46 (dd, J = 16.4 Hz, J= 8.2 Hz, 1 H), 3.71 (dd, J= 16.4 Hz, J= 4.5 Hz, 1 H), 4.62 (dd, J= 8.2 Hz, J= 4.2 Hz, 1 H), 7.54 (tt, J= 7.6 Hz, J= 1.3 Hz, 1
H), 7.63 (m, 1 H), 7.69 (dd, J= 8.1 Hz, J= 1.3 Hz, 1 H), 7.85 (dd, J= 7.7 Hz, J= 1.7 Hz,
1 H), 9.40 (s, 1 H).
MS (ESI+) m/z 429 (M+H)+.
Example 376 (BVT061948
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-{[(lS,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl]amino } -1 ,3-thiazol-4(5H)-one
Preparation according to the procedure described for Example 374 starting from (4-oxo-2-
{[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}-4,5-dihydro-l,3-thiazol-5- yl)acetic acid.
30 mg, yield 21%.
Η NMR (400 MHz, DMSO- ) δ 0.89-1.08 (m, 7 H), 1.18 (s, 3 H) 149-1.63 (m, 1 H),
1.71-2.09 (m, 3 H), 2.29-247 (m, 2 H), 345-3.55 (m, 1 H), 3.70-3.78 (m, 1 H), 4.32 (m, 1 H), 4.68^1.73 (m, 1 H), 7.52-7.57 (m, 1 H), 7.61-7.65 (m, 1 H), 7.68-7.71 (m, 1 H), 7.88-7.92 (m, 1 H), 9.35 (m, 1 H). MS (ESI+) m/z 445 (M+H)+.
Example 377 (BVT061931)
2-(bicyclo[2.2.1]hept-2-ylamino)-5-{[5-(2-chloroρhenyl)-l,3,4-oxadiazol-2-yl]methyl}- 1 ,3-thiazol-4(5H)-one
Preparation according to the procedure described for Example 374 starting from [2- (bicyclo [2.2.1 ]hept-2-ylamino)-4-oxo-4,5 -dihy dro- 1 ,3 -thiazol-5 -yl] acetic acid. 44 mg, yield 29%.
1H NMR (400 MHz, DMSO- 6) δ 1.05-1.51 (m, 7 H), 1.62-1.73 (m, 1 H), 2.10-2.22 (m, 2 H), 343-3.52 (m, 1 H), 3.69-3.77 (m, 2 H), 4.64-4.70 (m, 1 H), 7.55 (tt, J= 7.6 Hz, J= 1.4 Hz, 1 H), 7.64 (m, 1 H), 7.70 (m, 1 H), 7.89 (dd, J= 7.7 Hz, J= 1.7 Hz, 1 H), 9.14 (m, I H). MS (ESI+) m/z 403 (M+H)+.
Example 378 (BVT061947)
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-{[(lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]amino}-l,3-thiazol-4(5H)-one Preparation according to the procedure described for Example 374 starting from (4-oxo-2-
{[(lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]amino}-4,5-dihydro-l,3-thiazol-5- yl)acetic acid.
25 mg, yield 17%.
1H NMR (400 MHz, DMSO-^6) δ 0.89-1.08 (m, 7 H), 1.19 (s, 3 H) 149-1.63 (m, 1 H), 1.71-2.03 (m, 3 H), 2.28-247 (m, 2 H), 345-3.55 (m, 1 H), 3.70-3.78 (m, 1 H), 4.32 (m,
1 H), 4.68-4.73 (m, 1 H), 7.52-7.57 (m, 1 H), 7.61-7.65 (m, 1 H), 7.68-7.71 (m, 1 H),
7.88-7.92 (m, 1 H), 9.35 (m, 1 H).
MS (ESI+) m/z 445 (M+H)+.
Example 379 (BVT063208)
5-(lH-benzimidazol-2-ylmethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one ((l-cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)acetic acid (30 mg, 1 eq) was dissolved in a mixture of DCM/DMF (2 mL/2 mL) and O-phenylendiamine (15 mg, 1.1 eq), and l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC, 30 mg, 1.3 eq) were then added sequentially. The reaction mixture was stined 40 °C for 2 h. Separated between DCM and H O, the organic layer concentrated to give a crude orange brown oil. This material was taken up in HO Ac (2 mL) and heated by microwave at 150 °C for 1200 s. The reaction mixture was evaporated and then purified by HP-LCMS to give the title compound 29 mg, yield 46%.
IH NMR (400 MHz, METHANOL-D4) δ ppm 1.28 (m, 5 H) 1.77 (m, 5 H) 3.83 (m, 3 H) 4.81 (m, 1 H) 7.59 (m, 2 H) 7.76 (m, 2 H). MS [M+H]+ m/z = 329.
Example 380 (BNT063207)
2-anilino-5-(l,3-benzoxazol-2-ylmethyl)-l,3-thiazol-4(5H)-one
The title compound was prepared according to the method described for Example 379.
4mg, yield 11%.
1H ΝMR (400 MHz, METHAΝOL-D4) δ ppm 3.39 (m, 1 H) 3.87 (m, 1 H) 4.80 (m, 1 H) 6.90 (m, 1 H) 7.15 (m, 2 H) 7.32 (m, 4 H) 7.50 (m, 1 H) 7.62 (m, 1 H); MS [M+H]+ m/z =
324.
Example 381 (BVT067972) 5-(l,3-benzoxazol-2-ylmethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one The title compound was prepared according to the method described for Example 379. 5.2 mg, yield 8%.
IH NMR (400 MHz, METHANOL-D4) δ ppm 1.45 - 1.75 (m, 10 H), 1.91 - 2.06 (m, 2 H), 3.37 - 3.50 (m, 1 H), 3.77 - 3.89 (m, 1 H), 4.04 - 4.15 (m, 1 H), 4.50 - 4.75 (m, 1 H), 7.31 - 7.40 (m, 2 H), 7.53 - 7.59 (m, J=5.9, 2.2 Hz, 1 H), 7.60 - 7.68 (m, 1 H); MS [M+H]+ m/z = 344.
Example 382 (BVT066787)
2-anilino-5-(l,3-benzothiazol-2-ylmethyl)-l,3-thiazol-4(5H)-one The title compound was prepared according to the method described for Example 379. 6 mg, yield 9%.
IH NMR (400 MHz, METHANOL-D4) δ ppm 3.54 (m, 1 H) 4.04 (m, 1 H) 4.79 (m, 1 H) 7.16 (m, 2 H) 7.39 (m, 4 H) 7.63 (d, J=7.81 Hz, 1 H) 7.89 (m, 2 H); MS [M+H]+ m/z = 340. Example 383 rBVT063209)
5-(lH-benzimidazol-2-ylmethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-4(5H)-one The title compound was prepared according to the method described for Example 379. 34 mg, yield 54%.
IH NMR (400 MHz, METHANOL-D4) δ ppm 1.36 (m, 8 H) 1.76 (m, 1 H) 2.29 (m, 2 H) 3.79 (m, 3 H) 7.59 (dd, J=6.35, 3.17 Hz, 2 H) 7.76 (dd, J=5.98, 3.05 Hz, 2 H); MS [M+H]+ m/z = 341.
Example 384 (BVT066789')
5-(lH-benzimidazol-2-ylmethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one
The title compound was prepared according to the method described for Example 379.
15 mg, yield (24% yield).
IH NMR (400 MHz, METHANOL-D4) δ ppm 1.56 (m, 10 H) 1.97 (m, 2 H) 3.80 (m, 2 H) 4.04 (m, 1 H) 4.46 (m, 1 H) 7.58 (dd, J=6.10, 3.17 Hz, 2 H) 7.76 (dd, J=6.10, 3.17 Hz, 2
H); MS [M+H]+ m z = 343.
Example 385 (BVT067953
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-fluorobenzamide Prepared according to method K after initial methylation of the starting amine.
43 mg, yield 37%.
Η NMR (400 MHz, OMSO-d6) δ 1.39-1.90 (m, 15 H), 2.55 (m, 1 H, obscured by solvent signal), 2.82 (s, 3 H), 3.45 (m, 2 H), 4.14 (m, 1 H), 4.32 (m, 1 H), 7.07-7.23 (m, 2 H),
7.39-7.23 (m, 1 H), 10.09 (d, J= 6.6 Hz, 1 H). MS (ESI+) for C2 ιH27F2N3O2S m/z 424 (M+H)+.
Example 386 (BVT073642)
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6-difluoro-N- methylbenzamide Prepared according to method K after initial methylation of the starting amine. 43 mg, yield 37%. 1H NMR (400 MHz, DMSO- ) δ 1.39-1.90 (m, 15 H), 2.55 (m, 1 H, obscured by solvent signal), 2.82 (s, 3 H), 3.45 (m, 2 H), 4.14 (m, 1 H), 4.32 (m, 1 H), 7.07-7.23 (m, 2 H),
7.39-7.23 (m, 1 H), 10.09 (d, J= 6.6 Hz, 1 H).
MS (ESI+) for C2ιH27F2N3O2S m/z 424 (M+H)+.
Example 387 fBVT073641)
2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- methylbenzamide
Prepared according to method K after initial methylation of the starting amine. 54 mg, yield 47%.
1H NMR (400 MHz, DMSO- ) δ 142-1.91 (m, 15 H), 2.53 (m, 1 H, obscured by solvent signal), 2.82 (s, 3 H), 3.43 (m, 2 H), 4.18-4.35 (m, 2 H), 7.33-7.51 (m, 3 H), 7.73 (d, J=
7.3 Hz, 1 H), 9.91 (d, J= 6.0 Hz, 1 H).
MS (ESI+) for C2ιH28ClN3O2S m/z 422 (M+H)+.
Example 388 (BVT073643)
2,4-dichloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- methylbenzamide
Prepared according to method K after initial methylation of the starting amine. 71 mg, yield 57%).
1H NMR (400 MHz, DMSO- ) δ 1.40-1.91 (m, 15 H), 2.53 (m, 1 H, obscured by solvent signal), 2.82 (s, 3 H), 3.44 (m, 2 H), 4.18^1.33 (m, 2 H), 7.45 (d, J= 8.3 Hz, 1 H), 7.78 (s,
1 H), 7.78 (d, J= 8.2 Hz, 1 H), 10.00 (d, J= 6.1 Hz, 1 H).
MS (ESI+) for C2ιH27Cl2N3O2S m/z 456 (M+H)+.
PREPARATION OF A PHARMACEUTICAL COMPOSITION
EXAMPLE 389: Preparation of tablets Ingredients mε/tablet
1. Active compound of formula (I) 10.0
2. Cellulose, microcrystalline 57.0
3. Calcium hydrogen phosphate 15.0
4. Sodium starch glycolate 5.0
5. Silicon dioxide, colloidal 0.25
6. Magnesium stearate 0.75
The active ingredient 1 is mixed with ingredients 2, 3, 4 and 5 for about 10 minutes. The magnesium stearate is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.

Claims

Claims 1. A compound of the general formula (I)
Figure imgf000164_0001
wherein R1 and R2 are each independently selected from hydrogen; d-s-alkyl; C3-10-cycloalkyl optionally independently substkuted by one or more of d-8-alkyl; C2-8-alkenyl; C3-ι0- cycloalkyl-d-s-alkyl; C3-ι0-cycloalkenyl; C3-ιo-cycloalkenyl-Cι-8-alkyl; Cι-8-acyl; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl; heterocyclyl-Cι-8-alkyl; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι-8-alkyl, C]-8-alkoxy, and heterocyclyl; indanyl; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen and Ci-s-alkyl; aryl-C3-ιo- cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Ci_8-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2; Y is CH2, CO or a single bond; R3 is hydrogen; d-s-alkyl; C .ι0-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cj-s-alkyl, halo-Cι-8-alkyl, Cι-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci- 8-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; d-s-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3-ι0-cycloalkyl-Cι-8-alkyl; C3-ιo-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, d-8-alkoxy, halo-Cι-8- alkoxy, arylcarbonyl, and carboxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of Ci-s-alkyl and halogen; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-d-8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo-d-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl and aryl; heteroaryl-d-s-alkylcarbonyl; C3-ιo-cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR6, wherein R6 is selected from Cι-8-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and Cι-8-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C3.10-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Ci-s-alkyl, and Cι-8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, d-s-alkyl, Cι-8-alkoxy, d-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen, Ci-s- alkoxy, mono-, or di-Cι-8-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι-8-alkyl, Cι-8-alkoxy, and nitro; or pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof; with the provisos that: • R1 and R2 are each independently selected from hydrogen; 2-butyl; isobutyl; tert- butyl; 2-methylbutyl; 1,1,3,3-tetramethylbutyl; cyclopropyl; cyclopentyl; cycloheptyl; cyclooctyl; C3-ιo-bicycloalkyl; d.ϊo-tricycloalkyi; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl; (1 S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.l]hept- 3-yl; C3-ιo-cycloalkyl-Cι-8-alkyl; C3-ι0-cycloalkenyl; C3_ι0-cycloalkenyl-Cι-8-alkyl; heterocyclyl substituted by one or more of Cι-8-alkyl; heterocyclyl-Ci-s-alkyl; 1- naphthyl; phenyl substituted by one or more of halogen, Ci-s-alkyl, halo-Cι-8-alkyl, Ci-s-alkoxy, and heterocyclyl; indanyl; 4-chlorobenzyl; 4-methylbenzyl; (1R)-1- phenylethyl; (1S)-1 -phenylethyl; 2-phenylethyl; (2R)-2-phenylpropyl; (2S)-2- phenylpropyl; aryl-C3-ι0-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl substituted by one or more of aryloxy; heterocyclyl-Ci- 8-alkyl; or form together with the nitrogen atom bonded thereto azepan-1-yl; • when either R1 or R2 is 1 -naphthyl; phenyl substituted by one or more of halogen, Ci-s-alkyl, halo-Cι_8-alkyl, d-8-alkoxy, and heterocyclyl, then R4 and R5 are each independently selected from C3.10-cycloalkyl optionally substituted by one or more of Ci-s-alkyl; cyclopropylmethyl; C3-ι0-cycloalkylcarbonyl; 2-phenylethyl; 2- chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Ci-s-alkoxy, cyano, and halo- Ci-s-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl; C3-ι0- cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; or either of R4 and R5 is hydrogen and the other of R4 and R5 is selected from C -ιo-cycloalkyl optionally substituted by one or more of Ci-s-alkyl; cyclopropylmethyl; C _ιo- cycloalkylcarbonyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2- methylbenzyl; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, d-8-alkyl and aryl; heteroaryl-Cι-8- alkylcarbonyl; C3-ι0-cycloalkylcarbonyl;
• when both R1 and R2 are hydrogen, then R3 is C3-ιo-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Ci-s-alkyl, Cι_8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci_8-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; Ci-s-alkyl; C3.ιo-cycloalkyl optionally independently substituted by one or more ofCi-8-alkyl; C3.ι0-cycloalkyl-Cι-8-alkyl; C3-ιo-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι_8- alkoxy, halo-Cι-8-alkoxy, arylcarbonyl, and carboxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of Cι-8-alkyl and halogen; Ci.8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι_8-acyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, cyano, and halo-d-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl and aryl; heteroaryl-d-s-alkylcarbonyl; C3-ι0- cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR6, wherein R6 is selected from Ci-s-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and Ci-s-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; or wherein R3 is NHCONRuR12, wherein R11 and R12 are each independently selected from hydrogen; C3-ιo-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Ci-s-alkyl, and Cι-8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Ci-s-alkyl, Ci-s-alkoxy, Ci-s-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen, Ci-s-alkoxy, mono-, or di-d-8-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Cι.8-alkyl, halo-Cι-8-alkyl, Cι_8-alkoxy, and nitro.
2. The compound according to claim 1, wherein: R1 and R2 are each independently selected from hydrogen; Cι_8-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C3-ι0-cycloalkyl-Cι_8- alkyl; C3_ι0-cycloalkenyl; d-io-cycloalkenyl-Ci-s-alkyl; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl; heterocyclyl-d-8-alkyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-Cι-8-alkyl, Cι-8-alkoxy, and heterocyclyl; indanyl; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3-ι0-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Cι-8-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2;
Y is CH2, CO or a single bond;
R3 is hydrogen; Ci-s-alkyl; C3-ιo-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl, halo-Ci-s-alkyl, d-8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci- 8-alkyl; aryl optionally independently substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; d-8-alkyl; C3-ιo-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C3-ι0-cycloalkyl-Cι-8-alkyl; C3-ι0-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, d-8-alkyl, d.8-alkoxy, halo-Cι-8- alkoxy, arylcarbonyl, and carboxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of Ci_8-alkyl and halogen; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Ci-s-acyl optionally independently substituted by one or more of halogen, Cι_8-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, Cι_8-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl; C3.ι0- cycloalkylcarbonyl; heteroaryl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C .ι0-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-Cι-8-alkyl, and d_8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι-8-alkoxy, Cι_8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, mono-, or di-Cι_8- alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι_8-alkyl, Cι.8-alkoxy, and nitro. 3. The compound according to any one of claims 1 or 2, wherein 1 9
R and R are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0~3,7~]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1. l]hept-3-yl; ( 1 S ,2S,3 S,5R)-2,6,6-trimethylbicyclo[3.1.1 ]hept-3-yl; bicyclo[2.2.1]hept-5-en-2-yl; (lR)-l-cyclohexylethyl; (lS)-l-cyclohexylethyl; 2-(l- cyclohexenyl)ethyl; 4-(2,2,6,6-tetramethyl)piperidyl; 2-(4-moφholinyl)ethyl; 1 -naphthyl; 2-fluorophenyl; 3-chloro-2-methylphenyl; mesityl; 3,5-di(trifluoromethyl)phenyl; 2,6- dimethylphenyl, 4-(4-moφholinyl)phenyl; 2-methylphenyl; 2-isopropylphenyl; 2- methoxyphenyl; 2-indanyl; 4-chlorobenzyl; 4-methylbenzyl; (1R)-1 -phenylethyl; (1S)-1- phenylethyl; 2-phenylethyl; (2R)-2-phenylpropyl; (2S)-2-phenylpropyl; l-(4- chlorophenyl)cyclobutyl; 6-phenoxy-3-pyridyl; 2-(4-moφholinyl)ethyl; or R1 and R2 form together with the nitrogen atom bonded thereto azepan-1-yl; R3 is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- moφholinyl; N-phthalimidyl; piperidin-1-yl; 4-methylpiperidin-l-yl; 1 -(1,2,3, 4- tetrahydroquinolinyl); 2-(l,2,3,4-tetrahydroisoquinolinyl); 8-methyl-l-(l,2,3,4- tetrahydroquinolinyl); l-[7-(trifluoromethyl)-l,2,3,4-tetrahydroquinolinyl; 3,4- dihydroisoquinolin-2(lH)-yl; 6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl; azocan-1-yl; l-oxa-4-azaspiro[4.5]dec-4-yl; 2- decahydroisoquinolinyl; 1,4-diazepan-l-ium; l,3-dihydro-2H-isoindol-2-yl; 2,3-dihydro- lH-indol-1-yl; pynolidin-1-yl; 3-pyridinyl; 3-indolyl; l,3-benzoxazol-2-yl; 1,3- benzothiazol-2-yl; lH-benzimidazol-2-yl; 4-hydroxy-4-phenylpiperidin-l-yl; 5-(2- chlorophenyl)-l,3,4-oxadiazol-2-yl; 4-chlorophenyl; 4-hydroxyphenyl; 3,4- dihydroxyphenyl; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; methyl; ethyl; n-propyl; isopropyl; n-butyl; cyclohexyl; cycloheptyl; (lR,2R,4S)-bicyclo[2.2. l]hept-2-yl; 4-methylcyclohexyl; cyclopropylmethyl; cyclohexylmethyl; cyclohexylcarbonyl; 1-adamantylcarbonyl; phenyl; 1 -naphthyl; 4- bromophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 4-fluorophenyl; 2,6- difluorophenyl; 3-chloro-2-methylphenyl; 2-methylphenyl; 3-methylphenyl; 4- methylphenyl; 4-methoxyphenyl; 4-(trifluoromethoxy)phenyl; 2-benzoylphenyl; 3- carboxyphenyl; benzyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; 2,2-dimethylpropionamido; phenoxyacetyl; 2-chlorobenzoyl; 2-fluorobenzoyl; 4- chlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 2-chloro-6-fluorobenzoyl; 2,4- dichlorobenzoyl; 2,4,6-trichlorobenzoyl; 2-methoxybenzoyl; 4-methoxybenzoyl; 2-bromo- 5-methoxybenzoyl; 2,4-dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 4- (trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2,5 - di(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; 4-cyanobenzoyl; 2- chloro-6-fluorophenylacetyl; 2-chlorophenylsulfonyl; 2,6-difluorophenylsulfonyl; 2- chloro-3-pyridylcarbonyl; 2-furylcarbonyl; 2-thienylcarbonyl; 5-isoxazolylcarbonyl; 5- methyl-3-phenylisoxazol-4-ylcarbonyl; 2-thienylmethylcarbonyl; cyclopropylcarbonyl; cyclohexylcarbonyl; isopentanoyl; indazol-6-yl; OCONR9R10, wherein R9 and R10 are each independently selected from 2-chlorophenyl; 4- bromo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; 1 1 19 1 1 1 T
NHCONR R , wherein R and R are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2-
(trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl;
OR , wherein R is selected from hydrogen; phenyl; 2-chlorophenyl; 4-chloro-3- methylphenyl; 2-methoxyphenyl; 4-carbomethoxy-2-chlorophenyl; 3-(4- moφholinyl)phenyl; 4-phenoxyphenyl; 2-chlorobenzyl; 2-methylbenzyl; 2- methoxybenzyl; 3-(dimethylamino)benzyl; benzoyl; 2-chlorobenzoyl; 2,4-dichlorobenzoyl;
3,4-dichlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 3,4-difluorobenzoyl; 2- chloro-6-fluorobenzoyl; 2,4,6-trichlorobenzoyl; 2,3,4-trifluorobenzoyl; 3-methylbenzoyl;
4-methylbenzoyl; 4-tert-butylbenzoyl; 3-methoxybenzoyl; 4-n-butoxybenzoyl; 2,4- dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 2-bromo-5-methoxybenzoyl; 3-
(trifluoromethyl)benzoyl; 2,5-di(trifluoromethyl)benz;oyl; 3 ,5-di(trifluoromethyl)benzoyl;
2-fluoiO-4-(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; and 4-chloro-3- nitrobenzoyl. 4. A compound according to any one of claims 1 to 3, which is selected from: • N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-chloro-6-fluorobenzamide, • N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,6-dimethoxybenzamide, • N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,4-dimethoxybenzamide, • N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl} -2,6-difluorobenzamide, • 2- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl} - lH-isoindole- 1 ,3 (2H)-dione, • N-{2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl} -2,5-difluorobenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl} -2-chlorobenzamide,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } -2-bromo-5 -methoxybenzamide,
N-{2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-fluoro-4-(trifluoromethyl)benzamide,
N- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } -2 ,4-dichlorobenzamide,
2-chloro-N- {2-[4-oxo-2-(tricyclo[3.3.1.0-3 ,7~]non-3-ylamino)-4,5-dihydro- 1 ,3- thiazol-5 -yl] ethyl } benzamide,
2,6-difluoro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro-
1 ,3 -thiazol-5 -yl] ethyl } benzamide,
2-chloro-6-fluoro-N- {2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5- dihy dro- 1 ,3 -thiazol-5 -yl] ethyl } benzamide,
2,4-dichloro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro- l,3-thiazol-5-yl]ethyl}benzamide,
2-chloro-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl } ethyl)benzamide,
2-bromo-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} ethyl)-5-methoxybenzamide,
2,4-dichloro-N-(2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} ethyl)benzamide,
2-chloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } benzamide,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,6- difluorobenzamide,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,6- dimethoxybenzamide,
2-bromo-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5- methoxybenzamide,
2-chloro-Ν-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-6- fluorobenzamide, 2,4-dichloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl}benzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- difluorobenzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- bis(trifluoromethyl)benzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-fluoro-5-
(trifluoromethyl)benzamide,
2-chloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } nicotinamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-furamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}thiophene-2- carboxamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-(2- thienyl)acetamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}cyclopropanecarboxamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-3- methylbutanamide,
Ν-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } cy clohexanecarboxamide,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}isoxazole-5-carboxamide,
N- {2-[2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl}-2,4,6-trichlorobenzamide,
N-[(2-azepan-l-yl-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)methyl]-2-fluorobenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[methyl(phenyl)amino]ethyl}-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)ethyl]-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)ethyl]-
1 ,3-thiazol-4(5H)-one, 2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)ethyl]- l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-piperidin-l-ylethyl)-l,3-thiazol-4(5H)- one,
5-(2-Anilinoethyl)-2-{[(lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]amino}-l,3-thiazol-4(57 )-one hydrobromide,
5-(2-Anilinoethyl)-2-{[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3- yl]amino}-l,3-thiazol-4(5H)-one hydrobromide,
5-(2-Anilinoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-4(57ϊ)-one,
5-(2-anilinoethyl)-2-(bicyclo[2.2.1 ]hept-2-ylamino)- 1 ,3-thiazol-4(5Η)-one,
5-(2-anilinoethyl)-2-[(2-cyclohex- 1 -en- 1 -ylethyl)amino]- 1 ,3 -thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-[(l,l,3,3-tetramethylbutyl)amino]-l,3-thiazol-4(5H)-one hydrobromide,
5-(2-anilinoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-l,3-thiazol-4(5H)- one,
5-(2-anilinoethyl)-2-{[(lR)-l-phenylethyl]amino}-l,3-thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2-{[(lS)-l-phenylethyl]amino}-l,3-thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2-{[(2R)-2-phenylpropyl]amino}-l,3-thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2-(cycloheptylamino)- 1 ,3-thiazol-4(577)-one,
5-(2-anilinoethyl)-2-[(4-methylbenzyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one hydrobromide,
5-(2-anilinoethyl)-2-{[(lR)-l-cyclohexylethyl]amino}-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2- {[(1 S)- 1 -cyclohexylethyl]amino} - 1 ,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-azepan- 1 -yl- 1 ,3 -thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-{[(2S)-2-phenylpropyl]amino}-l,3-thiazol-4(5H)-one,
2-[(cyclohexylmethyl)amino]-5- {2-[(4-fluorophenyl)amino]ethyl} - 1 ,3-thiazol-
4(5H)-one trifluoroacetate,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one, 2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(3-chloro-2-methylphenyl)acetamide,
Ν-Benzyl-2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-
5-yl]acetamide,
N-benzyl-2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-
5 -yl] -N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-methoxyphenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-phenylacetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-(3-methylphenyl)acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N- [4-(trifluoromethoxy)phenyl] acetamide,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N- ethyl-N-[4-(trifluoromethoxy)phenyl]acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-oxo-2-[7-(trifluoromethyl)-3,4- dihydroquinolin- 1 (2H)-yl]ethyl} - 1 ,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-(2-methylphenyl)acetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-(4-methylphenyl)acetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-bromophenyl)-N-methylacetamide, 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-chlorophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-fluorophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(3-chlorophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-(2-methylphenyl)acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(8-methyl-3,4-dihydroquinolin-l(2H)- yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5-(2-oxo-2-piperidin- 1 -ylethyl)- 1 ,3-thiazol-
4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- isopropyl-N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(2,6-difluorophenyl)acetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-y -N- phenylacetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]|-N- lH-indazol-6-ylacetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-y -N-
(4-fluorophenyl)acetamide,
N-(2-benzoylphenyl)-2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-ditιydro-
1 ,3-thiazol-5-yl]acetamide,
3-({[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]acetyl}amino)benzoic acid,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methylacetamide,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3- thiazol-4(577)-one, 2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(2-chlorophenyl)-N-methylacetamide,
2-(Bicyclo[2.2.1]hept-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[(3-chloro-2-methylphenyl)amino]-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(l-Adamantylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-Ν-methyl-]Sf- phenylacetamide,
2-[2-(l-adamantylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2,6- difluorophenyl)acetamide,
2-[2-(tert-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-[2-(cyclopropylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-(cyclopentylamino)-5 - [2-(3 ,4-dihydroisoquinolin-2( 1 H)-yl)-2-oxoethyl] -1,3- thiazol-4(5H)-one,
2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-2-(isobutylamino)-l,3-thiazol-
4(5H)-one,
2-[2-(isobutylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-( 1 -adamantylamino)-5 -[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3- thiazol-4(5H)-one,
2-(cyclopropylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-(mesitylamino)- 1 ,3-thiazol-
4(5H)-one,
N-(2-chlorophenyl)-2-{2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} acetamide,
N-methyl-2-{2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide, 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-methylbutyl)amino]-l,3- thiazol-4(5H)-one,
N-methyl-2-{4-oxo-2-[(2-phenylethyl)amino]-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide,
5 - [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(2-ρhenylethyl)amino]- 1 ,3 - thiazol-4(5H)-one,
2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-
N-(2-chloro-6-fluorobenzyl)acetamide trifluoroacetate,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(4-moφholin-4- ylphenyl)amino]-l,3-thiazol-4(5H)-one,
5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-{[3,5- bis(trifluoromethyl)phenyl] amino} - 1 ,3-thiazol-4(577)-one,
2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-
N-(2-phenylethyl)acetamide,
5-[2-(3,4-Dihydroquinolin-l(27 )-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]-l,3- thiazol-4(5H)-one,
N-(2-Chloro-6-fluorobenzyl)-2- {2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro- 1 ,3- thiazol-5-yl} acetamide,
2-{2-[(2-Fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-(4- methylcyclohexyl)acetamide,
5-[2-(3,4-dihydroquinolin-l(2Η)-yl)-2-oxoethyl]-2-[(2,6-dimethylphenyl)amino]- l,3-thiazol-4(5H)-one,
N-(2-chloro-6-fluorobenzyl)-2-{2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-
1 ,3 -thiazol-5-yl } acetamide,
5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-[(2-methylphenyl)amino]-l,3- thiazol-4(57ϊ)-one,
5-(2-Azepan-l-yl-2-oxoethyl)-2-[(2-methylphenyl)amino]-l,3-thiazol-4(577)-one,
N-(2-Chloro-6-fluorobenzyl)-2-{2-[(2-methylphenyl)amino]-4-oxo-4,5-dihydro- l,3-thiazol-5-yl} acetamide,
5-(2-Azepan- 1 -yl-2-oxoethyl)-2-[(2-isopropylphenyl)amino]- 1 ,3-thiazol-4(57ϊ)- one,
N-benzyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} acetamide, N-methyl-2- {4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5 dihydro- 1 ,3-thiazol-5- y 1 } -N-phenylacetamide,
N-(2-chloro-6-fluorobenzyl)-2-{4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5- dihydro-l,3-thiazol-5-yl}acetamide,
2-[(2-cyclohex- 1 -en- 1 -ylethyl)amino]-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
N-(4-fluorophenyl)-2- {4-oxo-2-[(l , 1 ,3,3-tetramethylbutyl)amino]-4,5-dihydro-l ,3- thiazol-5-yl} acetamide,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(l, 1,3,3- tetramethylbutyl)amino]- 1 ,3-thiazol-4(5H)-one,
5 -(2-azepan- 1 -yl-2-oxoethyl)-2- [(1,1 ,3 ,3 -tetramethylbuty l)amino] - 1 ,3 -thiazol-
4(5H)-one,
5-(2-Azepan- 1 -yl-2-oxoethyl)- 2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)- 1 ,3- thiazol-4(577)-one,
2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-Ν-(2,6- difluorophenyl)acetamide,
2- {2-[(4-chlorobenzyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- 1 - naphthylacetamide,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-moφholin-4- ylethyl)amino]- 1 ,3-thiazol-4(5H)-one,
2-[2-(sec-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide trifluoroacetate,
2-(sec-butylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one trifluoroacetate,
2-[2-(sec-butylamino)-4-oxo-4,5-dihydiO-l,3-thiazol-5-yl]-N-(2- chlorophenyl)acetamide trifluoroacetate,
2-{2-[(cyclopropylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-
N-phenylacetamide trifluoroacetate,
2-{2-[(4-methylbenzyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide,
2- {2-[(4-chlorobenzyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- phenylacetamide, 5-[2-(3,4-Dihydroisoquinolin-2(177)-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-
3 -ylamino)- 1 ,3 -thiazol-4(577)-one,
2-(cycloheptylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5-(2-azepan- 1 -yl-2-oxoethyl)-2-(cycloheptylamino)- 1 ,3-thiazol-4(5H)-one,
5-(2-azepan-l-yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
5-[2-(4-Methylpiperidin- 1 -yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3 -thiazol-4(57 )-one,
5-[2-(l,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3-thiazol-4(577)-one,
2-[(cyclohexylmethyl)amino]-5-(2-oxo-2-pynolidin- 1 -ylethyl)- 1 ,3-thiazol-4(5Η)- one,
2-[(cyclohexylmethyl)amino]-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-
1 ,3-thiazol-4(5H)-one,
2-azepan- 1 -yl-5-(2-azepan- 1 -yl-2-oxoethyl)- 1 ,3-thiazol-4(5H)-one,
2-azepan- 1 -yl-5- [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3 -thiazol-4(5H)- one,
2-azepan-l-yl-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
2-(cycloheptylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
2-(cycloheptylamino)-5-(2-oxo-2-pynolidin- 1 -ylethyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-[2-(4-methylpiperidin- 1 -yl)-2-oxoethyl]- 1 ,3-thiazol-4(5H)- one,
N-cyclohexyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} acetamide,
N-Cyclohexyl-N-ethyl-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5- dihydro- 1 ,3-thiazol-5-yl]acetamide,
N-(Cyclopropylmethyl)-N-propylacetamide-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-
3-ylamino)-4,5-dihydro-l,3-thiazol-5-yl]acetamide, 5-(2-Azocan- 1 -yl-2-oxoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)- 1 ,3-thiazol-
4(577)-one,
5-[2-(l-Oxa-4-azaspko[4.5]dec-4-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3 -thiazol-4(577)-one,
2- { [( 1R)- 1 -cyclohexylethyl]amino} -5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-{[(lR)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
5-(2-azepan- 1 -yl-2-oxoethyl)-2- { [( 1R)- 1 -cyclohexylethyl] amino } - 1 ,3 -thiazol-
4(5H)-one,
2- { [( 1 S)- 1 -cyclohexylethyl]amino } -5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
2-{[(lS)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
5-(2-azepan- 1 -yl-2-oxoethyl)-2- { [( 1 S)- 1 -cyclohexylethyl]amino } - 1 ,3 -thiazol-
4(5H)-one,
2-[(cyclohexylmethyl)amino]-5-[2-(4-methylpiperidin- 1 -yl)-2-oxoethyl]- 1 ,3- thiazol-4(5H)-one,
N-cyclohexyl-2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl } -N-ethylacetamide,
2- [(cyclohexylmethy l)amino] -5 - [2-( 1 -oxa-4-azaspko [4.5] dec-4-yl)-2-oxoethyl] - l,3-thiazol-4(5H)-one,
5-(2-azocan- l-yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]- 1 ,3-thiazol-4(5H)-one,
2-[(cyclohexylmethyl)amino]-5-[2-(l ,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]- 1 ,3- thiazol-4(5H)-one,
N-(3 -chloro-2-methylbenzyl)-2- {2- [(cyclohexylmethyl)amino] -4-oxo-4,5-dihydro-
1 ,3-thiazol-5-yl} acetamide,
N-(cyclohexylmethyl)-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3- thiazol-5-yl} acetamide,
2-[(cyclohexylmethyl)amino]-5-[2-(octahydroisoquinolin-2(lH)-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one,
Ν-[(lR,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-{2-[(cyclohexylmethyl)amino]-4-oxo-
4,5-dihydro-l,3-thiazol-5-yl}acetamide, 4- { [2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]acetyl}- 1 ,4-diazepan-
1-ium trifluoroacetate,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-
(cyclopropylmethyl)-N-propylacetamide,
2-(cycloheptylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
5-(2-azocan- 1 -yl-2-oxoethyl)-2-(cycloheptylamino)- 1 ,3-thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-cyclohexyl-N- ethylacetamide,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide,
2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-(4- methoxyphenyl)-N-methylacetamide,
2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-ethyl-N- phenylacetamide,
N-butyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide,
N-butyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
N-benzyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-2-[(2,2,3,3- tetramethylcyclopropyl)amino]- 1 ,3-thiazol-4(5H)-one,
5-(2-azepan-l-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3- thiazol-4(5H)-one,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl benzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2-chlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 ,4-dichlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,6-difluorobenzoate, -[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl,5-bis(trifluoromethyl)benzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl ,4-difluorobenzoate trifluoroacetate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl ,4-difluorobenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl,5-difluorobenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl-methylbenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl-chloro-3-nitrobenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl -methylbenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino) 4-oxo-4,5-dihydro-l,3-thiazo: •5-yl]ethyl-(trifluoromethyl)benzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino) -4-oxo-4,5-dihydro- 1 ,3-thiazo ■5-yl]ethyl,3 ,4-trifluorobenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino -4-oxo-4,5-dihydro- 1 ,3-thiazo: ■5-yl]ethyl-bromo-5-methoxybenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino 4-oxo-4,5-dihydro-l,3-thiazo ■5-yl]ethyl-chloro-6-fluorobenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino -4-oxo-4,5-dihydro- 1 ,3-thiazo: -5-yl]ethyl-fluoro-5-(trifluoromethyl)benzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino -4-oxo-4,5-dihydro- 1 ,3-thiazo ■5-yl]ethyl-fluoro-4-(trifluoromethyl)benzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino -4-oxo-4,5-dihydro-l,3-thiazo •5-yl]ethyl -methoxybenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino; -4-oxo-4,5-dihydro- 1 ,3-thiazo: -5-yl]ethyl,6-dimethoxybenzoate,-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino; 4-oxo-4,5-dihydro-l ,3-thiazo^ ■5-yl]ethyl ,4-dimethoxybenzoate, 2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
4-butoxybenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3,5-bis(trifluoromethyl)benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
4-tert-butylbenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2 ,4-dichlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,4,6-trichlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
(2-chlorophenyl)carbamate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
(4-chloro-3-nitrophenyl)carbamate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
(4-bromo-2,6-difluorophenyl)carbamate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
(3 -phenoxyphenyl)carbamate,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2- fluorophenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(4- fluorophenyl)urea,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N-(2,6- difluorophenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,4- difluorophenyl)urea,
N-(2-chlorophenyl)-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl} urea,
N- [2-chloro-5 -(trifluoromethyl)pheny 1] -TV- {2- [2-(cycloheptylamino)-4-oxo-4, 5 - dihydro-l,3-thiazol-5-yl]ethyl}urea,
N-{2-[2-(cycloheρtylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-[4- fluoro-2-(trifluoromethyl)phenyl]urea, N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N-(2- methoxyphenyl)urea,
N-(5-chloro-2-methoxyphenyl)-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-
1 ,3-thiazol-5-yl]ethyl}urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,4- dimethoxyphenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,6- dichloropyridin-4-yl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- cyclohexylurea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- cyclopentylurea,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-chlorobenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-methylbenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one trifluoroacetate,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-methoxybenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-{[3-
(dimethylamino)benzyl]oxy } ethyl)- 1 ,3-thiazol-4(5H)-one,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
Methyl 4-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]ethoxy}-3-chlorobenzoate,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]-l,3- thiazol-4(5H)-one,
2-Chlorophenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5 -yl] acetate,
Phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate, 2-Methoxyphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5 -y 1] acetate,
3-Moφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5- dihydro- 1 ,3-thiazol-5-yl]acetate,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chlorophenyl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-l,3-thiazol-4(5i/)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-bromoethyl)-l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one,
[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetic acid,
5-(2-moφholin-4-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3- thiazol-4(5H)-one,
N- [(2- { [( 1 S)- 1 -cyclohexylethyl] amino } -4-oxo-4,5-dihydro- 1 ,3 -thiazol-5- yl)methyl] -2-methoxybenzamide,
2-(cyclooctylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- cycloheptylacetamide hydrochloride,
N-[(2- { [(IS)- 1 -cyclohexylethyl]amino} -4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl)methyl]-2-fluorobenzamide,
2-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5-dihydro-l,3- thiazol-5-yl} ethyl)benzamide,
2-(l-adamantylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]heρt-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2- chloro-6-fluorobenzyl)acetamide hydrochloride,
2-(cycloheptylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-
4(5H)-one,
2-(cyclooctylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3-thiazol-
4(5H)-one,
N-cyclohexyl-2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide, 5-(2-azepan-l-yl-2-oxoethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-4(5H)- one hydrochloride,
N-cyclohexyl-N-ethyl-2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5- dihydro- 1 ,3-thiazol-5-yl} acetamide,
2-chloro-N-{[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]methyl}-6- fluorobenzamide,
5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-2-[(2,2,3,3- tetramethylcyclopropyl)amino]- 1 ,3-thiazol-4(5H)-one,
2-chloro-N-{[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]methyl}-6- fluorobenzamide,
5-(2-anilinoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3-thiazol-4(5H)- one,
2-chloro-6-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5- dihydro- 1 ,3 -thiazol-5-yl} ethyl)benzamide,
5-(2-azepan-l-yl-2-oxoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one,
2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-6- fluorobenzamide,
2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } benzenesulfonamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,4-dichlorobenzoate,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzenesulfonamide,
N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3 -thiazol-5 -yl] ethyl} -2,6- difluorobenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } benzamide,
5-[2-(4-benzylpiperidin- 1 -yl)-2-oxoethyl]-2-(cycloheptylamino)- 1 ,3-thiazol-4(5H)- one,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } -2 ,4-dichlorobenzamide, 2-chlorophenyl [2-(bicyclo[2.2. l]hept-5-en-2-ylammo)-4-oxo-4,5-dihydro-l ,3- thiazol-5-yl]acetate,
N- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl} -2-chlorobenzamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5-methyl-3- phenylisoxazole-4-carboxamide,
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-[(cyclohexylmethyl)amino]-l,3- thiazol-4(5H)-one, methyl 4-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-
5 -y 1] ethoxy } -3 -chlorobenzoate, phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-bromo-5-methoxybenzamide,
N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2- phenoxyacetamide,
2-(cycloheptylamino)-5-[2-(l-oxa-4-azaspko[4.5]dec-4-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-fluoro-4-(trifluoromethyl)benzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]-l,3- thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N- phenylacetamide,
N-(2-chloro-6-fluorobenzyl)-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetamide,
2-methoxyphenyl [2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1,3- thiazol-5-yl]acetate,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}adamantane-
1-carboxamide,
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]- 1 ,3- thiazol-4(5H)-one, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,5-difluorobenzamide,
5-(2-anilinoethyl)-2- { [ 1 -(4-chlorophenyl)cyclobutyl]amino } - 1 ,3 -thiazol-4(5H)-one hydrobromide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- difluorobenzamide,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- methoxyphenyl)-N-methylacetamide,
2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]- 1 ,3-thiazol-
4(5H)-one,
4-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- y 1] ethyl } benzamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}cyclohexanecarboxamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4-
(trifluoromethyl)benzamide,
2-{[3,5-bis(trifluoromethyl)phenyl]amino}-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one
2-(cycloheptylamino)-5-[2-(4-hydroxy-4-phenylpiperidin- 1 -yl)-2-oxoethyl]- 1,3- thiazol-4(5H)-one,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N,N- diethylacetamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,2- dimethylpropanamide,
3-moφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5- dihydro- 1 ,3-thiazol-5-yl]acetate,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } -4-cy anobenzamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4- methoxybenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-chlorobenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one, 2- {2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-(4- methylcyclohexyl)acetamide,
2-[(cyclohexylmethyl)amino]-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)- one,
2-(cycloheptylamino)-5-isobutyl-l,3-thiazol-4(5H)-one,
(5R)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one,
(5S)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-(4-hydroxybenzyl)-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-(lH-indol-3-ylmethyl)-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-(4-hydroxybenzyl)-l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1 ]hept-2-ylamino)-5-(4-hydroxybenzyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-(3,4-dihydroxybenzyl)-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-(pyridin-3-ylmethyl)-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-propyl-l,3-thiazol-4(5H)-one hydrobromide,
5-butyl-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one hydrobromide,
2-(bicyclo[2.2.1]hept-2-ylamino)-5-ethyl-l,3-thiazol-4(5H)-one hydrobromide,
(5S)-2-(cycloheptylamino)-5-methyl-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-methyl- 1 ,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-ethyl-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-ethyl-l,3-thiazol-4(5H)-one,
2-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-lH-isoindole-l,3(2H)-dione,
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-[(2-fluorophenyl)amino]-
1 ,3-thiazol-4(5H)-one,
5- { [5-(2-chlorophenyl)-l ,3 ,4-oxadiazol-2-yl]methyl} -2-(tricyclo[3.3.1.0-3 ,7~]non-
3-ylamino)-l,3-thiazol-4(5H)-one,
5 - { [5-(2-chlorophenyl)- 1 ,3 ,4-oxadiazol-2-yl]methyl} -2- { [( 1 S,2S,3 S,5R)-2,6,6- trimethylbicyclo [3.1.1 ]hept-3 -yl]amino } - 1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-2-ylamino)-5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2- yl]methyl} - 1 ,3-thiazol-4(5H)-one,
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-{[(lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]amino}-l,3-thiazol-4(5H)-one,
5 -(1 ,3 -benzoxazol-2-ylmethyl)-2-(cycloheptylamino)- 1 ,3 -thiazol-4(5H)-one, • 5-(lH-benzimidazol-2-ylmethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol- 4(5H)-one, • 5-(lH-benzimidazol-2-ylmethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one, • N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- fluorobenzamide, • N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6-difluoro- N-methylbenzamide, • 2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- methylbenzamide, and • 2,4-dichloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- N-methylbenzamide.
5. A process for the preparation of a compound according to any one of claims 1 to 4, comprising at least one of the following steps: a) reaction of an isothiocyanate with ammonia to give a thiourea, b) reaction of an amine with ethoxycarbonylisothiocyanate to give a thiourea, c) reaction of a thiourea with maleic anhydride to give a thiazolone carboxylic acid, d) reaction of a thiazolone carboxylic acid with 2-chloro-l-methylpyridinium iodide in the presence of an amine to give a thiazolone amide, e) reaction of a thiourea with 2-bromo-γ-butyrolactone to give a thiazolone alcohol, f) reaction of a thiazolone alcohol with an acid chloride or an isocyanate in the presence of a base to give a thiazolone ester, g) reaction of a thiazolone alcohol with triphenylphosphine and then with a benzyl alcohol in the presence of dietyl azodicarboxylate to give a thiazolone ether, h) reaction of a thiourea with an N-substituted 3-bromo-l-phenylpynolidin-2-one to give a thiazolone amine, i) reaction of a thiazolone alcohol with triphenylphosphine dibromide to give a thiazolone bromide, j) reaction of a thiazolone bromide with an N-substituted aniline to give a thiazolone amine, k) reaction of a thiourea with 3-(4-chlorobenzoyl)acrylic acid to give a thiazolone,
1) reaction of a thiourea with 3-bromopynolidin-2-one to give a thiazolone amine, m) reaction of a thiazolone amine with a benzoyl chloride or a sulfonyl chloride to give a thiazolone amide or a thiazolone sulfonamide, respectively, n) hydrolysis of a thiazolone amide with hydrazine to give a thiazolone amine, o) esterification of a thiazolone carboxylic acid with a phenol in the presence of a base and a coupling agent to give a thiazolone phenol ester, p) reaction of a thiourea with a lH-pynole-2,5-dione to give a thiazolone amide, q) reaction of a thiazolone carboxylic acid with diphenylphosphoryl azide and then with a benzoyl chloride to give a thiazolone amide, r) amidification of a thiazolone carboxylic acid with an amine in the presence of a base and a coupling agent to give a thiazolone amide, s) reaction of an N-C3.ι0-cycloalkylthiourea with a carboxylic acid to give a thiazolone, t) reaction of an N-C3-ιo-cycloalkylthiourea with a bromo substituted carboxylic ester to give a thiazolone, u) reaction of a thiazolone carboxylic acid with 2-chlorobenzohydrazide in the presence of POCl3 to give a thiazolone containing a triazole group, v) reaction of a thiazolone carboxylic acid with an aromatic amine to give a thiazoline containing a benzimidazole, benzoxazole or a benzothiazole group, and w) alkylation of a thiazolone amine.
6. A compound of the general formula (I)
Figure imgf000191_0001
wherein R1 and R2 are each independently selected from hydrogen; Ci-s-alkyl; C3-ιo-cycloalkyl optionally independently substkuted by one or more of Cι-8-alkyl; C2.8-alkenyl; C -ιo- cycloalkyl-Ci-s-alkyl; C3_ιo-cycloalkenyl; C -ι0-cycloalkenyl-Cι.8-alkyl; Cj-s-acyl; heterocyclyl optionally independently substituted by one or more of Cι-8-alkyl; heterocyclyl-Cι-8-alkyl; aryl optionally independently substituted by one or more of halogen, Cι_8-alkyl, halo-Ci-s-alkyl, Ci-s-alkoxy, and heterocyclyl; indanyl; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen and Cι-8-alkyl; aryl-C3-ι0- cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Cι.8-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2;
Y is CH2, CO or a single bond;
R3 is hydrogen; Cι-8-alkyl; C .10-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl, halo-Cι-8-alkyl, Ci-s-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci- s-alkyl; aryl substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; Cι-8-alkyl; C3-ι0-cycloalkyl optionally independently substituted by one or more of Cι-8-alkyl; C -10-cycloalkyl-d-8-alkyl; C -ι0-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι-8-alkoxy, halo-Ci-s- alkoxy, arylcarbonyl, and carboxy; aryl-Ci-s-alkyl optionally independently substituted by one or more of Ci-s-alkyl and halogen; Cι-8-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι-8-acyl optionally independently substituted by one or more of halogen, Ci-s-alkoxy, cyano, and halo-Cι-8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally independently substituted by one or more of halogen, Cι-8-alkyl and aryl; heteroaryl-d_8-alkylcarbonyl;
C -ιo-cycloalkylcarbonyl; heterocyclylcarbonyl; heteroaryl; COOR , wherein R is selected from d-s-alkyl and aryl; CONR7R8, wherein R7 and R8 are each independently selected from hydrogen and d-8-alkyl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl optionally independently substituted by one or more of halogen, nitro, and aryloxy; or wherein R is NHCONR R , wherein R and R are each independently selected from hydrogen; C3-10-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-d-8-alkyl, and Cι-8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R is OR , wherein R is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι-8-alkoxy, Cι-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Cι-8-alkyl optionally independently substituted by one or more of halogen, Ci-s- alkoxy, mono-, or di-Cι-8-alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci_8-alkyl, halo-Cι-8-alkyl, Cι-8-alkoxy, and nitro; or pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers, N-oxides and prodrug forms thereof; for use in therapy.
7. The compound according to claim 6, wherein
R1 and R2 are each independently selected from hydrogen; Ci-s-alkyl; C3_ιo-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3-10-cycloalkyl-Cι_8- alkyl; C3-ι0-cycloalkenyl; C3-ι0-cycloalkenyl-Cι_8-alkyl; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl; heterocyclyl-Cι_8-alkyl; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, halo-Cι-8-alkyl, Ci-8-alkoxy, and heterocyclyl; indanyl; aryl-Ci_8-alkyl optionally independently substituted by one or more of halogen and Ci-s-alkyl; aryl-C3-ι0-cycloalkyl optionally independently substituted by one or more of halogen; heteroaryl optionally independently substituted by one or more of aryloxy; heterocyclyl-Cι-8-alkyl; or form together with the nitrogen atom bonded thereto heterocyclyl; X is CH2; Y is CH2, CO or a single bond;
R is hydrogen; Cι-8-alkyl; C3-ιo-cycloalkyl; halogen; heterocyclyl optionally independently substituted by one or more of Ci-s-alkyl, halo-Ci_8-alkyl, Ci_8-alkoxy, hydroxy, aryl optionally independently substituted by one or more of halogen, and aryl-Ci- 8-alkyl; aryl optionally independently substituted by one or more of halogen or hydroxy; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; Ci-s-alkyl; C3_ι0-cycloalkyl optionally independently substituted by one or more of Ci-s-alkyl; C3_ιo-cycloalkyl-Cι-8-alkyl; C3-ι0-cycloalkylcarbonyl; aryl optionally independently substituted by one or more of halogen, Cι_8-alkyl, d.8-alkoxy, halo-Cι_8- alkoxy, arylcarbonyl, and carboxy; aryl-Ci_8-alkyl optionally independently substituted by one or more of Cι-8-alkyl and halogen; Ci-s-acyl optionally independently substituted by one or more of aryloxy; aryl-Cι.8-acyl optionally independently substituted by one or more of halogen, Ci-s-alkoxy, cyano, and halo-Cι_8-alkyl; arylsulfonyl optionally independently substituted by one or more of halogen; heteroarylcarbonyl optionally substituted by one or more of halogen, Cι_8-alkyl and aryl; heteroaryl-Cι-8-alkylcarbonyl; C3-ι0- cycloalkylcarbonyl; heteroaryl; or wherein R3 is OCONR9R10, wherein R9 and R10 are each independently selected from aryl substituted by one or more of halogen, nitro, and aryloxy; or wherein R3 is NHCONRnR12, wherein R11 and R12 are each independently selected from hydrogen; C3-ι0-cycloalkyl; aryl optionally independently substituted by one or more of halogen, halo-d-8-alkyl, and Cι-8-alkoxy; heteroaryl optionally independently substituted by one or more of halogen; or wherein R3 is OR13, wherein R13 is selected from hydrogen; aryl optionally independently substituted by one or more of halogen, Cι-8-alkyl, Cι-8-alkoxy, Cι-8-alkoxycarbonyl, heterocyclyl, and aryloxy; aryl-Cι_8-alkyl optionally independently substituted by one or more of halogen, Cι-8-alkoxy, mono-, or di-Cι_8- alkylamino; arylcarbonyl optionally independently substituted by one or more of halogen, Ci-s-alkyl, halo-Cι.8-alkyl, Cι_8-alkoxy, and nitro.
8. The compound according to any one of claims 6 to 7, wherein
R and R are selected from hydrogen; 2-butyl; isobutyl; tert-butyl; 2-methylbutyl; 1,1,3,3- tetramethylbutyl; cyclopropyl; cyclopentyl; cyclohexyl; cycloheptyl; bicyclo[2.2.1]hept-2- yl; cyclooctyl; 1-adamantyl; tricyclo[3.3.1.0~3,7~]non-3-yl; cyclopropylmethyl; cyclohexylmethyl; 2,2,3,3-tetramethylcyclopropyl; (lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl; (lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl; bicyclo[2.2.1]hept-5-en-2-yl; (lR)-l-cyclohexylethyl; (lS)-l-cyclohexylethyl; 2-(l- cyclohexenyl)ethyl; 4-(2,2,6,6-tetramethyl)piperidyl; 2-(4-moφholinyl)ethyl; 1 -naphthyl; 2-fluorophenyl; 3-chloro-2-methylphenyl; mesityl; 3,5-di(trifluoromethyl)phenyl; 2,6- dimethylphenyl, 4-(4-moφholinyl)phenyl; 2-methylphenyl; 2-isopropylphenyl; 2- methoxyphenyl; 2-indanyl; 4-chlorobenzyl; 4-methylbenzyl; (lR)-l-phenylethyl; (1S)-1- phenylethyl; 2-phenylethyl; (2R)-2-phenylpropyl; (2S)-2-phenylpropyl; l-(4- chlorophenyl)cyclobutyl; 6-phenoxy-3-pyridyl; 2-(4-moφholinyl)ethyl; or R1 and R2 form together with the nitrogen atom bonded thereto azepan-1-yl; R is hydrogen; methyl; ethyl; isopropyl; cyclohexyl; bromo; 1-hexahydroazepinyl; 4- moφholinyl; N-phthalimidyl; piperidin- 1 -yl; 4-methylpiperidin- 1-yl; 1 -( 1 ,2,3 ,4- tetrahydroquinolinyl); 2-(l,2,3,4-tetrahydroisoquinolinyl); 8-methyl-l-(l,2,3,4- tetrahydroquinolinyl); 1 -[7-(trifluoromethyl)- 1 ,2,3 ,4-tetrahydroquinolinyl; 3 ,4- dihydroisoquinolin-2(lH)-yl; 6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl; 4- benzylpiperidin-1-yl; azepan-1-yl; azocan-1-yl; l-oxa-4-azaspiro[4.5]dec-4-yl; 2- decahydroisoquinolinyl; 1,4-diazepan-l-ium; l,3-dihydro-2H-isoindol-2-yl; 2,3-dihydro- lH-indol-1-yl; pynolidin-1-yl; 3-pyridinyl; 3-indolyl; l,3-benzoxazol-2-yl; 1,3- benzothiazol-2-yl; lH-benzimidazol-2-yl; 4-hydroxy-4-phenylpiperidin-l-yl; 5-(2- chlorophenyl)-l,3,4-oxadiazol-2-yl; 4-chlorophenyl; 4-hydroxyphenyl; 3,4- dihydroxyphenyl; or wherein R3 is NR4R5, wherein R4 and R5 are each independently selected from hydrogen; methyl; ethyl; n-propyl; isopropyl; n-butyl; cyclohexyl; cycloheptyl; (lR,2R,4S)-bicyclo[2.2. l]hept-2-yl; 4-methylcyclohexyl; cyclopropylmethyl; cyclohexylmethyl; cyclohexylcarbonyl; 1-adamantylcarbonyl; phenyl; 1 -naphthyl; 4- bromophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 4-fluorophenyl; 2,6- difluorophenyl; 3-chloro-2-methylphenyl; 2-methylphenyl; 3-methylphenyl; 4- methylphenyl; 4-methoxyphenyl; 4-(trifluoromethoxy)phenyl; 2-benzoylphenyl; 3- carboxyphenyl; benzyl; 2-phenylethyl; 2-chloro-6-fluorobenzyl; 3-chloro-2-methylbenzyl; 2,2-dimethylpropionamido; phenoxyacetyl; 2-chlorobenzoyl; 2-fluorobenzoyl; 4- chlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 2-chloro-6-fluorobenzoyl; 2,4- dichlorobenzoyl; 2,4,6-trichlorobenzoyl; 2-methoxybenzoyl; 4-methoxybenzoyl; 2-bromo- 5-methoxybenzoyl; 2,4-dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 4- (trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2,5- di(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; 4-cyanobenzoyl; 2- chloro-6-fluorophenylacetyl; 2-chlorophenylsulfonyl; 2,6-difluorophenylsulfonyl; 2- chloro-3-pyridylcarbonyl; 2-furylcarbonyl; 2-thienylcarbonyl; 5-isoxazolylcarbonyl; 5- methyl-3-phenylisoxazol-4-ylcarbonyl; 2-thienylmethylcarbonyl; cyclopropylcarbonyl; cyclohexylcarbonyl; isopentanoyl; indazol-6-yl; OCONR9R10, wherein R9 and R10 are each independently selected from 2-chlorophenyl; 4- bronιo-2,6-difluorophenyl; 4-chloro-3-nitrophenyl; 3-phenoxyphenyl; 1 1 19 1 1 19
NHCONR R , wherein R and R are each independently selected from hydrogen, cyclopentyl, cyclohexyl, 2-chlorophenyl, 2-fluorophenyl, 4-fluorophenyl, 2,4- difluorophenyl, 2,6-difluorophenyl, 2-chloro-5-(trifluoromethyl)phenyl, 4-fluoro-2- (trifluoromethyl)phenyl, 2-methoxyphenyl, 2,4-dimethoxyphenyl, 5-chloro-2- methoxyphenyl, 2,6-dichloropyridin-4-yl;
OR13, wherein R13 is selected from hydrogen; phenyl; 2-chlorophenyl; 4-chloro-3- methylphenyl; 2-methoxyphenyl; 4-carbomethoxy-2-chlorophenyl; 3-(4- moφholinyl)phenyl; 4-phenoxyphenyl; 2-chlorobenzyl; 2-methylbenzyl; 2- methoxybenzyl; 3-(dimethylamino)benzyl; benzoyl; 2-chlorobenzoyl; 2,4-dichlorobenzoyl; 3,4-dichlorobenzoyl; 2,5-difluorobenzoyl; 2,6-difluorobenzoyl; 3,4-difluorobenzoyl; 2- chloro-6-fluorobenzoyl; 2,4,6-trichlorobenzoyl; 2,3,4-trifluorobenzoyl; 3-methylbenzoyl; 4-methylbenzoyl; 4-tert-butylbenzoyl; 3-methoxybenzoyl; 4-n-butoxybenzoyl; 2,4- dimethoxybenzoyl; 2,6-dimethoxybenzoyl; 2-bromo-5-methoxybenzoyl; 3- (trifluoromethyl)benzoyl; 2,5-di(trifluoromethyl)benzoyl; 3,5-di(trifluoromethyl)benzoyl; 2-fluoro-4-(trifluoromethyl)benzoyl; 2-fluoro-5-(trifluoromethyl)benzoyl; and 4-chloro-3- nitrobenzoyl.
9. The compound according to any one of claims 6 to 8, which is selected from: N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-chloro-6-fluorobenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,6-dimethoxybenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,4-dimethoxybenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,6-difluorobenzamide, 2-{2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } - lH-isoindole- 1 ,3 (277)-dione, • N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethy 1 } -2, 5 -difluorobenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-chlorobenzamide, N-{2-[2-(bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-bromo-5-methoxybenzamide, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-fluoro-4-(trifluoromethyl)benzamide, N- {2-[2-(bicyclo[2.2. l]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro- l,3-thiazol-5- yl]ethyl}-2,4-dichlorobenzamide, • 2-chloro-N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl}benzamide, N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,6- difluorobenzamide, N-{2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- dimethoxybenzamide, 2-bromo-N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -5- methoxybenzamide, 2-chloro-N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -6- fluorobenzamide,
2,4-dichloro-N- {2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl } benzamide,
2-chloro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0-3,7~]non-3-ylamino)-4,5-dihydro-l,3- thiazol-5 -yl] ethyl } benzamide,
2,6-difluoro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0-3,7~]non-3-ylamino)-4,5-dihydro- l,3-thiazol-5-yl]ethyl}benzamide,
2-chloro-6-fluoro-N-{2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5- dihydro-l,3-thiazol-5-yl]ethyl}benzamide,
2,4-dichloro-N- {2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5-dihydro- l,3-thiazol-5-yl]ethyl}benzamide,
2-chloro-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} ethyl)benzamide,
2-bromo-N-(2- {2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl}ethyl)-5-methoxybenzamide,
2,4-dichloro-N-(2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl } ethyl)benzamide,
2-chloro-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}benzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- dimethoxybenzamide,
2-bromo-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5- methoxybenzamide,
2-chloro-Ν- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -6- fluorobenzamide,
2,4-dichloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl]ethyl} benzamide,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,5- difluorobenzamide, N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- bis(trifluoromethyl)benzamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-fluoro-5-
(trifluoromethyl)benzamide,
2-chloro-N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } nicotinamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-furamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}thiophene-2- carboxamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2-(2- thienyl)acetamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}cyclopropanecarboxamide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-3- methylbutanamide,
Ν-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } cyclohexanecarboxamide,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}isoxazole-5-carboxamide,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,4,6-trichlorobenzamide,
N-[(2-azepan-l-yl-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)methyl]-2-fluorobenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[methyl(phenyl)amino]ethyl}-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)ethyl]-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)ethyl]- l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)ethyl]-
1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-piperidin-l-ylethyl)-l,3-thiazol-4(5H)- one, 5-(2-Anilinoethyl)-2- {[(lR,2R,3R,5S)-2,6,6-trimethylbicyclo[3.1. l]hept-3- yl]amino}-l,3-thiazol-4(57 )-one hydrobromide,
5-(2-Anilinoethyl)-2- {[(lS,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1. l]hept-3- yl] amino } - 1 ,3 -thiazol-4(577)-one hydrobromide,
5-(2-Anilinoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-4(577)-one,
5-(2-anilinoethyl)-2-(bicyclo[2.2. l]hept-2-ylamino)- 1 ,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-[(2-cyclohex-l-en-l-ylethyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-[(l,l,3,3-tetramethylbutyl)amino]-l,3-thiazol-4(5H)-one hydrobromide,
5-(2-anilinoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-[(2,2,6,6-tetramethylpiperidin-4-yl)amino]-l,3-thiazol-4(5H)- one,
5-(2-anilinoethyl)-2-(cyclohexylamino)- 1 ,3-thiazol-4(5H)-one hydrobromide,
5-(2-anilinoethyl)-2-{[(lR)-l-phenylethyl]amino}-l,3-thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2- { [( 1 S)- 1 -phenylethyl]amino} - 1 ,3 -thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2- { [(2R)-2-phenylpropyl]amino} - 1 ,3-thiazol-4(5H)-one hydrochloride,
5-(2-anilinoethyl)-2-(cycloheptylamino)-l,3-thiazol-4(577)-one,
5-(2-anilinoethyl)-2-[(4-methylbenzyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one hydrobromide,
5-(2-anilinoethyl)-2- { [( 1 R)- 1 -cyclohexylethyl] amino } - 1 ,3 -thiazol-4(5H)-one,
5 -(2-anilinoethyl)-2- { [( 1 S)- 1 -cyclohexylethyl] amino } - 1 ,3 -thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-azepan- 1 -yl- 1 ,3-thiazol-4(5H)-one,
5-(2-anilinoethyl)-2-{[(2S)-2-phenylpropyl]amino}-l,3-thiazol-4(5H)-one,
2-[(cyclohexylmethyl)amino]-5-{2-[(4-fluorophenyl)amino]ethyl}-l,3-thiazol-
4(5H)-one trifluoroacetate,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(3-chloro-2-methylphenyl)acetamide, N-Benzyl-2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-
5 -yl] acetamide,
N-benzyl-2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-
5 -yl] -N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-methoxyphenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-phenylacetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2,3-dihydro-lH-indol-l-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-(3-methylphenyl)acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-[4-(trifluoromethoxy)phenyl]acetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-[4-(trifluoromethoxy)phenyl]acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-oxo-2-[7-(trifluoromethyl)-3,4- dihydroquinolin- l(2H)-yl]ethyl} - 1 ,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-(2-methylphenyl)acetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methyl-N-(4-methylphenyl)acetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-bromophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-chlorophenyl)-N-methylacetamide, 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-fluorophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(3-chlorophenyl)-N-methylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethyl-N-(2-methylphenyl)acetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(8-methyl-3,4-dihydroquinolin-l(2H)- yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-
4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- isopropyl-N-phenylacetamide,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(2 , 6-difluorophenyl)acetamide,
N-(2-Chlorophenyl)-2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]acetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- lH-indazol-6-ylacetamide,
2-[2-(Bicyclo[2.2.1]heρt-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(4-fluorophenyl)acetamide,
N-(2-benzoylphenyl)-2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-
1 ,3-thiazol-5-yl]acetamide,
3-({[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]acetyl}amino)benzoic acid,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide,
2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methylacetamide,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3- thiazol-4(577)-one, 2-[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(2-chlorophenyl)-N-methylacetamide,
2-(Bicyclo[2.2.1]hept-2-ylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[(3-chloro-2-methylphenyl)amino]-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-[2-(l-Adamantylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-Ν-methyl-Ν- phenylacetamide,
2-[2-(l-adamantylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2,6- difluorophenyl)acetamide,
2-[2-(tert-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-[2-(cyclopropylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-(cyclopentylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-2-(isobutylamino)-l,3-thiazol-
4(5H)-one,
2-[2-(isobutylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
2-( 1 -adamantylamino)-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3- thiazol-4(5H)-one,
2-(cyclopropylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5- [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-(mesitylamino)- 1 ,3 -thiazol-
4(5H)-one,
N-(2-chlorophenyl)-2- {2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl} acetamide,
N-methyl-2-{2-[(2-methylbutyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide, 5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-methylbutyl)amino]-l,3- thiazol-4(5H)-one,
N-methyl-2- {4-oxo-2-[(2-phenylethyl)amino]-4,5-dihydro- 1 ,3-thiazol-5-yl} -N- phenylacetamide,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2-phenylethyl)amino]-l,3- thiazol-4(5H)-one,
2-(2- { [3 ,5-Bis(trifluoromethyl)phenyl]amino} -4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl)-
N-(2-chloro-6-fluorobenzyl)acetamide trifluoroacetate,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(4-moφholin-4- ylphenyl)amino]- 1 ,3 -thiazol-4(5H)-one,
5- [2-(3 ,4-Dihydroquinolin- 1 (277)-yl)-2-oxoethyl]-2- {[3,5- bis(trifluoromethyl)phenyl]amino } - 1 ,3 -thiazol-4(57ϊ)-one,
2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-
N-(2-phenylethyl)acetamide,
5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]-l,3- thiazol-4(577)-one,
N-(2-Chloro-6-fluorobenzyl)-2- {2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro- 1 ,3- thiazol-5-yl} acetamide,
2- {2-[(2-Fluorophenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -N-(4- methylcyclohexyl)acetamide,
5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-2-[(2,6-dimethylphenyl)amino]-
1 ,3-thiazol-4(5H)-one,
N-(2-chloro-6-fluorobenzyl)-2-{2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydiO- l,3-thiazol-5-yl}acetamide,
5-[2-(3,4-Dihydroquinolin-l(277)-yl)-2-oxoethyl]-2-[(2-methylphenyl)amino]-l,3- thiazol-4(577)-one,
5-(2-Azepan-l-yl-2-oxoethyl)-2-[(2-methylphenyl)amino]-l,3-thiazol-4(577)-one,
N-(2-Chloro-6-fluorobenzyl)-2-{2-[(2-methylphenyl)amino]-4-oxo-4,5-dihydro-
1 ,3 -thiazol-5-yl } acetamide,
5-(2-Azepan-l-yl-2-oxoethyl)-2-[(2-isopropylphenyl)amino]-l,3-thiazol-4(577)- one,
N-benzyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} acetamide, 2-(cyclohexylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
N-methyl-2-{4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5-dihydro-l,3-thiazol-5- yl} -N-phenylacetamide,
N-(2-chloro-6-fluorobenzyl)-2-{4-oxo-2-[(6-phenoxypyridin-3-yl)amino]-4,5- dihydro- 1 ,3-thiazol-5-yl} acetamide,
2-[(2-cyclohex- 1 -en- 1 -ylethyl)amino]-5-[2-(3 ,4-dihydroquinolin- l(2H)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
N-(4-fluorophenyl)-2- {4-oxo-2-[(l , 1 ,3 ,3-tetramethylbutyl)amino]-4,5-dihydro- 1 ,3- thiazol-5-yl} acetamide,
5-(2-azepan-l-yl-2-oxoethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one,
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(l , 1,3,3- tetramethylbutyl)amino]- 1 ,3-thiazol-4(5H)-one,
5-(2-azepan-l-yl-2-oxoethyl)-2-[(l,l,3,3-tetramethylbutyl)amino]-l,3-thiazol-
4(5H)-one,
2-(cyclohexylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
N-benzyl-2-[2-(cyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- methylacetamide,
2-(cyclohexylamino)-5-[2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-(cyclohexylamino)-l,3-thiazol-4(5H)- one,
5-(2-Azepan-l-yl-2-oxoethyl)- 2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3- thiazol-4(57 )-one,
2-[2-(cyclopentylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-Ν-(2,6- difluorophenyl)acetamide,
2-{2-[(4-chlorobenzyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-l- naphthylacetamide,
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(2-moφholin-4- ylethyl)amino]- 1 ,3-thiazol-4(5H)-one, 2-[2-(sec-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide trifluoroacetate,
2-(sec-butylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one trifluoroacetate,
2-[2-(sec-butylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(2- chlorophenyl)acetamide trifluoroacetate,
2-{2-[(cyclopropylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-
TV-phenylacetamide trifluoroacetate,
2-{2-[(4-methylbenzyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide,
2 - {2- [(4-chlorobenzyl)amino] -4-oxo-4, 5 -dihy dro- 1 ,3 -thiazol-5 -yl } -N- phenylacetamide,
5-[2-(3,4-Dihydroisoquinolin-2(177)-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-
3-ylamino)-l,3-thiazol-4(57: )-one,
2-(cycloheptylamino)-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5 -(2-azepan- 1 -yl-2-oxoethyl)-2-(cycloheptylamino)- 1 ,3 -thiazol-4(5H)-one,
5-(2-azepan-l-yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]-l,3-thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
5-[2-(4-Methylpiperidin-l-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3-thiazol-4(577)-one,
5-[2-(l,3-Dihydro-2H-isoindol-2-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)-l,3-thiazol-4(57 )-one,
2-[(cyclohexylmethyl)amino]-5-(2-oxo-2-pynolidin-l-ylethyl)-l,3-thiazol-4(5Η)- one,
2-[(cyclohexylmethyl)amino]-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-
1 ,3-thiazol-4(5H)-one,
2-[2-(Dicyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-benzylacetamide,
2-azepan- 1 -yl-5-(2-azepan- 1 -yl-2-oxoethyl)- 1 ,3-thiazol-4(5H)-one,
2-azepan- 1 -yl-5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]~ 1 ,3-thiazol-4(5H)- one, 2-azepan-l-yl-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
2-(cycloheptylamino)-5-[2-(2,3-dihydro- lH-indol- 1 -yl)-2-oxoethyl]- 1 ,3-thiazol-
4(5H)-one,
2-(cycloheptylamino)-5-(2-oxo-2-pynolidin- 1 -ylethyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-l,3-thiazol-4(5H)- one,
2-[2-(Dicyclohexylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-phenylacetamide,
N-cyclohexyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} acetamide,
N-Cyclohexyl-N-ethyl-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-4,5- dihydro- 1 ,3-thiazol-5-yl]acetamide,
N-(Cyclopropylmethyl)-N-propylacetamide-2-[4-oxo-2-(tricyclo[3.3.1.0~3,7~]non-
3 -ylamino)-4,5 -dihydro- 1 ,3 -thiazol-5 -y 1] acetamide,
5-(2-Azocan-l-yl-2-oxoethyl)-2-(tricyclo[3.3.1.0~3,7~]non-3-ylamino)-l,3-thiazol-
4(577)-one,
5-[2-(l-Oxa-4-azaspiro[4.5]dec-4-yl)-2-oxoethyl]-2-(tricyclo[3.3.1.0~3,7~]non-3- ylamino)- 1 ,3-thiazol-4(577)-one,
2- { [( 1R)- l-cyclohexylethyl]amino} -5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
2-{[(lR)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
5-(2-azepan- 1 -yl-2-oxoethyl)-2- { [( 1 R)- 1 -cyclohexylethyl]amino } - 1 ,3 -thiazol-
4(5H)-one,
2-{[(lS)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]-l,3-thiazol-4(5H)-one,
2-{[(lS)-l-cyclohexylethyl]amino}-5-[2-(3,4-dihydroisoquinolin-2(lH)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one,
5-(2-azepan- 1 -yl-2-oxoethyl)-2- { [(IS)- 1 -cyclohexylethyl]amino} - 1 ,3-thiazol-
4(5H)-one,
2-[(cyclohexylmethyl)amino]-5-[2-(4-methylpiperidin-l-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one, N-cyclohexyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5- yl} -N-ethylacetamide,
2-[(cyclohexylmethyl)amino]-5-[2-(l-oxa-4-azaspiro[4.5]dec-4-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one,
5-(2-azocan- 1 -yl-2-oxoethyl)-2-[(cyclohexylmethyl)amino]- 1 ,3-thiazol-4(5H)-one,
2- [(cyclohexylmethyl)amino] -5 - [2-( 1 ,3 -dihy dro-2H-isoindol-2-yl)-2-oxoethyl] -1,3- thiazol-4(5H)-one,
N-(3-chloro-2-methylbenzyl)-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro- l,3-thiazol-5-yl}acetamide,
N-(cyclohexylmethyl)-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3- thiazol-5-yl } acetamide,
2-[(cyclohexylmethyl)amino]-5-[2-(octahydroisoquinolin-2(lH)-yl)-2-oxoethyl]- l,3-thiazol-4(5H)-one,
Ν-[(lR,2R,4S)-bicyclo[2.2.1]hept-2-yl]-2-{2-[(cyclohexylmethyl)amino]-4-oxo-
4,5-dihydro- 1 ,3-thiazol-5-yl} acetamide,
4- { [2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]acetyl}- 1 ,4-diazepan-
1-ium trifluoroacetate,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-
(cyclopropylmethyl)-N-propylacetamide,
2-(cycloheptylamino)-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
5-(2-azocan- 1 -yl-2-oxoethyl)-2-(cycloheptylamino)- 1 ,3-thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-cyclohexyl-N- ethylaceta ide,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl-N- phenylacetamide,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-(4- methoxyphenyl)-N-methylacetamide,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-ethyl-N- phenylacetamide,
N-butyl-2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N- phenylacetamide, N-butyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
N-benzyl-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
5-[2-(l,3-dihydra-2H-isoindol-2-yl)-2-oxoethyl]-2-[(2,2,3,3- tetramethylcyclopropyl)amino]-l,3-thiazol-4(5H)-one,
5-(2-azepan-l-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3- thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2-chlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 ,4-dichlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,6-difluorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,5-bis(trifluoromethyl)benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 ,4-difluorobenzoate trifluoroacetate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 ,4-difluorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,5-difluorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
4-methylbenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
4-chloro-3 -nitrobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 -methylbenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3-(trifluoromethyl)benzoate, 2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3 -thiazol-5 -yl] ethyl
2,3,4-trifluorobenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2-bromo-5-methoxybenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2-chloro-6-fluorobenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2-fluoro-5-(trifluoromethyl)benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2-fluoro-4-(trifluoromethyl)benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
3 -methoxybenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2,6-dimethoxybenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2 ,4-dimethoxybenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
4-butoxybenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
3,5-bis(trifluoromethyl)benzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
4-tert-butylbenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2,4-dichlorobenzoate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
2,4,6-trichlorobenzoate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
(2-chlorophenyl)carbamate,
2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
(4-chloro-3-nitrophenyl)carbamate,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
(4-bromo-2,6-difluorophenyl)carbamate, 2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl
(3 -phenoxyphenyl)carbamate,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2- fluorophenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(4- fluorophenyl)urea,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N-(2,6- difluorophenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,4- difluorophenyl)urea,
N-(2-chlorophenyl)-7V-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl} urea,
N-[2-chloro-5-(trifluoromethyl)phenyl]-N-{2-[2-(cyclolιeptylamino)-4-oxo-4,5- dihydro- 1 ,3-thiazol- 5 -yl] ethyl } urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-[4- fluoro-2-(trifluoromethyl)phenyl]urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2- methoxyphenyl)urea,
N-(5-chloro-2-methoxyphenyl)-N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- l,3-thiazol-5-yl]ethyl}urea,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N-(2,4- dimethoxyphenyl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N-(2,6- dichloropyridin-4-yl)urea,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- cyclohexylurea,
N- {2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -N- cyclopentylurea,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-chlorobenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5- {2-[(2-methylbenzyl)oxy]ethyl} - 1 ,3- thiazol-4(5H)-one trifluoroacetate, 2-(bicyclo[2.2.1 ]hept-5-en-2-ylamino)-5- {2-[(2-methoxybenzyl)oxy]ethyl} - 1 ,3- thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-{[3-
(dimethylamino)benzyl]oxy}ethyl)-l ,3-thiazol-4(5H)-one,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one,
2-(Bicyclo[2.2. l]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]- 1 ,3-thiazol-
4(5H)-one,
Methyl 4- {2-[2-(bicyclo[2.2.1 ]hept-5 -en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3- thiazol-5-yl]ethoxy}-3-chlorobenzoate,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]-l,3- thiazol-4(5H)-one,
2-Chlorophenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5 -yl] acetate,
Phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]acetate,
2-Methoxyphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetate,
3-Mθφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5- dihydro- 1 ,3 -thiazol-5 -yl]acetate,
2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-chlorophenyl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
5-(2-aminoethyl)-2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-l,3-thiazol-4(577)-one,
5-(2-aminoethyl)-2-(cyclohexylamino)- 1 ,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-(2-bromoethyl)-l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2.1]heρt-2-ylamino)-5-(2-hydroxyethyl)-l,3-thiazol-4(5H)-one,
[2-(Bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]acetic acid,
5-(2-Anilinoethyl)-2-[(2-methylphenyl)amino]-l,3-thiazol-4(5iϊ)-one hydrobromide,
5-(2-Anilinoethyl)-2-[(2-methoxyphenyl)amino]-l,3-thiazol-4(57 r)-one hydrobromide, 5-(2-anilinoethyl)-2-(2,3-dihydro-lH-inden-2-ylamino)-l,3-thiazol-4(5H)-one, 2- Anilino-5 -(2-anilinoethyl)- 1 , 3 -thiazol-4(577)-one hydrobromide, N-(2-Chlorophenyl)-2-(4-oxo-2-piperidin- 1 -yl-4,5-dihydro- 1 ,3-thiazol-5- yl)acetamide,
2- {2-[(3-chloro-2-methylphenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl} -Ν- methyl-Ν-phenylacetamide,
2-(2-{[3,5-Bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)- N-methyl-N-phenylacetamide trifluoroacetate,
2- {2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl}-Ν- phenylacetamide,
N-methyl-2- {2-[(4-moφholin-4-ylphenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl } -N-phenylacetamide,
N-Benzyl-2-(2-{[3,5-bis(trifluoromethyl)phenyl]amino}-4-oxo-4,5-dihydro-l,3- thiazol-5 -yl)acetamide,
2- {2-[(2-Fluorophenyl)amino]-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl}-N-methyl-N- phenylacetamide,
2-{2-[(2,6-dimethylphenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-methyl- N-phenylacetamide,
2-[2-(mesitylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-methyl-N- phenylacetamide,
N- 1 -naphthyl-2-[2-( 1 -naphthylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] acetamide,
2-(2-anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N-methyl-N-phenylacetamide, 2-(2-anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-Ν-(2-chlorophenyl)acetamide, N-methyl-2-[2-(l-naphthylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- phenylacetamide,
2-Anilino-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one, 2-(2-Anilino-4-oxo-4,5-dihydro-l,3-thiazol-5-yl)-N-phenylacetamide, 5-[2-(3,4-dihydroisoquinolin-2(lΗ)-yl)-2-oxoethyl]-2-piperidin-l-yl-l,3-thiazol- 4(5H)-one, 5- [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-piperidin- 1 -yl- 1 ,3 -thiazol- 4(5H)-one, 5-(2-moφholin-4-yl-2-oxoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3- thiazol-4(5H)-one,
N-[(2-{[(lS)-l-cyclohexylethyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5- yl)methyl]-2-methoxybenzamide,
2-(cyclooctylamino)-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)-one,
2-[2-(bicyclo[2.2.1]hept-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- cycloheptylacetamide hydrochloride,
N-[(2-{[(lS)-l-cyclohexylethyl]amino}-4-oxo-4,5-dihydro-l,3-thiazol-5- yl)methy 1] -2-fluorobenzamide,
2-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5-dihydro-l,3- thiazol-5-yl} ethyl)benzamide,
2-( 1 -adamantylamino)-5- [2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]- 1 ,3 - thiazol-4(5H)-one,
2-[2-(bicyclo[2.2. l]hept-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]-N-(2- chloro-6-fluorobenzyl)acetamide hydrochloride,
2-(cycloheptylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
2-(cyclooctylamino)-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2-oxoethyl]-l,3-thiazol-
4(5H)-one,
N-cyclohexyl-2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N- ethylacetamide,
5-(2-azepan-l-yl-2-oxoethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-4(5H)- one hydrochloride,
N-cyclohexyl-N-ethyl-2- {4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5- dihydro- 1 ,3-thiazol-5-yl} acetamide,
2-chloro-N- { [2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]methyl} -6- fluorobenzamide,
5-[2-(4-methylpiperidin- 1 -yl)-2-oxoethyl]-2- [(2,2,3 ,3- tetramethylcyclopropyl)amino]- 1 ,3-thiazol-4(5H)-one,
2-chloro-N-{[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]methyl}-6- fluorobenzamide,
5-(2-anilinoethyl)-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-l,3-thiazol-4(5H)- one, 2-chloro-6-fluoro-N-(2-{4-oxo-2-[(2,2,3,3-tetramethylcyclopropyl)amino]-4,5- dihydro- 1 ,3-thiazol-5-yl} ethyl)benzamide,
5-(2-azepan-l-yl-2-oxoethyl)-2-(cyclooctylamino)-l,3-thiazol-4(5H)-one,
2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-6- fluorobenzamide,
2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5- yl] ethyl } benzenesulfonamide,
2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl
2 ,4-dichlorobenzoate,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6- difluorobenzenesulfonamide,
N- {2-[2-(cyclooctylamino)-4-oxo-4,5 -dihydro- 1 ,3-thiazol-5-yl]ethyl} -2,6- difluorobenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(2-chlorophenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
2-chloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } benzamide,
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-(cycloheptylamino)-l,3-thiazol-4(5H)- one,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } -2 ,4-dichlorobenzamide,
2-chlorophenyl [2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l ,3- thiazol-5-yl]acetate,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } -2-chlorobenzamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-5-methyl-3- phenylisoxazole-4-carboxamide,
5-[2-(4-benzylpiperidin-l-yl)-2-oxoethyl]-2-[(cyclohexylmethyl)amino]-l,3- thiazol-4(5H)-one, methyl 4- {2-[2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-
5 -yl] ethoxy } -3 -chlorobenzoate, phenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] acetate, N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-bromo-5-methoxybenzamide,
N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro- 1 ,3-thiazol-5-yl]ethyl} -2- phenoxyacetamide,
2-(cycloheptylamino)-5-[2-(l-oxa-4-azaspiro[4.5]dec-4-yl)-2-oxoethyl]-l,3- thiazol-4(5H)-one,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2-fluoro-4-(trifluoromethyl)benzamide,
2-(bicyclo[2.2. l]hept-5-en-2-ylamino)-5-[2-(4-chloro-3-methylphenoxy)ethyl]- 1 ,3- thiazol-4(5H)-one,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-ethyl-N- phenylacetamide,
N-(2-chloro-6-fluorobenzyl)-2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetamide,
2-methoxyphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3- thiazol-5-yl]acetate,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}adamantane-
1-carboxamide,
5-[2-(3 ,4-dihydroquinolin- 1 (2H)-yl)-2-oxoethyl]-2-[(2-fluorophenyl)amino]- 1 ,3- thiazol-4(5H)-one,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl}-2,5-difluorobenzamide,
5-(2-anilinoethyl)-2- { [ 1 -(4-chlorophenyl)cyclobutyl]amino } - 1 ,3 -thiazol-4(5H)-one hydrobromide,
N-{2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,5- difluorobenzamide,
2-[2-(cycloheptylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]-N-(4- methoxyphenyl)-N-methylacetamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-[2-(4-phenoxyphenoxy)ethyl]-l,3-thiazol-
4(5H)-one,
4-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } benzamide, N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl] ethyl } cyclohexanecarb oxamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4-
(trifluoromethyl)benzamide,
2-{[3,5-bis(trifluoromethyl)phenyl]amino}-5-[2-(3,4-dihydroquinolin-l(2H)-yl)-2- oxoethyl]- 1 ,3-thiazol-4(5H)-one
2-anilino-5-[2-(l,3-dihydro-2H-isoindol-2-yl)-2-oxoethyl]-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5- [2-(4-hydroxy-4-phenylpiperidin- 1 -yl)-2-oxoethyl]- 1,3- thiazol-4(5H)-one,
2-{2-[(cyclohexylmethyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N,N- diethylacetamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,2- dimethylpropanamide,
2-anilino-5-(2-azepan- 1 -yl-2-oxoethyl)- 1 ,3-thiazol-4(5H)-one,
3-moφholin-4-ylphenyl [2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5- dihydro-l,3-thiazol-5-yl]acetate,
N-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl} -4-cyanobenzamide,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-4- methoxybenzamide,
2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-5-{2-[(2-chlorobenzyl)oxy]ethyl}-l,3- thiazol-4(5H)-one,
2-{2-[(2-fluorophenyl)amino]-4-oxo-4,5-dihydro-l,3-thiazol-5-yl}-N-(4- methylcyclohexyl)acetamide,
2-[(cyclohexylmethyl)amino]-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-4(5H)- one,
2-(cycloheptylamino)-5-isobutyl- 1 ,3-thiazol-4(5H)-one,
(5R)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one,
(5S)-2-(cycloheptylamino)-5-(cyclohexylmethyl)-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-(4-hydroxybenzyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-( 1 H-indol-3-ylmethyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5 -(4-hydroxybenzyl)- 1 ,3 -thiazol-4(5H)-one,
2-(bicyclo[2.2.1 ]hept-2-ylamino)-5-(4-hydroxybenzyl)- 1 ,3-thiazol-4(5H)-one, 2-(cycloheptylamino)-5-(3 ,4-dihydroxybenzyl)- 1 ,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-(pyridin-3-ylmethyl)-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-propyl- 1 ,3-thiazol-4(5H)-one hydrobromide,
5-butyl-2-(cyclooctylamino)- 1 ,3-thiazol-4(5H)-one hydrobromide,
2-(bicyclo[2.2.1]hept-2-ylamino)-5-ethyl-l,3-thiazol-4(5H)-one hydrobromide,
2-(cyclohexylamino)-5-ethyl-l,3-thiazol-4(5H)-one hydrobromide,
5-ethyl-2-[(2-methylphenyl)amino]-l,3-thiazol-4(5H)-one,
(5S)-2-(cycloheptylamino)-5-methyl-l,3-thiazol-4(5H)-one,
5-ethyl-2-[(2-isopropylphenyl)amino]- 1 ,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-methyl-l,3-thiazol-4(5H)-one,
2-(cyclooctylamino)-5-ethyl-l,3-thiazol-4(5H)-one,
2-(cycloheptylamino)-5-ethyl-l,3-thiazol-4(5H)-one,
2-{2-[2-(bicyclo[2.2.1]hept-5-en-2-ylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5- yl]ethyl } - 1 H-isoindole- 1 ,3 (2H)-dione,
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-[(2-fluorophenyl)amino]-
1 ,3-thiazol-4(5H)-one,
5- { [5-(2-chlorophenyl)- 1 ,3,4-oxadiazol-2-yl]methyl} -2-(tricyclo[3.3.1.0~3,7~]non-
3-ylamino)- 1 ,3-thiazol-4(5H)-one,
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-{[(lS,2S,3S,5R)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]amino}-l,3-thiazol-4(5H)-one,
2-(bicyclo[2.2. l]hept-2-ylamino)-5- {[5 -(2-chlorophenyl)- 1 ,3,4-oxadiazol-2- yl]methyl} - 1 ,3-thiazol-4(5H)-one,
5-{[5-(2-chlorophenyl)-l,3,4-oxadiazol-2-yl]methyl}-2-{[(lR,2R,3R,5S)-2,6,6- trimethylbicyclo[3.1.1]hept-3-yl]amino}-l,3-thiazol-4(5H)-one,
5-(lH-benzimidazol-2-ylmethyl)-2-(cyclohexylamino)-l,3-thiazol-4(5H)-one,
2-anilino-5-(l,3-benzoxazol-2-ylmethyl)-l,3-thiazol-4(5H)-one,
5-(l,3-benzoxazol-2-ylmethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one,
2-anilino-5-(l,3-benzothiazol-2-ylmethyl)-l,3-thiazol-4(5H)-one,
5-(lH-benzimidazol-2-ylmethyl)-2-(bicyclo[2.2.1]hept-2-ylamino)-l,3-thiazol-
4(5H)-one,
5-(lH-benzimidazol-2-ylmethyl)-2-(cycloheptylamino)-l,3-thiazol-4(5H)-one,
N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2- fluorobenzamide, • N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-2,6-difluoro- N-methylbenzamide, • 2-chloro-N-{2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}-N- methylbenzamide, and • 2,4-dichloro-N- {2-[2-(cyclooctylamino)-4-oxo-4,5-dihydro-l,3-thiazol-5-yl]ethyl}- N-methylbenzamide.
10. The compound according to any one of claims 6 to 9 for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
11. The compound according to claim 10, wherein the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
12. The compound according to claim 10 for the treatment or prophylaxis of a medical disorder involving delayed or impaired wound healing.
13. The compound according to claim 12, wherein the medical disorder involving delayed or impaired wound healing is diabetes.
14. The compound according to claim 12, wherein the medical disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
15. The compound according to any one of claims 10 to 14 for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
16. The compound according to claim 10, wherein the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
17. A pharmaceutical formulation comprising a compound according to any one of claims 6 to 9 as active ingredient, in combination with a pharmaceutically acceptable diluent or canier.
18. A pharmaceutical formulation for use in the prophylaxis or treatment of a 11-β- hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno- modulation.
19. The pharmaceutical formulation according to claim 18, wherein the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
20. The pharmaceutical formulation according to claim 18 for the treatment or prophylaxis of a medical disorder involving delayed or impaired wound healing.
21. The pharmaceutical formulation according to claim 20, wherein the medical disorder involving delayed or impaired wound healing is diabetes.
22. The pharmaceutical formulation according to claim 20, wherein the medical disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
23. The pharmaceutical formulation according to any one of claims 18 to 22 for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
24. The pharmaceutical formulation according to claim 18, wherein the immuno- modulation is selected from tuberculosis, lepra, and psoriasis.
25. A method for the prophylaxis or treatment of a 11-β-hydroxy steroid dehydrogenase type 1 enzyme-mediated disorder and or achieving immuno-modulation comprising administering the compound of any of claims 6 to 9 to an individual.
26. The method according to claim 25, wherein the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
27. The method according to claim 25, wherein the disorder involves delayed or impaired wound healing.
28. The method according to claim 27, wherein the disorder involving delayed or impaired wound healing is diabetes.
29. The method according to claim 27, wherein the disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
30. The method according to any one of claims 25 to 29, wherein the compound is used for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
31. The method according to claim 25, wherein the individual suffers from a disorder selected from tuberculosis, lepra, and psoriasis.
32. A method for inhibiting a 11-β-hydroxysteroid dehydrogenase type 1 enzyme, which comprises administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 6 to 9.
33. Use of a compound according to any one of claims 6 to 9 for the manufacture of a medicament for use in the prophylaxis or treatment of a 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder or achieving immuno-modulation.
34. The use according to claim 33, wherein the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, and inflammatory diseases.
35. The use according to claim 33 for the treatment or prophylaxis of a disorder involving delayed or impaired wound healing.
36. The use according to claim 35, wherein the disorder involving delayed or impaired wound healing is diabetes.
37. The use according to claim 35, wherein the disorder involving delayed or impaired wound healing is caused by treatment with glucocorticoids.
38. The use according to any one of claims 33 to 37 for the promotion of wound healing in chronic wounds, such as diabetic ulcers, venous ulcers or pressure ulcers.
39. The use according to claim 33, wherein the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
PCT/SE2005/000140 2004-02-04 2005-02-04 Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors WO2005075471A2 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0400227-5 2004-02-04
SE0400227A SE0400227D0 (en) 2004-02-04 2004-02-04 New compounds
US55580804P 2004-03-24 2004-03-24
US60/555,808 2004-03-24
SE0401324-9 2004-05-24
SE0401324A SE0401324D0 (en) 2004-05-24 2004-05-24 New compounds
SE0402509A SE0402509D0 (en) 2004-10-15 2004-10-15 New compounds
SE0402509-4 2004-10-15

Publications (2)

Publication Number Publication Date
WO2005075471A2 true WO2005075471A2 (en) 2005-08-18
WO2005075471A3 WO2005075471A3 (en) 2005-10-06

Family

ID=34841859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2005/000140 WO2005075471A2 (en) 2004-02-04 2005-02-04 Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors

Country Status (4)

Country Link
US (1) US20050239853A1 (en)
AR (1) AR047535A1 (en)
TW (1) TW200530206A (en)
WO (1) WO2005075471A2 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116002A2 (en) * 2004-05-24 2005-12-08 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006124887A1 (en) * 2005-05-13 2006-11-23 Wyeth Iminothiazolidinone derivatives as sfrp-1 antagonists
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
WO2007061661A3 (en) * 2005-11-22 2008-12-11 Amgen Inc Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2009532454A (en) * 2006-04-03 2009-09-10 マトリックス ラボラトリーズ リミテッド Novel dipeptidyl peptidase IV inhibitor, method for preparing the same, and pharmaceutical composition containing the inhibitor
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
CN102464628A (en) * 2010-11-10 2012-05-23 上海药明康德新药开发有限公司 Preparation method of cyclic alpha,beta-unsaturated sulfamide derivative
GB2497858A (en) * 2011-12-19 2013-06-26 Isis Innovation Substituted heterocyclic compounds and their use as PIM kinase inhibitors
WO2013128465A1 (en) * 2011-12-22 2013-09-06 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3233087B1 (en) 2014-12-16 2019-10-02 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
AU2016274694A1 (en) 2015-06-10 2018-01-18 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors
JP2018523707A (en) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー Geminal-substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
BR112021015481A2 (en) * 2019-02-08 2021-12-07 Sanofi Sa Biotechnological optimization of microorganisms for the 1,2-dehydrogenation of steroids

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130318A1 (en) * 2001-11-22 2003-07-10 Tjeerd Barf Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2264870A (en) * 1938-11-05 1941-12-02 Monsanto Chemicals Vulcanization of rubber
DE69206725T2 (en) * 1991-09-10 1996-05-02 Zeneca Ltd Benzenesulfonamide derivatives as 5-lipoxygenase inhibitors
DE4425677A1 (en) * 1994-07-20 1996-01-25 Basf Ag Preparation of carbamic acid vinyl esters
WO1996016650A1 (en) * 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130318A1 (en) * 2001-11-22 2003-07-10 Tjeerd Barf Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [Online] RN 771492-53-6 XP002987342 Retrieved from STN *
DATABASE REGISTRY [Online] RN 784186-62-5 XP002987341 Retrieved from STN *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116002A3 (en) * 2004-05-24 2006-07-06 Amgen Inc Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2005116002A2 (en) * 2004-05-24 2005-12-08 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA014419B1 (en) * 2004-05-24 2010-12-30 Эмджен Инк. 5,5-disubstituted-2-amino-4-thiazolidinone and process for preparation thereof, pharmaceutical composition and method for treatment
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7563813B2 (en) 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
WO2006124887A1 (en) * 2005-05-13 2006-11-23 Wyeth Iminothiazolidinone derivatives as sfrp-1 antagonists
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
JP2009516741A (en) * 2005-11-22 2009-04-23 アムゲン インコーポレイティッド Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1
WO2007061661A3 (en) * 2005-11-22 2008-12-11 Amgen Inc Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
JP2009532454A (en) * 2006-04-03 2009-09-10 マトリックス ラボラトリーズ リミテッド Novel dipeptidyl peptidase IV inhibitor, method for preparing the same, and pharmaceutical composition containing the inhibitor
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
CN102464628B (en) * 2010-11-10 2015-07-01 天津药明康德新药开发有限公司 Preparation method of cyclic alpha,beta-unsaturated sulfamide derivative
CN102464628A (en) * 2010-11-10 2012-05-23 上海药明康德新药开发有限公司 Preparation method of cyclic alpha,beta-unsaturated sulfamide derivative
GB2497858A (en) * 2011-12-19 2013-06-26 Isis Innovation Substituted heterocyclic compounds and their use as PIM kinase inhibitors
WO2013128465A1 (en) * 2011-12-22 2013-09-06 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
KR20140127226A (en) * 2011-12-22 2014-11-03 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
CN104125956A (en) * 2011-12-22 2014-10-29 康内克斯生命科学私人有限公司 Cyclic amide as inhibitors of 11-beta-hydroxysteroid dehydrogenase and uses thereof
JP2015521154A (en) * 2011-12-22 2015-07-27 コネクシオス ライフ サイエンシズ プライベート リミテッド Cyclic amide derivatives and their use as 11-β-hydroxysteroid dehydrogenase inhibitors
US9453014B2 (en) 2011-12-22 2016-09-27 Connexios Life Sciences Pvt. Ltd. Cyclic amide derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase and uses thereof
KR102083040B1 (en) 2011-12-22 2020-02-28 커넥시오스 라이프 사이언시즈 피브이티. 리미티드 Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof

Also Published As

Publication number Publication date
US20050239853A1 (en) 2005-10-27
WO2005075471A3 (en) 2005-10-06
TW200530206A (en) 2005-09-16
AR047535A1 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
WO2005075471A2 (en) Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
JP4789934B2 (en) Inhibitors of type 1 11-beta-hydroxysteroid dehydrogenase
EP1283832B1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP5204662B2 (en) Inhibitors of 11-β-hydroxysteroid dehydrogenase type 1
KR20050044577A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2008250436A1 (en) Hetarylanilines as modulators for amyloid beta
JP2005509677A (en) Inhibitors of type 1 11-beta-hydroxysteroid dehydrogenase
KR20050044578A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
RU2172737C2 (en) Thiophene derivative and pharmaceutical composition based on thereof
BRPI0619835A2 (en) organic compounds
JP5944483B2 (en) Sulfamide derivative having adamantyl group and pharmaceutically acceptable salt thereof
NZ255301A (en) N-(2-amino-2-oxoethyl)butanediamide derivatives, preparation and pharmaceutical compositions thereof
KR101296408B1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001260931B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001260931A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001260932A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase